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Ring closing metathesis in synthesis of natural products 
 
Abstract 
 
Only twenty years have elapsed since Grubbs and Fu reported that Schrock’s molybdenum 
catalyst could be used to induce efficient cyclization of functionalized ,-diene-amines. 
Since then, a wide range of ring-closing metathesis reactions to form nitrogen heterocyclic 
products have been reported, including applications in the synthesis of natural products. 
These applications have been greatly facilitated by the advent of new and more reactive 
RCM catalysts, thereby continuously widening the range of substrates and increasing the 
scope of the metathesis processes. This Chapter shows that especially five- and six-
membered heterocyclic rings are ideal targets for RCM and that applications in larger rings 
are lacking behind. On the one hand this is due to the lower occurrence of the larger rings in 
natural products, on the other hand especially eight-membered rings are significantly more 
difficult to form using the metathesis reaction.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Part of this chapter is published in: S. A. M. W. van den Broek, S. A. Meeuwissen, F. L. van Delft, F. P. J. T. 
Rutjes, Metathesis in Natural Product Synthesis: Strategies, Substrates and Catalysts, 2010 Wiley-VCH Verlag 
GmbH & Co. KgaA. 
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1.1 Introduction 
The formation of carbon-carbon bonds is a crucial issue in organic synthesis. Out of all 
methodologies available, the metathesis reaction has over the past decade evolved as one of 
the most useful tools in this field to rapidly construct the skeleton of carba- and heterocyclic 
molecules.1 The key step of the metathesis reaction entails the metal-catalyzed 
redistribution of two carbon-carbon double bonds by a scission-recombination process.2 
Among various applications of the metathesis reaction, ring-closing metathesis (RCM) has 
emerged as one of the most powerful tools for the construction of natural and unnatural 
cyclic compounds (Scheme 1.1).3 Other types of metathesis reactions developed so far 
include cross-metathesis (CM), ring-opening metathesis (ROM), ring rearrangement 
metathesis (RRM, combining ROM with RCM in a tandem sequence), ring opening 
metathesis polymerisation (ROMP)and ene-yne methathesis.3 
 
RCM
+
 
 
Scheme 1.1. Schematic illustration of the ring-closing metathesis reaction. 
 
The metathesis reaction has already been used for several decades in polymer chemistry for 
ring-opening metathesis polymerization (ROMP).4 Only since the development of well-
defined molybdenum and ruthenium carbene complexes by Schrock5 and Grubbs6 in 1990 
and 1992, respectively, an explosion of their application in organic synthesis has been 
witnessed. Initially, it was demonstrated that the Schrock catalyst S1 could serve as a 
homogeneous catalyst for olefin ring-closing metathesis (Figure 1.1).7 Unfortunately, metal 
carbene complex S1 suffers from extreme sensitivity to air and moisture, which precluded 
widespread use among organic chemists. Not long thereafter, the more stable yet less 
reactive benzylidene ruthenium complex G4 was developed.8 Additional research in this field 
led in 1995 to the ruthenium carbene catalyst G1,9 which is currently commercially available 
as the Grubbs-I or 1st generation Grubbs catalyst. This catalyst still appeared to be somewhat 
less reactive reactive than catalyst S1 in olefin metathesis but yet retained the remarkable 
air and water stability characteristics of ruthenium complex G4. In 1999, the effectiveness of 
the ruthenium-based metathesis catalysts was even further enhanced by replacing one of 
the phosphine ligands with a heterocyclic carbene, the 1,3-bis(2,4,6-trimethylphenyl)-2-
imidazolidinylidene (IMesH2) ligand to give catalyst G2.
10 This carbene complex exhibits high 
olefin metathesis activity in RCM reactions due to amongst others a higher thermal stability 
and wider functional group tolerance, and is nowadays commercially available as the 
Grubbs-II or 2nd generation Grubbs catalyst. Many (commercially available) modifications of 
these catalysts exist,11 in particular ones in which the tricyclohexylphosphine and 
benzylidene groups have been replaced by an ortho-isopropoxy-substituted benzylidene, the 
so-called Grubbs-Hoveyda catalysts G3 and G5.12 
Ring closing metathesis in synthesis of natural products 
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Figure 1.1. Metal-alkylidene complexes as metathesis catalysts: Schrock’s catalyst S1, the first 
benzylidene ruthenium complex G4, Grubbs-I catalyst G1, Grubbs-II catalyst G2, Grubbs-Hoveyda-I 
catalyst G5, Grubbs-Hoveyda-II catalyst G3, Ru-catalyst G6-G10. 
 
Formation of heterocycles by ring-closing metathesis was first reported by Grubbs and Fu, 
who found that a di-N-allylated trifluoroacetamide underwent cyclization in the presence of 
Schrock’s catalyst S1 to give the corresponding 3-pyrroline.13 At that time it was shown that 
the ruthenium-alkylidene complex G4 gave also excellent yields for similar heterocyclic RCM 
reactions, even when performed in undistilled solvents and in the presence of air. Although 
it was well established that free amines are generally incompatible with the metathesis 
reaction,14 later work demonstrated that this problem could be overcome by protection of 
the basic nitrogen atom as an amide or carbamate. In addition, protonation of the amine to 
give the corresponding ammonium salts and thus avoiding protecting groups is tolerated by 
catalysts G1 and G2. 
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As a result of the compatibility of the Ru-catalysts with nitrogen-based functional groups, 
RCM became a widely applied synthetic tool in the total synthesis of nitrogen-containing 
natural products. In particular the formation of medium-sized (five- to eight-membered) 
heterocyclic systems, which frequently occur in naturally occurring alkaloids, became a key 
target for metathesis-mediated synthesis. Hence, the aim of this account is to provide an 
overview of the majority of syntheses of alkaloid natural products in which a medium-sized 
nitrogen-containing ring was constructed using RCM.  
 
1.2 Five-membered nitrogen heterocycles 
 
1.2.1 Dihydropyrroles 
 
Interesting candidates for the application of RCM are the linear marine peptides 
(aeruginosins) that share a common 7-aza[4.3.0] bicyclic core unit. Hanessian et al. recently 
described the total syntheses of dysinosin A (1),15 isolated from a new genus of sponge of 
the family Dysideida and oscillarin (2)16 that was found in the algal cultures of Oscillatoria 
agardhii (Scheme 2). Both alkaloids were constructed via two peptide couplings between 
three common subunits: an indolizidine carboxylic acid (4 or 6) derived from L-glutamic acid, 
an acyclic peptide chain (5 or 7) and 3 (Scheme 1.2).  
 
 
 
Scheme 1.2. Retrosynthesis of the natural products dysinonin A (1) and oscillarin (2) sharing the RCM 
product 3. 
 
The synthesis of the ∆-3 pyrroline unit 3 is shown in Scheme 1.3 and started with readily 
available ɣ-butyrolactone. Six steps involving ring opening to the hydroxy ester and 
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substitution of the reduced ester with allylamine were required to form metathesis 
precursor 8. Cyclization of N-Boc protected 8 into pyrroline 9 employing G1 (10 mol %) went 
smoothly in a high yield of 90%. The six-membered carbocycle of dysinonin A fragment 
dihydroxyindolizidine 4 was prepared via RCM as well (99% yield) using the same catalyst (1 
mol %) as for 8. 
 
 
Scheme 1.3. Synthesis of the ∆-3 pyrroline unit. 
 
1.2.2 Pyrrolidine alkaloids 
 
1.2.2.1 Pyrrolidines 
 
(–)-(S)-Nicotine (12) is one of the many piperidine and pyrrolidine alkaloids isolated from the 
leaves of Nicotaiana tabacum. Welter and coworkers developed a synthesis route where 12 
was obtained in only six steps from pyridinylallyl carbonate 10 involving RCM (Scheme 1.4).17 
The synthesis commenced with an Ir-catalyzed asymmetric allylic amination of 10 to produce 
diene 11 in excellent enantiomeric purity when using phosphoramidate ligand L1. 
Subsequently, secondary amine 11 was N-protected prior to RCM in order to prevent 
catalyst deactivation. Best RCM results were achieved with G2 yielding the corresponding 
dihydropyrrole derivative in >90% yield. The synthesis of (S)-nicotine was completed through 
a deprotection step and finally reduction of the double bond.  
 
 
 
Scheme 1.4. Synthesis of (S)-nicotine. 
 
Over the past few decades, the biosyntheses of tropane alkaloids such as (–)-hyoscyamine, 
(–)-scopolamine and (–)-cocaine have been studied extensively.18 The skeletons of all these 
alkaloids feature the tropinone moiety, produced by oxidation and subsequent cyclization of 
(+)-hygrine (17).19 It was envisioned that RCM could be invoked in order to develop an 
enantioselective synthesis of 17.20 As depicted in Scheme 1.5, a phase-transfer catalytic 
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allylation reaction with methallyl bromide converted t-butyl ester 13 into product 14 in 97% 
ee. Metathesis precursor 15 was then prepared in six more steps, including transformation 
of the t-butyl ester of 14 into a terminal olefin. Dihydropyrrole 16 was formed in quantitative 
yield by RCM employing G2 (8 mol %). Subsequent hydrogenation and deprotection of 16 led 
to (+)-hygrine 17 in overall yield of 29% and an ee of 97%. 
 
 
 
Scheme 1.5. Synthesis of (+)-hygrine and tropinone. 
 
1.2.2.2 Dipyrrolidines 
 
A total synthesis of the dipyrrolidine alkaloid (–)-trans-dendrochrysine (22), isolated from 
the orchid endemic Dendrobium chrysanthum was achieved by Blechert and coworkers 
utilizing ring rearrangement metathesis (RRM).21 The asymmetric synthesis commenced with 
preparation of diolefin 20 from commercially available tropone (19, Scheme 1.6) in 11 steps 
involving a solid-phase supported Candida antarctica lipase B (Cal-B)-mediated 
desymmetrization.  
 
 
 
Scheme 1.6. Synthesis of ()-trans-dencrochrysine. 
 
Different ruthenium catalysts were evaluated for the RRM process and it appeared that G3 
(5 mol %) in refluxing toluene under an ethylene atmosphere22 gave the best results 
providing bicycle 21 in 91% yield. Thus, (–)-trans-dendrochrysine (22) was synthesized in a 
yield of 5.9% over 18 linear steps. 
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1.2.2.3 Polyhydroxypyrrolidines 
 
Naturally occurring iminosugars (azasugars) have been prominent target molecules for the 
utilization of RCM, involving formation of a cyclic olefin, followed by dihydroxylation. The 
mulberry tree (Morus alba) alkaloid 1,4-dideoxy-1,4-imino-D-ribitol [(+)-DRB, 27] is a potent 
inhibitor of glucosidases and of eukaryotic DNA polymerases. The Riera synthesis of 
polyhydroxypyrrolidine 27 featured a five-membered ring formation via RCM as illustrated in 
Scheme 1.7.23 
 
 
 
Scheme 1.7. Synthesis of DBR. 
 
Divinylmethanol 23 was converted in a number of steps into the enantiomerically pure RCM 
precursor 25 (ee = 99%) via a Sharpless epoxidation and subsequent Payne rearrangement 
as the key steps. RCM under influence of the G2 catalyst (8 mol %) proceeded uneventfully 
despite the two unprotected alcohols to give intermediate 26 in a surprisingly high yield of 
90%. Synthesis of (+)-DBR (27) was completed in several steps including a side chain-directed 
syn-dihydroxylation with OsO4 of the ring olefin. 
A similar metathesis strategy was utilized by Trost et al. for total syntheses of the azasugars 
2,5-dideoxy-2,5-imino-D-mannitol [(+)-DMDP, 28], (–)-bulgecinine (29) and the somewhat 
more complex (+)-broussonetine G (30).24,25 (+)-DMDP (28) can be isolated from several 
sources, but was initially discovered in the leaves of Derris eliptica. (–)-Bulgecinine was 
  
 
 
Scheme 1.8. Natural products (+)-DMDP (28), (–)-bulgecinine (29) and (+)-broussonetine G (30) 
sharing the same RCM-made building block 31.  
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found in bacterial cultures of Pseudomonas acidophila and Pseudomonas mesoacidophila, 
and the broussonetine family including broussonetine G in branches of the deciduous tree 
Broussontia kazinoki. All three natural products were obtained from the same metathesis 
product 31 (Scheme 1.8), from which broussonetine G was derived via a Grignard addition of 
33 onto 32. Key steps in the synthesis of the central intermediate 31 were a palladium-
catalyzed dynamic kinetic asymmetric transformation (DYKAT) and RCM. 
 
 
Scheme 1.9. Synthesis of ()-bulgecine and (+)-broussonetine. 
 
The synthesis of 31 started with a double dynamic asymmetric allylic amination for the 
enantioselective construction of diallylamine 36 from allylic epoxide (34, Scheme 1.9) 
involving ligand (R,R)-L3. While RCM with a free hydroxyl (36) appeared troublesome, the 
ring-closure proceeded smoothly in high yield using G2 (1.2 mol %) after benzyl protection 
(37), which presumably prevents undesired coordination to ruthenium. Finally, seven steps 
including a Grignard reaction between alkyl bromide 33 and the corresponding Weinreb-
amide of 32 were required to afford (+)-broussonetine G (30) in 8.2% overall yield. 
 
1.2.3 Indolizidine alkaloids 
 
1.2.3.1 Polycyclic indolizidines 
 
Alkaloids with polycyclic skeletal frameworks are, when it comes to their synthesis, excellent 
candidates for RCM. Illustrative are the indolizidines rhynchophylline (43) and its C(7)-
epimer iso-rhynchophylline (44), both isolated from the plant Uncaria rhynchophylla 
(Rubiaceae).26 Deiterss’ total synthesis of 43 started with the efficient construction of 
diallylamine 39 via amide formation between indole-3-acetic acid (38) and diallylamine 
(Scheme 1.10). One-pot RCM-carbomagnesation of 39 was smoothly achieved with only 1 
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mol % of G1 catalyst and 4 equiv of EtMgCl to afford the 2-ethyl-3-buten-1-amine derivative 
in 71% yield. It appeared that the electron-withdrawing carbonyl moiety was critical to the 
success of the RCM-carbomagnesation steps. Amide reduction and subsequent treatment 
with acryloyl chloride delivered the second metathesis precursor 40. Cyclization with G1 (5 
mol %) then furnished the ,-unsaturated lactam 41 in a high yield of 91%. Continuation of 
the total synthesis of alkaloid 43 included a Bischler-Napieralski cyclization (42) and 
subsequent rearrangement into the oxindole framework.  
 
 
Scheme 1.10. Synthesis of rhynchophylline. 
 
The erythrina alkaloids form a widely distributed family that lately has received considerable 
attention as a result of their unique tetracyclic skeleton and biological activities. 
Erythrocarine (46)27,28, erythravine (50)29 and (+)--erythroidine (56)30 are three members of 
this family that have been synthesized with metathesis as a key step. The molecular 
structures of erythrocarine, found in the seeds of Erythrina caribaea, and erythravine, 
isolated from Erythrina cochleata, are related. As a result, total syntheses independently 
proposed by respectively Mori et al. and Hatakeyama et al. proceeded via the comparable 
intermediates 45 and 48, respectively, as shown in Scheme 1.11. Enyne 49a was synthesized 
in a number of steps. This substrate was subjected to HCl, followed by the G1 catalyst (10 
mol %) to induce a tandem enyne-ring-closing metathesis process to yield the acetylated 
natural product in a quantitative conversion as a 1:1 mixture of diastereoisomers. After 
separation of the two isomers, acetyl cleavage provided erythocarine (46) in pure form. 
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Scheme 1.11. Synthesis of erythrocarine and erythravine. 
 
Intermediate 49 was prepared from 48 in eight steps. The crucial tandem ene-yne-RCM 
process was also performed with the G1 catalyst (10 mol %) and afforded the tetracyclic 
product in 78% in a diastereomeric ratio of -OAc-50:-OAc-50 is 63:37. Once more, 
separation of the products, followed by deacetylation of -OAc-50 afforded erythravine (50) 
in an overall yield of 7.0%. 
 
 
 
Scheme 1.12. Synthesis of (+)-β-erythroidine. 
 
The efficient approach to erythravine paved the way for a second erythrina alkaloid 
synthesis by Hatakeyama et al., (+)--erythroidine (56). This alkaloid was found in several 
species of the Erythrina genus and synthesized in 26 linear steps as depicted in Scheme 1.12. 
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Starting from 54, tandem enyne RCM of the isomeric mixture 55 underwent cyclization with 
the G1 catalyst (10 mol %) to furnish (+)--erythroidine (56) in a moderate yield together 
with a small amount of a mono-ring-closed byproduct. 
 
(–)-Antofine 61 is a member of the small group of phenanthroindolizidine alkaloids and was 
initially found in Vincetoxicum nigrum, belonging to the Asclepiadaeceae family. Recently, 
Kim et al. described two routes to enantiopure (–)-antofine.31,32 Both routes began with the 
coupling of homoveratric acid (57) and p-anisaldehyde in order to form phenanthryl alcohol, 
the precursor of bromide 58 (Scheme 1.13). In the first article, the synthesis was continued 
via enantioselective catalytic phase transfer alkylation of a protected glycine derivative with 
58. The glycine fragment was further transformed into the diallylamine of 59 in three steps. 
In the more recent article, enantiopure 60 was obtained via a Stille coupling with an 
enantiopure fragment and subsequent Overman rearrangement. Both routes converged to 
61 after an RCM step that was high yielding in both cases, followed by hydrogenation and 
Pictet-Spengler cyclization. Interestingly, RCM with diolefin 60 went ten times faster and was 
somewhat higher yielding in comparison with 59, probably as a result of different catalyst 
loading. Overall it can be concluded that the second approach to (–)-antofine was, though 
one step longer, more efficient and higher yielding. 
 
 
Scheme 1.13. Synthesis of ()-antofine. 
 
The tricyclic tetraponerines form an unusual class of alkaloids representing the major 
constituents of contact poison of the New Guinean ant Tetraponera sp. A flexible synthesis 
of tetraponerines T1-T8 is challenging as they differ in side chain, stereochemistry at C-9 and 
size of one of the rings. Stragies et al. proposed a combined ROM-RCM strategy that led to 
four of these alkaloids.33 One of them was tetraponerine T6 (65), synthesized in only six 
steps. The synthesis commenced with a palladium-catalyzed domino allylic alkylation on 
dicarbonate 62 to deliver the disulfonamide 63. A G1-induced (5 mol %) ROM-RCM yielded 
an equilibrium between precursor 63 and product 64 in a 1:10 ratio. Subsequent elaboration 
of the side chain, followed by cyclization finally provided tetraponerine T6 (65) in a good 
30% overall yield. 
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Scheme 1.14. Synthesis of tetraponerine T6. 
 
One of the simple representatives of the indolizidine series isolated as a trace compound 
from the skin of the neotropical frog Dendrobates speciosus is indolizidine 167B (70). 
Although neither the relative nor the absolute configuration of 70 was known, Blechert and 
coworkers synthesized the alkaloid in accordance with literature data via RRM (Scheme 
1.15).34 The two olefinic side chains of product 67 required for RRM process were introduced 
in four steps from cycloheptenediol-monoacetate (66). A RRM under the influence of G1 (5 
mol %) was in situ followed by TBAF-mediated silyl ether cleavage into alcohol 69 in an 
outstanding 92% yield. Final ring closure via reductive amination and hydrogenation 
delivered natural product 70 in a stereocontrolled way in an overall yield of 35%. 
 
 
 
Scheme 1.15. Synthesis of indolizidine 167B. 
 
Another member of the indolizidine family derived from the frog genera Dendrobatid is  
(–)-indolizidine 223A (73). Davis et al. discovered that an intramolecular Mannich reaction 
combined with metathesis provided a high yielding and enantioselective solution for its 
synthesis (Scheme 1.16).35 Reaction of 4-heptanone with enantiopure sulfinyl imine 71, 
followed by treatment with crotonaldehyde gave via an intramolecular Mannich reaction the 
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tetrasubstituted piperidinone 72. Subsequent RCM with G1 (5 mol %), followed by 
hydrogenation as the key steps afforded (–)-indolizidine 223A 73 in an overall yield of 9.3%. 
 
 
 
Scheme 1.16. Synthesis of ()-indolizidine 223A. 
 
The first enantiomeric synthesis of the pentacyclic boehmeriasin A was reported by Couture 
et al. in 2010 (Scheme 1.17).36 Its synthesis started with benzyl-protected 3-
hydroxypropionaldehyde 74, that was converted to the desired diene hydrazide 76 in two 
sequential steps introducing chirality with the SAMP-hydrazone S-(75). Next, ring-closing 
metathesis using the G1 catalyst provided the chiral piperidine 77 in an acceptable yield of 
75%. From there, four additional steps were required to provide the intermediate amino 
alcohol 78. Finally, acylation of 78 with bromobenzoyl chloride and sequential cyclization to 
the phenanthrene framework provided boehmeriasin A after reduction of the lactam.   
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Scheme 1.17. Synthesis of boehmeriasin A. 
 
In 2010 the first enantioselective natural product application of RCM was described in 
literature for the synthesis of (+)-isolysergol featuring a diastereoselective microwave-
mediated ring-closing metathesis reaction using a chiral molybdenum catalyst (Scheme 
1.18).37 The RCM precursor was constructed in five sequential steps from the known 
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dehydroamino acid 80. While initial attempts failed with commercially available catalysts, 
the molybdenum catalyst S1 successfully converted precursor 81 into 82 upon microwave 
irradiation in a varying yield of 55%. With the core structure completed, another three steps 
were required to afford (+)-isolysergol 83. 
 
 
 
Scheme 1.18. Synthesis of (+)-isolysergol. 
 
1.2.3.2 Polyhydroxyindolizidines 
 
Despite the availability of various existing synthetic procedures, application of RCM in the 
synthesis of polyhydroxyindolizidines recently became increasingly popular. The skeletons of 
all alkaloids described below were produced according to the same strategy involving  
N-alkenylation and RCM for the formation of five- and six-membered nitrogen heterocycles 
(Scheme 1.19). 
 
 
 
Scheme 1.19. Retrosyntheses of (+)-lentiginosine (84) and the putative structure of uniflorine A (85) 
proceed via similar RCM precursors (86 for 84, 87 for 85). 
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The total synthesis of lengtinosine, isolated from Australahus lentiginosus, was performed in 
the group of Spino. Uniflorine A, recently discovered in the tree Eugenia uniflora L., and 
initially proposed as structure 85, was independently synthesized by various groups 
including those of White, Pyne and Dhavale. However, NMR data of 85 did not correspond 
with the data of natural uniflorine A. 
Synthesis of (+)-lentiginosine’s metathesis precursor 90 commenced with the stereoselective 
transformation of commercially available L-menthone into compound 89 (Scheme 1.20). An 
RCM precursor 90 was efficiently cyclized with G1 (5 mol %) to dihydropyrrolidine 86, while 
the L-menthone auxiliary was recovered. From there, lentiginosine (84) was eventually 
synthesized in five steps. 
 
 
 
Scheme 1.20. Synthesis of (+)-lentiginosine. 
 
In 2004, White et al. were the first to report a synthesis of putative uniflorine 85 in which 
RCM was used as the key step (Scheme 1.19). A three-component boronic acid-Mannich 
reaction (Petasis reaction) of L-xylose, allylamine and (E)-styrene boronic acid provided the 
amino tetrol 91 as a single diastereoisomer in good yield. Application of G1 (10 mol %) on N-
Boc and O-trityl protected 91 afforded metathesis product 87 in 86% yield. The route to 
tetrahydroxyindolizidine 85 was completed by catalytic syn-dihydroxylation of 86 and six-
membered ring formation. Further investigations involving five-membered RCM in the quest 
to find the correct structure of uniflorine A provided 2-epi-85 and 1,2-diepi-8538 and 8a-epi-
85 and 2,8a-diepi-85.39 Yet, all these putative structures delivered mismatching NMR data as 
well. In 2008, White et al. suggested therefore that uniflorine A is 1,2,6,7-tetrahydroxy-3-
hydroxymethylpyrrolizidine.38 
Next, Pyne et al. successfully utilized the synthetic methodology created for putative 
uniflorine 85 to construct the analogous castanospermine (94, Scheme 1.21).40 In this case, 
amino tetrol 91 had to be protected with three different protecting groups resulting in 
compound 92. Treatment of 92 with G2 (10 mol %) yielded pyrrolo-oxazolone 93 in 88% 
yield. Diastereoselective syn-dihydroxylation of the olefin, followed by several steps led then 
to castanospermine (94).  
 
Chapter 1 
 
 26 
 
 
 
Scheme 1.21. Synthesis of castanospermine. 
 
Another asymmetric synthesis of castanospermine was published in 2010 (Scheme 1.22). 
The addition of allenylzinc reagent 97 to sulfinyl imine 96, to obtain enantiopure sulfinyl 
imine 98, was used to access the enantiopure acetylenic amino alcohol bearing the anti-1,2-
amino alcohol moiety of castanospermine.41 Another three steps were then required to 
obtain the pyrrolidine ring 99. Next, RCM using the G2 catalyst, followed by dihydroxylation 
and deprotection of the alcohols provided (+)-6-epi-castanospermine 101 in 18 steps in an 
overall yield of 8.5%.  
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Scheme 1.22. Synthesis of 6-epi-castanospermine.  
 
Trihydroxyindolizidine (–)-swainsonine 106 was first isolated from the fungus Rhizoctonia 
leguminicolain and has since then attracted great attention from chemists and biologists. In 
2002, both Blechert et al.42 and Pyne et al.43 reported a metathesis-based approach to 
alkaloid 106 via the creation of a five-membered heterocycle. The route by Blechert et al. 
began with the enantioselective formation of oxazolidinone 103 via palladium-catalyzed 
desymmetrization of the meso-bis-carbamate derivative of diol 102 (Scheme 1.23). From 
there, the metathesis precursor 104 was delivered in excellent yield. Tandem RRM 
employing the G1 catalyst (5 mol %) under an ethylene atmosphere converted compound 
Ring closing metathesis in synthesis of natural products 
  27 
 
104 into the desired 3-pyrroline 105 in yields up to 89%, while the stereochemical integrity 
of the two chiral centers was completely preserved during the reaction. Next, elaboration of 
the side chain, ring-closure and olefin dihydroxylation using commercially available AD-mix- 
afforded swainsonine 106 in an overall yield of 40%.  
 
 
Scheme 1.23. Synthesis of ()-swainsonine. 
 
Pyne and coworkers reported a completely different synthetic approach to (–)-swainsonine 
(110) starting from readily available 4-pentynol (Scheme 1.24). This was elaborated via cis-
diol 107 into the enantiopure metathesis precursor 108 in a number of steps. Next, RCM 
with G2 (6.5 mol %) converted 108 into the cyclic product 109 in 95% yield. Intramolecular 
N-alkylation and stereoselective cis-dihydroxylation via the same methodology as applied by 
Blechert et al. completed the synthesis of swainsonine (110).43 
 
 
 
Scheme 1.24. Synthesis of ()-swainsonine. 
1.2.4 Pyrrolizidine alkaloids 
 
The family of polyhydroxyindizolidine alkaloids is not the only target of interest in the field of 
natural product synthesis when it comes to application of RCM. Several approaches for the 
formation of the hindered 5,5-fused bicyclic (poly)hydroxypyrrolidines have been reported 
as well. The RCM methodology is in some of these cases applied to construct the second 
pyrrole, while on the other hand a larger number of cases exist of both natural and non-
natural products where the first cycle is created this way. 
(+)-Australine (114)44 and its epimer (+)-1-epi-australine (111)45 constitute two examples in 
which RCM was used in the construction of the second pyrrole (Scheme 1.25). Both alkaloids 
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were, together with other australine epimers, isolated from the seeds of Castanospermum 
australe.  
 
 
Scheme 1.25. (+)-1-epi-Australine and (+)-australine derived from a similar RCM precursor. 
 
Pyne et al. were the first to use RCM in the synthesis of a tetrahydropyrrolizidine, namely 1-
epi-australine 111. Ring-opening of epoxide 115, readily obtained from 3-butynol, with an 
enantiopure allylic amine provided the desired diallylamine in moderate selectivity (Scheme 
1.26). Conversion of the diallylamine into oxazolidinone 116 opened the door to the first 
RCM cyclization. Portionwise addition of G1 catalyst (30 mol % in total) gave product 117 in 
97% yield. When less catalyst was used, significantly lower yields of 117 were obtained. A 
Cis-dihydroxylation of the 3-pyrroline 117 and an additional five more steps were required to 
obtain (+)-1-epi-australine (111) as a colorless oil. 
 
 
 
Scheme 1.26. Synthesis of (+)-epi-australine.  
 
Unfortunately, an identical approach failed for the synthesis of (+)-australine (114) since a 
Mitsunobu ring-closure of the second ring did not take place. A few years later, however, 
Trost and coworkers published a different route that made an RCM-mediated synthesis of 
(+)-australine (114) possible. In a similar procedure as described for the synthesis of 
compound 31,24,25 triolefin 119 was prepared in enantiomerically pure form. Interestingly, 
application of RCM on unprotected 119 with only 1 mol % of G2 afforded the corresponding 
product 120 in 77% yield. Next, benzylation of the primary alcohol, followed by selective 
epoxidation and subsequent opening with benzyl alcohol provided an improved precursor 
for the second cyclization. Thus, (+)-australine (114) was eventually successfully prepared 
and isolated as its hydrochloride salt. 
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Scheme 1.27. Synthesis of (+)-australine. 
 
In Martin’s synthesis of (+)-hyacinthacine A2 (123), one of the alkaloids occurring in the bulbs 
of Muscari armeniacum (Hyacintheceae), RCM was used for the second ring formation 
(Scheme 1.28).46 Starting from D-arabinofuranose, only four steps were required to prepare 
metathesis precursor 122, including reductive amination with allylamine an intramolecular 
displacement of the allylic benzoate ester. Ring closing was performed on the corresponding 
hydrochloride salt of compound 122 in the presence of G1 (16 mol %) in toluene to provide 
the corresponding trihydroxypyrrolizine in 30% yield (75% based on recovered starting 
material). (+)-Hyacinthacine A2 (123) was eventually delivered by concomitant debenzylation 
and double bond hydrogenation. 
 
 
 
Scheme 1.28. Synthesis of (+)-hyacinthacine A2. 
 
Chang et al. reported a synthesis of the monohydroxypyrrolidine (–)-trachelanthamidine 
(128) also utilizing RCM to create the second cycle (Scheme 1.29).47 The synthesis of this 
alkaloid, isolated from the plant Trachelanthus korolkovi, commenced with a stereo- and 
regioselective stepwise [3+2]-annulation reaction of bromoacrylate 124 with 
sulfonylacetamide 125 leading in two more steps to compound 126. Preparation of the 
diene for the metathesis reaction was achieved by subsequent Swern oxidation and Wittig 
olefination. The pyrrolidizine skeleton 127 was formed upon ring closure, employing G2 
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(5 mol %), in 81%. Through hydrogenation and subsequent lactam reduction, the authors 
achieved a synthesis of (–)-trachelantamidine (128) in a total of seven steps. 
 
 
 
Scheme 1.29. Synthesis of trachelanthamidine. 
 
1.3. Six-membered nitrogen heterocycles 
 
Alkaloids incorporating six-membered nitrogen heterocycles are abundantly present in 
nature and occur in a multitude of alkaloid natural product families. Many of these alkaloids 
exhibit a wide range of diverse biological activities. As a result, extensive research has been 
devoted to the synthesis of many of the natural products and derivatives. This has led to an 
enormous variety of synthetic methodology that has been efficiently applied to synthesize 
many of these alkaloids. Among these methods, metathesis-based processes have played an 
increasingly important role as will be illustrated in the sequel. 
 
1.3.1 Piperidine alkaloids 
 
1.3.1.1 Piperidines 
 
(–)-Allosedamine (134) and (+)-sedamine (139), two piperidine alkaloids isolated from 
Lobelia inflate, have been used for the treatment of respiratory disorders such as asthma, 
bronchitis and pneumonia. While several racemic syntheses have been reported, there are 
much less asymmetric ones. An enantioselective route to (–)-allosedamine (134) was 
developed by Raghaven et al., which commenced with addition of lithium compound 130 
onto the imine 129 providing the separable allylic amine 131 as a 3:1 mixture of 
diastereoisomers (Scheme 1.30).48,49 Six additional steps were required to form metathesis 
precursor 132 from the major isomer 131s. Straightforward RCM (G1, 5 mol %) provided the 
corresponding heterocycle 133, which upon hydrogenation, deprotection and methylation 
afforded (–)-allosedamine (134). 
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Scheme 1.30. Synthesis of ()-allosedamine. 
 
Yadav et al. developed via a similar strategy stereoselective syntheses of both (–)-
allosedamine (134) and (+)-sedamine (139), starting from the Sharpless epoxidation product 
of cinnamyl alcohol (135, Scheme 1.31).50 The latter compound was converted in a number 
of steps into a separable diastereomeric mixture of amino alcohols 136a and 136b. N-
Allylation gave in both cases the corresponding RCM precursors, which on exposure to the 
G1 catalyst (20 mol %, benzene, 50 °C) yielded the cyclic compounds 137 and 138 in 90% and 
92% yield, respectively. Finally, deprotection and methylation led to (–)-allosedamine (134) 
and (+)-sedamine (139) via identical procedures.  
 
 
 
Scheme 1.31. Synthesis of ()-allosedamine and (+)-sedamine. 
 
A different approach to synthesize (+)-sedamine (139), reported by Cossy et al.,51,52 was 
based on a double enantioselective allyltitanation of the aldehydes 140 and 142 (Scheme 
1.32). Next, transformation of the resulting homoallylic alcohol 143 into amine 144 was 
accomplished via a Mitsunobu reaction which was in a two-step procedure converted into 
the RCM precursor 144. Completion of the synthesis was achieved through RCM (catalyst 
G1, benzene, reflux), followed by hydrogenation of the alkene and deprotection in 52% over 
four steps. 
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Scheme 1.32. Synthesis of (+)-sedamine. 
 
A synthesis of (+)-allosedamine, described by Chang et al. in 2004, started with a hydrolytic 
kinetic resolution of 146, which in turn was prepared in three steps from (+)-styrene oxide 
(Scheme 1.33).53 Subsequent formation of the diallylamine 149 as shown below, followed by 
G2-catalyzed RCM (10 mol %, benzene, 70 °C) afforded (+)-allosedamine (134).  
 
 
 
Scheme 1.33. Synthesis of (+)-allosedamine. 
 
In 2010, another synthesis of (+)-sedamine (139) and (+)-allosedamine (134) was described 
by Couture (Scheme 1.34).54 In this SAMP-based approach the piperidine core structure was 
prepared from hydrazone 151, that was readily converted into the dienehydrazide 152, the 
precursor for RCM. Next, ring closure was accomplished by treatment with the G1 catalyst 
( 10 mol %) for 12 hours in refluxing dichloromethane affording, after reduction, the desired 
natural products. 
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Scheme 1.34. Synthesis of (+)-sedamine and (+)-allosedamine. 
 
-Conhydrine, one of the alkaloids occurring in hemlock, was isolated from the seeds and 
leaves of the poisonous plant Conium maculatum. A synthesis of -conhydrine (155)55 
started with transformation of prolinol derivative 152 into amino alcohol 153 via a 
regioselective Baeyer Villiger oxidation of ketone 152 (Scheme 1.35). Compound 153 was 
then subjected to oxidation and subsequent Wittig olefination to afford RCM precursor 154. 
Smooth RCM under influence of catalyst G2 (15 mol %, CH2Cl2, reflux) gave the 
corresponding unsaturated heterocycle in 92% yield, which upon hydrogenation and 
desulfonylation provided target compound 155.  
 
 
 
Scheme 1.35. Synthesis of α-conhydrine. 
 
Another approach to -conhydrine (155) involved an Overman rearrangement of 156, which 
was prepared from (S)-glycidol in seven consecutive steps.56 Deprotection of amine 158, 
followed by acylation provided RCM precursor 159. Ring-closure under the influence of 
catalyst G1 (CH2Cl2, reflux) afforded the corresponding unsaturated piperidine in 
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quantitative yield. Finally, hydrogenation and subsequent MOM deprotection afforded 155 
in 42% yield.  
 
 
 
Scheme 1.36. Synthesis of (S)-(+)-coniine.HCl and (+)-(β)-conhydrine. 
 
An auxiliary-based synthesis of the related alkaloid (+)--conhydrine (164) commenced with 
conversion of enantiopure benzyl-protected 2-hydroxypropionaldehyde into hydrazone 160b 
(Scheme 1.36). Diastereoselective alkylation and subsequent acylation provided RCM precursor 
161b, which upon treatment with G2 (5 mol %, CH2Cl2, rt) led to the corresponding product in 75% 
yield. Subsequent hydrogenation and deprotection gave  (+)--conhydrine (164) in a yield of 
23% over six steps.57 Fairly similar procedures were applied in the synthesis of (S)-(+)-coniine 
(163).58  
A formal synthesis of (S)-(+)-coniine (163) was developed by Chang et al. in 1999 starting 
from L-norvaline (164), which was converted into diolefin 165 in several steps.59 Finally, RCM 
(G1, CH2Cl2, rt), followed by hydrogenation led to the known intermediate 166
60 thus 
completing a formal synthesis. 
 
 
 
Scheme 1.37. Synthesis of (S)-(+)-coniine·HCl. 
 
Another approach in the synthesis of functionalized piperidine alkaloids (–)-coniine (169a) 
and (–)-pipecoline (169b) commenced with the imines 167a and 167b using (R)--
methylbenzylamine as a chiral auxiliary (Scheme 1.38).61 Consecutive diastereoselective 
vinylation and N-allylation afforded compounds 168a and 168b as two diastereoisomers 
(71% de, major isomer shown). RCM (G1, CH2Cl2, rt) gave rise to the corresponding cyclic 
products in good yields, of which the diastereoisomers were separated via silica gel 
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chromatography. Eventually, straightforward hydrogenation led to the natural products 
169a and 169b. 
 
 
 
Scheme 1.38. Synthesis of ()-coniine and ()-pipecoline. 
 
An auxiliary-mediated approach reported by Agami et al. also led to a synthesis of (–)--
conhydrine (176, Scheme 1.39).62 This time, (S)-phenylglycinol (170) was used as the starting 
material, which via Weinreb amide 171 and N,O-acetal 172 was converted into 
oxazolidinone 173. The latter compound was then diastereoselectively allylated via the 
corresponding N-acyliminium ion, deprotected and allylated at the nitrogen atom. The 
resulting diolefin 174 was then subjected to RCM (catalyst G1 (4 mol %), CH2Cl2, reflux, 79%) 
and another four consecutive steps to give (–)--conhydrine (176). 
 
 
 
Scheme 1.39. Synthesis of ()-β-conhydrine. 
 
Probably, the most well-known alkaloid in Nicotaiana tabacum is (S)-nicotine (paragraph 
2.2), which plays an important role in modulation of nicotinic acetylcholine receptors 
(nAChR). However, also related alkaloids have been isolated from the same source, such as 
the homologous analogues (S)-anabasine (180a) and (S)-anatabine (181a). In 2000, Felpin et 
al. published a synthesis of the latter alkaloids starting from an asymmetric allylboration of 
3-pyridinecarbaldehyde into compound 177.63,64  
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Scheme 1.40. Synthesis of (S)-anatabine and (S)-N-methylanatabine. 
 
Azide substitution of the alcohol, followed by reduction and functionalization provided RCM 
precursor 178. Subsequent protonation of the pyridine ring, followed by RCM proceeded 
uneventfully (G1 catalyst, CH2Cl2) to give the ring-closed product 179 that via hydrogenation 
was both converted into (S)-anabasine (180a) and its methylated counterpart 180b. 
Alternatively, (S)-anatabine (181a) and its methylated derivative 181b could be directly 
obtained from the metathesis intermediate 179. 
 
En route to the natural products ent-CP-99,9994 (185) and ent-L-733,060 (186), in 2005 
Nakano et al. reported a highly enantioselective palladium-catalyzed asymmetric allylic 
amination (>99% ee) of the allylic acetate 182 using the ligand L6 (Scheme 1.41).65 
Conversion of the resulting allylic amine 183 with 3-butenoic acid in the presence of DCC 
followed by RCM (catalyst G2, CH2Cl2, reflux, 94%) yielded the piperidinone core structure 
184, which was readily converted into the target molecules 185 and 186. 
 
 
 
Scheme 1.41. Synthesis of ent-CP-99.9994 and ent-L-733.060. 
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A synthesis of the sedum alkaloid ()-sedinine was achieved employing silver(I)-catalyzed 
allenic hydroxylamine cyclization and ring-closing metathesis to form the bicyclic N,O-acetal 
188.66 Ring opening of this acetal with a silyl enol ether under Lewis acidic conditions was 
exclusively trans-selective, leading to the natural product 191 after reduction.  
 
 
 
Scheme 1.42. Synthesis of ()-sedinine. 
 
 
1.3.1.2 Piperidine carboxylic acids 
 
A significant number of alkaloids contain the 2-piperidinecarboxylic acid (pipecolic acid) unit 
as a core structure. Being a proline homologue, the pipecolic acid moiety has been used in 
many modified peptides and synthetic drugs.  
For example, naturally occurring 4-hydroxy-2-pipecolic acids have been isolated from various 
green plants and constitute important chiral building blocks of biologically active molecules 
such as palinavir. A synthesis of 4-hydroxy-2-pipecolic acid derivatives described by Johnson 
et al. involved conversion of (S)-192 in the corresponding oxazolidinone, which was N-
allylated using allyl bromide and then subjected to G1 (CH2Cl2, rt) catalyst to give cyclic 
product 193.67 The metathesis product was either readily converted into the protected 
trans-4-hydroxypipecolic acid derivative 194, but upon elaboration of the side chain also to 
the natural product (2S,4S)-(–)-SS20846A (196).  
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Scheme 1.43. Synthesis of (2S,4S)-()-SS20846A. 
 
Baikiain (200), another example of a natural product containing the pipecolic acid core 
structure, was synthesized in 2000 by Rutjes et al. via a metathesis route.68 
Amidopalladation of methyl propadienyl ether with the enantiopure L-allylglycine derivative 
197 provided the RCM precursor 198 in good yield. Cyclization (G1 catalyst, 10 mol %, 
CH2Cl2, rt) afforded the corresponding cyclic N,O-acetal 199, which was readily transformed 
into the natural product via N-acyliminium mediated reduction with Et3SiH, followed by 
deprotection.  
 
 
 
Scheme 1.44. Synthesis of baikiain. 
 
A different approach to baikiain (200) was also reported two years later by Riera et al.69 
Their synthesis commenced with a Sharpless epoxidation of 2,5-hexadienol to give the 
enantiopure epoxide 201. Subsequent epoxide ring-opening with allylamine and N-Boc-
protection afforded the RCM precursor 202, which was readily ring-closed (G1, CH2Cl2) in 
72% to the tetrahydropyridine derivative. Finally, oxidative cleavage of the diol, followed by 
Pinnick oxidation led to the N-Boc-protected natural product 203. 
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Scheme 1.45. Synthesis of baikiain. 
 
1.3.1.3 Piperidones 
 
The 2-(1H)-pyridone ring system is abundantly encountered in a wide variety of naturally 
occurring alkaloids, but also in synthetic intermediates of piperidine, (iso)quinoline, 
indolizidone and quinolizidine alkaloids. Plants belonging to genus Lycopodium are known to 
contain alkaloids possessing unique skeletal characteristics and biological activities, such as 
acetylcholine esterase (AChE) inhibition. One of them is the Phlegmarine-type alkaloid 
lycoposerramine-V (208).70 Its synthesis featured the initial formation of cyclohexene 204 
from (R)-3-methylcyclohexanone (Scheme 1.46). Removal of the t-Butyldiphenylsilyl group, 
subsequent Swern oxidation and elaboration of the double bond provided aldehyde 205, 
which was then converted into quinoline derivative 206. The aldehyde function was in a 
number of steps transformed into diolefin 207, proceeding via an asymmetric allylation with 
B-allyldiisopinocampheylborane. Ring closing metathesis (G2, CH2Cl2, rt) proceeded in near 
quantitative yield and was followed by hydrogenation and lactam reduction to afford the 
targeted lycoposerramine-V (208). 
 
 
Scheme 1.46. Synthesis of lycoposerramine-V. 
 
Pipermethystine is a major constituent of the leaves of Piper methysticum, a large shrub 
indigenous to the Islands of the South Pacific.71 Its synthesis commenced with butenamide 
209, which upon subjection to the G1 catalyst (4 mol %, CH2Cl2, reflux) gave the pyridinone 
210 in good yield. Epoxidation of 210, followed by treatment with t-BuOK afforded the allylic 
alcohol 211, which was enzymatically resolved with a lipase to give the fully protected 
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enantiopure (S)-pipermethystine ((S)-213). The non-reacted alcohol (R)-212 was afterwards 
also converted into (R)-pipermethystine (R)-213 upon esterification with acetic anhydride. 
 
 
 
Scheme 1.47. Synthesis of (R)-pipermethystine and (S)-pipermethystine. 
 
1.3.1.4 Polyhydroxypiperidines 
 
In addition to five-membered ring azasugars, a large number of different six-membered ring 
azasugars exist in nature. Since these compounds resemble the glycopyranosyl cation after 
protonation of the nitrogen atom, their structures show promising potential in the 
treatment of several diseases. Two syntheses of six-membered ring azasugars are described 
in Scheme 1.48, both starting from the protected diacetone glucose derivative 214. After 
inversion of the free hydroxyl group, compound 215 was converted into RCM precursor 216. 
G1-mediated ring-closure (CH2Cl2, rt) led to the unsaturated bicyclic intermediate 217 in 90% 
yield. From there, D-1-deoxyallonojirimycin (218) was prepared via face selective 
dihydroxylation of the cyclic olefin.72 In addition, L-1-deoxyallonojirimycin (219) was directly 
prepared from diacetone glucose derivative 214 according to identical procedures. 
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Scheme 1.48. Synthesis of L-1-deoxyallonojirimycin and D-1-deoxyallonojirimycin. 
 
A similar approach to synthesize six-membered ring azasugars was published by Takahata et 
al. which commenced with a Wittig reaction of the D-serine-derived Garner aldehyde 218. 
Facile elaboration into metathesis precursor 219, followed by treatment with G1 (CH2Cl2, rt) 
afforded tetrahydropyridine 220 in virtually quantitative yield. The latter structure was 
shown to be a good starting point for the preparation of fagomine (222) and its congeners 
221 and 223.73  
 
Scheme 1.49. Synthesis of 3-epi-fagomine and 2,4-di-epi-fagomine. 
 
1.3.2 Indolizidine alkaloids 
Coniceine (227), a bicyclic alkaloid containing the simplest indolizidine skeleton, has 
attracted much attention as a building block of indolizidine alkaloids. An early RCM-based 
synthesis was described by Chang et al. in 2001 (Scheme 1.50).74 It started with the ethyl 
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ester of proline (224), which was converted in four steps into the RCM precursor 225. 
Subsequent metathesis under the influence of catalyst G2 (CH2Cl2, rt) provided the 
corresponding cyclic olefin (226), which is a known intermediate en route to coniceine 
(227).75 
 
 
 
Scheme 1.50. Synthesis of ()-coniceine. 
 
Another synthesis was reported in 2005 by Génisson et al. who constructed the six-
membered indolizidine skeleton via RCM starting from the epoxide 228 (Scheme 1.51). 
Selective epoxide hydrolysis, followed by alkylation with the triflate of 3-butenol led to 
diolefin 229 in 72%. Subsequent RCM (G2 (5 - 10 mol %), PhMe, 70 °C) afforded the 
tetrahydropyridine 230 in 66% yield. Completion of the synthesis enclosed hydrogenolysis 
followed by ring closure to afford the targeted alkaloid (–)-lentiginosine (231).76  
 
 
 
Scheme 1.51. Synthesis of ()-lentiginosine. 
 
In 2006 Jung et al. reported another synthesis of (–)-lentiginosine (231) starting from the 
D-xylose-derived olefin 233.77 Subjection to chlorosulfonyl isocyanate (CSI) provided the 
allylic amine 234 in a high diastereoselectivity (syn/anti = 1:26) in 84% yield. With this 
compound in hand, the corresponding pyrrolidine was readily formed via intramolecular 
bromide displacement. Cbz-hydrogenolysis and introduction of the 3-butenyl moiety as 
described by Génisson led to the RCM precursor 235. Cyclization (catalyst G2, PhMe, 70 °C) 
proceeded readily in 85% yield to give the bicyclic skeleton which upon benzyl deprotection 
and dihydroxylation of the olefin gave (–)-lentiginosine (231).  
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Scheme 1.52. Synthesis of (–)-lentiginosine. 
 
A different approach leading to ent-lentiginosine (84) was adopted by Schmidt et al.78 who 
prepared pyrrolidine 236 in three steps from L-tartrate. N-Acyliminium ion-mediated 
allylation provided 237 in quantitative yield as a diastereomeric mixture (1:1), which was 
separated via column chromatography. RCM (G1 (0.4 mol %), CH2Cl2, reflux, 12 h) afforded 
the corresponding indolizidine in 78% yield, which was converted into the natural product 
via deacetylation and hydrogenation.  
 
 
 
Scheme 1.53. Synthesis of (+)-lentiginosine. 
 
In 1994, the tricyclic perhydropyrrolo[2,1]-quinolone lepadiformine (244)79 was isolated 
from the tunicate Clavelina lepadiformis by Biard et al. and exhibits moderate cytotoxic 
activity against various tumor cell lines in vitro, as well as high cardiovascular effects in vitro 
and in vivo. Unfortunately, many synthetic efforts were initially directed to a wrongly 
assigned structure. However, since 2001 several elegant syntheses have been reported. One 
Chapter 1 
 
 44 
 
of them included RCM of 241 (Scheme 1.54), which was prepared via an Ireland-Claisen 
rearrangement of amino acid ester 239. Further elaboration provided diolefin 241, which 
upon RCM (G2, CH2Cl2, 40 °C, 1 h) afforded the bicyclic skeleton 242 in 98% yield. Via an 
additional five steps, the tricyclic cyanide 243 was prepared from which (–)-lepadiformine 
(244) could be readily synthesized following known procedures.80 
 
 
 
Scheme 1.54. Synthesis of ()-lepadiformine. 
 
Melodinus alkaloids, also known as meloquinolines, represent a group of monoterpenoid 
indole alkaloids isolated from certain Apocynacea species, amongst which is (+)-meloscine 
(251). While in 1989 Overman et al. described a first racemic synthesis of meloscine, it was 
not until recently that Bach et al. succeeded in synthesizing (+)-meloscine (251) in 
enantiopure form.81 Its synthesis started with a [2+2]-photocycloaddition of enone 245 in 
the presence of the chiral auxiliary A (Scheme 1.55). Ring expansion of cyclobutane 246 into 
the -hydroxycyclopentenone 247 was then accomplished by a retro-benzylic ester 
rearrangement. Further conversion of 247 via 248 provided diolefin 249 which after RCM 
(catalyst G2 (15 mol %), PhMe, 65 °C) gave the corresponding product 250 in an excellent 
95% yield. The latter compound was then transformed in five steps into the targeted natural 
product (+)-meloscine (251). 
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Scheme 1.55. Synthesis of (+)-meloscine. 
 
Daly et al. isolated numerous alkaloids from the skin of neotropical poison-frogs such as 
steroidal batrachotoxins, histrionicotoxins, gephyrotoxins and pumiliotoxins. One of these 
alkaloids, (–)-205B (258) possessed an unusual aza-acenaphthylene ring system (Scheme 
1.56).82  
 
 
Scheme 1.56. Synthesis of ()-205B. 
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In 2005, Smith et al. published a first total synthesis of alkaloid 205B (258) based on a three 
component linchpin coupling of compounds 252 - 254, followed by a one-pot sequential 
cyclization of intermediate 255 to complete the indolizidine core structure 256. Upon 
treatment with Me3SiCl in the presence of LHMDS, the corresponding kinetic silyl enol ether 
was formed, which was then directly subjected to metathesis catalyst G2 (benzene, 65 °C) to 
provide after an aqueous workup the cyclic ketone 257 in a satisfactory 81% yield. From this 
aza-acenaphthylene skeleton, (–)-205B (258) was readily synthesized in six steps. 
 
1.3.3 Quinolizidine alkaloids 
 
The structure of quinolizidine 233A (264), obtained from skin extracts of poisonous frogs of 
the genera Dendrobates and Mantella, was published in 1993. Following up on racemic 
syntheses, a formal synthesis of enantiopure 264 was reported by Rutjes et al. based on a 
cationic cyclization of allylic N,O-acetals (Scheme 1.57).83 The approach commenced with 
cross metathesis (G5 catalyst, 5 mol %, CH2Cl2, reflux) of the enantiopure protected 2-amino-
6-heptenoic ester 259 with allyltrimethylsilane to afford the modified side chain via 
unexpected double bond isomerization. Subsequent amidopalladation with benzyl 
propadienyl ether gave the allylic N,O-acetal 260, which smoothly cyclized (Sn(OTf)2 (2 
mol %), CH2Cl2) to give 261 as a 3:1 mixture of diastereoisomers (major isomer shown). 
Deprotection, introduction of the second alkene and subsequent RCM (catalyst G2 
(5 mol %), CH2Cl2, reflux) afforded 262 in 83 % yield. Finally, hydrogenation and reduction of 
both carbonyl groups provided 263, thereby constituting a formal synthesis of quinolizidine 
233A (264).84 
 
 
Scheme 1.57. Synthesis of quinolizidine 233A. 
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In 2005 Honda et al. published a first total synthesis of a quinolizidine alkaloid using RCM as 
one of the key steps, namely (–)-deoxynupharidine (268).85 The alkaloid was isolated from 
plants of the genus Nuphar and exhibited amongst others immunosuppressive activity. Its 
synthesis commenced with a stereoselective construction of the enantiopure 5,6-
disubstituted piperidinone building block 266 by modification and ring expansion of the 
protected D-pyroglutamic acid derivative 265 (Scheme 1.58). Subsequent RCM of 266 
(catalyst G2, PhMe, 60 °C) afforded quinolizidinone 267 in 96% yield, whereafter three 
consecutive steps led to the natural product itself. 
 
 
 
Scheme 1.58. Synthesis of ()-deoxynupharidine. 
 
Blaauw et al. described a first synthesis of the quinolizidine alkaloid (+)-epiquinamide 
(272).86 This compound was isolated from the skin of the Ecuadorian frog Epipedobates 
tricolor and was claimed to show activity on the nicotinic receptor. The approach started 
with the efficient conversion of commercially available L-allysine ethylene acetal (269) in the 
functionalized pipecolic acid derivative 270. RCM under the influence of catalyst G2 (PHMe, 
rt), followed by hydrogenation provided the bicyclic skeleton 271 in excellent yield. Further 
functional group manipulation then provided (+)-epiquinamide (272) in an overall yield of 
22% from RCM precursor 270.  
 
 
 
Scheme 1.59. Synthesis of (+)-epiquinamide. 
 
The Lythraceae plants produce a large variety of bioactive alkaloids. A number of them 
comprise the quinolizidine scaffold, such as (–)-lasubine II. Liao et al. described in 2006 a 
synthesis of (–)-lasubine II (276)87 involving RCM to construct one of the two rings (Scheme 
1.60). Most efforts were directed to an enantioselective synthesis of the functionalized 
piperidine and RCM precursor 275. This was achieved via SN2-type cyclization of amino 
alcohol 274, which in turn was prepared via two sequential Roush asymmetric allylboration 
steps from the protected amino alcohol 273. RCM under the influence of catalyst [Ru]-I 
(CH2Cl2, reflux) gave the corresponding ring-closed product in 92% yield, which upon 
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catalytic hydrogenation in the presence of HF·Et3N was efficiently converted into (–)-
lasubine II (276). 
 
 
Scheme 1.60. Synthesis of ()-lasubine II. 
 
A concise stereoselective route providing access to both enantiomers of the bioactive 
quinolizidine alkaloid lasubine II has been developed in 2009 by Rutjes et al. The 
enantioselectivity was introduced by taking advantage of a proline-catalyzed asymmetric 
Mannich reaction. Next, the bicyclic system was constructed via a diastereoselective 
Mannich cyclization and subsequent ring-closing metathesis as the key steps. 
 
 
 
Scheme 1.61. Synthesis of ()-lasubine II. 
 
A synthesis of the highly conjugated pentacyclic quinolizidine alkaloid mitralactonine (282), 
isolated in 1999 by Takayama et al., shows the usefulness of RCM in constructing polycyclic 
frameworks.88 It commenced with a protected tryptamine derivative, which amongst other 
steps via a Pictet Spengler cyclization was converted into RCM precursor 280. RCM (catalyst 
G2 (10 mol %), PHMe, 80 °C) proceeded smoothly both on the N-Ts-protected (87%) as well 
as on the unprotected compound. The tosyl protection, however, was crucial in the next 
steps involving osmium-catalyzed dihydroxylation and oxidation into the corresponding 
hydroxyl enone intermediate. TBAF-mediated Ts-deprotection then gave rise to the free 
indole 281, which is a known precursor for preparing mitralactonine (282).89 
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Scheme 1.62. Synthesis of mitralactonine. 
 
The sparteine group of alkaloids, abundant in common papilionaceaous plants, is 
characterized by an asymmetric exo-endo rearrangement of bridgehead hydrogen atoms at 
C6 and C11. (–)--Sparteine, obtained from commercially available (–)-sparteine by 
isomerization, has found widespread use as chiral ligand in asymmetric catalysis and 
asymmetric deprotonation reactions. Therefore a practical stereocontrolled entry into the 
sparteine core structure would contribute to exo-ending the versatility of existing 
asymmetric methods. An elegant approach was detailed in 2005 by Blakemore et al. who 
identified the tetraoxobispidine (285) as a synthetically versatile scaffold, which could be 
readily prepared starting from a Knoevenagel condensation of dimethyl malonate (283) with 
paraformaldehyde (Scheme 1.63).90 The intermediate was directly treated with ammonia 
(284), followed by cyclization and subsequent double allylation to provide key intermediate 
285. Subsequent Grignard addition resulted in a remarkably regioselective diallylation 
affording the tetraene and RCM precursor 286. Subjection to the G1 catalyst (4 mol %, 
CH2Cl2, rt) provided the tetracyclic structure 287 in 82% yield. Finally, racemic -sparteine 
(288) was obtained upon global reduction of all olefin, aminal and carbonyl functions. 
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Scheme 1.63. Synthesis of (±)-α-isosparteine. 
 
Alkaloids isolated by Rakotoson et al. in 1998 from Galipea officinalis consisted of several 
2-substituted quinolines among which (+)-(S)-angustureine (293). A RCM-mediated synthesis 
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of this compound started with a Mitsunobu alkylation of sulfonamide 292 with the 
enantiopure secondary alcohol 289 to give the desired ,-diene 288 in 78% yield (Scheme 
1.64). With the RCM precursor in hand, subjection to the G2 catalyst (CH2Cl2, 50 °C) gave 
quinoline 292 in 92% yield. Finally, hydrogenation, deprotection and subsequent 
methylation provided (+)-(S)-angustureine (293) in 68% yield.91 
 
 
 
Scheme 1.64. Synthesis of (+)-(S)-angustureine. 
 
In 2012 a novel synthesis of tangutorine based on RCM as key step was published starting 
from building block 294 which is described in more detail in chapter 7.92  
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Scheme 1.65. Synthesis of (±)-tangutorine. 
 
1.4. Seven-membered nitrogen heterocycles 
 
In contrast to the large abundance of RCM examples of five- and six-membered nitrogen 
heterocycles en route to natural products, RCM to prepare seven-membered rings has been 
used considerably less frequently. 
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Scheme 1.66. Synthesis of balanol. 
 
One of the examples concerns a formal synthesis of (–)-balanol 300 (Scheme 1.66). Balanol 
was first isolated in 1993 from the fungus Verticillium balanoids and is a potent inhibitor of 
human protein kinase C. Because of its high inhibitory activity, balanol has been a target for 
a number of synthetic efforts. In 1999, Cook and coworkers published a formal synthesis of 
balanol (300) based on RCM to form a seven-membered nitrogen heterocycle as a key step.93 
The balanol synthesis started with D-serine derivative 296, which via oxazoline 295 was 
transformed into metathesis precursor 298. Ring closing metathesis using the G1 catalyst (2 
 5 mol %, CH2Cl2, reflux) provided the corresponding unsaturated heterocycle in 77% yield, 
which upon acidic hydrolysis of the oxazoline and hydrogenation with Wilkinson’s catalyst 
afforded 299, thereby completing the formal synthesis.94  
 
Two years later, Fürstner et al. developed a synthesis of azepine 306 based on a selective 
Sharpless asymmetric epoxidation of divinylmethanol (Scheme 1.67).95 The resulting epoxide 
301 was then regioselectively opened with allylamine to give the corresponding diene. 
Protection of the secondary amine with a N-Boc-group provided precursor 304 for RCM. 
Cyclization proceeded in 94% yield using the S1 catalyst (CH2Cl2, 30 min, reflux, 94%). 
Subsequent conversion of the secondary alcohol into the azide, reduction and acylation gave 
the Boc-protected derivative of 306, which also represents a formal synthesis of balanol.94 
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Scheme 1.67. Formal synthesis of balanol. 
 
An additional example involves the synthesis of (–)-stemoamide (311) (Scheme 1.68).96 In a 
five-step procedure 307 was synthesized starting from commercially available (S)-
pyroglutaminol. Next, a vinyl iodide was installed via a chemoselective iodoboration of the 
alkyne substituent and subsequently subjected to the Reformatsky reagent derived from 
ethyl -bromoacetate to yield RCM precursor 308.  
 
 
 
Scheme 1.68. Synthesis of stemoamide. 
 
By using the G2 catalyst under high dilution conditions (c = 0.005 M), azepine 309 was 
formed in an excellent yield of 92%. Since installation of the C8-hydroxy group via 
hydroboration was unsuccessful, an alternative was sought in hydrolyzing the ester and 
exposure to CuBr2 on alumina which gave the desired lactone 308. Conjugate hydride-
addition from the sterically most accessible -face using NiCl2·6H2O and NaBH4, followed by 
methylation completed the synthesis. 
 
1.5 Eight-membered nitrogen heterocycles 
 
Manzamine A (317) has attracted much attention over the past years because of its potent 
antitumor activity and since it was the first member of a group of similar alkaloids to be 
isolated in 1986. The combination of the complex and unusual structure of manzamine A 
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together with its promising biological activity has led to numerous synthetic efforts. One of 
these comes from Martin et al. involving two cyclizations via RCM (Scheme 1.69).97 The 
advanced intermediate 312 was converted by a domino Stille/Diels Alder reaction into the 
tricyclic system 313. From there, eight sequential steps were required for installing the two 
olefinic moieties required for the macrocyclic ring formation (315). This very early RCM 
macrocyclization was carried out using the G1 catalyst giving rise to the 13-membered ring 
containing predominantly the Z-olefin (Z/E = 8:1) in a respectable 67% yield. Then, hydrolysis 
of the cyclic carbamate followed by N-acylation provided diolefin 316, thereby setting the 
stage for the formation of the eight-membered ring. RCM with the G1 catalyst went in a 
moderate yield of 26%. Promotion of RCM with the Schrock catalyst (S1) did not improve the 
yield. Nevertheless, in a few more steps the synthesis of manzamine A (317) could be 
successfully completed.  
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Scheme 1.69. Synthesis of manzamine A. 
 
1.6. Purpose and outline of this investigation 
 
Considering the examples of natural products synthesized using RCM to form the 
heterocycle, as discussed in this chapter, we set out to investigate the metathesis behaviour 
of ,β-unsaturated didehydroamino acids, thereby generating a general building block for 
further functionalization. Chapter 2 describes the synthesis of didehydroamino acids from 
condensation of olefinic amides with a pyruvate followed by RCM, leading to the 
introduction of substituents at both the allylic and the -position of the amide. Similarly, 
condensation of hydroxy-substituted amides followed by intramolecular conjugate addition 
gives rise to the synthesis of highly functionalized morpholines, as described in Chapter 3. 
Chapter 4 describes the condensation of more elaborated olefinic amides to optically active 
3- and 4-substituted cyclic dehydroamino acids. The application to more elaborated 2-
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substituted pipecolic acids is discussed in Chapter 5 upon intermolecular conjugate addition 
for the synthesis of trans-substituted derivatives. Moreover, synthesis of cis-substituted 
variants is described based on reduction of tetrasubstituted cyclic dehydroamino acids. As 
an extension of this research, asymmetric hydrogenation of the cyclic dehydroamino acids is 
discussed in Chapter 6. Inspired by the results of RCM on dehydroamino acids, we applied 
the developed methodology to a synthesis of the natural product tangutorine, which is 
described in Chapter 7. 
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2 
 
Ring closing metathesis of α,β-unsaturated didehydroamino esters 
 
  
Abstract 
Non-proteinogenic α,β-unsaturated dididehydroamino esters are widespread in nature and 
exhibit a wide range of biological activities. Many chemists have been inspired by these 
important bioactivities and also due to their interesting structures have become interested 
in the development of new enantioselective methodologies for their synthesis. This chapter 
describes a ring-closing metathesis (RCM)-mediated approach for the formation of cyclic 
dididehydroamino esters. Drawbacks of a method previously developed in our group, 
involving alkylation of didehydroamino esters with enantiopure allylic iodides followed by 
RCM, included a poor reproducibility of the dididehydroamino ester synthesis, limitations in 
possibilities to diversify the heterocycles and moderate ee’s of the cyclization precursors. In 
a new approach, we focused on the condensation of simple unsaturated amines and amides 
with pyruvates to directly obtain the cyclization precursors (vide infra). While condensation 
of unsaturated amines appeared to be troublesome leading to low yields, condensation of 
unsaturated amides proceeded smoothly providing the corresponding α,β-unsaturated 
didehydroamino esters in a single transformation. Subsequent RCM led to the formation of 
the targeted (6-oxo)piperidine carboxylic esters.  
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Sebastiaan (Bas) A. M. W. van den Broek, Peter G. W. Rensen, Floris L. van Delft, Floris P. J. T. Rutjes, Expedient 
pathway into optically active 6-oxopiperidines, Eur. J. Org. Chem., 2010, 5906 - 5912. 
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2.1 Introduction 
 
Non-proteinogenic α,β-unsaturated dididehydroamino esters are widespread in nature and 
exhibit a broad range of biological activities.1 Inspired by the relevant bioactivities and 
challenged by their structures, organic chemists continue to develop new methodologies for 
the synthesis of such molecules. Since ring-closing metathesis (RCM) has been fully 
integrated in organic synthesis nowadays, we envisioned that RCM might serve as a 
powerful technique for the construction of cyclic dididehydroamino esters. As exemplified in 
the first chapter, a variety of functional appendages have already been constructed via this 
method. For example, as early as in 1992 Grubbs and Fu revealed that RCM could be 
successfully exploited to form five-, six-, and seven-membered oxygen and nitrogen 
heterocycles (Scheme 2.1).  
 
 
 
Scheme 2.1. Ring-closing metathesis (RCM) of enamide and enol ether double bonds. 
 
While the first examples of olefin metathesis relied on cyclization of neutral and often mono-
substituted alkenes, the scope of RCM has steadily been broadened into more highly 
substituted olefins with both electron-donating and electron-withdrawing groups. Despite 
the fact that several literature examples illustrate the metathesis opportunities of electron-
poor olefins, their scope has remained limited until now.2 This is most likely due to the fact 
that electron-poor olefins are less reactive in RCM than regular ones.3  
 
 
 
 
Scheme 2.2. Ring-closing metathesis (RCM) of enol ether double bonds. 
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Moreover, carbene intermediates of electron-poor olefins are relatively unstable due to the 
electron-deficient metal carbene bonds.4 Secondly, after metathesis of the more reactive 
unhindered olefin, the carbonyl function can chelate to the metal center thereby lowering 
the rate of catalysis.5 This effect can sometimes be circumvented by the addition of a Lewis 
acid (e.g. Ti(OiPr)4).
6 The G2-catalyst, however, is less prone to chelation because of its more 
electron-rich ruthenium metal center. Ring closing metathesis of electron-rich alkenes, e.g. 
enol ethers and enamides, to form oxygen- and nitrogen-heterocycles, respectively, is also 
known. Since the relatively fast reaction of enol ethers leads to a Fischer-type carbene 
(Scheme 2.2) thereby deactivating the catalyst, ring closing metathesis of enol ethers 
appeared to be limited. For this reason, enamides were long thought to be unsuitable for 
metathesis too. In the past years, however, several successful examples of ring closing 
metathesis on enamides were published.7,8,9,10,11 
 
Previous examples of ring closing metathesis of both electron-rich and electron-poor olefins 
originating from our group, concerning the metathesis behavior of α-alkoxyacrylates 
resulted in the formation of a variety of heterocyclic products.12 Moreover, synthesis and 
cyclization of α,β-unsaturated didehydroamino acids containing allylic substituents were 
performed using a similar strategy (Scheme 2.3).13 Additionally, RCM was successfully used in 
the cyclization of fluoroolefins as a general strategy for the synthesis of fluorinated 
(aromatic) heterocycles.14 
 
 
 
Scheme 2.3. RCM of didehydroamino acids by Hekking et al. 
 
Based on our previous RCM examples on dididehydroamino acids, we set out to further 
determine the scope and limitations of this approach using more elaborate didehydroamino 
esters as a general entry into functionalized piperidines 6. A severe drawback of the 
previously developed method involved the poor reproducibility of the synthesis of the 
didehydroamino esters. Moreover, the method was rather limited in diversity and the 
enantiopurity of the didehydroamino esters 4 was not complete. We therefore focused on 
the condensation of simple unsaturated amines (8, X = H2) and amides (8, X = O) with 
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pyruvate esters to directly obtain the cyclization precursors 7 (Scheme 2.4). In case this was 
successful, this strategy might also be applied on more complex amines and amides. With 
the objective to prepare α,β-unsaturated didehydroamino esters, we envisaged that this 
should be possible via condensation of unsaturated amines and amides with ethyl pyruvate 
under DeanStark conditions (PhMe, 110 °C). Imine formation, followed by tautomerization 
to the more stable enamine (7, X = H2) or enamide (7, X = O) would then provide the 
corresponding didehydroamino ester 7 in a single transformation (Scheme 2.4).15 
 
 
 
Scheme 2.4. RCM approach to functionalized piperidines 6. 
 
2.2 α,β-Unsaturated didehydroamino ester precursors for RCM 
 
A preliminary study was performed to synthesize didehydroamino ester 11a from 
condensation of n-butylamine (9) with ethyl pyruvate (Scheme 2.5). While TLC showed a 
rapid consumption of ethyl pyruvate, no clear product was observed. Addition of a drying 
agent (e.g., sodium sulfate or 4 Å molecular sieves) to the reaction mixture to capture water 
did not give better results. When the conversion was monitored by 1H NMR, it was indicated 
that formation of the unstable imine was already complete within one hour at room 
temperature, but decomposed on TLC. Subsequent addition of a base, e.g., triethylamine or 
N,N-diethylaniline, followed by dropwise addition of acetyl or benzoyl chloride afforded the 
stable unsaturated didehydroamino esters 11a and 11b.  
 
 
 
Scheme 2.5. Condensation of n-butylamine with ethyl pyruvate. 
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Encouraged by these results, we decided to use 3-butenylamine (14) and  
4-pentenylamine (15) as precursors for the condensation reaction, starting from the 
commercially available hydrochloric acid salts 12 and 13, respectively (Scheme 2.6). 
Subjection to 1 equivalent of base (DBU), followed by addition of ethyl pyruvate provided 
the desired imines. Subsequent addition of triethylamine and acetyl chloride then provided 
the didehydroamino esters 16 and 17 in yields of 19 and 12%, respectively. In order to raise 
the yields, several nitrogen protecting groups were investigated. Disappointingly, inducing 
tautomerization to the enamide could only be achieved by reaction with acid chlorides. 
Addition of a (strong) base (e.g., LDA, LHMDS, or K2CO3) to the intermediate imine to 
promote tautomerization in the absence of an acid chloride electrophile only led to 
decomposition.  
 
 
 
Scheme 2.6. Condensation reaction with 3-butenyl- (n = 1) and 4-pentenylamine (n = 2).  
 
The low yields and limited scope of nitrogen protecting groups in case of the amines, 
prompted us to shift our focus to the condensation of amides with ethyl pyruvate. Contrary 
to the amine condensation, elevated temperatures were required in combination with a 
catalytic amount of p-toluenesulfonic acid (10 mol%) in accordance with results reported 
(Scheme 2.7).16  
 
Scheme 2.7. Condensation reaction of n-butylamide (18) with ethyl pyruvate. 
 
More specifically, butanamide (18) was reacted with ethyl pyruvate in the presence of p-
toluenesulfonic acid (10 mol%) under DeanStark conditions in three hours to provide 20 in 
18% yield after aqueous workup. The low yield was thought to result from enamide-imine 
tautomerization, followed by hydrolysis of the imine. Applying a non-aqueous workup, 
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involving filtration of the reaction mixture through neutral aluminum oxide, followed by 
column chromatographic purification, on the other hand afforded the α,β-didehydroamino 
ester 20 in a moderate yield of 51%. The yield of the reaction was even further increased to 
83% by applying anhydrous p-toluenesulfonic acid, which was obtained by stirring in 
concentrated hydrochloric acid and coevaporation with toluene. With this result in hand, the 
stage was set for the condensation reaction of various unsaturated amides. 
 
 
Scheme 2.8. Condensation of olefinic amides with ethyl pyruvate. 
 
The olefinic amides 22a-c were readily prepared from the commercially available carboxylic 
acids 21a-c (Scheme 2.8). Successive chlorination with oxalyl chloride and treatment with 
ammonia provided the primary amides in pure form after recrystallization from diethyl 
ether/heptane (1:1). Both condensation of 4-pentenamide (22b) and 5-hexenamide (22c) 
with ethyl pyruvate were high yielding, condensation of 3-butenamide (22a) on the other 
hand, led to isomerization of the terminal olefin. 
 
2.3 Ring-closing metathesis of α,β-unsaturated didehydroamino esters 
 
With the precursors 16, 17 and 24b-c in hand, we set out to investigate the behavior of the 
α,β-didehydroamino esters under metathesis conditions. The first RCM reactions were 
performed with the first generation Grubbs catalyst (G1, 10 mol%, Table 2.1) in 
dichloromethane at 40 °C in the presence of 1,4-benzoquinone (10 mol%) to prevent double 
bond isomerization.17 However, treatment of 16 with G1 did not lead to any ring closure 
(entry 1). Surprisingly, in the absence of 1,4-benzoquinone only homodimerization was 
observed together with a substantial amount of starting material. Subjection of enamide 17 
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to G1 led to similar results (entry 2). Treatment of 16 and 17 with G1 in toluene at 80 °C did 
not offer any improvement either (entry 3 and 4).  
 
Table 2.1. RCM-mediated generation of five- and six-membered heterocycles. 
 
 
 
Entry solvent T (°C) Catalyst (10 mol%) Yield of 25 (%) Yield of 26 (%)* 
1 (n = 1) CH2Cl2 40 G1 – 12 
2 (n = 2) CH2Cl2 40 G1 – 34 
3 (n = 1) PhMe 80 G1 – 31 
4 (n = 2) PhMe 80 G1 – 26 
5 (n = 1) CH2Cl2 40 G2 81 – 
6 (n = 2) CH2Cl2 40 G2 – 17 
7 (n = 1) PhMe 80 G2 89 – 
8 (n = 2) PhMe 80 G2 – 29 
* Yields obtained in the absence of 1,4-benzoquinone 
 
After these unsatisfactory results, we decided to subject diolefin 16 to the more reactive 
second generation Grubbs catalyst (G2, 10 mol%) under identical conditions. Interestingly, 
ring closing metathesis with 16 proceeded smoothly leading to the five-membered 
heterocycle 25a in high yield (entries 5 and 7). On the other hand, Treatment of 17 with G2 
only led to multiple products (entries 6 and 8).  
 
Much to our surprise, subjection of 24b to G2 (10 mol%) in toluene gave no reaction at all 
(Scheme 2.9). Free amines are typically incompatible with metathesis reactions owing to 
catalyst inhibition by the basic nitrogen. Ring closing metathesis in the presence of amides 
on the other hand is known,18 however, previous results in literature suggest that protection 
of the nitrogen is required for ring closing metathesis to proceed.17b Attempts to Cbz-protect 
the nitrogen in the presence of DMAP resulted in the recovery of starting material and 
reaction with LHMDS at low temperatures only led to decomposition. Interestingly, 
protection of the amide with a Boc-group (CH2Cl2, Boc2O, DMAP, rt) led to the formation of 
the desired didehydroamino ester 28 in 85% yield. Disappointingly, the didehydroamino 
ester remained unreactive toward ring closing metathesis upon treatment with G2 (10 
mol%) leading to multiple products upon prolonged reaction times. Since the energetically 
unfavored s-cis-conformation of the didehydroamino ester is required for cyclization to 
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proceed, carbamate-protection of the amide probably renders s-cis-trans-isomerization 
sterically impossible. 
 
  
Scheme 2.9. Attempted RCM of didehydroamino ester 24b and its Boc-protected derivative 28. 
 
Rather than by introducing a second acyl group on the nitrogen, cis-trans-isomerization 
might also be influenced by straightforward N-alkylation. Therefore, 24b was treated with 
LHMDS and benzyl bromide in DMF. Yet, 24b readily decomposed under these basic 
conditions. By using sodium hydride, 30a was obtained in 34% yield. Due to the moderate 
yield of the N-benzylation, the more reactive p-methoxybenzyl bromide (PMBBr) was 
successfully coupled in a yield of 53%. In a later stage, we found that the yield for N-
alkylation was substantially increased to 83% via portionwise addition of sodium hydride 
(five times 0.25 equiv). Furthermore, subjection to p-bromobenzyl bromide also resulted in 
the desired product 30c. Purification of the latter, however, appeared to be troublesome, 
resulting in only 23% yield. Upon subjection of the PMB-protected precursors 30b (entry 2) 
and 30d (entry 3) to RCM, we were pleased to find that 31b was formed smoothly in a yield 
of 71%, while unfortunately in case of 30d only homodimeric species were observed. The 
RCM-precursors 30a (entry 2) and 30c (entry 4) reacted similarly, albeit with a slightly lower 
yield.  
 
Table 2.2. RCM of didehydroamino acids 
 
Entry Compound R Yield (%) Compound R Yield (%) 
1 30a Bn (n = 1) 83 31a Bn (n = 1) 58
a 
2 30b PMB (n = 1) 53 31b PMB (n = 1) 71
b 
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3 30c PBB (n = 1) 23 31c PBB (n = 1) 47
a 
4 30d PMB (n = 2) 79 31d PMB (n = 2) – 
a
Conversion based on 
1
H NMR. 
b
Isolated yield. 
 
With the 6-oxopiperidine carboxylic ester 31b in hand, we encountered the problem that 
upon increased concentration of the reaction a mixture of the cyclic structure and its 
homologous dimeric species (32) were isolated using 10 mol% of G2. When the dimer 32 was 
subjected to a fresh portion of G2, a full conversion into the heterocycle was observed. In 
view of this result, the G2-catalyst was then in a new experiment added portionwise (three 
times 2 mol%), resulting in the formation of the heterocycle 31b as a single product in 71% 
yield. 
 
 
 
Scheme 2.10. Cyclization of didehydroamino ester 30b. 
 
2.4 Introduction of substituents 
 
Having this new method established, the stage was set for condensation of more elaborate, 
substituted unsaturated amides. At first, we decided to investigate the influence of allylic 
substituents on the amide. For this purpose, the readily available 3-methyl pent-4-enoic acid 
33a was converted into the corresponding acid chloride by treatment with oxalyl chloride. 
Careful concentration of the acid chloride and quenching with ammonia yielded the amide 
34a in 53% yield. Condensation of 34a with ethyl pyruvate in the presence of  
p-toluenesulfonic acid afforded 35a in 46% yield as anticipated. Next, alkylation of the 
nitrogen using PMBBr afforded 36a in a yield of 64%. Finally, ring closing metathesis resulted 
in the 5-methyl-6-oxopiperidine carboxylic ester 37a in excellent yield (91%). Similar results 
were obtained from ring closing metathesis of the 2-methyl-substituted derivative 36b, 
providing cyclic product 37b in 71% yield.   
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Scheme 2.11. Condensation and cyclization of methyl-substituted olefinic enamides. 
 
2.5 Synthesis of 1-oxoisoquinoline carboxylic esters 
 
1-Oxoisoquinoline carboxylates (39) are interesting structural entities. They are not only 
important as building blocks in natural product synthesis (e.g., Marinamide (38), Scheme 
2.12), but also play an important role in the synthesis of stereochemically defined ligands. 
These ligands offer a coordinating environment related to the one present in the Salen 
ligands, but with chirality stemming from restricted rotation around the biaryl axis, rather 
than from central asymmetry in a diamine bridge.19 
 
 
Scheme 2.12. natural products containing the 1-oxoisoquinoline carboxylate (39). 
 
Stimulated by the previous results, we set out to apply this methodology in a synthetic 
approach to 1-oxoisoquinoline carboxylates 48 starting from 2-vinylbenzamide 45a. Scheme 
2.13 shows the preparation of 45a as well as of its methyl-substituted analogue 45b. Olefins 
43a-b were prepared from commercially available 2-formylbenzoic acid 41 and 2-
acetylbenzoic acid 42 under standard Wittig conditions, following known procedures.20 Due 
to the low yield of the reaction, the acid was converted into the corresponding methyl ester 
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prior to olefination. However, in our hands the yield remained moderate. Surprisingly, 
reaction of methyl esters 43a-b with ammonia did not lead to formation of the amides. 
Alternatively, the ester was hydrolyzed using potassium hydroxide in dioxane/H2O to give 
44a-b in good yield. Next, the carboxylic acid was converted into the amide using the same 
two-step procedure that was used previously.  
 
 
 
Scheme 2.13. 2-Vinylbenzamide and 2-propenylbenzamide as precursors for isoquinoline synthesis. 
 
Next, condensation of unsaturated amide 45a with ethyl pyruvate proceeded well, resulting 
in isolation of the didehydroamino ester 46a in a good yield of 75% (Scheme 2.14). 
Subsequent PMB-protection followed by RCM using G2 at 80 °C in toluene yielded the 1-
oxoisoquinoline carboxylic ester 48a in 82%. The condensation of 45b proceeded in a similar 
fashion as for 45a, resulting in 67% of the desired product. Paramethoxy benzyl protection of 
46b, however, proved to be more difficult, resulting in only trace amounts of product 46b 
(5%). The little product obtained was subjected to RCM using G2. As might have been 
expected, the less reactive disubstituted alkene did not undergo any RCM. In 2007, the more 
reactive o-tolyl-imidazolidine catalysts G6 and G7 came onto the market, which were 
especially developed for ring-closing metathesis of sterically more demanding alkenes. 
Disappointingly, the didehydroamino ester 47b remained unreactive towards cyclization 
with the latter catalyst. 
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Scheme 2.14. Synthesis of isoquinoline 48a. 
 
2.6 Conclusion 
 
Condensation of unsaturated amines with ethyl pyruvate appeared to be troublesome. The 
reaction was low yielding and the protection of nitrogen was limited to acid chlorides. 
Moreover, five-membered nitrogen heterocycles were formed in good yield, while formation 
of the six-membered analogues failed entirely, leading only to dimerization. Condensation of 
unsaturated amides with ethyl pyruvate on the other hand proceeded smoothly yielding the 
desired didehydroamino esters in a single transformation. Although unprotected 
didehydroamino esters failed to undergo ring-closing metathesis, we were pleased to find 
that the N-alkylated counterparts underwent smooth ring-closing metathesis with the G2 
catalyst to provide the cyclic didehydroamino esters. 
 
Having a new method established, more elaborate unsaturated amides were successfully 
introduced in order to synthesize 4- and 5-methyl-substituted 6-oxopiperidine carboxylic 
esters. Finally, the 1-oxoisoquinoline carboxylic ester moiety has been successfully 
synthesized via the developed method. Unfortunately, the Ru-catalyzed ring closure to 
tetrasubstituted alkenes was unsuccessful. 
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2.7 Experimental section 
 
General information 
 
Solvents were distilled from appropriate drying agents prior to use and stored under nitrogen. Chemicals were 
purchased from Sigma-Aldrich or Acros chemicals and used as received, unless stated otherwise. Reactions 
were carried out under inert atmosphere of dry nitrogen or argon. Standard syringe techniques were applied 
for the transfer of dry solvents and air- or moisture-sensitive reagents. Reactions were followed and Rf values 
are obtained using thin layer chromatography (TLC) on silica gel-coated plates (Merck 60 F254) with the 
indicated solvent mixture. Detection was performed with UV-light, and/or by charring at ~150 °C after dipping 
into a solution of either 2% anisaldehyde in ethanol/H2SO4 or (NH4)6Mo7O24.4H2O (25 g/L) and 
(NH4)4Ce(SO4)4.2H2O (10 g/L) in 10% H2SO4. IR spectra were recorded on an ATI Mattson Genesis Series FTIR 
spectrometer, or a Bruker Tensor 27 FTIR spectrometer. NMR spectra were recorded on a Bruker DMX 300 
(300 MHz), and a Varian 400 (400 MHz) spectrometer in CDCl3 solutions (unless otherwise reported). Chemical 
shifts are given in ppm with respect to tetramethylsilane (TMS) as internal standard. Coupling constants are 
reported as J-values in Hz. Column or flash chromatography was carried out using ACROS silica gel (0.035–0.070 
mm, and ca 6 nm pore diameter). Optical rotations were determined with a Perkin Elmer 241 polarimeter. High 
resolution mass spectra were recorded on a JEOL AccuTOF (ESI), or a MAT900 (EI, CI, and ESI).  
 
Ethyl-2-[acetyl(butyl)amino]acrylate (11a) 
To a solution of ethyl pyruvate (492 µL, 4.5 mmol) in PhMe (50 mL), was added n-
butylamine (445 µL, 1.0 equiv). The reaction was stirred for 3 hours at room temperature 
and then cooled to 0 °C. Acetyl chloride (320 µL, 1.0 equiv) was added dropwise followed 
by a slow addition of diethylaniline (720 µL, 1.0 equiv). The reaction was stirred for 16 h 
and then poured onto ice-water. The organic layer was washed with NaCl, dried (MgSO4) and concentrated in 
vacuo. The residue was purified by column chromatography (EtOAc/heptane 1:1) to give 11a (389 mg, 1.70 
mmol, 43%) as a colorless oil. Rf 0.42 (EtOAc/heptane 1:1). FTIR (ATR) 1193, 1628, 1665, 1723, 2957 cm
-1
. 
1
H 
NMR (CDCl3, 400 MHz): δ 6.51 (s, 1 H), 5.74 (s, 1H), 4.30 (q, 2H, J = 7.2 Hz), 3.52-3.46 (m, 2H), 1.97 (s, 3H), 1.54-
1.21 (m, 7H), 0.98 (t, 3H, J = 7.2 Hz). 
13
C NMR (CDCl3, 75 MHz): δ 162.24, 137.68, 126.19, 61.39, 59.92, 46.79, 
29.32, 19.53, 13.72, 13.67, 13.34. HRMS (ESI) m/z calcd for C11H19NO3Na (M+Na)
+
: 236.1263, found: 236.1265. 
 
Ethyl-2-[benzoyl(butyl)amino]acrylate (11b) 
To a solution of ethyl pyruvate (492 µL, 4.5 mmol) in PhMe (50 mL), was added n-
butylamine (445 µL, 1.0 equiv). The reaction was stirred for 3 hours at room temperature 
and then cooled to 0 °C. Benzoyl chloride (523 µL, 1.0 equiv) was added dropwise followed 
by a slow addition of diethylaniline (720 µL, 1.0 equiv). The reaction stirred for 16 h and 
then poured onto ice-water. The organic layer was washed with NaCl, dried (MgSO4) and 
concentrated in vacuo. The residue was purified by column chromatography (EtOAc/heptane 1:1) to give 11b 
(546 mg, 2.57 mmol, 57%) as a colorless oil. Rf 0.46 (EtOAc/heptane 1:1). FTIR (ATR) 1193, 1628, 1665, 1723, 
2957 cm
-1
. 
1
H NMR (CDCl3, 400 MHz): δ 8.12-7.23 (m, 5H), 6.06 (s, 1H), 5.47 (s, 1H), 4.04 (q, 2H, J = 6.8 Hz), 3.65 
(t, 2H, J = 6.6 Hz), 1.63-1.58 (m, 2H), 1.48-1.40 (m, 2H), 1.14 (t, 3H, J = 7.0 Hz), 0.90 (t, 3H, J = 7.3 Hz). 
13
C NMR 
(CDCl3, 75 MHz): δ 170.31, 163.54, 140.53, 135.72, 130.01, 129.52, 128.32, 127.50, 61.02, 48.61, 29.23, 19.62, 
13.52, 13.32. HRMS (ESI) m/z calcd for C16H21NO3Na (M+Na)
+
: 298.142, found: 298.141. 
 
Ethyl-2-[Acetyl(but-3-enyl)amino]acrylate (16) 
To a solution of n-butenylamine hydrochloric acid (535 mg, 5.0 mmol) in CH2Cl2 (10 mL) 
was added DBU (755 µL, 1.0 equiv). The reaction mixture was stirred for 1 hour. Then ethyl 
pyruvate (545 µL, 1.0 equiv) was added and the reaction was stirred for another 3 hours. 
The reaction was then cooled to 0 °C and acetyl chloride (355 µL, 1.0 equiv) was added 
dropwise followed by a slow addition of triethylamine (1395 µL, 10.0 mmol). The reaction was stirred for 16 h 
and then poured onto ice-water. The organic layer was washed with NaCl, dried (MgSO4) and concentrated in 
N CO2Et
O
N CO2Et
O
N CO2Et
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vacuo. The residue was purified by column chromatography (EtOAc/heptane 1:1) to give 16 (205 mg, 0.97 
mmol, 19%) as a colorless oil. Rf 0.36 (EtOAc/heptane 1:1). FTIR (ATR) 1192, 1630, 1667, 1724, 2980 cm
-1
. 
1
H 
NMR (CDCl3, 400 MHz): δ 6.48 (s, 1H), 5.77-5.70 (m, 2H), 5.09-5.03 (m, 2H), 4.28 (q, 2H, J = 7.1 Hz), 3.55 (t, 2H, J 
= 7.4 Hz), 2.29-2.26 (m, 2H), 1.94 (s, 3H), 1.33 (t, 3H, J = 7.1 Hz). 
13
C NMR (CDCl3, 75 MHz): δ 169.62, 163.21, 
144.56, 134.78, 126.70, 116.08, 61.42, 46.23, 31.62, 21.61, 13.73. HRMS (ESI) m/z calcd for C11H17NO3Na 
(M+Na)
+
: 234.1263, found: 234.1265 
 
Ethyl-2-[acetyl(pent-4-enyl)amino]acrylate (17) 
To a solution of n-butenylamine (340 mg, 4.0 mmol) in CH2Cl2 (10 mL) was added ethyl 
pyruvate (438 µL, 2.0 equiv) and the reaction was stirred for 1 hour. The reaction was 
then cooled to 0°C and acetyl chloride (285 µL, 1.0 equiv) was added dropwise followed 
by a slow addition of triethylamine (554 µL, 1.0 equiv). The reaction stirred for 16 h and 
then poured onto ice-water. The organic layer was washed with NaCl, dried (MgSO4) and concentrated in 
vacuo. The residue was purified by column chromatography (EtOAc/heptane 1:1) to give 17 (162 mg, 0.72 
mmole, 18%) as a colorless oil. Rf 0.36 (EtOAc/heptane 1:1). 
1
H NMR (CDCl3, 400 MHz): δ  6.46 (s, 1H), 5.80-5.75 
(m, 2H), 5.73 (s, 1H), 5.01-4.96 (m, 2H), 4.28, (q, 2H, J = 7.1 Hz), 3.50 (dt, 2H, J = 7.6 Hz, J = 3.6 Hz), 2.07-2.02 (m, 
2H), 1.95 (s, 3H), 1.63-1.58 (m, 2H), 1.32 (t, 3H, J = 7.1 Hz). 
  
Ethyl-2-(butanoylamino)acrylate (20) 
To a solution of n-butylamide (380 mg, 4.5 mmole) in PhMe (25 mL), were added 
hydroquinone (81 mg, 10 mol%), p-TsOH (86 mg, 10 mol%) and ethyl pyruvate (987 µL, 
2.0 equiv). The reaction mixture was stirred under Dean-Stark conditions applying 
vacuum for regulation. After 3 h the reaction was cooled to room temperature and 
poured over a plug of neutral Al2O3. The Al2O3 was washed two times with PhMe (25 mL). The organic layer was 
concentrated in vacuo. The residue was purified by column chromatography (EtOAc/heptane 1:1) to give 20 
(692 mg, 3.7 mmol, 83%) as a colorless oil. Rf 0.76 (EtOAc/heptane 1:1). FTIR (ATR) 1181, 1224, 1512, 1658, 
1731, 2958, 3356 cm
-1
. 
1
H NMR (CDCl3, 400 MHz): δ 7.79 (br. s, 1H), 6.60 (s, 1H), 5.87 (d, 1H, J = 1.5 Hz), 4.29 (q, 
2H, J = 7.1 Hz), 2.31-2.28 (m, 2H), 1.73-1.68 (m, 2H), 1.35 (t, 3H, J = 7.1 Hz), 0.98 (t, 3H, J = 7.4Hz). 
13
C NMR 
(CDCl3, 75 MHz): δ 171.35, 163.77, 130.63, 107.68, 61.65, 39.08, 18.36, 13.58, 13.45. HRMS (ESI) m/z calcd for 
C9H15NO3Na (M+Na)
+
: 208.0950, found: 208.0948.  
 
Ethyl-2-(pent-4-enoylamino)acrylate (24b) 
To a solution of 22b (515 mg, 5.2 mmol) in PhMe (50 mL), were added hydroquinone 
(57.2 mg, 10 mol%), p-TsOH (98.8 mg, 10 mol%) and ethyl pyruvate (1.14 mL, 2.0 equiv). 
The reaction mixture was stirred under Dean-Stark conditions applying vacuum for 
regulation. After 3 h the reaction was cooled to room temperature and poured over a plug of neutral Al2O3. The 
Al2O3 was washed two times with PhMe (50 mL). The organic layer was concentrated in vacuo. The residue was 
purified by column chromatography (EtOAc/heptane 1:1) to give 24b (594 mg, 3.02 mmol, 82%) as a colorless 
oil. Rf 0.75 (EtOAc/heptane 1:1). FTIR (ATR) 1187, 1314, 1512, 1683, 2980, 3355 cm
-1
. 
1
H NMR (CDCl3, 400 MHz): 
δ 7.82 (br. s, 1H), 6.60 (s, 1H), 5.88 (d, 1H, J = 1.5 Hz), 5.82-5.79 (m, 1H), 5.07-5.03 (m, 2H), 4.29 (q, 2H, J = 7.1 
Hz), 2.46-2.40 (m, 4H), 1.34 (t, 3H, J = 7.1 Hz). 
13
C NMR (CDCl3, 75 MHz): δ 170.54, 163.61, 136.07, 130.56, 
115.29, 107.62, 61.65, 36.24, 28.61, 13.56. HRMS (ESI) m/z calcd for C10H15NO4Na (M+Na)
+
: 220.0949, found: 
220.0952.  
 
Ethyl-2-(hex-5-enoylamino)acrylate (24c) 
To a solution of 22c (113 mg, 1.0 mmol) in dry PhMe (25 mL), were added 
hydroquinone (11.0 mg, 10 mol%), p-TsOH (19.0 mg, 10 mol %) and ethyl pyruvate 
(218 µL, 2.0 equiv). The reaction mixture was stirred under Dean-Stark conditions 
applying vacuum for regulation. After 3 h the reaction was cooled to room temperature and poured over a plug 
of neutral Al2O3. The Al2O3 was washed two times with PhMe (25 mL). The organic layer was concentrated in 
vacuo. The residue was purified by column chromatography (EtOAc/heptane 1:1) to give 24c (96 mg, 0.45 
mmol, 45%) as a colorless oil. Rf 0.78 (EtOAc/heptane 1:1). FTIR (ATR) 1187, 1515, 1683, 2976 cm
-1
. 
1
H NMR 
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(CDCl3, 400 MHz): δ 7.73 (br s, 1H), 6.60 (s, 1H), 5.87 (d, 1H, J = 1.5 Hz), 5.79 (m, 1H), 5.05-5.00 (m, 2H), 4.29 (q, 
2H, J = 7.1 Hz), 2.35-3.29 (m, 2H), 2.17-2.11 (m, 2H), 1.77 (dd, 2H, J = 7.6 Hz, J = 3.4 Hz), 1.35 (t, 3H, J = 7.1 Hz). 
13
C NMR (CDCl3, 75 MHz): δ 171.26, 170.94, 137.18, 130.53, 115.19, 107.36, 61.75, 36.44, 32.58, 23.96, 13.63. 
HRMS (ESI) m/z calcd for C11H17NO3Na (M+Na)
+
: 234.1090, found: 234.1109.  
 
Ethyl-1-(acetyl-4,5-dihydro-1H-pyrrole-2-carboxylate (25a) 
A solution of 6a (27 mg, 0.13 mmol) in dry PhMe (10 mL) was flushed with nitrogen for 15 min 
after which the temperature was raised to 80 °C. At 80 °C G2 (10 mol %, 11.0 mg) was added and 
the reaction was stirred for 3 h. After 3 h the organic layer was concentrated in vacuo. The residue 
was purified by column chromatography (EtOAc/heptane 2:1 to 1:0) to give 25a (21 mg, 0.12 
mmol, 89%) as a brown oil. Rf 0.20 (EtOAc/heptane 1:1). FTIR (ATR) 1406, 1660, 1726, 2958 cm
-1
. 
1
H NMR 
(CDCl3, 400 MHz): δ 5.97 (bt s, 1H), 4.31 (dq, 2H, J = 1.2 Hz, J = 7.1 Hz), 4.02 (t, 2H, J = 8.6 Hz), 2.70 (dt, 2H, J = 
2.3 Hz, J = 8.6 Hz), 2.08 (s, 3H), 1.33 (t, 3H, J = 1.2 Hz, J = 7.1 Hz). 
13
C NMR (CDCl3, 75 MHz): δ 171.20, 136.42, 
87.63, 61.01, 48.32, 28.32, 22.29, 13.58. HRMS (ESI) m/z calcd for C9H13NO3Na (M+Na)
+
: 206.0793, found: 
206.0800.  
 
Ethyl-2-[tert-butoxy(carbonylpent-4-enoyl)amino]acrylate (28) 
To a solution of 24b (200 mg, 1.02 mmol) in dry THF (10 mL), were added Boc2O (360 mg, 
1.6 equiv) and DMAP (120 mg, 1.0 equiv). The reaction mixture was stirred at room 
temperature. After 1 h the reaction was quenched with NH4Cl, extracted with CH2Cl2 (3 × 
25 mL), dried (MgSO4) and concentrated in vacuo. The residue was purified by column 
chromatography (EtOAc/heptane 1:3) to give 28 (244 mg, 0.082 mmol, 85%) as a colorless oil. Rf 0.47 
(EtOAc/heptane 1:3). FTIR (ATR) 1627, 1670, 1735 cm
-1
. 
1
H NMR (CDCl3, 400 MHz): δ 6.43 (s, 1H), 5.86-5.82 (m, 
1H), 5.60 (s, 1H), 5.06 (d, 1H, J = 17.2 Hz), 4.98 (d, 1H, J = 10.1 Hz), 4.21 (q, 2H, J = 7.0 Hz), 3.04 (t, 2H, J = 7.4 
Hz), 2.40 (dd, 2H, J = 6.8 Hz, J = 13.8 Hz), 1.44 (s, 9H), 1.28 (t, 3H, J = 7.1 Hz). 
13
C NMR (CDCl3, 75 MHz): δ 174.28, 
162.63, 151.07, 136.65, 125.13, 114.80, 83.14, 61.025, 36.50, 28.31, 27.34, 13.67. HRMS (ESI) m/z calcd for 
C15H23NO5Na (M+Na)
+
: 320.1474, found: 320.1468. 
  
Ethyl-2-[benzyl(pent-4-enoyl)amino]acrylate (30a) 
To a solution of 24b (50 mg, 0.26 mmol) in dry DMF (10 mL), were added at 0 °C NaH 
(15.9 mg, 1.25 equiv) and then benzyl bromide (37.0 µL, 1.2 equiv). The reaction mixture 
was stirred for 1 h and then quenched with H2O (10 mL) and extracted with a mixture of 
EtOAc/heptane (1:1) (3 × 25 mL). The organic layer was dried (MgSO4) and concentrated 
in vacuo. The residue was purified by column chromatography (EtOAc/heptane 1:2) to give 30a (42 mg, 0.145 
mmol, 57%) as a colorless oil. Rf 0.47 (EtOAc/heptane 1:1). FTIR (ATR) 1180, 1632, 1667, 1724, 2967 cm
-1
. 
1
H 
NMR (CDCl3, 400 MHz): δ 7.28-7.19 (m, 5H), 6.33 (s, 1H), 5.84-5.79 (m, 1H), 5.38 (s, 1H), 5.03 (dd, 1H, J = 0.8 Hz, 
J = 17.1 Hz), 4.97 (dd, 1H, J = 0.7 Hz, J = 10.2 Hz), 4.70 (s, 2H), 4.23 (q, 1H, J = 7.1 Hz), 2.41 (dd, 2H, J = 6.7 Hz, J = 
13.9 Hz), 2.30-2.26 (m, 2H), 1.28 (t, 3H, J = 7.1 Hz). 
13
C NMR (CDCl3, 75 MHz): δ 171.50, 163.27, 138.36, 136.82, 
136.70, 131.06, 130.20, 128.50, 127.93, 127.44, 114.70, 61.36, 50.45, 32.76, 28.78, 13.64. HRMS (ESI) m/z calcd 
for C17H21NO3Na (M+Na)
+
: 310.14191, found: 310.14237.  
 
Ethyl-2-[(4-methoxybenzyl)pent-4-enoylamino]acrylate (30b) 
To a solution of 24b (95 mg, 0.48 mmol) in dry DMF (5 mL), were added at 0 °C NaH (39 
mg, 2.0 equiv) and then PMBBr (171 µL, 2.0 equiv). The reaction mixture was stirred for 
1 h and then quenched with H2O (10 mL) and extracted with a mixture of 
EtOAc/heptane (1:1) (3 × 25 mL). The organic layer was dried (MgSO4) and concentrated 
in vacuo. The residue was purified by column chromatography (EtOAc/heptane 1:2) to give 30b (115 mg, 0.36 
mmol, 76%) as a colorless oil. Rf 0.62 (EtOAc/heptane 1:1). FTIR (ATR) 1175, 1246, 1511, 1663, 1723, 2936 cm
-1
. 
1
H NMR (CDCl3, 400 MHz): δ 7.09 (d, 2H, J = 8.0 Hz), 6.82 (d, 2H, J = 8.2 Hz), 6.32 (s, 1H), 5.66-5.60 (m. 1H), 5.19 
(s, 1H), 4.84-4.79 (m, 2H), 4.56 (s, 2H), 4.17 (q, 2H, J = 7.0 Hz), 3.77 (s, 3H), 2.14-1.90 (m, 4H), 1.71-1.68 (m, 2H), 
1.12 (t, 3H, J = 7.1 Hz). 
13
C NMR (CDCl3, 75 MHz): δ 171.38, 163.30, 158.52, 138.26, 136.85, 129.88, 128.91, 
O
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127.49, 114.65, 113.27, 70.97, 61.33, 54.74, 49.77, 32.79, 28.78, 13.64. HRMS (ESI) m/z calcd for C18H24NO4 
(M+H)
+
: 318.1705, found: 318.1689. 
 
Ethyl-2-[(4-bromobenzoyl)pent-4-enoylamino]acrylate (30c) 
To a solution of 24b (60 mg, 0.30 mmol) in dry DMF (3 mL), were added at 0 °C NaH (14 
mg, 1.1 equiv) and then PBBBr (84 mg, 1.1 equiv). The reaction mixture was stirred for 1 
h and then quenched with H2O, (10 mL) and extracted with a mixture of EtOAc/hep (1:1) 
(3 × 25 mL). The organic layer was dried (MgSO4) and concentrated in vacuo. The residue was purified by 
column chromatography (EtOAc/heptane 1:2) to give 30c (108 mg, 0.28 mmol, 89%) as a colorless oil. Rf 0.57 
(EtOAc/heptane 1:1). FTIR (ATR) 1180, 1633, 1667, 1725, 2932, 2967 cm
-1
. 
1
H NMR (CDCl3, 400 MHz): δ 7.40 (d, 
2H, J = 7.7 Hz), 7.13 (d, 2H, J = 7.9 Hz), 6.33 (s, 1H), 5.79-5.75 (m, 1H), 5.39 (s, 1H), 5.00 (d, 1H, J = 18.2 Hz), 4.95 
(d, 1H, J = 10.7 Hz), 4.62 (s, 2H), 4.21 (q, 2H, J = 7.0 Hz), 2.32-2.27 (m, 4H), 1.27 (t, 3H, J = 7.1 Hz). 
13
C NMR 
(CDCl3, 75 MHz): δ 171.58, 163.12, 138.34, 136.69, 135.76, 131.05, 130.20, 127.45, 121.02, 115.40, 114.77, 
107.86, 61.47, 49.94, 32.68, 28.72, 13.63. HRMS (ESI) m/z calcd for C17H20BrNO3Na (M+Na)
+
: 388.05243, found: 
388.05311.  
 
Ethyl-2-[(4-methoxybenzyl)pent-4-enoylamino]acrylate(30d) 
To a solution of 24c (187 mg, 0.88 mmol) in dry DMF (9 mL), were added at 0 C NaH 
(40 mg, 1.1 equiv) and then PMBBr (190 µL, 1.5 equiv). The reaction mixture was 
stirred for 1 h and then another portion of NaH (18 mg, 0.5 equiv) was added. After 
stirring for another hour, the reaction was quenched with H2O (10 mL) and extracted with a mixture of 
EtOAc/heptane (1:1) (3 × 25 mL). The organic layer was dried (MgSO4) and concentrated in vacuo. The residue 
was purified by column chromatography (EtOAc/heptane 1:2) to give 30d (248 mg, 0.73 mmol, 83%) as a 
colorless oil. Rf 0.48 (EtOAc/heptane 1:1). FTIR (ATR) 1175, 1246, 1511, 1663, 1723, 2936 cm
-1
. 
1
H NMR (CDCl3, 
400 MHz): δ 7.09 (d, 2H, J = 8.0 Hz), 6.91 (d, 2H, J = 8.2 Hz), 6.33 (s, 1H), 5.82-5.77 (m, 1H), 5.29 (s, 1H), 4.90-
4.96 (m, 2H), 4.56 (s, 2H), 4.12 (q, 2H, J = 7.0 Hz), 3.87 (s, 3H), 2.11-1.94 (m, 4H), 1.27 (t, 3H, J = 7.0 Hz). 
13
C 
NMR (CDCl3, 75 MHz): δ 171.94, 163.33, 158.50, 138.32, 137.55, 129.85, 129.75, 127.29, 114.55, 113.25, 61.28, 
54.72, 49.73, 32.72, 32.64, 23.88, 13.09. HRMS (ESI) m/z calcd for C19H25NO4Na (M+Na)
+
: 354.1681, found: 
354.1694. 
 
Ethyl-1-(4-methoxybenzyl)-6-oxo-1,4,5,6-tetrahydropyridine-2-carboxylate (31b) 
A solution of 30b (170 mg, 0.54 mmol) in dry PhMe (25 mL) was flushed with nitrogen for 15 
min after which the temperature was raised to 80 C. At 80 C G2 (5 mol %, 23 mg) was added 
and the reaction was stirred for 1 h. After 1 h the organic layer was concentrated in vacuo. The 
residue was purified by column chromatography (EtOAc/heptane 1:2) to give 31b (111 mg, 0.38 mmol, 71%) as 
a brown oil. Rf 0.34 (EtOAc/heptane 1:1). FTIR (ATR) 1249, 1513, 1677, 1720 cm
-1
. 
1
H NMR (CDCl3, 400 MHz): δ 
7.12 (d, 2H, J = 8.0 Hz), 6.85 (d, 2H, J = 8.0 Hz), 6.31 (t, 1H, ), 5.06 (s, 2H), 4.17 (q, 2H, J = 7.2 Hz), 3.82 (s, 3H), 
2.77-2.68 (m, 2H), 2.45-2.35 (m, 2H), 1.25 (t, 3H, J = 7.0 Hz). 
13
C NMR (CDCl3, 75 MHz): δ 170.04, 158.32, 133.98, 
129.91, 128.77, 120.76, 113.40, 60.83, 54.74, 44.07, 30.55, 19.32, 13.59. HRMS (ESI) m/z calcd for C16H19NO4Na 
(M+Na)
+
: 312.1212, found: 312.1204.  
 
Ethyl-2-(3-methyl pent-4-enoylamino)acrylate (35a) 
To a solution of 34a (900 mg, 7.96 mmol) in dry PhMe (80 mL), were added p-TsOH 
(143.1 mg, 10 mol%) and ethyl pyruvate (1.75 mL, 2.0 equiv). The reaction mixture was 
stirred under Dean-Stark conditions applying vacuum for regulation. After 3 h the 
reaction was cooled to room temperature and poured over a plug of neutral Al2O3. The 
Al2O3 was washed two times with PhMe (25 mL). The organic layer was concentrated in vacuo to give 35a (772 
mg, 3.66 mmol, 46%). FTIR (ATR) 1190, 1509, 1685, 2984, 3338 cm
-1
. 
1
H NMR (CDCl3, 400 MHz): δ 7.77 (br s, 
1H), 6.74 (s, 1H), 5.95 (s, 1H), 5.80-5.88 (m, 1H), 5.11-5.00 (m, 2H), 4.27 (q, 2H, J = 7.1 Hz), 2.33-2.25 (m, 2H), 
2.10-2.22 (m, 1H), 1.27 (t, 3H, J = 7.1 Hz), 1.14 (d, 3H, J = 6.8 Hz). 
13
C NMR (CDCl3, 75 MHz): δ 170.11, 163.68, 
141.83, 130.50, 112.98, 107.92, 61.71, 44.29, 34.15, 19.22, 13.62. HRMS (ESI) m/z calcd for C11H17NO3Na 
(M+Na)
+
: 234.1090, found: 234.1105.  
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Ethyl-2-(2-methyl pent-4-enoylamino) acrylate (35b) 
To a solution of 34b (1.0 g, 8.85 mmol) in dry PhMe (90 mL), were added p-TsOH (159.0 
mg, 10 mol%) and ethyl pyruvate (1.94 mL, 2.0 equiv). The reaction mixture was stirred 
under Dean-Stark conditions applying vacuum for regulation. After 3 h the reaction was 
cooled to room temperature and poured over a plug of neutral Al2O3. The Al2O3 was washed two times with 
PhMe (25 mL). The organic layer was concentrated in vacuo to give 35b (803 mg, 3.80 mmol, 43%). FTIR (ATR) 
1186, 1314, 1513, 1680, 2974, 3364 cm
-1
. 
1
H NMR (CDCl3, 400 MHz): δ 7.79 (br s, 1H), 6.77 (s, 1H), 5.91 (s, 1H), 
5.89-5.81 (m, 2H), 5.01 (m, 1H), 4.29 (q, 2H, J = 7.1 Hz), 2.74 (ttd, 1H, J = 1.1 Hz, J = 7.0 Hz, J = 14.0 Hz), 2.37 (dd, 
1H, J = 7.3 Hz, J = 14.5 Hz), 2.27 (dd, 1H, J = 7.2Hz, J = 14.5 Hz), 1.31 (q, 3H, 7.1 Hz), 1.09 (d, 3H, J = 6.8 Hz). 
13
C 
NMR (CDCl3, 75 MHz): δ 174.16, 163.76, 134.80, 130.50, 116.77, 107.92, 61.73, 41.77, 37.72, 16.73, 13.63. 
HRMS (ESI) m/z calcd for C11H17NO3Na (M+Na)
+
: 234.1106, found: 234.1106.  
 
Ethyl-2-[(4-methoxybenzyl)-(2-methyl pent-4-enoyl) amino] acrylate (36a) 
To a solution of 35a (200 mg, 0.95 mmol) in dry DMF (10 mL), were added at 0°C NaH (39 
mg, 1.0 equiv) and then PMBBr (150 µL, 1.1 equiv). The reaction mixture was stirred for 1 
h and then quenched with H2O (10 mL) and extracted with a mixture of EtOAc/heptane 
(1:1) (3 × 25 mL). The organic layer was dried (MgSO4) and concentrated in vacuo. The 
residue was purified by column chromatography (EtOAc/heptane 1:2) to give 35a (231 mg, 0.75 mmol, 68%) as 
a colorless oil. Rf 0.69 (EtOAc/heptane 1:1). FTIR (ATR) 1177, 1246, 1512, 1663, 1724, 2967 cm
-1
. 
1
H NMR (CDCl3, 
400 MHz): δ 7.13 (d, 2H, J = 8.5 Hz), 6.81 (d, 2H, J = 8.5 Hz), 6.33 (s, 1H), 5.71 (ddd, 1H, J = 7.1, Hz, J = 10.3 Hz, J 
= 17.3 Hz), 5.44 (s, 1H), 4.96 (d, 1H, J = 17.2 Hz), 4.89 (d, 1H, J = 10.4 Hz), 4.64-4.50 (m, 2H), 4.17 (q, 2H, J = 7.1 
Hz), 3.73 (s, 3H), 2.72-2.61 (m, 1H), 2.24 (dd, 1H, J = 7.0 Hz, J = 14.9 Hz), 2.14 (dd, 1H, J = 7.4 Hz, J = 15.0 Hz), 
1.23 (t, 3H, J = 7.1 Hz), 0.97 (d, 3H, J = 6.8Hz).
 13
C NMR (CDCl3, 75 MHz): δ 171.89, 163.08, 158.84, 142.12, 
138.10, 129.52, 128.29, 127.43, 112.94, 111.79, 61.35, 53.81, 49.47, 39.94, 34.10, 18.14, 12.55. HRMS (ESI) m/z 
calcd for C19H25NO4Na (M+Na)
+
: 354.1681, found: 354.1688. 
 
Ethyl-2-[(4-methoxybenzyl)-(2-methyl pent-4-enoyl)amino] acrylate (36b) 
To a solution of 35b (200 mg, 0.95 mmol) in dry DMF (10 mL), were added at 0 °C NaH 
(39 mg, 1.0 equiv) and then PMBBr (150 µL, 1.1 equiv). The reaction mixture was stirred 
for 1 h and then quenched with H2O (10 mL) and extracted with a mixture of 
EtOAc/heptane (1:1) (3 × 25 mL). The organic layer was dried (MgSO4) and concentrated 
in vacuo. The residue was purified by column chromatography (EtOAc/heptane 1:2) to give 36b (247 mg, 0.80 
mmol, 73%) as a colorless oil. Rf 0.73 (EtOAc/heptane 1:1). FTIR (ATR) 1176, 1246, 1512, 1662, 1723, 2967 cm
-1
. 
1
H NMR (CDCl3, 400 MHz): δ 7.13 (d, 2H, J = 8.1 Hz), 6.80 (d, 2H, J = 8.1 Hz), 6.38 (s, 1H), 5.63-5.52 (m, 1H), 5.41 
(s, 1H), 4.98-4.88 (m, 2H), 4.71-4.35 (br s, 2H), 4.22 (q, 2H, J = 7.2 Hz), 3.75 (s, 3H), 2.56-2.49 ( m, 1H), 2.33 (dq, 
2H, J = 7.2 Hz. J = 15.0 Hz), 1.2 (t, 1H, J = 7.1 Hz), 1.04 (d, 1H, J = 6.8 Hz). 
13
C NMR (CDCl3, 75 MHz): δ 171.89, 
163.08, 158.84, 142.30, 138.10, 129.52, 128.29, 127.43, 112.94, 111.79, 61.16, 53.81, 49.47, 39.94, 34.10, 
18.144, 12.55. HRMS (ESI) m/z calcd for C19H25NO4Na (M+Na)
+
: 354.1681, found: 354.1693. 
 
Ethyl-1-(4-methoxybenzyl)-4-methyl-6-oxo-1,4,5,6-tetrahydro pyridine-2-carboxylate (37a)  
A solution of 36a (50 mg, 0.14 mmol) in dry PhMe (2 mL) was flushed with nitrogen for 15 min 
after which the temperature was raised to 80 C. At 80 °C G2 (5 mol %, 6 mg) was added and 
the reaction was stirred for 16 h. After 1 h the organic layer was concentrated in vacuo. The 
residue was purified by column chromatography (EtOAc/heptane 1:2) to give 37a (35 mg, 0.11 
mmol, 91%) as a colorless oil. Rf 0.57 (EtOAc/heptane 1:1). FTIR (ATR) 1249, 1513, 1677, 1720 
cm
-1
. 
1
H NMR (CDCl3, 400 MHz): δ 7.11 (d, 2H, J = 8.3 Hz), 6.88 (d, 2H, J = 8.3 Hz), 6.17 (dd, 1H, J = 0.8 Hz, J = 4.1 
Hz), 5.31 (d, 1H, J = 14.9 Hz), 4.97 (d, 1H, J = 14.9 Hz), 4.17 (q, 2H, 7.2 Hz), 3.76 (s, 3H), 2.64-2.55 (m, 2H), 2.35-
2.20 (m, 1H), 1.27 (t, 3H, J = 7.2 Hz), 1.09 (d, 3H, J = 6.8 Hz). 
13
C NMR (CDCl3, 75 MHz): δ 169.81, 162.28, 158.34, 
132.63, 129.01, 126.57, 113.36, 60.88, 54.73, 44.00, 38.45, 25.99, 18.06, 13.62. HRMS (ESI) m/z calcd for 
C17H21NO4Na (M+Na)
+
: 326.1368, found: 326.1368.  
 
Ethyl-1-(4-methoxybenzyl)-5-methyl-6-oxo-1,4,5,6-tetrahydro pyridine-2-carboxylate (37b) 
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A solution of 36b (42 mg, 0.12 mmol) in dry PhMe (2 mL) was flushed with nitrogen for 15 
min after which the temperature was raised to 80 C. At 80 °C G2 (5 mol %, 6 mg) was added 
and the reaction was stirred for 16 h. After 1 h the organic layer was concentrated in vacuo. 
The residue was purified by column chromatography (EtOAc/heptane 1:2) to give 37b (27 
mg, 0.08 mmol, 71%) as a colorless oil. Rf 0.61 (EtOAc/heptane 1:1). FTIR (ATR) 1249, 1513, 1677, 1720 cm
-1
. 
1
H 
NMR (CDCl3, 400 MHz): δ 7.11 (d, 2H, J = 8.3 Hz), 6.88 (d, 2H, J = 8.3 Hz), 6.17 (dd, 1H, J = 0.8 Hz, J = 4.1 Hz), 5.31 
(d, 1H, J = 14.9 Hz), 4.97 (d, 1H, J = 14.9 Hz), 4.17 (q, 2H, 7.2 Hz), 3.76 (s, 3H), 2.62-2.51 (m, 2H), 2.34-2.20 (m, 
1H), 1.27 (t, 3H, J = 7.2 Hz), 1.09 (d, 3H, J = 6.8 Hz). 
13
C NMR (CDCl3, 75 MHz): δ 169.81, 162.28, 158.34, 132.63, 
129.01, 126.57, 113.36, 60.88, 54.73, 44.00, 38.45, 25.99, 18.06, 13.62. HRMS (ESI) m/z calcd for C17H21NO4Na 
(M+Na)
+
: 326.1368, found: 326.1368.  
 
Methyl-2-vinylbenzoate (43a)
21 
 
To a solution of 2-formyl-benzoic acid (4.0 g, 26.7 mmol) in acetone (40 mL) were added K2CO3 
(11.6 g, 3.0 equiv) and MeI (1.68 mL, 1.0 equiv). The reaction mixture was stirred at reflux 
erature. After 1 h the temperature was decreased to room temperature, filtered and the organic 
layer was concentrated in vacuo. The residue was then redissolved in CH2Cl2 and washed with 
H2O, dried (MgSO4) and concentrated in vacuo. The product was purified by column 
chromatography (EtOAc/heptane 1:2) to give 26 (2.56 g, 15.6 mmol, 58%) as a colorless oil. Rf 0.76 
(EtOAc/heptane 1:1). 
1
H NMR (CDCl3, 400 MHz): δ 10.58 (s, 1H), 7.93-7.46 (m, 4H), 3.97 (s, 3H). Data are similar 
as described in literature. 
 
Next, a solution of MePPh3Br (14.7 g, 2.15 equiv) in dry THF (20 mL) was added KO
t
Bu (3.9 g, 1.0 equiv) at 0 °C. 
After 30 min 41 (2.0 g, 12.2 mmol) in dry THF (30 mL) was added dropwise. The reaction mixture was stirred for 
another 2 h and then quenched with NH4Cl, extracted with CH2Cl2, dried (MgSO4) and concentrated in vacuo. 
The product was purified by column chromatography (EtOAc/heptane 1:2) to give 43a (744 mg, 4.54 mmol, 
37%) as a colorless oil. Rf 0.85 (EtOAc/heptane 1:1). 
1
H NMR (CDCl3, 400 MHz): δ 7.78-7.46 (m, 5H), 7.31 (dt, 1H, 
J = 1.4 Hz, J = 3.4 Hz), 5.65 (dd, 1H, J = 1.4 Hz, J = 17.4 Hz), 3.91 (s, 3H). 
13
C NMR (CDCl3, 75 MHz): δ 167.36, 
139.09, 135.38, 131.62, 129.82, 128.43, 126.72, 126.72, 115.98, 51.60. Data are similar as described in 
literature. 
 
2-Vinyl benzoic acid (44a)
19
 
To a solution of 43a (744 mg, 4.54 mmol) in a mixture of MeOH/H2O (1:1, 60 mL) was added KOH 
(1.29 g, 5.0 equiv) in H2O (10 mL). The reaction mixture was stirred at room temperature. After 5 
h the reaction was quenched by a dropwise addition of concentrated HCl until the solution 
changed color (blue to yellow). The organic layer was extracted with CH2Cl2, dried (MgSO4) and 
concentrated in vacuo. The product was purified by column chromatography (EtOAc/heptane 
1:1) to give 44a (594 mg, 4.01 mmol, 89%) as a colorless oil. Rf 0.52 (EtOAc/heptane 1:1). ). 
1
H NMR (CDCl3, 400 
MHz): δ  7.84 (dd, 1H, J = 1.2 Hz, J = 8.0 Hz), 7.79-7.47 (m, 3H),7.32 (dt, 1H, J = 1.3 Hz, J = 7.6 Hz), 5.65 (dd, 1H, J 
= 1.4 Hz, J = 17.5 Hz), 5.27 (dd, 1H, J = 1.4 Hz, J = 11.0 Hz). 
13
C NMR (CDCl3, 75 MHz): δ 173.01, 142.53, 139.21, 
135.04, 133.41, 132.92, 130.52, 129.56, 118.42. Data are similar as described in literature. 
  
2-Vinylbenzamide (45a) 
To a solution of 44a (594 mg, 4.01 mmol) in CH2Cl2 (40 mL) was added SOCl2 (438 µL, 1.0 equiv). 
The reaction mixture was stirred at reflux temperature. After 2 h the reaction was carefully 
concentrated. The residue was redissolved in THF and dropwise added to a 7 M NH3/MeOH 
solution. The reaction was stirred for 2 h and then concentrated in vacuo. The residue was 
redissolved in cold Et2O and the product is filtered to give 45a (347 mg, 2.36 mmol, 60%) as a 
white solid. Rf 0.43 (EtOAc/heptane 1:1). FTIR (ATR) 1397, 1621, 1661, 3168, 3336 cm
-1
. 
1
H NMR (MeOD, 400 
MHz): δ 7.65 (d, 1H, J = 7.8 Hz), 7.44-7.37 (m, 2H), 7.29 (dt, 1H, J = 1.2Hz, J = 7.5 Hz), 7.05 (dd, 1H, J = 11.0 Hz, J 
= 17.5 Hz), 5.79 (d, 1H, J = 1.1 Hz), 5.74 (d, 1H, J = 1.1 Hz). 
13
C NMR (MeOD, 75 MHz): δ 173.22, 134.94, 134.76, 
133.65, 129.33, 126.83, 126.55, 124.97, 114.64. HRMS (ESI) m/z calcd for C16H18NO4Na (M+Na)
+
: 170.05818, 
found: 170.05802.  
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Ethyl-2-[2-vinyl(benzoyl)amino]acrylate (46a) 
To a solution of 45a (374 mg, 2.36 mmol) in dry PhMe (25 mL), were added hydroquinone 
(26.0 mg, 10 mol %), p-TsOH (44.8 mg, 10 mol%) and ethyl pyruvate (388 µL, 1.5 equiv). 
The reaction mixture was stirred under Dean-Stark conditions applying vacuum for 
regulation. After 5 h the reaction was cooled to room temperature and poured over a 
plug of neutral Al2O3. The Al2O3 was washed two times with PhMe (25 mL). The organic layer was concentrated 
in vacuo to give 46a (436 mg, 1.77 mmol, 75%). FTIR (ATR) 1187, 1321, 1504, 1677, 2975 cm
-1
. 
1
H NMR (CDCl3, 
400 MHz): δ 8.15 (br s, 1H), 7.25-7.61 (m, 4H), 7.07 (dd, 1H, J = 11.0 Hz, J = 17.4 Hz), 6.77 (s, 1H), 5.98 (s, 1H), 
5.73 (d, 1H, J = 17.4 Hz), 5.38 (d, 1H, J = 11.0 Hz), 4.30 (q, 2H, 7.1 Hz), 1.34 (t, 3H, 7.1 Hz). 
13
C NMR (CDCl3, 75 
MHz): δ 167.25, 163,56, 135.98, 134.25, 133.83, 130.95, 130.37, 127.28, 127.08, 126.36, 117.04, 108.45, 61.83, 
13.65. HRMS (ESI) m/z calcd for C14H15NO3Na (M+Na)
+
: 268.0944, found: 268.0937. 
 
Ethyl-2-[(4-methoxybenzyl)(2-vinylbenzoyl)amino]acrylate (47a) 
To a solution of 46a (436 mg, 0.1.77 mmol) in dry DMF (20 mL), were added at 0 C NaH 
(145 mg, 1.2 equiv) and then PMBBr (409 µL, 1.6 equiv). The reaction mixture was stirred 
for 1 h and then quenched with H2O (10 mL) and extracted with a mixture of 
EtOAc/heptane (1:1) (3 × 25 mL). The organic layer was dried (MgSO4) and concentrated in 
vacuo. The residue was purified by column chromatography (EtOAc/heptane 1:2) to give 47a (497 mg, 1.36 
mmol, 77%) as a colorless oil. Rf 0.69 (EtOAc/heptane 1:1). FTIR (ATR) 1723, 1654, 1512, 1246, 1177 cm
-1
. 
1
H 
NMR (CDCl3, 400 MHz): δ 7.42-6.68 (m, 8H), 6.91 (s, 1H), 5.69 (d, 1H, J = 17.4 Hz), 5.37-5.21 (m, 1H), 5.34 (d, 1H, 
11.0 Hz), 5.12 (s, 1H), 4.95 (br s, 2H), 4.09 (q, 2H, J = 7.0 Hz), 3.89 (s, 3H), 1.14 (t, 3H, J = 7.0 Hz). 
13
C NMR 
(CDCl3, 75 MHz): δ 169.81, 163.18, 158.63, 138.06, 134.73, 134.66, 133.57, 133.42, 129.93, 128.83, 126.73, 
126.58, 125.60, 124.73, 115.76, 113.37, 61.09, 54.77, 49.74, 13.59 HRMS (ESI) m/z calcd for C16H18NO4Na 
(M+Na)
+
: 388.1525, found: 388.1522. 
 
Ethyl-2-(4-methoxybenzyl)-1-oxo-1,2-dihydroisoquinoline-3-carboxylate (48a) 
A solution of 47a (2.17 g, 6.0 mmol) in dry PhMe (60 mL) was flushed with nitrogen for 15 min 
after which the temperature was raised to 80 °C. At 80°C G2 (5 mol %, 254 mg) was added and 
the reaction was stirred for 1 h. After 1 h the organic layer was concentrated in vacuo. The 
residue was purified by column chromatography (EtOAc/heptane 1:2) to give 48a (1.65 g, 4.92 
mmol, 82%) as a brown oil. Rf 0.31 (EtOAc/heptane 1:1). FTIR (ATR) 1249, 1513, 1677, 1720 
cm
-1
. 
1
H NMR (CDCl3, 400 MHz): δ 8.48 (tdd, 1H, J = 0.6Hz, J = 1.3Hz, J = 8.0Hz), 7.72-7.55 (m, 3H), 7.21-7.04 (m, 
3H), 7.78 (d, 2H, J = 8.8 Hz), 5.61 (s, 1H), 4.21 (q, 2H, J = 7.1 Hz), 1.26 (q, 3H, J = 7.1 Hz). 
13
C NMR (CDCl3, 75 
MHz): δ 162.61, 162.15, 158.30, 134.06, 132.66, 132.20, 129.47, 128.54, 128.47 , 128.21, 126.62, 113.37, 
111.94, 61.57, 54.76, 45.93, 13.56. HRMS (ESI) m/z calcd for C20H19NO4Na (M+Na)
+
: 360.1212, found: 360.1194.  
 
Methyl-2-isopropenyl benzoate (43b) 
To a solution of MePPh3Br (12.85 g, 2.15 equiv) in dry THF (40 mL) was added KO
t
Bu (4.0 g, 1.0 
equiv) at 0 °C. After 30 min 42 (2.233 g, 12.0 mmol) in dry THF (30 mL) was added dropwise. The 
reaction mixture was stirred for another 2 h and then quenched with NH4Cl, extracted with  
CH2Cl2, dried (MgSO4) and concentrated in vacuo. The product was purified by column 
chromatography (EtOAc/heptane 1:2) to give 43b (900 mg, 5.11 mmol, 41%) as a colorless oil. Rf 0.78 
(EtOAc/heptane 1:2). FTIR (ATR) 1280, 1721 cm
-1
. 
1
H NMR (CDCl3, 400 MHz): δ 7.78 (ddd, 1H, J = 0.5 Hz, J = 1.4 
Hz, J = 7.8 Hz), 7.44 (dt, 1H, J = 1.4 Hz, J = 7.5 Hz), 7.31 (dt, 1H, J = 1.4 Hz, J = 7.5 Hz), 7.24 (ddd, 1H, J = 0.5Hz, J = 
1.3Hz, J = 7.6Hz), 5.13-5.05 (m, 1H), 4.84-4.72 (m, 1H), 3.81 (s, 3H), 2.07 (s, 3H). 
13
C NMR (CDCl3, 75 MHz): δ 
167,96, 145,98, 144,69, 131,03, 129,20, 128,77, 126,41, 113,21, 51,54, 23,67. HRMS (ESI) m/z calcd for 
C11H13NO2Na (M+Na)
+
: 177.0916, found: 177.0903. 
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2-Isopropenylbenzoic acid (44b) 
To a solution of 43b (600 mg, 3.40 mmol) in a mixture of MeOH/H2O (1:1, 60 mL) was added KOH 
(1.29 g, 5.0 equiv) in H2O (10 mL). The reaction mixture was stirred at room temperature. After  
5 h the reaction was quenched by a dropwise addition of concentrated HCl until the solution 
changed color (blue to yellow). The organic layer was extracted with CH2Cl2, dried (MgSO4) and 
concentrated in vacuo. The product was purified by column chromatography (EtOAc/heptane 
1:2) to give 44b (505 mg, 3.12 mmol, 92%) as a colorless oil. Rf 0.24 (EtOAc/heptane 1:2). 
1
H NMR (CDCl3, 400 
MHz): δ 7.78-7.64 (m, 4H), 5.68 (d, 1H, J = 8.1 Hz), 5.21 (d, 1H, J = 8.1 Hz), 3.27 (s, 3H). 
13
C NMR (CDCl3, 75 
MHz): δ 172.16, 146.12, 145.68, 132.00, 130.20, 129.21, 126.53, 113.47, 23.80. HRMS (ESI) m/z calcd for 
C20H18NO4Na (M+Na)
+
: 345.1103, found: 345.1129. 
 
2-Isopropenylbenzamide (45b) 
To a solution of 44b (500 mg, 3.10 mmol) in CH2Cl2 (30 mL) was added SOCl2 (338 µL, 1.0 equiv). 
The reaction mixture was stirred at reflux temperature. After 2 h the reaction was carefully 
concentrated. The residue was redissolved in THF and dropwise added to a 7 M NH3/MeOH 
solution. The reaction was stirred for 2 h and then concentrated in vacuo. The residue was 
recrystallized from EtOAc/heptane 1:5 to give 45b (150 mg, 0.93 mmol, 30%) as a white solid. Rf 
0.31 (EtOAc/heptane 1:1). FTIR (ATR) 1397, 1643, 2359, 2187, 3377 cm
-1
. 
1
H NMR (MeOD, 400 MHz): δ 7.74 
(ddd, 1H, J = 0.4 Hz, J = 1.5, Hz, J = 7.6 Hz), 7.42 (dt, 1H, J = 1.5 Hz, J = 7.5 Hz). 7.34 (dt, 1H, J = 1.4 Hz, J = 7.6 Hz), 
7.22 (ddd , 1H, J = 0.4 Hz, J = 1.4Hz, J = 7.6 Hz), 6.33 (br s, 1H), 6.14 (br s, 1H), 5.25 (m, 1H), 5.11 (m, 1H), 2.13 
(dd, 1H, J = 0.9 Hz, J = 1.5Hz). 
13
C NMR (MeOD, 75 MHz): δ 170.54, 146.36, 141.75, 132.30, 130.35, 128.51, 
128.37, 127.23, 115.51, 23.93. HRMS (ESI) m/z calcd for C10H11NONa (M+Na)
+
: 184.0738, found: 184.0728.  
 
Ethyl-2-(2-isopropenylbenzoylamino)acrylate(46b) 
To a solution of 45b (100 mg, 0.62 mmole) in dry PhMe (15 mL), were added 
hydroquinone (9.0 mg, 10 mol %), p-TsOH (12.0 mg, 10 mol %) and ethyl pyruvate (340 µL, 
5 equiv). The reaction mixture was stirred under Dean-Stark conditions applying vacuum 
for regulation. After 5 h the reaction was cooled to room temperature and poured over a 
plug of neutral Al2O3. The Al2O3 was washed two times with PhMe (25 mL). The organic layer was concentrated 
in vacuo to give 46b (57 mg, 1.77 mmol, 34%). FTIR (ATR) 1187, 1321, 1504, 1677, 2975 cm
-1
. 
1
H NMR (CDCl3, 
400 MHz): δ 8.15 (br s, 1H), 7.61-7.25 (m, 4H), 7.07 (dd, 1H, J = 11.0 Hz, J = 17.4 Hz), 6.77 (s, 1H), 5.98 (s, 1H), 
5.73 (d, 1H, J = 17.4 Hz), 5.38 (d, 3H, J = 11.0 Hz), 4.30 (q, 2H, 7.1 Hz), 1.34 (t, 3H, 7.1 Hz). 
13
C NMR (CDCl3, 75 
MHz): δ 167.2, 163,5, 144.80, 141.55, 133.29, 131.07, 130.36, 128.08, 128.31, 127.61, 116.34, 108.22, 61.69, 
23.69, 13.56. HRMS (ESI) m/z calcd for C14H15NO3Na (M+Na)
+
: 268.0944, found: 268.0937.
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3 
 
Diastereoselective synthesis of substituted morpholines 
 
 
Abstract 
 
In this project we developed a diastereoselective synthesis of cis-2,5-disubstituted 
morpholines via intramolecular conjugate addition of β-hydroxylated didehydroamino 
esters. Two transformations were of critical importance, namely 1) condensation of a 
(substituted) hydroxy amide with a pyruvate to prepare the β-hydroxy didehydroamino 
ester, and 2) cyclization to the corresponding morpholine. After this sequence had been 
successfully developed, substituents were introduced onto the morpholine to determine the 
scope and limitations of this approach.  
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3.1 Introduction 
 
3.1.1 Morpholines and their biological relevance 
 
For many years, non-substituted morpholines have been used in organic synthesis as a 
simple base or as an amine substituent. Hence, the synthesis of substituted morpholine 
derivatives is relatively unexplored. Nevertheless, C-substituted morpholines show relevant 
biological activity as antidepressant (1),1 antioxidant (2)2, appetite suppressant (3-4),3,4 and 
are also known to exhibit antitumor activity (5)5 (Scheme 3.1).  
 
 
 
Scheme 3.1. Biologically relevant C-substituted morpholines. 
 
C-Substituted morpholines have been mainly prepared from enantiomerically pure amino 
acids and the corresponding amino alcohols. The first enantiomerically pure building blocks 
were reported in 1956 with the synthesis of phendimetrazine (8) derived from a reaction of 
L-ephedrine (6) with chloroethanol (7) (Scheme 3.2).6 Since then, syntheses of various  
C-substituted morpholines have appeared in literature.7 
 
 
Scheme 3.2. Synthesis of phendimetrazine. 
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In conjunction with previous morpholine syntheses in our group,8 in this project we aimed to 
prepare 2,5-disubstituted morpholines. These types of morpholines are known to show 
biological activity, e.g. as anti-inflammatory agent (9), GABAB-receptor antagonist (10), and 
as antitumor agent (11) (Scheme 3.3).7 Generally applicable methods for their synthesis, 
however, are rare and often lead to diastereomeric mixtures.  
 
 
Scheme 3.3. Biologically active trans-2,5-disubstituted morpholines. 
 
The first diastereoselective synthesis of enantiopure trans-2,5-disubstituted morpholines 
was reported in 2004 by Myers et al.9 The synthesis involved nucleophilic ring opening of an 
enantiopure epoxide (e.g. 12) with an amino alcohol (13). Selective tosylation at nitrogen 
and the primary alcohol of diol 14 and subsequent cyclization afforded the N-tosyl-protected 
morpholine 15 as a single diastereoisomer (Scheme 3.4). Although high selectivity was 
reached in the cyclization, this route lacks some generality because enantiopure epoxides 
are not commonly commercially available and therefore first need to be prepared. 
 
 
Scheme 3.4. Diastereoselective synthesis of morpholine 15. 
 
Selected examples of cis-disubstituted morpholines include the cis-2,3-disubstituted 
morpholine Aprepitant (16),10 a neurokinin-1 receptor antagonist, widely used against 
Alzheimer’s disease, and the cis-3,5-disubstituted morpholine 17, which is a γ-secretase 
inhibitor (Scheme 3.5).11 
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Scheme 3.5. Biologically relevant cis-disubstituted morpholines. 
 
Another example of a stereoselective synthesis of cis-disubstituted morpholines was 
published by Breuning et al. in 2007 (Scheme 3.6).12 The benzyl-protected amine 18 was 
reacted with enantiopure epichlorohydrin (19) to obtain the cis-2,5-disubstituted 
morpholines 20. 
 
 
 
Scheme 3.6. Enantiopure synthesis of cis-2,5-disubstituted morpholine 20. 
 
In 2011, Medina et al. reported a synthesis of cis-2,5-disubstituted morpholines 21 as 
potential 3-phosphoinositide-dependent kinase-1 (PDK1) inhibitors (Scheme 3.7).13 
 
 
 
Scheme 3.7. Cis-2,5-disubstituted morpholines 21. 
 
A more versatile synthesis of enantiomerically pure cis- and trans-2,5-disubstituted 
morpholines was recently developed in our group starting from enantiopure cyanohydrins 
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(22) and amino esters (23) (Scheme 3.8), resulting in complete control over both 
stereocenters in the resulting morpholines.8  
  
 
 
Scheme 3.8. Synthesis of enantio- and diastereomerically pure morpholines 24. 
 
3.1.2 Retrosynthesis 
 
We envisaged that the synthesis of 2,5-disubstituted morpholine derivatives might proceed 
via intramolecular conjugate addition of β-hydroxy-substituted didehydroamino acids and 
hence should lead to morpholines with new substitution patterns. Retrosynthetically, 
morpholines of type 25 might therefore be prepared through deprotection-induced 
cyclization of didehydroamino esters 27, followed by reduction (Scheme 3.9). The 
didehydroamino esters 27 can be prepared by condensing hydroxyl amide 28 with methyl 
pyruvate. 
 
 
Scheme 3.9. Retrosynthesis of 2,5-disubstituted morpholines. 
 
3.2 Synthesis of cyclic amino acids 
 
3.2.1 N-Alkylation of didehydroamino acids 
 
The first attempts to synthesize the required β-hydroxy-substituted didehydroamino acids 
were based on N-alkylation of didehydroamino acid 30 which was readily obtained from a 
condensation reaction of benzyl urethane (29) with ethyl pyruvate. Unfortunately, no 
conversion was observed and only starting material was recovered. A raise in temperature 
did not lead to any product formation either. Adding potassium iodide (KI) or 
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tetrabutylammonium iodide (TBAI) to the reaction mixture, thereby in situ converting the 
bromide into the corresponding iodide, did result in some formation of 33. Encouraged by 
these results, 31 was fully converted into its iodinated derivative 32 prior to alkylation.14 
Alkylation however, was unproductive due to degradation of the iodide.15   
 
 
Scheme 3.10. Alkylation of didehydroamino ester 30. 
 
Since N-alkylation appeared to be troublesome, the potential of an alternative N-alkylation 
procedure with chiral epoxides was investigated, similarly as published by Breuning.12 
Reaction of 30 and 34 could result in the formation of the intermediate 35, which may then 
undergo intramolecular conjugate addition to the morpholine derivative 36 in a one-pot. To 
test this hypothesis, N-alkylation of commercially available (S)-phenyloxirane (34) was 
investigated. Much to our disappointment, the didehydroamino acid appeared to be 
unreactive towards N-alkylation and only degradation of the didehydroamino acid was 
observed upon prolonged reaction times (Scheme 3.11).  
 
 
Scheme 3.11. Synthesis of enantiopure morpholine precursor 36. 
 
3.2.2 Condensation of hydroxyl amides with ethyl pyruvate 
 
Since N-alkylation could not be properly achieved, we focused on the preparation of  
β-hydroxy-substituted didehydroamino esters by condensation of protected β-hydroxy 
amides with ethyl pyruvate. The hydroxy amides were prepared from commercially available 
amides and esters. Since the stability of the protecting group must comply with the acidic 
conditions of the condensation reaction, we used several protecting groups with different 
acid reactivity. At first, the benzoyl-protected amide 38 was prepared in a nearly 
quantitative yield by substitution of 2-bromoacetamide (37) with benzoic acid in the 
presence of N,N-diisopropylethylamine (DIPEA) (entry 1, Scheme 3.12).16 
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Scheme 3.12. Synthesis of hydroxyl protected β-hydroxyl amides. 
 
In addition, the TBDPS- and PMB-protected derivatives 41 and 43 were prepared from ethyl 
glycolate (39). Mixing ethyl glycolate with TBDPSCl in the presence of imidazole resulted in 
ester 40 in 95%,17 which was readily converted into the corresponding amide (41) by 
treatment with ammonia in methanol18 and isolated in a moderate yield of 59%, (Scheme 
3.12). When ethyl glycolate was reacted in THF with p-methoxybenzyl bromide in the 
presence of sodium hydride,19 PMB-protected 42 was obtained, albeit in a moderate yield of 
42%. In an additional step, the ester was converted into amide 43, similar as for amide 41.  
 
With the hydroxy-substituted amides successfully prepared, the next step in the synthesis 
involved condensation with ethyl pyruvate under DeanStark conditions, as depicted in 
Scheme 3.13.20 The protected hydroxy amides 38, 41 and 43 were reacted in refluxing 
toluene with ethyl pyruvate in the presence of a catalytic amount of p-toluenesulfonic acid. 
Condensation of 38 led to the desired β-hydrox0 ydidehydroamino acid 44a in varying yields. 
This was in sharp contrast to the ether-protected alcohols, which despite a clear full 
conversion in the condensation of amide 43, only gave trace amounts of products (11%). 
Probably, both the silyl- and the PMB ether are too acid labile under the acidic condensation 
conditions.  
 
 
 
Scheme 3.13. Condensation to form the didehydroamino esters 44 under Dean Stark conditions. 
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3.2.3 Intramolecular conjugate addition of β-hydroxy didehydroamino esters 
 
With β-hydroxy didehydroamino ester 44a successfully prepared, cyclization was attempted 
by hydrolysis of the benzoyl ester in methanol in the presence of potassium carbonate. 
Although the hydrolysis was complete within minutes, the resulting alkoxide did not cyclize 
in a conjugate fashion to morpholine 46 (Scheme 3.14). The amide function of 44a21 was 
then alkylated since we anticipated that forcing the didehydroamino ester into the s-cis 
conformation might facilitate the cyclization process. 
 
 
Scheme 3.14. Synthesis of PMB-protected β-hydroxy didehydroamino acid 45. 
 
Several attempts were undertaken to induce the intramolecular oxa-Michael reaction by 
deprotection of the alcohol (Scheme 3.15). This was initially performed by dissolving  
β-hydroxy didehydroamino ester 45 in methanol and treatment with potassium carbonate. A 
rapid transesterification was observed, but more importantly the simultaneously liberated 
alkoxide underwent smooth cyclization in an excellent yield of 99% to the morpholine 
carboxylate 46.  
 
 
Scheme 3.15. Synthesis and reaction sequence of the cyclization reaction. 
 
3.3 Synthesis of (2S,5S)-(5-phenylmorpholin-2-yl)methanol 
 
With the synthesis route successfully developed for non-substituted morpholines, a 
substituent was introduced on the hydroxy amide to increase the biological relevance of the 
resulting products. This concept was initially validated on enantiopure mandelic acid (47).  
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Scheme 3.16. Synthesis of protected hydroxyl amides, starting from enantiopure mandelic acid. 
 
Enantiopure mandelic acid was esterified in a mixture of hydrochloric acid in methanol at 
70 °C (Scheme 3.16),22 and stirred in methanolic ammonia18 to afford the desired hydroxy 
amide 48. Protection with either acetic anhydride23 or benzoyl chloride24 afforded the 
desired protected hydroxyl amides 49a and 49b in moderate to good yield. According to 
chiral HPLC-measurements, no racemization occurred (Figure 3.1). 
                
Figure 3.1. Left: HPLC chromatogram of (S)-benzoyl-protected hydroxy amide 49. Right: HPLC 
chromatogram of racemic benzoyl-protected hydroxy amide 49 
 
The condensation reaction of hydroxy amides 49a and 49b with methyl pyruvate esters and 
subsequent PMB-protection led to the corresponding β-hydroxy didehydroamino esters 51a 
and 51b in good yields (Scheme 3.17).  
 
 
 
Scheme 3.17. Synthesis of PMB-protected β-hydroxy didehydroamino acids. 
Figure 3.2 shows HPLC chromatograms of the (S)-enantiomer (51a) and racemic 
didehydroamino acid 51a. According to these measurements, no racemization occurred 
during the PMB-protection.  
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Figure 3.2. Left: HPLC chromatogram of (S)-PMB-protected β-hydroxy didehydroamino ester 51a. 
Right: HPLC chromatogram of racemic PMB-protected β-hydroxy didehydroamino ester 51a. 
 
In sharp contrast to the cyclization of the non-substituted didehydroamino ester 45, the 
intramolecular oxa-Michael of phenyl-substituted substrate 51a was rather troublesome, 
resulting in only trace amounts of product. In these attempts, the carboxylic acid was 
formed as a byproduct, which may prevent the cyclization from occurring. Extensive 
research on conjugate cyclization of the benzoyl-protected precursor 51b, on the other 
hand, did result in product formation. Upon addition of 0.5 equivalent of K2CO3 and stirring 
at 50 °C for 4.5 h, an isolated yield of 33% of the cyclic compound (S)-52 was obtained as a 
single diastereoisomer (Table 3.1). The enantiomer (R)-52 was formed from (R)-51b in a 
similar yield of 37%, also as a single product. 
 
Table 3.1. Synthesis of the morpholine rings via oxa-Michael addition, both the cis- and trans-
configuration. 
 
 
 
Entry PG Solvent Base Temperature Time Yield 
1 Ac MeOH (wet) 1.0 eq K2CO3 rt to 50 °C 10 min - 
2 Ac  MeOH (CaH2) 1.0 eq K2CO3 rt to 50 °C 16 h - 
3 
4 
Ac 
Ac 
MeOH (dry) 
MeOH (dry) 
2.5 eq K2CO3 
1.0 eq K2CO3 
rt to 50 °C 
rt to 50 °C 
16 h 
40 min 
- 
- 
5 Ac MeOH (dry) 0.2 eq K2CO3 rt to 50 °C 4 h - 
6 Ac THF 0.95 eq NaOMe rt 16 h - 
7 Bz MeOH (dry) 1.0 eq K2CO3 rt to 50 °C 2 h 17% 
8 Bz MeOH (dry) 0.5 eq K2CO3 rt to 50 °C 50 min 24% 
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9 Bz MeOH (dry) 1.0 eq K2CO3 50 °C 2 h 26% 
10 Bz MeOH (dist.) 0.5 eq K2CO3 50 °C 4.5 h 33% 
 
The relative configuration of the cyclic amino acids 52 was determined by NMR studies after 
subsequent ester and lactam reduction (Scheme 3.18). The morpholine derivative 52 was 
therefore subjected to lithiumaluminum hydride in THF25 to afford the desired 2,5-
disubstituted morpholine 53. 13C NMR data revealed a diastereoselectivity of >99%, but the 
configuration of the second stereocenter could not be determined. Additional COSY, NOESY 
and HSQC-spectroscopic experiments did not result in conclusive evidence either. 
 
 
Scheme 3.18. Synthesis of 2,5-disubstituted morpholine 53. 
 
The crystal structure on the other hand showed that the substituents on the morpholine ring 
were cis-configured, as depicted in Figure 3.3. The ring has adopted a chairlike conformation 
with the phenyl substituent in the equatorial orientation, while the methanol substituent is 
axially oriented.  
                  
Figure 3.3. Crystal structure of 2,5-disubstituted morpholine 53. 
 
3.4 Diversity of substitution pattern 
 
With the successful incorporation of a phenyl substituent, the stage was set to introduce a 
larger variety of substituents. Hydroxy amides 56 were synthesized from the enantiopure 
amino acids 54 in four consecutive steps. An initial three-step procedure, involving 1) 
diazotation of amino acids 54, 2) conversion into methyl esters, and 3) treatment with 
ammonia in methanol afforded the hydroxy amides. Finally, the alcohol was protected with 
a benzoyl group to yield the desired protected hydroxy amides 56 (Scheme 3.19). 
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Subsequently, condensation with methyl pyruvate, followed by PMB-protection afforded the 
didehydroamino acids 58 in low to reasonable yields. 
 
 
 
Scheme 3.19. Synthesis of benzoyl-protected didehydroamino esters 60. 
 
Next, deprotection of the alcohol allowed cyclization to afford the morpholine derivatives 61 
(Scheme 3.20). Although the cyclization appeared to proceed well for all four derivatives, 
only low yields of 61 were obtained because two side reactions were observed, namely 1) 
the hydrolysis of the cyclic product 61 leading to acid 62 and 2) ester hydrolysis of 60, which 
prevents cyclization resulting in byproduct 63. The use of dry methanol did not lead to a 
substantial increase in product formation either. When the reaction was performed in a non-
protic organic solvent, hydrolysis of the methyl ester was prevented, but also the benzoyl 
ester remained unreactive.   
 
 
 
 
 
Scheme 3.20. Synthesis of morpholine 61, carboxylic acid 62 and hydrolysed starting compound 63. 
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3.5 Conclusion 
 
A small set of 2,5-disubstituted morpholines were synthesized via intramolecular conjugate 
addition of enantiopure β-hydroxy didehydroamino esters. Condensation of hydroxyl amides 
with pyruvate to the β-hydroxy didehydroamino esters and subsequent hydrolysis of the 
protected hydroxyl group allowed intramolecular conjugate addition to the morpholine in 
only three consecutive steps. While a high yield of the non-substituted morpholine was 
obtained, the yields drastically decreased when substituents were introduced. This might be 
due to basic hydrolysis of both starting material and product during the reaction.  
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3.7 Experimental section 
 
General procedure A 
To a 0.1 M solution of the amide in toluene were added methyl pyruvate (2.0 equiv) and p-TsOH (0.1-1 equiv). 
The reaction was refluxed for 5 h under Dean Stark conditions, during which the reaction mixture was 
concentrated stepwise to a 0.2 M solution. The mixture was cooled to room temperature and filtrated over 
Al2O3. The residue was washed with toluene and EtOAc. The solvent was removed under reduced pressure and 
the residue was purified by silica gel column chromatography as indicated.  
 
General procedure B 
To a 0.1 M solution of the didehydroamino ester in DMF were added PMBBr (1.2 equiv) and NaH (1.25 equiv). 
The reaction was stirred for 30 min at room temperature, diluted with EtOAc/heptane (1:1) and quenched with 
H2O. The mixture was extracted with EtOAc/heptane (1:1) and the combined organic layers were washed with 
H2O (2  100 mL) and dried over Na2SO4. The solvent was removed under reduced pressure and the residue 
was purified by silica gel column chromatography as indicated. 
 
General procedure C 
To a 0.1 M solution of the didehydroamino ester in DMF were added BnBr (1.2 equiv) and NaH (1.25 equiv). 
The reaction was stirred for 30 min at room temperature, diluted with EtOAc/heptane (1:1) and quenched with 
H2O. The mixture was extracted with EtOAc/heptane (1:1) and the combined organic layers were washed with 
H2O (2  100 mL) and dried over Na2SO4. The solvent was removed under reduced pressure and the residue 
was purified by silica gel column chromatography as indicated. 
 
General procedure D  
To a 0.4 M solution of the methyl ester in MeOH was added liquid NH3 (50% v/v). The reaction was stirred for 
16 h at room temperature, after which the solvent was removed under reduced pressure. The resulting white 
solid was recrystallized from Et2O.  
 
General procedure E 
To a 0.1 M solution of the amide in pyridine was added BzCl (1.2 equiv). The reaction was stirred for 16 h at 
room temperature, concentrated and extracted with CH2Cl2. The organic layer was washed with saturated 
aqueous NH4Cl (2  100 mL), H2O (2 × 100 mL) and dried over Na2SO4. The solvent was removed under reduced 
pressure and the crude product co-evaporated with toluene. The product was then dissolved in Et2O and the 
residue was filtered. The Et2O was removed under reduced pressure and the residue was now dissolved in hot 
EtOAc. The residue was again filtered and the solvent was removed under reduced pressure. Finally, the 
product was recrystallized from Et2O.  
 
General procedure F 
To a 0.1 M solution of the protected didehydroamino acid in dry MeOH was added K2CO3 (10 mol%). The 
reaction was stirred for 10 min at room temperature. More K2CO3 (40 mol%) was added and the mixture was 
stirred for 40 min at 50 °C. The reaction was cooled to room temperature and stirred with Amberlite IR-120+ 
for 20 min. After vacuum filtration, the solvent was removed under reduced pressure and the residue was 
purified by silica gel column chromatography as indicated. 
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General procedure G 
A solution of the amino acid in 2 M aqueous H2SO4 was cooled to 0 °C. A 0.5 M solution of NaNO2 (2 equiv) in 
H2O was added dropwise at 0 °C for 2 h and the reaction was stirred for 16 h at 0 °C. The mixture was stirred 
for 2 h at room temperature and brought to pH 4 with 50% aqueous NaOH. EtOAc (3  100 mL) was added and 
the mixture was stirred vigorously. The reaction was brought to pH 2 with 2 M aqueous H2SO4, extracted with 
EtOAc (3  100 mL) and the combined organic layers were dried over Na2SO4. The solvent was removed under 
reduced pressure. 
 
General procedure H 
A solution of the alcohol in a 1.2 M solution of hydrochloric acid in methanol was refluxed for 1 h. The reaction 
was cooled to room temperature and quenched with saturated aqueous NaHCO3. The mixture was extracted 
with Et2O, the organic layers were washed with H2O (2  100 mL) and dried over Na2SO4. The solvent was 
removed under reduced pressure. 
 
2-Benzoyloxyacetamide (38) 
To a solution of 2-bromoacetamide (37, 2.00 g, 14.5 mmol) in DMF (50 mL) were added 
benzoic acid (3.50 g, 29.0 mmol) and DIPEA (6.29 mL, 36.3 mmol). The solution was stirred for 
16 h at room temperature. The reaction was diluted with EtOAc/H2O (1:1) (100 mL) and 
quenched with saturated aqueous NaHCO3 (100 mL). The mixture was extracted with EtOAc/H2O (1:1) (2  100 
mL). The organic layer was washed with H2O (2  100 mL), with saturated aqueous NaCl (2 × 100 mL) and dried 
over Na2SO4. The solvent was removed under reduced pressure and the residue was purified by silica gel 
column chromatography (EtOAc) to provide 2.56 g of acetamide 38 (99%). FTIR (ATR): 711, 1420, 1494, 1612, 
1677, 1714, 3188, 3415 cm
-1
. 
1
H NMR (300 MHz, CDCl3): δ 8.08-7.94 (m, 2H), 7.62-7.55 (m, 1H), 7.48-7.31 (m, 
2H), 5.94-6.16 (d, 2H, J = 6.1 Hz), 4.83 (s, 2H). 
13
C NMR (75 MHz, CDCl3): δ 169.23, 164.74, 133.37, 129.35, 
128.23, 62.62. HRMS (ESI) m/z calcd for C9H9NO3Na [M+Na]
+
: 202.04801, found: 202.04713. 
 
2-(tert-Butyldiphenylsilyl)acetamide (41) 
To a solution of ethyl glycolate (2.00 g, 19.2 mmol) in CH2Cl2 (100 mL) were added 
imidazole (1.57 g, 23.1 mmol), TBSCl (6.8 mL, 28.8 mmol) and DMAP (235 mg, 1.92 
mmol). The solution was stirred for 4 h at room temperature, diluted with 
EtOAc/heptane (1:1) (100 mL) and quenched with H2O (100 mL). The mixture was extracted with 
EtOAc/heptane (1:1) (2  100 mL), and the organic layers were washed with H2O (2 × 100 mL) and dried over 
Na2SO4. The solvent was removed under reduced pressure and the residue was purified by silica gel column 
chromatography (EtOAc/heptane 1:1) to provide 3.50 g of acetamide 41 (53%). FTIR (ATR): 606, 839, 1111, 
1689, 2923. cm
-1
. 
1
H NMR (300 MHz, CDCl3): δ 6.55 (br. s, 1H), 6.45 (br. s, 1H), 4.06 (s, 2H), 1.88 (s, 9H), 0.27 (s, 
6H). 
13
C NMR (75 MHz, CDCl3): δ 174.27, 62.55, 25.43, 18.64, -7.81. HRMS (ESI) m/z calcd for C9H9NO3Na 
[M+Na]
+
: 212.10827, found: 212.10752.  
 
2-(4-Methoxybenzyloxy)acetamide (43) 
To a solution of ethyl glycolate (1.00 g, 4.46 mmol) in MeOH (60 mL) was added liquid NH3 
(10 mL) and the reaction was stirred for 16 h at room temperature. The solvent was 
removed under reduced pressure. The resulting white solid was redissolved in Et2O, the 
residue was filtered and the solution was removed under reduced pressure to obtain 43 in 508 mg (58%). FTIR 
(ATR): 814, 1029, 1097, 1247, 1631, 2937, 3192, 3390 cm
-1
. 
1
H NMR (300 MHz, CDCl3): δ 7.26 (d, 2H, J = 8.7 Hz), 
6.90 (d, 2H, J = 8.7 Hz), 5.45 (s, 1H), 6.51 (s, 1H), 3.96 (s, 2H), 4.51 (s, 1H), 3.81 (s, 3H). 
13
C NMR (75 MHz, CDCl3): 
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δ 172.04, 159.25, 129.23, 128.49, 113.55, 72.84, 68.65, 54.88. HRMS (ESI) m/z calcd for C10H13NO3Na [M+Na]
+
: 
218.07931, found: 218.07881. 
 
Ethyl-2-[2-(benzoyloxy)acetylamino]acrylate (44a) 
Acetamide 38 (1.20 g, 6.7 mmol) was reacted according to the general procedure A. 
Instead of methyl pyruvate, ethyl pyruvate was used. Silica gel column chromatography 
(EtOAc/heptane 1:1) afforded 424 mg of 44a (23%). FTIR (ATR): 710, 1024, 1265, 1688, 
1724, 2902, 3308 cm
-1
. 
1
H NMR (300 MHz, CDCl3): δ 8.64 (s, 1H), 8.13-7.95 (m, 2H), 
7.66-7.51 (m, 3H), 6.68 (s, 1H), 5.99 (d, 1H , J = 1.5 Hz), 4.89 (s, 2H), 4.30 (q, 2H , J = 7.1 Hz), 1.32 (t, 3H, J = 7.1 
Hz). 
13
C NMR (300 MHz, CDCl3): δ 165.26, 164.54, 163.27, 133.37, 132.95, 130.03, 129.56, 128.37, 128.04, 
109.14, 62.95, 61.96, 14.66. HRMS (ESI) m/z calcd for C14H15NO5Na [M+Na]
+
 300.08479:, found: 300.08460. 
 
Ethyl-2-[2-(4-methoxybenzyloxy)acetylamino]acrylate (44c) 
Amide 43 (436 mg, 2.23 mmol) was reacted according to the general procedure A. 
Instead of methyl pyruvate, ethyl pyruvate was used. Silica gel column 
chromatography (EtOAc/heptane 1:1) afforded 70 mg of 44c (11%). FTIR (ATR): 804, 
1031, 1096, 1187, 1250, 1323, 1504, 1694, 2963, 3378 cm
-1
. 
1
H NMR (300 MHz, 
CDCl3): δ 7.27 (d, 2H, 8.7 Hz), 6.87 (d, 2H, J = 8.7), 6.60 (s, 1H), 5.90 (d, 1H, J = 1.6 Hz), 4.28 (q, 2H, J = 7.1 Hz), 
3.98 (s, 2H), 3.78 (s, 2H), 1.30 (t, 3H, J = 7.1 Hz). 
13
C NMR (75 MHz, CDCl3): δ 168.93, 163.39, 159.68, 131.17, 
130.03, 129.24, 112.52, 108.81, 72.45, 69.14, 61.93, 55.03, 13.81. HRMS (ESI) m/z calcd for C15H19NO5Na 
[M+Na]
+
: 316.11609, found: 316.11554. 
 
Ethyl-2-{(4-benzoyloxy)-[2-(4-methoxybenzyl)acetyl]amino}acrylate (45) 
Amide 44a (110 mg, 0.40 mmol) was reacted according to general procedure B. Silica 
gel column chromatography (EtOAc/heptane 1:1) afforded 115 mg of 45 (73%). FTIR 
(ATR): 1120, 1180, 1243, 1271, 1687, 1725, 2989 cm
-1
. 
1
H NMR (300 MHz, CDCl3): δ 
8.08-7.96 (m, 2H), 7.55-7.47 (m, 1H), 7.43-7.36 (m, 2H), 7.18 (d, 2H, J = 8.6 Hz), 6.81 (d, 
2H, J = 8.6 Hz), 6.38 (s, 1H), 4.81 (s, 2H), 5.53 (s, 1H), 4.67 (s, 2H), 4.20 (q, 2H, J = 7.1 Hz), 3.77 (s, 3H), 1.26 (t, 
3H, J = 7.1 Hz). 
13
C NMR (75 MHz, CDCl3): δ 165.93, 165.64, 162.86, 158.72, 132.85, 130.06, 129.54, 128.92, 
127.91, 113.49, 61.6, 61.3, 54.8, 50.2, 13.6. HRMS (ESI) m/z calcd for C22H23NO6Na [M+Na]
+
: 420.14231, found: 
420.14271. 
 
Methyl-4-(4-Methoxybenzyl)-5-oxomorpholine-3-carboxylate (46) 
To a solution of 45 (28.7 mg, 0.072 mmol) in MeOH (1 mL) was added K2CO3 (2 mg, 0.014 
mmol). The reaction was stirred for 1 h at 50 °C. The mixture was cooled to room 
temperature and stirred with Amberlite IR-120+ for 20 min. After vacuum filtration, the 
solvent was removed under reduced pressure and the residue was purified by silica gel 
column chromatography (EtOAc/heptane 3:1) to provide 20 mg of 46 (99%). FTIR (ATR): 1101, 1246, 1652, 2361  
cm
-1
. 
1
H NMR (300 MHz, CD3OD): δ 7.38 (d, 2H, J = 8.2 Hz), 6.89 (d, 2H, J = 8.2 Hz), 5.35 (d, 1H, 3.8 Hz), 4.21-
4.14 (m, 1H), 4.02 (dd, 1H, J = 1.2, J = 2.7 Hz), 3.93 (d, 1H, J = 4.5 Hz), 3.87 (dd, 1H, J = 2.6, J = 4.4 Hz), 3.77 (s, 
3H), 3.74 (s, 3H). 
13
C NMR (75 MHz, CD3OD): δ 169.65, 167.43, 159.12, 129.27, 126.85, 113.37, 66.76, 65.78, 
56.95, 53.84, 51.45. HRMS (ESI) m/z calcd for C14H17NO5Na [M+Na]
+
: 302.1004, found: 302.1007. 
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(S)-2-Hydroxy-2-phenylacetamide ((S)-48) 
Compound (S)-47 (3.00 g, 18.1 mmol) was reacted according to general procedure D to give 
2.44 g of (S)-48 (90%). [ ] 
   +70.7 (c 0.02). FTIR (ATR): 700, 1062, 1643, 3259, 3407 cm
-1
. 
1
H 
NMR (300 MHz, CD3OD): δ 7.46 (d, J = 6.8 Hz, 2H), 7.32-7.24 (m, 3H), 4.98 (s, 1H). 
13
C NMR (75 
MHz, CD3OD): δ 176.73, 139.87, 127.56, 127.25, 126.08, 73.54. HRMS (ESI) m/z calcd for 
C8H9NO2Na [M+Na]
+
: 174.05310, found: 174.05202.  
 
(R)-2-Hydroxy-2-phenylacetamide ((R)-48) 
Compound (R)-47 (5.88 g, 35 mmol) was reacted according to general procedure D. (R)-48 was 
obtained in 5.34 g (quant). [ ] 
   -61.3 (c 0.02). FTIR (ATR): 695, 1061, 1459, 1620, 2388, 2557, 
3309 cm
-1
. 
1
H NMR (300 MHz, CD3OD): δ 7.45-7.38 (m, 2H), 7.32-7.24 (m, 3H), 4.99 (s, 1H). 
13
C 
NMR (75 MHz, CD3OD): δ 176.73, 139.84, 127.56, 127.23, 126.13, 73.54. HRMS (ESI) m/z calcd for C9H9NO3Na 
[M+Na]
+
: 174.05310, found: 174.05212.  
 
(S)-2-Acetoxy-2-phenylacetamide ((S)-49a) 
To a solution of (S)-48 (2.44 g, 16.1 mmol) in CH2Cl2 (80 mL) were added pyridine (20 mL) and 
Ac2O (20 mL). The mixture was stirred for 16 h at room temperature. The solvents were 
removed under reduced pressure and the residue was dissolved in CH2Cl2. The reaction was 
quenched with saturated aqueous NaHCO3 (100 mL) and extracted with CH2Cl2 (100 mL). The organic layer was 
washed with H2O (2 × 100 mL) and dried over Na2SO4. The solvent was removed under reduced pressure and 
the residue was purified by silica gel column chromatography (EtOAc) to provide 2.39 g of (S)-49a (77%). [ ] 
   
+31.4 (c 0.02). FTIR (ATR): 698, 1041, 1227, 1675, 3188, 3373 cm
-1
. 
1
H NMR (300 MHz, CDCl3): δ 7.46-7.39 (m, 
2H), 7.35-7.31 (m, 3H), 5.90 (s, 1H), 2.15 (s, 3H). 
13
C NMR (75 MHz, CDCl3): δ 174.64, 139.86, 127.48, 127.25, 
126.03, 73.5. HRMS (ESI) m/z calcd for C10H11NO3Na [M+Na]
+
: 216.06366, found: 216.06316.  
 
(S)-2-Benzoyloxy-2-phenylacetamide ((S)-49b) 
Compound (S)-48 (7.45 g, 49.35 mmol) was reacted according to general procedure E. (S)-49b 
was obtained in 9.96 g (79%). [ ] 
   +134.0 (c 0.02). FTIR (ATR): 711, 1108, 1266, 1685, 3188, 
3330 cm
-1
. 
1
H NMR (300 MHz, CDCl3): δ 7.99-8.10 (m, 2H), 7.63-7.37 (m, 8H), 6.34 (s, 1H), 6.20 
(s, 1H), 6.02 (s, 1H). 
13
C NMR (75 MHz, CDCl3): δ 170.33, 164.43, 134.75, 133.32, 129.45, 
128.74, 128.47, 128.62, 127.07, 75.23. HRMS (ESI) m/z calcd for C15H13NO3Na [M+Na]
+
: 278.07931, found: 
278.07905.  
 
(R)-2-Benzoyloxy-2-phenylacetamide ((R)-49b) 
Substrate (R)-48 (5.43 g, 35.4 mmol) was reacted according to general procedure E. (R)-49b 
was obtained in 4.1 g (45%). [ ] 
   +12.8 (c 0.02). FTIR (ATR): 712, 110, 1270, 1683, 3188, 3347 
cm
-1
. 
1
H NMR (300 MHz, CDCl3): δ 7.99-8.10 (m, 2H), 7.57-7.69 (m, 3H), 7.49-7.38 (m, 5H), 6.34 
(s, 1H), 6.22 (s, 1H), 5.91 (s, 1H). 
13
C NMR (75 MHz, CDCl3): δ 170.31, 164.54, 144.75, 140.93, 
134.88, 133.25, 129.44, 128.73, 128.46, 128.26, 127.05, 75.2. HRMS (ESI) m/z calcd for C15H14NO3 [M+H]
+
: 
256.09737, found: 256.09743. 
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Ethyl-(S)-2-(2-acetoxy-2-phenylacetylamino)acrylate ((S)-50a) 
(S)-49a (1.00 g, 5.18 mmol) was reacted according to the general procedure A. Instead 
of methyl pyruvate, ethyl pyruvate was used. Silica gel column chromatography 
(EtOAc/heptane 1:3) afforded 759 mg of (S)-50a (50%). [ ] 
   +41.3 (c 0.02). FTIR 
(ATR): 810, 1035, 1243, 1521, 1695, 1722 cm
-1
. 
1
H NMR (300 MHz, CDCl3): δ 8.46 (s, 1H), 
7.44-7.38 (m, 2H), 7.30-7.24 (m, 3H), 6.53 (s, 1H), 6.07 (s, 1H), 5.84 (d, 1H, J = 1.4 Hz), 4.22 (q, 2H, J = 7.1 Hz), 
2.16 (s, 3H), 1.26 (t, 3H, J = 7.1 Hz). 
13
C NMR (75 MHz, CDCl3): δ 168.0, 165.9, 162.8, 134.0, 129.5, 128.4, 128.2, 
128.0, 127.9, 127.2, 126.4, 126.3, 125.3, 124,3, 108.4, 74.6, 61.3, 19.9, 13.0. HRMS (ESI) m/z calcd for 
C15H17NO5Na [M+Na]
+
: 314.10044, found: 314.10101. 
 
Ethyl-(S)-2-(2-benzoyloxy-2-phenylacetylamino)acrylate ((S)-50b) 
Compound (S)-49b (5.00 g, 19.6 mmol) was reacted according to the general procedure 
A. After vacuum filtration over Al2O3, the solvent was removed under reduced 
pressure. The product was recrystallized from Et2O and after vacuum filtration, 
dehydro amino ester (S)-50b was obtained in 2.75 g (41%). [ ] 
   +87.1 (c 0.02). FTIR 
(ATR): 710, 1095, 1258, 1521, 1695, 1723, 2950, 3062, 3391 cm
-1
. 
1
H NMR (300 MHz, CDCl3): δ 8.80 (s, 1H), 
7.99-8.18 (m, 2H), 7.63-7.41 (m, 8H), 6.71 (s, 1H), 6.45 (s, 1H), 5.97 (d, 1H, J = 1.4 Hz), 3.84 (s, 3H). 
13
C NMR (75 
MHz, CDCl3): δ 166.66, 164.25, 163.88, 134.64, 133.30, 133.07, 129.96, 129.75, 129.54, 129.47, 128.84, 128.53, 
128.43, 128.32, 128.06, 127.28, 126.81, 109.34, 75.56, 52.64. HRMS (ESI) m/z calcd for C19H18NO5 [M+H]
+
: 
340.11850, found: 340.11812.  
 
Methyl-(R)-2-(2-benzoyloxy-2-phenylacetylamino)acrylate ((R)-50b) 
Compound (R)-49b (3.74 g, 14.8 mmol) was reacted according to the general 
procedure A. After vacuum filtration over Al2O3, the solvent was removed under 
reduced pressure. The solid was dried for 16 h on the freeze dryer. Heptane was added 
and after vacuum filtration, (R)-50b was obtained in 2.81 g (75%). [ ] 
   -9.8 (c 0.02). 
FTIR (ATR): 711, 1094, 1257, 1522, 1692, 1723, 2946, 3062, 3391 cm
-1
. 
1
H NMR (300 MHz, CDCl3): δ 8.73 (s, 1H), 
8.18-7.98 (m, 2H), 7.62-7.38 (m, 8H), 6.66 (s, 1H), 6.39 (s, 1H), 5.93 (d, 1H, J = 1.4 Hz), 3.84 (s, 3H). 
13
C NMR (75 
MHz, CDCl3): δ 166.67, 164.24, 163.82, 134.62, 133.38, 129.96, 129.55, 129.46, 128.83, 128.58, 128.36, 128.05, 
127.24, 126.83, 109.33, 75.51, 52.64. HRMS (ESI) m/z calcd for C19H18NO5 [M+H]
+
: 340.11850, found: 
340.11831.  
 
Ethyl-(S)-2-[(2-acetoxy-2-phenylacetyl)(4-methoxybenzyl)amino]acrylate ((S)-51a) 
Compound (S)-50a (380 mg, 1.31 mmol) was reacted according to general procedure B. 
Silica gel column chromatography (EtOAc/heptane 1:1) afforded 382 mg of (S)-51a 
(71%). [ ] 
   +158.0 (c 0.02). FTIR (ATR): 711, 1030, 1177, 1233, 1513, 1676, 1727, 
2946, 3062, 3391 cm
-1
. 
1
H NMR (300 MHz, CDCl3): δ 7.42-6.91 (m, 10H), 6.40 (s, 1H), 6.16 (s, 1H), 5.36 (s, 2H), 
4.01 (t, 2H, J = 7.1 Hz), 3.9 (s, 3H), 2.10 (s, 3H), 1.12 (t, 1H, J = 7.1 Hz). 
13
C NMR (75 MHz, CDCl3): δ 170.11, 
167.02, 162.45, 158.61, 136.37, 130.24, 129.86, 128.84, 128.63, 128.22, 127.96, 113.37, 72.92, 61.24, 54.74, 
49.76, 20.37, 13.43. HRMS (ESI) m/z calcd for C23H25NO6Na [M+Na]
+
: 434.15796, found: 434.15743.  
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Ethyl-(S)-2-[(2-benzoyloxy-2-phenylacetyl)(4-methoxybenzyl)amino]acrylate ((S)-51b) 
Compound (S)-50b (800 mg, 2.36 mmol) was reacted according to general procedure B. 
Silica gel column chromatography (EtOAc/heptane 1:3) afforded 700 mg of (S)-51b 
(65%). [ ] 
   +69.9 (c 0.02). FTIR (ATR): 713, 1030, 1174, 1249, 1512, 1677, 1724, 
2950, 2997, 3032 cm
-1
. 
1
H NMR (300 MHz, CDCl3): δ 7.42-6.91 (m, 15H), 6.45 (s, 1H), 
6.42 (s, 1H), 3.90 (s, 3H), 3.61 (br. s, 3H). 
13
C NMR (75 MHz, CDCl3): δ 167.01, 165.53, 163.04, 158.65, 136.06, 
132.87, 130.53, 129.93, 129.59, 129.06, 128.85, 128.63, 128.23, 127.87, 113.42, 73.35, 54.76, 51.97, 49.74. 
HRMS (ESI) m/z calcd for C27H25NO6Na [M+Na]
+
: 482.15796, found: 482.15749.  
Methyl-(R)-2-[(2-benzoyloxy-2-phenylacetyl)(4-methoxybenzyl)amino]acrylate ((R)-51b) 
Compound (R)-50b (200 mg, 0.59 mmol) was reacted according to general procedure B. 
Silica gel column chromatography (EtOAc/heptane 1:3) afforded 150 mg of (R)-51b 
(56%). [ ] 
   -7.2 (c 0.02). FTIR (ATR): 713, 1108, 1174, 1248, 1677, 1724, 2954, 3028 
cm
-1
. 
1
H NMR (300 MHz, CDCl3): δ 7.42-6.91 (m, 15H), 6.45 (s, 1H), 6.42 (s, 1H), 3.90 (s, 
3H), 3.61 (br. s, 3H). 
13
C NMR (75 MHz, CDCl3): δ 167.04, 165.53, 163.05, 158.64, 136.07, 132.82, 130.54, 
129.93, 129.55, 129.03, 128.87, 128.69, 128.23, 127.80, 113.46, 73.35, 54.74, 51.98, 49.73. HRMS (ESI) m/z 
calcd for C27H25NO6Na [M+Na]
+
: 482.15796, found: 482.15675.  
 
Methyl-(3R,6S)-4-(4-Methoxybenzyl)-5-oxo-6-phenylmorpholine-3-carboxylate ((3R,6S)-52) 
Ester (S)-51b (500 mg, 1.09 mmol) was reacted according to general procedure F. Silica gel 
column chromatography (EtOAc/heptane 1:1) afforded 92 mg of (3R,6S)-52 (33%). [ ] 
   
+3.5 (c 0.02). FTIR (ATR): 605, 1246, 1512, 1661, 1749 cm
-1
. 
1
H NMR (300 MHz, CDCl3): δ 
7.42-7.47 (m, 2H), 7.37-7.27 (m, 3H), 7.20 (d, 2H, J = 8.6 Hz), 6.87 (d, 2H, J = 8.7 Hz), 5.47 (d, 1H, J = 14.7 Hz), 
5.17 (s, 1H), 4.35 (d, 1H, J = 11.1 Hz), 3.96 (s, 1H), 3.83 (s, 3H), 3,81 (s, 1H), 3.80 (s, 3H), 3.75 (d, 1H, J = 14.7 Hz). 
13
C NMR (75 MHz, CDCl3): δ 169.84, 167.25, 159.03, 136.67, 129.75, 128.24, 128.03, 127.93, 127.16, 113.83, 
80.72, 65.91, 57.04, 54.84, 52.47, 48.15. HRMS (ESI) m/z calcd for C20H21NO5Na [M+Na]
+
: 378.13174, found: 
378.13092.  
 
(3S,6S)-[4-(4-Methoxybenzyl)-6-phenylmorpholin-3-yl]methanol ((3S, 6S)-53) 
To a solution of (3R,6S)-52 (46 mg, 0.13 mmol) in THF (2 mL) was added LiAlH4 (25 mg, 0.65 
mmol). The mixture was stirred for 16 h at 55 °C. The reaction was quenched with H2O (33 
μL, 1.3 mg/mg LiAlH4). An aqueous NaOH solution (15% in H2O, 33 μL, 1.3 mg/mg LiAlH4) 
and H2O (82 μL, 3.25 mg/mg LiAlH4) were added. The mixture was stirred for 15 min. After 
vacuum filtration, the solvent was removed under reduced pressure and the residue was purified by silica gel 
column chromatography (EtOAc/heptane 1:1) to provide 23 mg of (3S,6S)-53 (57%). [ ] 
   +1.5 (c 0.02). FTIR 
(ATR): 700, 1032, 1246, 1511, 2907, 3404 cm
-1
. 
1
H NMR (400 MHz, CDCl3): δ 7.29-7.26 (m, 7H), 6.87 (d, 2H, J = 
8.7 Hz), 4.66 (dd, 1H, J = 2.8, 10.5 Hz), 4.07-4.04 (m, 1H), 4.04-4.00 (m, 1H), 3.97 (d, 1H, J = 13.0 Hz), 3.93-3.87 
(m, 1H), 3.87 (d, 1H, J = 13.0 Hz), 3.80 (s, 3H), 3.82-3.79 (m, 1H), 2.91 (dd, 1H, J = 10.6, 13.4 Hz), 2.77-2.73 (m, 
1H), 2.67 (dd, 1H, J = 2.8, 13.4 Hz). 
13
C NMR (75 MHz, CDCl3): δ 158.55, 139.72, 129.96, 129.52, 128.26, 127.93, 
127.34, 125.66, 113.44, 74.77, 64.88, 57.95, 57.32, 56.24, 54.87, 52.04. HRMS (ESI) m/z calcd for C19H23NO3Na 
[M+Na]
+
: 336.15756, found: 336.15659.  
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(S)-2-Hydroxypropionamide ((S)-55a) 
Methyl (S)-(-)-lactate (5.0 mL, 52.4 mmol) was reacted according to general procedure D. The 
product was recrystallized from Et2O and after vacuum filtration, (S)-55a was obtained in 4.33 g 
(93%). [ ] 
   -1.6 (c 0.02). FTIR (ATR): 972, 1117, 1642, 2484, 3340 cm
-1
. 
1
H NMR (300 MHz, 
CD3OD): δ 4.09 (q, 1H, J = 6.9 Hz), 1.34 (d, 3H, J = 6.9 Hz). 
13
C NMR (75 MHz, CD3OD): δ 179.25, 67.12, 19.36. 
HRMS (ESI) m/z calcd for C3H7NO2Na [M+Na]
+
: 90.05550, found: 90.05429.  
 
(S)-2-Hydroxy-3-methylbutanamide ((S)-55b) 
L-Valine (5.00 g, 43.0 mmol) was reacted according to general procedure G. The crude product 
(3.92 g, 33.2 mmol) was reacted according to general procedure H. The crude product (4.38 g, 
33.2 mmol) was reacted according to general procedure D. The product was recrystallized from 
Et2O and after vacuum filtration, (S)-55b was obtained in 1.39 g (28% over 3 steps). [ ] 
   -2.2 (c 0.02). FTIR 
(ATR): 1022, 1661, 2964, 3331 cm
-1
. 
1
H NMR (300 MHz, CDCl3): δ 6.33 (s, 1H), 5.74 (s, 1H), 3.93 (d, 1H, J = 3.3 
Hz), 2.09-2.06 (m, 1H), 0.98 (d, 3H, J = 7.0 Hz), 0.83 (d, 3H, J = 6.9 Hz). 
13
C NMR (75 MHz, CDCl3): δ 175.66, 
75.73, 31.44, 18.65, 15.06. HRMS (ESI) m/z calcd for C5H11NO2Na [M+Na]
+
: 140.06875, found: 140.06883.  
 
S)-2-hydroxy-3-methylpentanamide ((S)-55c) 
L-Leucine (4.00 g, 30.5 mmol) was reacted according to general procedure G. The crude product 
(3.00 g, 22.7 mmol) was reacted according to general procedure H. The crude product (2.67 g, 
18.3 mmol) was reacted according to general procedure D. The product was recrystallized from 
Et2O and after vacuum filtration, (S)-55c was obtained in 1.91 g (45% over 3 steps). [ ] 
   -37.6 
(c 0.02). FTIR (ATR): 973, 1120, 2473, 3343 cm
-1
. 
1
H NMR (300 MHz, CD3OD): δ 4.02-3.97 (m, 1H), 1.88-1.83 (m, 
1H), 1.56-1.47 (m, 2H), 0.95 (d, 3H, J = 1.3 Hz), 0.93 (d, 3H, J = 1.2 Hz). 
13
C NMR (75 MHz, CD3OD): δ 179.47, 
69.44, 42.92, 23.77, 22.13, 19.91. HRMS (ESI) m/z calcd for C6H13NO2Na [M+Na]
+
: 154.08440, found: 154.08442.  
 
(S)-2-Hydroxy-3-phenylpropionamide ((S)-55d) 
L-Phenylalanine (10.0 g, 60.5 mmol) was reacted according to general procedure G. The crude 
(S)-55d (9.17 g, 55.2 mmol) was reacted according to general procedure H. The crude product 
(8.18 g, 45.4 mmol) was reacted according to general procedure D. The product was 
recrystallized from Et2O and after vacuum filtration, (S)-55d was obtained in 6.56 g (66% over 3 
steps). [ ] 
   -4.1 (c 0.02). FTIR (ATR): 699, 1247, 1616, 1674, 3352 cm
-1
. 
1
H NMR (300 MHz, CDCl3): δ 7.24-7.19 
(m, 5H), 6.32 (s, 1H), 5.50 (s, 1H), 4.25 (dd, 1H, J = 4.1, 8.6 Hz), 3.17 (dd, 1H, J = 4.2, 13.9 Hz), 2.85 (dd, ,J = 8.6, 
13.9 Hz), 2.52 (s, 1H). 
13
C NMR (75 MHz, CDCl3): δ 174.85, 136.22, 129.05, 128.46, 126.73, 72.32, 40.46. HRMS 
(ESI) m/z calcd for C9H12NO2 [M+H]
+
: 166.08680, found: 166.08558.  
 
(S)-2-(Benzoyloxy)propionamide ((S)-56a) 
Alcohol (S)-55a (4.32 g, 48.6 mmol) was reacted according to general procedure E. After 
removal of the solvent under reduced pressure, the residue was purified by silica gel column 
chromatography (MeOH/CH2Cl2 1:19) to provide 6.74 g of (S)-56a (72%). [ ] 
   +77.7 (c 0.02). 
FTIR (ATR): 710, 1109, 1267, 1681, 3192, 3347 cm
-1
. 
1
H NMR (300 MHz, CDCl3): δ 8.01-8.08 (m, 2H), 7.61-7.57 
(m, 1H), 7.49-7.43 (m, 2H), 6.21 (s, 2H), 5.47 (q, 1H, J = 6.9 Hz), 1.61 (d, 3H, J = 6.9 Hz). 
13
C NMR (75 MHz, 
CDCl3): δ 172.9, 164.8, 133.2, 129.2, , 128.8, 128.2, 127.8, 70.2, 17.2. HRMS (ESI) m/z calcd for C10H11NO3Na 
[M+Na]
+
: 216.06366, found: 216.06264.  
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(S)-2-(Benzoyloxy)-3-methylbutanamide ((S)-56b) 
Alcohol (S)-55b (1.37 g, 11.7 mmol) was reacted according to general procedure E. After 
removal of the solvent under reduced pressure, the residue was purified by silica gel column 
chromatography (EtOAc/heptane 1:1) to provide 1.54 g of (S)-56b (59%). [ ] 
   +17.7 (c 0.02). 
FTIR (ATR): 710, 1107, 1271, 1678, 2958, 3205, 3347 cm
-1
. 
1
H NMR (300 MHz, CDCl3): δ 8.09-8.02 (m, 2H), 7.58-
7.63 (m, 1H), 7.46-7.50 (m, 2H), 6.02 (s, 1H), 5.74 (s, 1H), 5.32-5.25 (m, 1H), 2.42-2.247 (m, 1H), 1.08 (ddd, 6H, J 
= 0.8, 6.9, 13.0 Hz). 
13
C NMR (75 MHz, CDCl3): δ 171.94, 165.06, 133.28, 129.33, 128.26, 77.83, 30.27, 18.53, 
16.62. HRMS (ESI) m/z calcd for C12H15NO3Na [M+Na]
+
: 244.09496, found: 244.09417.  
 
(S)-2-(Benzoyloxy)-3-methylpentanamide ((S)-56c) 
Alcohol (S)-57c (1.88 g, 14.4 mmol) was reacted according to general procedure E. The product 
was recrystallized from Et2O and after vacuum filtration, (S)-56c was obtained in 1.86 g (55%). 
[ ] 
   +12.9 (c 0.02). FTIR (ATR): 3330, 3188, 2946, 1679, 1269, 1108, 711 cm
-1
. 
1
H NMR (300 
MHz, CDCl3): δ 8.09-8.03 (m, 2H), 7.62-7.56 (m, 1H), 7.48-7.44 (m, 2H), 6.06 (s, 1H), 5.86 (s, 1H), 5.45 (dd, 1H, J 
= 3.7, 9.2 Hz), 1.82-1.88 (m, 3H), 0.97 (dd, 6H, J = 4.9, 6.1 Hz). 
13
C NMR (75 MHz, CDCl3): δ 172.6, 165.0, 133.2, 
129.3, 128.2, 72.5, 40.3, 24.2, 22.7, 21.3. HRMS (ESI) m/z calcd for C13H18NO3 [M+H]
+
: 236.12867, found: 
236.12815.  
 
(S)-2-(Benzoyloxy)-3-phenylpropionamide ((S)-56d) 
Alcohol (S)-55d (6.38 g, 38.6 mmol) was reacted according to general procedure E. The product 
was recrystallized from Et2O and after vacuum filtration, (S)-56d was obtained in 6.86 g (66%). 
[ ] 
   +7.4 (c 0.02). FTIR (ATR): 710, 1108, 1269, 1679, 3183, 3326 cm
-1
. 
1
H NMR (300 MHz, 
CDCl3): δ 7.99-7.95 (m, 2H), 7.63-7.57 (m, 1H), 7.45-7.42 (m, 2H), 7.25-7.22 (m, 5H), 5.93 (d, 
2H, J = 15.5 Hz), 5.65 (dd, 1H, J = 5.2, 6.4 Hz), 3.34 (d, 1H, J = 2.1 Hz), 3.32 (d, 1H, J = 3.2 Hz). 
13
C NMR (75 MHz, 
CDCl3): δ 171.44, 164.75, 135.36, 133.25, 129.28, 129.25, 128.29, 128.05, 126.64, 74.07, 37.21. HRMS (ESI) m/z 
calcd for C16H15NO3Na [M+Na]
+
: 292.09496, found: 292.09357.  
 
Methyl-(S)-2-[2-(benzoyloxy)propionylamino]acrylate ((S)-57a) 
Compound (S)-56a (3.50 g, 18.1 mmol) was reacted according to general procedure A. 
Silica gel column chromatography (EtOAc/heptane 1:1) afforded 413 mg of (S)-57a 
(8%). [ ] 
   +39.9 (c 0.02). FTIR (ATR): 712, 1110, 1265, 1722, 2946, 3399 cm
-1
. 
1
H NMR 
(300 MHz, CDCl3): δ 8.71 (br. s, 1H), 8.09-7.31 (m, 10H), 6.72 (s, 1H), 5.93 (s, 1H), 5.42 
(q, 1H, J = 6.8 Hz), 5.31 (q, 1H, J = 7.1 Hz), 3.92 (s, 3H), 3.88 (s, 3H), 1.59 (t, 6H, J = 6.8 Hz,). 
13
C NMR (75 MHz, 
CDCl3): δ 170.74, 168.63, 165.42, 164.46, 163.77, 133.28, 132.84, 130.04, 129.38, 129.25, 128.96, 128.62, 
128.59, 128.20, 127.96, 127.79, 108.95, 70.63, 68.66, 52.54, 51.83, 17.37, 16.63. HRMS (ESI) m/z calcd for 
C14H15NO5Na [M+Na]
+
: 300.08479, found: 300.08445.  
 
Methyl-(S)-2-[2-(benzoyloxy)-3-methylbutanoylamino]acrylate ((S)-57b) 
Compound (S)-56b (1.00 g, 4.52 mmol) was reacted according to general procedure A. 
Silica gel column chromatography (EtOAc/heptane 1:1) afforded 391.0 mg of (S)-57b 
(28%). [ ] 
   +53.0 (c 0.02). FTIR (ATR): 608, 711, 1093, 1257, 1693, 1724, 2963, 3399 
cm
-1
. 
1
H NMR (300 MHz, CDCl3): δ 8.48 (s, 1H), 8.16-8.10 (m, 2H), 7.62-7.55 (m, 1H), 
7.55-7.62 (m, 2H), 6.66 (s, 1H), 5.91 (d, 1H, J = 1.5 Hz), 5.39 (d, 1H, J = 4.2 Hz), 3.78 (s, 3H), 2.42-2.48 (m, 1H), 
1.04 (d, 3H, J = 6.7 Hz), 1.00 (d, 3H, J = 6.8 Hz). 
13
C NMR (75 MHz, CDCl3): δ 167.84, 164.81, 163.83, 133.26, 
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129.78, 129.33, 128.62, 128.33, 109.05, 77.97, 52.53, 30.77, 18.43, 16.61. HRMS (ESI) m/z calcd for 
C16H19NO5Na [M+Na]
+
: 328.11609, found: 328.11550.  
 
Methyl-(S)-2-[2-(benzoyloxy)-3-phenylpropionylamino]acrylate ((S)-57d) 
Compound (S)-56d (4.00 g, 14.9 mmol) was reacted according to general procedure A. 
Silica gel column chromatography (EtOAc/heptane 1:1) afforded 2.18 g of (S)-57d 
(42%). [ ] 
   +2.4 (c 0.02). FTIR (ATR): 710, 1093, 1260, 1520, 1693, 1723, 2950, 3029, 
3391 cm
-1
. 
1
H NMR (300 MHz, CDCl3): δ 8.38 (s, 1H), 8.04-8.00 (m, 2H), 7.61-7.57 (m, 1H), 7.44-7.48 (m, 2H), 
7.25-7.21 (m, 5H), 6.67 (s, 1H), 5.91 (d, 1H, J = 1.5 Hz), 5.70 (dd, 1H, J = 5.0, 6.6 Hz), 3.76 (s, 3H), 3.37-3.32 (m, 
2H). 
13
C NMR (75 MHz, CDCl3): δ 167.44, 164.45, 163.67, 135.09, 133.21, 129.83, 129.35, 129.17, 128.55, 
128.23, 128.02, 126.67, 109.18, 74.33, 52.54, 37.48. HRMS (ESI) m/z calcd for C20H19NO5Na [M+Na]
+
: 
376.11609, found: 376.11584.  
 
 
Methyl-(S)-2-[(2-(benzoyloxy)propionyl)-(4-methoxybenzyl)amino]acrylate ((S)-58a) 
Compound (S)-57a (413 mg, 1.49 mmol) was reacted according to general procedure B. 
Silica gel column chromatography (EtOAc/heptane 1:1) afforded 196 mg of (S)-58a 
(37%). [ ] 
   +129.9 (c 0.02). FTIR (ATR): 713, 803, 1110, 1246, 1512, 1674, 1721, 
2954, 2997 cm
-1
. 
1
H NMR (300 MHz, CDCl3): δ 8.05-8.01 (m, 2H), 7.52-7.49 (m, 1H), 
7.42-7.39 (m, 2H), 7.16 (d, 2H, J = 8.4 Hz), 6.80 (d, 2H, J = 8.6 Hz), 6.34 (s, 1H), 5.59 (s, 1H), 5.51 (t, 1H, J = 6.6 H), 
4.30-5.08 (br. s, 2H), 3.74 (s, 3H), 3.65 (s, 3H), 1.51 (d, 3H, J = 6.7 Hz). 
13
C NMR (75 MHz, CDCl3): δ 169.67, 
165.25, 163.44, 158.63, 136.47, 132.82, 129.96, 129.47, 129.05, 128.54, 128.04, 127.92, 113.47, 67.35, 54.78, 
52.19, 49.75, 16.44. HRMS (ESI) m/z calcd for C22H23NO6Na [M+Na]
+
: 420.14231, found: 420.14201.  
 
Methyl-(S)-2-[(2-(benzoyloxy)-3-methylbutanoyl)-(4-methoxybenzyl)amino]acrylate ((S)-58b) 
Compound (S)-57b (391 mg, 1.28 mmol) was reacted according to general procedure B. 
Silica gel column chromatography (EtOAc/heptane 1:1) afforded 409 mg of (S)-58b 
(75%). [ ] 
   +93.8 (c 0.02). FTIR (ATR): 712, 807, 1111, 1173, 1248, 1513, 1674, 1723, 
2959 cm
-1
. 
1
H NMR (300 MHz, CDCl3): δ 7.52-7.56 (m, 2H), 7.46-7.49 (m, 1H), 7.45-7.41 (m, 2H), 7.17 (d, 2H, J = 
8.3 Hz), 6.81 (d, 2H, J = 8.5 Hz), 6.42 (s, 1H), 5.57 (s, 1H), 5.34 (d, 1H, J = 5.7 Hz), 4.36-5.02 (br. s, 2H), 3.78 (s, 
3H), 3.73 (s, 3H), 2.27-2.24 (m, 1H), 1.05 (d, 3H, J = 6.7 Hz), 0.99 (d, 3H, J = 6.8 Hz).  
13
C NMR (75 MHz, CDCl3): δ 
168.44, 165.55, 163.67, 158.63, 136.67, 132.79, 130.06, 129.43, 129.24, 128.22, 127.97, 113.34, 74.83, 54.71, 
52.23, 49.74, 29.85, 18.86, 16.86. HRMS (ESI) m/z calcd for C24H27NO6 [M+H]
+
: 426.19166, found: 426.19173.  
 
Methyl-(S)-2-[(2-(benzoyloxy)-4-methylpentanoyl)-(4-methoxybenzyl)amino]acrylate ((S)-58c) 
Substrate (S)-57c (1.11 g, 3.32 mmol) was reacted according to general procedure B. 
Silica gel column chromatography (EtOAc/heptane 1:3) afforded 300 mg of (S)-60c 
(20%). [ ] 
   +63.7 (c 0.02). FTIR (ATR): 713, 1111, 1242, 1512, 1677, 1723, 2954 cm
-1
. 
1
H NMR (300 MHz, CDCl3): δ 8.08-8.06 (m, 2H), 7.57-7.61 (m, 1H), 7.45-7.40 (m, 2H), 7.16 (d, 2H, J = 8.2 Hz), 
6.82 (d, 2H, J = 8.6 Hz), 6.43 (s, 1H), 5.68 (s, 1H), 5.45 (d, 1H, J = 8.1 Hz), 3.78 (s, 3H), 3.76 (s, 3H), 1.99-1.96 (m, 
1H), 1.81-1.77 (m, 2H), 0.95 (d, 3H, J = 6.7 Hz), 0.85 (d, 3H, J = 6.6 Hz). 
13
C NMR (75 MHz, CDCl3): δ 169.56, 
163.53, 158.67, 136.38, 132.72, 129.96, 129.44, 127.97, 69.68, 54.79, 52.16, 49.64, 39.59, 24.34, 22.83, 21.02. 
HRMS (ESI) m/z calcd for C25H29NO6Na [M+Na]
+
: 462.18926, found: 462.18979.  
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Methyl-(S)-2-[(2-(benzoyloxy)-3-phenylpropionyl)-(4-methoxybenzyl)amino]acrylic acid methyl ester ((S)-
58d) 
Compound (S)-57d (550 mg, 1.56 mmol) was reacted according to general procedure B. 
Silica gel column chromatography (EtOAc/heptane 1:3) afforded 500 mg of (S)-58d 
(68%). [ ] 
   +8.2 (c 0.02). FTIR (ATR): 712, 1111, 1174, 1249, 1513, 1678, 1723, 2950,  
3028 cm
-1
. 
1
H NMR (300 MHz, CDCl3): δ 8.02-7.95 (m, 2H), 7.55-7.51 (m, 1H), 7.44-7.40 (m, 2H), 7.23-7.20 (m, 
8H), 6.81 (d, 2H, J = 8.6 Hz), 6.31 (s, 1H), 5.60 (t, 1H, J = 6.7 Hz), 4.30-5.00 (br. s, 2H), 3.79 (s, 3H), 3.72 (s, 3H), 
3.21-3.19 (m, 2H). 
13
C NMR (75 MHz, CDCl3): δ 168.47, 165.22, 163.54, 158.67, 136.32, 132.73, 130.90, 129.48, 
129.04, 128.63, 128.09, 127.92, 127.76, 126.46, 124.88, 113.34, 71.69, 54.83, 52.22, 49.86, 37.38. HRMS (ESI) 
m/z calcd for C28H28NO6 [M+H]
+
: 474.19166, found: 474.19210.  
 
Methyl-(3R,6S)-4-(4-methoxybenzyl)-5-oxo-6-methylmorpholine-3-carboxylate ((3R,6S)-60a) 
Compound (S)-58a (98 mg, 0.25 mmol) was reacted according to general procedure F. 
Silica gel column chromatography (EtOAc/heptane 1:1) afforded 6 mg of (3R,6S)-60a (8%). 
[ ] 
   -22.0 (c 0.02). FTIR (ATR): 610, 1242, 1317, 1638, 1763 cm
-1
. 
1
H NMR (300 MHz, 
CDCl3): δ 7.21 (d, 1H, J = 8.1 Hz), 6.90 (d, 2H, J = 8.1 Hz), 5.32 (d, 1H, J = 14.7 Hz),  4.36 (q, 
1H, J = 4.3 Hz), 4.18 (d, 1H, J = 11.0 Hz), 4.18 (d, 1H, J = 11.0 Hz), 3.85 (m, 2H), 3.84 (s, 3H), 3.81 (s, 3H), 3.75 (d, 
1H, J = 14.7 Hz), 1.48 (d, 2.4 Hz, 3H). 
13
C NMR (75 MHz, CDCl3): δ 170.25, 170.23, 169.65, 159.48, 130.02, 
129.94, 114.23, 74.86, 66.15, 57.52, 55.37, 52.88, 48.34, 18.35 HRMS (ESI) m/z calcd for C15H19NO5Na [M+Na]
+
: 
326.13256, found: 326.13124. 
 
Methyl-(3R,6S)-4-(4-Methoxybenzyl)-5-oxo-6-benzylmorpholine-3-carboxylate ((3R,6S)-60d) 
Compound (S)-58d (120 mg, 0.25 mmol) was reacted according to general procedure F. 
Silica gel column chromatography (MeOH/CH2Cl2 1:5) afforded 16 mg of (3R,6S)-60d (24%). 
[ ] 
   -14.5 (c 0.02). FTIR (ATR): 590, 1261, 1329, 1628, 1749 cm
-1
. 
1
H NMR (300 MHz, 
CDCl3): δ 6.94-7.61 (m, 9H), 5.31 (d, 1H, J = 14.7 Hz), 5.19 (s, 1H), 4.68 (s, 1H), 4.38 (d, 1H, J 
= 11.1 Hz), 4.02-3.94 (m, 1H), 3.84 (s, 3H), 3.78 (s, 3H), 3.72 (d, 1H, J = 14.7 Hz). 
13
C NMR (300 MHz, CDCl3): δ 
169.86, 167.25, 159.02, 136.66, 129.78, 128.23, 128.02, 127.97, 127.15, 113.84, 80.77, 65.93, 57.06, 54.82, 
52.44, 48.15. HRMS (ESI) m/z calcd for C9H9NO3Na [M+Na]
+
: 392.16501, found: 392.16454.  [α]D = -14.5. 
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4 
 
Synthesis of optically active 2-oxopiperidine carboxylates 
 
Abstract  
 
The piperidine ring system is one of the most common structural subunits in natural 
products. Moreover, piperidine alkaloids and derivatives thereof are of great interest for the 
pharmaceutical industry because they exhibit a wide range of biological activities. We 
realized that enantiopure olefinic amides may represent valuable intermediates en route to 
highly substituted pipecolic acids as well as more elaborate heterocycles. This chapter 
describes the synthesis of highly functionalized nitrogen heterocycles by condensation of 
substituted olefinic amides with a pyruvate. The zinc-mediated ring opening of iodolactones 
was the key step  to provide easy access to enantiopure building blocks.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sebastiaan (Bas) A. M. W. van den Broek, Peter G. W. Rensen, Floris L. van Delft, Floris P. J. T. Rutjes, Expedient 
pathway into optically active 6-oxopiperidines, Eur. J. Org. Chem., 2010, 5906 - 5912. 
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4.1 Introduction 
  
Pipecolic acid, or 2-piperidinecarboxylic acid, is a non-proteinogenic amino acid, which is 
encountered in plants and fungi,1 but also in human physiological fluids and is thought to 
play an important role in the central inhibitory-aminobutyric acid system.2 Moreover, 
pipecolic acid serves as a substrate of some peptides and polyketide synthetases, resulting in 
the formation of secondary metabolites with interesting pharmacological activities such as 
the immunosuppressors rapamycin (1)3, immunomycin (2)4 and FK506 (3)5, or the antitumor 
antibiotic sandramycin (4) (Figure 4.1).6 It is also a precursor to numerous compounds such 
as synthetic peptides,7 local anaesthetics and potential enzyme inhibitors.8 As a result, 
stereoselective synthesis of pipecolic acids and derivatives thereof has been of interest to 
many chemists.  
 
 
 
Figure 4.1. Biologically relevant pipecolic acid derivatives. 
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We realized that the substituted 2-oxopiperidine carboxylic acid 5 as described in Chapter 2 
with different substitution patterns, may represent valuable intermediates en route to highly 
substituted pipecolic acids as well as more elaborate heterocycles (Figure 4.2). Because of 
their importance in several pharmaceutically relevant structures, we decided to focus our 
efforts on the synthesis of 4-substituted pipecolic acids. To underline their relevance, a 4-
ethylpipecolic acid moiety has been integrated in pyrlimycin (6),9 which is used in the 
treatment of bovine metastasis caused by Gram-positive bacteria, specifically 
Staphylococcus aureus and coagulase negative species of Staphylococcus and Streptococcus. 
Furthermore, the 4-substituted pipecolic acids LY233053 (7)10 and selfotel (8)11 show some 
potential as NMDA receptor antagonists. Hydroxy-substituted derivatives on the other hand, 
represent valuable building blocks for more elaborate structures, e.g. clathrotropine (9),12 
and plumerinine (10).13  
 
 
 
 
Figure 4.2. Therapeutically relevant pipecolic acids and derivatives thereof. 
 
While the heterocyclic structures described in Chapter 2 are all racemic, enantiopure 
variants would increase the biological relevance of the building blocks. Logically, if a similar 
approach as in Chapter 2 would be followed, i.e. (1) condensation of unsaturated amides 
with pyruvate, (2) N-alkylation, and (3) cyclization by RCM, a general procedure for the 
synthesis of enantiopure olefinic amides would be a requisite (Scheme 4.1). Although several 
syntheses of olefinic amides are known in literature,14 synthesis of enantiopure variants has 
remained limited.15 
 
For the synthesis of 4-hydroxy-substituted olefinic amides, we envisaged that iodolactones 
15 (R1 = H, OH, R2 = OH) would serve as suitable precursors. Such lactones are readily derived 
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from the corresponding alcohols (viz. 16) and are known to give a ring-opening in the 
presence of zinc (Boord reaction), with concomitant formation of a terminal olefin.16 
Furthermore, derivatives of 14 (R1 = H, R2 = NH2) might be accessible from the non-
proteinogenic amino acid L-allylglycine (17), or from 1,4-addition onto furanone 18 (R1 = H, 
R2 = aliphatic, aromatic).  
 
 
 
Scheme 4.1. Retrosynthetic approach. 
 
4.2 Hydroxy-substituted olefinic amides 
 
To probe the feasibility of forming hydroxy-substituted unsaturated amides, we decided to 
focus our attention on the ring-opening of selectively protected ribolactonic acids. Thus, 
iodide 19 was synthesized in two steps via a reported procedure.17 Ring-opening of the 
iodide went smoothly in the presence of zinc, after which the carboxylic acid 20 was isolated 
in 53% yield (Scheme 4.2). Treatment with oxalyl chloride and subsequent quenching with 
ammonia resulted in formation of amide 21, but the isopropylidene protecting group was 
cleaved in the process as well. To avoid this deprotection, carboxylic acid 20 was converted 
into methyl ester 22 by addition of TMSCHN2. Disappointingly, again low yields were 
observed after silica gel purification. The volatility of ester 22, in combination with the 
problematic acid reactivity of the isopropylidene, led us to search for an alternative 
protecting group strategy. 
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Scheme 4.2. Ring-opening of isopropylidene protected ribolactonic acid 19. 
 
Following the procedure of Ireland,18 commercially available ribolactonic acid was reacted 
with trityl chloride in pyridine at 70 °C to provide 23 in 56% yield together with a substantial 
amount of starting material. Nevertheless, protection with tert-butyl dimethylsilyl chloride in 
the presence of imidazole led to the formation of the protected ribolactonic acid 24 in 
quantitative yield (Scheme 4.3). Next, hydrogenolysis of 24 led to the formation of the 
primary alcohol 25. This trityl deprotection, however, appeared to be less trivial than 
anticipated. Acidic removal with hydrochloric acid (0.1 N) led to multiple products, while on 
the other hand hydrogenolysis (10% Pd/C) in methanol gave no reaction. In sharp contrast, 
reaction with 10% Pd/C in chloroform, resulted in 25 in a high yield of 80%. Probably, 
hydrolysis of the trityl group is facilitated by addition of slightly acidic chloroform. Finally, 
iodolactone 26 was prepared in excellent yield via iodination of the primary alcohol under 
standard conditions (I2, PPh3, imidazole, THF, rt).     
 
 
 
Scheme 4.3. Synthesis of iodolactone 26. 
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 Subjection of iodolactone 26 to the previously described zinc-mediated ring-opening 
protocol, led to the corresponding carboxylic acid in only 27% yield after silica gel 
purification. Conversion into the methyl ester prior to purification using TMSCHN2, afforded 
the methyl ester 27 in a moderate yield of 50%, calculated over two steps. Generally, 
treatment of the methyl ester with an excess of ammonia should convert the ester into the 
amide. Much to our surprise, however, even in concentrated ammonium hydroxide the ester 
appeared to be unreactive towards amidation. Subjection to a solution of ammonia (7M) in 
methanol only led to the recovery of starting material. Gratifyingly, dissolving the methyl 
ester in liquid ammonia in a sealed tube for eight days at room temperature led to the 
corresponding amide 28 in 70% isolated yield. 
 
 
 
Scheme 4.4. Synthesis of the protected olefinic amide 28. 
 
Encouraged by the efficient synthesis of the enantiopure building block 28 via a selective 
olefination/ring-opening sequence, we decided to apply the same methodology to the 
corresponding benzylated derivative. Since O-alkylation of lactonic acids in the presence of a 
strong base is known to be impossible and an imidate coupling in the presence of triflic acid 
most probably will lead to hydrolysis of the trityl protecting group, we shifted our focus to 
the ring opening of functionalized 1-O-methyl riboses.  
 
 
 
Scheme 4.5. Synthesis of amides 35 and 36. 
 
Following a literature procedure,19 the iodinated acetal 29 was synthesized in four 
consecutive steps starting from D-ribose. With the iodide in hand, a zinc-mediated ring-
opening should provide aldehyde 31 (Scheme 4.5). Indeed, the aldehyde was formed, albeit 
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that high temperatures were required for the reaction to proceed, resulting in only 12% of 
the aldehyde after silica gel purification. Moreover, the aldehyde rapidly decomposed upon 
standing at room temperature. In order to enhance the reactivity of the zinc, a catalytic 
amount of acetic acid was added to the reaction mixture. Although the reaction was now 
completed within minutes, the yield remained low. Eventually, we found that performing 
the reaction at room temperature in a H2O/THF-mixture (1:9) increased the yield to 80%. 
Due to its instability, the aldehyde 31 was immediately oxidized to the more stable 
carboxylic acid. While the reaction conditions of both the Pinnick and the Jones oxidation 
were too harsh resulting in decomposition, treatment with the milder oxidant pyridinium 
dichromate (PDC) resulted in the desired carboxylic acid. Esterification of the acid prior to 
purification, using TMSCHN2, afforded methyl ester 33 in 89% yield, calculated over two 
steps. Finally, treatment with ammonia in methanol gave amide 35 in 71% yield. In addition 
to the synthesis of the disubstituted amide 35, the monosubstituted amide 36 was prepared 
according to similar procedures (Scheme 4.5). Selective protection of the alcohols and 
subsequent iodonation to the acetal 30 provided the precursor for ring opening. 
Disappointingly, treatment of 30 with zinc in the presence of a catalytic amount of acetic 
acid resulted in only 36% yield of 32. A plausible explanation could lie in the volatility of the 
aldehyde. Oxidation of the crude aldehyde to the carboxylic acid followed by esterification 
on the other hand yielded the carboxylic ester 34 in 63% yield starting from the iodide 30. 
Again, treatment of the ester with ammonia provided the amide (36) as described 
previously.  
 
At this point, having successfully synthesized the hydroxy-substituted olefinic amides 35 and 
36, we decided to also synthesize the 2-hydroxy-substituted amide 42 (Scheme 4.6). 
Although a zinc-mediated ring opening approach of iodinated 3-deoxypentose seemed 
logical, an additional four steps would be required for its synthesis.20 Alternatively, the 
commercially available non-proteinogenic amino acid L-allylglycine (2-amino-4-pentenoic 
acid, 37) was used.21 Diazotation in a mixture of THF and methanol (1:1) in the presence of 
sodium nitrite gave the diazonium salt, which was readily converted into 2-hydroxypent-4-
enoic acid (38 upon) loss of nitrogen with full overall retention of stereochemistry. Due to 
the poor isolated yield (<10%), the crude acid was immediately converted into methyl ester 
39. Since this did not improve the yield, the alcohol function was benzylated prior to 
purification. Formation of the dianion (2.5 equiv of sodium hydride), followed by addition of 
1 equiv of benzyl bromide provided 40 in 41% isolated yield (calculated over 2 steps) and a 
small amount of benzyl ester 41. Although the reaction did not reach completion, additional 
benzyl bromide only led to an increase of 41. Because of the moderate yield of the reaction, 
the reaction was repeated with 2.5 equiv of benzyl bromide to give 41, followed by 
saponification of the benzyl ester with potassium hydroxide. The overall yield was similar, 
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but since the second pathway required an additional step, the first method had our 
preference.  
Carboxylic acid 40 was successively treated with oxalyl chloride and quenched with ammonia 
to form amide 42 (Scheme 4.6). Much to our surprise, HPLC-measurements showed that 
complete racemization had occurred. This was probably caused by ketene formation from 
the corresponding acid chloride intermediate. To avoid the racemization, carboxylic acid 40 
was converted into methyl ester 39. Next, conversion into amide 42 was successfully 
accomplished by treatment of the ester with ammonia. 
  
  
 
Scheme 4.6. Reagents and conditions: a) i: (COCl)2, rt, 2 h, PhMe, ii: NH3, rt, 16 h, MeOH (74%); b) i: 
TMSCHN2, rt, 10 min, MeOH, ii: NH3, rt, 16 h, MeOH (67%). 
 
4.4 Introduction of N-substituents 
 
Since we previously found that secondary amides and carbamates are unreactive toward 
condensation with ethyl pyruvate (Chapter 2), it was suggested that also protected amines 
could be introduced as substituents instead of hydroxy groups. This should be possible via 
conversion of L-allylglycine into the corresponding amide 43, followed by protection of the 
amine. To this end, L-allylglycine was treated with oxalyl chloride and the reaction was 
quenched with ammonia to afford the amino amide 43 in 67% yield. In sharp contrast with 
the 2-hydroxypent-4-enoic acid variants, the stereocenter remained unaffected. In a second 
transformation, the amine group was protected as carbamate or azide resulting in 
precursors 44-46 for condensation with ethyl pyruvate (Scheme 4.7).  
 
                                                                                 Synthesis of optically 2-oxopiperidine carboxylate  
 
  117 
 
 
 
Scheme 4.7. a) BzCl, NaHCO3, 0 °C, H2O; b) CbzCl, Na2CO3, 0 °C, acetone; c) TfN3, Et3N, CuSO4, rt, 
CH2Cl2/ MeOH/H2O 3:10:3. 
 
4.5 Introduction of allylic C-substituents 
 
With the oxygen- and nitrogen-substituted olefinic amides successfully synthesized, we 
envisioned that C4-substituted pipecolic acids (aliphatic, aromatic) could also be readily 
prepared via the developed methodology. To this end, we explored the possibilities of 1,4-
addition onto commercially available 5-hydroxymethylfuran-2-(5H)-one (47) using 
organocopper reagents. A bulky group on the primary alcohol would then be necessary to 
maximize the diastereoselectivity. Following literature precedent,22 furanone 47 was initially 
reacted with trityl chloride in pyridine at room temperature leading to the corresponding 
product in a moderate yield of 44%. Silylation with the bulky TBDPS-group on the other hand 
led to the protected furanone 48 in an excellent yield of 89% (Scheme 4.8).  
 
 
 
 
Scheme 4.8. Reagents and conditions: a) R = Et, iPr: RMgBr, PhSCu, -30 °C, 10 min, THF; b) R = Ph: 
PhLi, CuI, TMSCl, -78 °C, 1 h, Et2O 
 
 
With the TBDPS-protected furanone 48 in hand, a first conjugate addition was performed 
with ethylmagnesium bromide in the presence of PhSCu (1 equiv) in THF at  
-78 °C. Unfortunately, this resulted in multiple products. Most likely, the transmetallation 
from magnesium to copper did not occur at these low temperatures. For that reason the 
reaction was repeated at -30 °C. Upon a dropwise addition of the furanone to the cuprate, 
the reaction was now completed within minutes, resulting in the formation of 49 as a single 
diastereoisomer in yields ranging from 43-78% yield. In addition, a branched aliphatic 
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analogue (50) and an aromatic substituted derivative (51) were successfully incorporated. 
Although 1,4-addition with phenylmagnesium bromide led to low yields, treatment of 
furanone 48 with phenyllithium in the presence of copper iodide and TMSCl on the other 
hand, resulted in a high conversion into 51. To probe the feasibility of the sequence to the 
required olefinic amide, lactone 49 was transformed into the ethyl-substituted olefinic 
amide 55 in four consecutive steps (desilylation, iodination, ring-opening, amidation) in 
satisfactory yields (Scheme 4.9).  
 
 
 
Scheme 4.9. Synthesis of 3-ethyl-substituted olefinic amide 55. 
 
4.5 Condensation and RCM of optically active amides 
 
With the desired unsaturated amides successfully synthesized, the stage was set for the 
condensation to the corresponding RCM precursors. First, amide 28 was subjected to ethyl 
pyruvate under Dean-Stark conditions, as described in Chapter 2. TLC showed a distinct new 
product, but the reaction was proceeding very slowly. Most likely due to the long reaction 
time and the additional amount of p-toluenesulfonic acid that was added, eventually only 
decomposition occurred (e.g., desilylation, elimination, etc) (Table 4.1). 
Gratingfyingly, condensation of the O-benzyl-protected amides 35, 36 and 42 with ethyl 
pyruvate afforded the corresponding dehydroamino esters 57-59. In sharp contrast, 
condensation of the amine substituted olefinic amides 44-46 did not lead to any product at 
all. The amides 44 and 45 appeared to be insoluble in toluene and benzene. Condensation in 
dry ethanol resulted only in recovery of starting material. The azido-protected amide 46 on 
the other hand decomposed upon heating. Finally, the ethyl-substituted derivative 55 was 
successfully condensed, providing the dehydroamino ester 63 in 57% yield. 56-63 were then 
N-protected prior cyclization by treatment with PMBBr in the presence of NaH.  
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Table 4.1. Condensation of unsaturated amides 35, 36, 42 and 55. 
 
 
 
Entry Reactant R1 R2 Product Yield (%) 
1 28 OTBS OTBS 56 - 
2 35 OBn OBn 57 73 
3 36 H OBn 58 38 
4 42 OBn H 59 69 
5 44 NHBz H 60 - 
6 45 NHCbz H 61 - 
7 46 N3 H 62 - 
8 55 Et H 63 57 
9 57 OBn OBn 64 66 
10 58 H OBn 65 58 
11 59 OBn H 66 78 
12 60 Et H 67 77 
 
The three hydroxy-substituted didehydroamino esters (64-66)were subjected to ring-closing 
metathesis conditions using 10 mol% of G2 in toluene at 80 °C. Disappointingly, 
disubstituted 64 appeared to be unreactive to G2 (Table 4.2). Addition of the more reactive 
third generation Grubbs catalysts (G6 and G7, see Section 2.5) did also not lead to any 
product formation either. Chelation of the allylic ether to the metal center of the catalyst 
could be invoked as a possible explanation for the observed lack of reactivity.23 However, 
when the reaction was performed in the presence of Ti(OiPr)4, a known method for 
circumventing intramolecular chelation,25c only decomposition of the starting material was 
observed. In case of the mono-substituted dehydroamino esters (65, 66), the expected cyclic 
products were formed in yields of 58 and 88% respectively. This result clearly indicates that 
the lack of reactivity of 64 is based on steric hindrance of the bulky benzyl groups thereby 
preventing cis/trans rotation, rather than chelation of the allylic alcohol to the metal 
complex. Finally, we were pleased to find that reaction of the ethyl-substituted 
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didehydroamino ester 67 with the second generation Grubbs catalyst G2 in toluene at 80 °C 
for 2 h resulted in the formation of the cyclic dehydroamino ester 71 in a good yield of 91%.   
Table 4.2. Preparation of the cyclic dehydroamino esters 68-71 
 
 
 
Entry Reactant R1 R2 Product Yield (%) 
1 64 OBn OBn 68 - 
2 65 H OBn 69 58 
3 66 OBn H 70 88 
4 67 Et H 71 91 
 
   
4.6 Conclusions 
 
This chapter shows the scope and limitations for preparing enantiopure C34- and C5-
hydroxy- and alkyl-substituted cyclic dehydroamino esters via a condensation/ring-closing 
metathesis approach. The enantiopure olefinic amides are readily prepared, starting from 
either 1-O-methylriboses (or its oxidized form) or the unnatural amino acid L-allylglycine. A 
zinc-mediated ring opening of iodinated pentoses proved to be a useful method for the 
synthesis of enantiopure olefinic amides. Moreover, a diastereoselective conjugate addition 
onto furanoses provided enantiopure alkyl- and aryl- amides substituted at the allylic 
position. Unfortunately, amine-substituted derivatives prepared from L-allylglycine appeared 
incompatible with the condensation reaction. Finally, RCM of the enantiopure substituted 
dehydroamino esters proceeded smoothly, yielding the cyclic didehydroamino esters in 
moderate to good yield. 
 
4.7 Acknowledgements 
 
Peter G. W. Rensen is kindly thanked for his contribution to this chapter. Chiralix BV 
(Nijmegen, The Netherlands) is kindly acknowledged for providing L-allylglycine. 
 
                                                                                 Synthesis of optically 2-oxopiperidine carboxylate  
 
  121 
 
4.9     Experimental section 
 
General information 
 
For general experimental details, see section 2.7 
 
(4R,5R)-2,2-Dimethyl-5-vinyl-1,3-dioxolane-4-carboxylic acid (20) 
To a solution of 19 (894 mg, 3 mmole) in MeOH (30 mL) Zn (981 mg, 5 equiv.) was added. 
The mixture was refluxed for 1 h and allowed to cool to rt. Next, it was filtered through Celite 
and concentrated in vacuo to afford the product 20 (275 mg, 53% yield). Rf 0.04 (EtOAc). 
1
H 
NMR (CDCl3, 300 MHz): δ 5.48 (ddd, 1H, J = 7.2 Hz, J = 10.2 Hz, J = 17.1 Hz), 5.39 (d, 1H, J = 
17.1 Hz), 5.22 (d, 1H, J = 10.2 Hz), 4.80 (t, 1H, J = 7.2 Hz), 4.69 (d, 1H, J = 7.2 Hz), 1.61 (s, 3H), 1.40 (s, 3H). 
13
C 
NMR (CDCl3, 75 MHz): δ 171.04, 132.42, 117.45, 110.06, 78.05, 76.97, 25.44, 23.83. Data are in agreement with 
literature.
17
 
 
(4R,5R)-Methyl-2,2-dimethyl-5-vinyl-1,3-dioxolane-4-carboxylate (22) 
To a solution of 20 (70 mg, 0.4 mmole) in MeOH/THF (2 mL, 1:1), TMS-diazomethane 2.0 M 
in hexane (400 µL, 2 equiv.) was added. This mixture was stirred for 2 h at rt. Next, it was 
diluted with EtOAc/H2O (8 ml, 1:1) and the organic layer was washed with H2O (3 × 4 mL) and 
brine (3 × 3 mL). the organic layer was dried (MgSO4) and purified by column 
chromatography (EtOAc/heptane, 1:3) to afford 22 (3.7 mg, 5%) as a colorless oil. Rf 0.37 (EtOAc/heptane, 1:3). 
1
H NMR (CDCl3, 300 MHz): δ 5.78-5.66 (m, 1H), 5.42 (ddd, 1H, J = 1.2 Hz, J = 1.5 Hz, J = 17.1 Hz), 5.26 (ddd, 1H, 
J= 0.9, 1.5, 10.2 Hz,), 4.73 (tt, 1H, J = 0.9 Hz, J = 7.2 Hz), 4.68 (d, J = 7.2 Hz, 1H), 3.70 (s, 3H), 1.63 (s, 3H), 1.39 (s, 
3H). 
13
C NMR (CDCl3, 75 MHz): δ 169.45, 131.67, 118.94, 110.76, 78.33, 77.36, 51.38, 26.53, 25.13. Data are in 
agreement with literature.
24
 
 
(3R,4S,5R)-3,4-Dihydroxy-5-(trityloxymethyl)dihydrofuran-2(3H)-one (23) 
Ribolactonic acid (4.61 g, 34.9 mmole) was dissolved in pyridine (100 mL). To this solution TrtCl 
(12.66 g, 1.3 eq.) was added and the mixture was heated at 60 °C for 1 d. The reaction was 
concentrated and CH2Cl2 (200 mL) was added. The solution was washed with brine (3 × 50 mL) 
and concentrated in vacuo. The crude product was dissolved in MeOH (150 mL), filtered over 
celite, dried (Na2SO4) and concentrated in vacuo. The residue was purified by column chromatography 
(EtOAc/heptane = 1:2 → 1:1) to give 23 (8.5 g, 65% yield) as a white solid. Rf 0.30 (CH2Cl2/MeOH, 6:1). IR (ATR) 
1787, 2509, 3364 cm
−1
. 
1
H NMR (CDCl3, 200 MHz): δ 7.41-7.20 (m, 15H), 4.77 (dd, 1H, J = 0.3 Hz, 8.4 Hz), 4.42 (t, 
1H, J = 4.5 Hz, 1H), 4.14 (dd, 1H, J = 0.9 Hz, J = 8.1 Hz), 3.56 (dd, 1H, J = 4.5 Hz, J = 16.2 Hz), 3.21 (dd, 1H, J = 7.5 
Hz, J = 16.2 Hz). 
13
C NMR (CDCl3, 75 MHz): δ 176.77, 143.74, 143.33, 142.86, 128.17, 127.93, 127.26, 126.84, 
126.68, 126.12, 87.04, 84.05, 73.37, 72.04, 62.47. Data are in agreement with literature.
18
 
 
(3R,4R,5R)-3,4-Bis(tert-butyldimethylsilyloxy)-5-(trityloxymethyl)dihydrofuran-2(3H)-one (24) 
Compound 23 (3.25 g, 8.69 mmole) and imidazole (1.2 g, 1.6 eq.) were dissolved in DMF (60 
mL). This mixture was cooled to 0 °C and then TBSCl (3.2 g, 1.9 eq.) and DMAP (10 mol%) were 
added. The resulting mixture was allowed to warm to rt and stirred for 2 d. Next, it was 
diluted with EtOAc (200 mL), washed with water (3 × 50 mL), dried (Na2SO4) and concentrated 
in vacuo. The residue was purified by column chromatography (EtOAc/heptane, 1:6) to give 24 (5.37 g, >99% 
yield) as a yellow oil. Rf 0.41 (EtOAc/heptane, 1:4). [ ] 
   +22.0 (c 3.39). IR (ATR) 1791, 2854, 2932, 2949 cm
−1
. 
1
H NMR (CDCl3, 300 MHz): δ 7.43-7.23 (m, 15H), 4.68 (d, 1H, J = 5.1 Hz), 4.30 (dt, 1H, J = 0.9, J = 3.3 Hz), 3.97 
(dd, 1H, J = 0.9 Hz, J = 5.1 Hz), 3.61 (dd, 1H, J = 3.9 Hz, J = 11.1 Hz, 1H), 3.21 (dd, 1H, J = 2.7 Hz, J = 10.8 Hz), 0.94 
(s, 9H), 0.81 (s, 9H), 0.19 (s, 3H), 0.11 (s, 3H), 0.02 (s, 3H), -0.05 (s, 3H). 
13
C NMR (CDCl3, 75 MHz): δ 174.67, 
142.63, 128.15, 127.63, 126.96, 87.17, 84.19, 71.62, 69.95, 61.87, 25.44, 25.27, 17.98, 17.65, -5.04, -5.17, -5.35, 
-5.64. HRMS (ESI) m/z calcd for C36H50O5Si2 (M+Na)
+
: 641.3085, found: 641.3094. 
O
O
TrtO
HO OH
O
O
TrtO
TBSO OTBS
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(3R,4R,5R)-3,4-Bis(tert-butyldimethylsilyloxy)-5-(hydroxymethyl)dihydrofuran-2(3H)-one (25) 
Compound 24 (4.0 g, 6.62 mmole) was dissolved in CHCl3 (50 mL). To this solution a catalytic 
amount of 10% Pd/C was added. H2 was bubbled through the solution and the reaction was 
stirred for 2 d at rt. Then it was filtered through celite, dried (Na2SO4), concentrated in vacuo 
and purified using column chromatography (EtOAc/heptane, 1:5 → 1:1) to afford 25 (1.12 g, 
80% yield) as a white solid. Rf 0.15 (EtOAc/heptane, 1:5). [ ] 
   +36.0 (c 1.63). IR (ATR) 1778, 2846, 2884, 2923, 
2958, 3235 cm
−1
. 
1
H NMR (CDCl3, 300 MHz): δ 4.51 (d, 1H, J = 5.1 Hz), 4.35-4.29 (m, 2H), 3.95 (ddd, 1H, J = 3.0 
Hz, J = 5.4 Hz, J = 12.6 Hz, 1H), 3.75 (ddd, 1H, J = 3.0 Hz, J = 6.6 Hz, J = 12.6 Hz), 2.49 (t, 1H, J = 6.0 Hz), 0.93 (s, 
9H), 0.89 (s, 9H), 0.17 (s, 3H), 0.14 (s, 3H), 0.10 (s, 6H). 
13
C NMR (CDCl3, 75 MHz): δ 174.87, 85.23, 70.96, 70.13, 
60.76, 25.38, 25.25, 17.99, 17.73, -5.14, -5.35, -5.63. HRMS (CI) m/z calcd for C17H36O5Si2Na (M+Na)
+
: 399.1986, 
found: 399.1999.  
 
(3R,4R,5S)-3,4-Bis(tert-butyldimethylsilyloxy)-5-(iodomethyl)dihydrofuran-2(3H)-one (26) 
Compound 25 (3.2 g, 8.5 mmole) and PPh3 (2.71 g, 1.2 eq.) were dissolved in THF (75 mL). The 
solution was heated to 70 °C and a solution of imidazole (963 mg, 1.5 eq.), I2 (2.9 g, 1.2 eq.) in 
CH2Cl2 (75 mL) were added. After stirring for 3 d at rt, the mixture was diluted with CH2Cl2 (15 
mL) washed with 10% Na2S2O3 (15mL), H2O (20 mL) and brine (15 mL). The organic layer was 
dried (Na2SO4), concentrated in vacuo and purified using column chromatography (EtOAc/heptane = 1:5) to 
give 26 (1.49 g, 96% yield) as a white wax. Rf 0.67 (EtOAc/heptane, 1:1). [ ] 
   -4.0 (c 0.65). IR (ATR) 512, 1783, 
2854, 2928, 2954 cm
−1
. 
1
H NMR (D6-acetone, 300 MHz): δ 4.84 (dd, 1H, J = 0.3 Hz, J = 4.8 Hz), 4.55 (dd, 1H, J = 
1.2 Hz, J = 4.8 Hz), 4.48-4.43 (m, 1H), 3.59 (dd, 1H, J = 7.8 Hz, J = 10.5 Hz), 3.49 (dd, 1H, J = 6.9 Hz, J = 10.5 Hz), 
0.95 (s, 9H), 0.91 (s, 9H), 0.20 (s, 3H), 0.19 (s, 3H), 0.17 (s, 3H), 0.16 (s, 3H). 
13
C NMR (CDCl3, 75 MHz): δ 204.76, 
132.93, 128.26, 83.97, 72.58, 69.74, 24.95, 1.34, -5.53, -5.87, -6.08. HRMS (CI) m/z calcd for C17H36O4ISi2 
(M+H)
+
: 487.1197, found: 487.1189. 
 
(2R,3R)-Methyl 2,3-bis(tert-butyldimethylsilyloxy)pent-4-enoate (27) 
To a solution of 26 (889 mg, 1.83 mmole) in MeOH (20 mL), zinc (1.81 g, 15 equiv.) was added 
and this mixture was stirred for 2 h at 70 °C. Next, it was filtered through celite and 
concentrated in vacuo. The residue was filtered through a short plug of silica gel 
(EtOAc/heptanes, 1:3), concentrated in vacuo and dissolved in MeOH (30 mL). To this solution TMSCHN2 (2.0 M 
in hexane) (1.38 mL, 1.5 equiv.) was added and this mixture was stirred for 1 h at rt. The mixture was 
concentrated in vacuo and purified by column chromatography (EtOAc/heptane, 1:4) to afford 27 (342 mg, 50% 
yield over 2 steps) as a colorless oil. Rf 0.71 (EtOAc/heptane, 1:5). [ ] 
   +2.6 (c 0.50).  IR (ATR) 1749, 2848, 
2930, 2958 cm
−1
. 
1
H NMR (CDCl3, 300 MHz): δ 5.83 (ddd, 1H, J = 6.9 Hz, J = 10.2 Hz, J = 17.1 Hz), 5.24 (ddd, 1H, J 
= 1.2 Hz, J = 1.8 Hz, J = 17.4 Hz), 5.16 (ddd, 1H, J = 0.9 Hz, J = 1.8 Hz, J = 10.2 Hz), 4.27 (tt, 1H, J = 1.2 Hz, J = 6.6 
Hz, 1H), 4.03 (d, 1H, J = 6.6 Hz, 1H), 3.70 (s, 3H), 0.87 (s, 9H), 0.85 (s, 9H), 0.03 (s, 6H), 0.02 (s, 3H), 0.01 (s, 3H). 
13
C NMR (CDCl3, 75 MHz): δ 171.94, 137.58, 116.66, 51.29, 35.04, 31.46, 25.28, 25.20, 22.24, 13.65, 0.56, -4.88, 
-5.58, -5.65. HRMS (ESI) m/z calcd for C18H38O4Si2Na (M+Na)
+
: 397.2210, found: 397.2206. 
 
(2R,3R)-2,3-Bis(tert-butyldimethylsilyloxy)pent-4-enamide (28) 
Compound 27 (337 mg, 0.94 mmole) was dissolved in MeOH (5 mL) and put in a sealed tube. 
Liquid NH3 (20 mL) was added, the tube was sealed and the mixture was stirred at 40 °C for 8 
days. The tube cooled to -78 °C, opened and allowed to warm to rt. The reaction mixture was 
concentrated in vacuo and purified by column chromatography (EtOAc/heptane = 1:5) to 
afford 28 (238 mg, 70% yield) as a colorless oil. Rf 0.62 (EtOAc/heptane, 1:1). [ ] 
   +16.3 (c 0.65). IR (ATR) 
1696, 2854, 2919, 2954, 3477 cm
−1
. 
1
H NMR (CDCl3, 300 MHz): δ 7.44 (s, 1H), 5.83 (ddd, 1H, J = 6.9 Hz, J = 10.2 
Hz, J = 17.1 Hz, 1H), 5.16 (ddd, 1H, J = 1.2 Hz, J = 1.8 Hz, J = 27 Hz, 1H), 5.16-5.14 (m, 1H), 4.43-4.47 (m, 1H), 
4.20 (d, 1H, J = 2.4 Hz), 0.92 (s, 9H), 0.90 (s, 9H), 0.15 (s, 3H), 0.11 (s, 3H), 0.09 (s, 3H), 0.05 (s, 3H). 
13
C NMR 
(CDCl3, 75 MHz): δ 173.76, 135.72, 116.27, 78.44, 76.59, 25.55, 25.44, 17.96, 17.74, -4.97, -5.25, -5.93. HRMS 
(ESI) m/z calcd for C17H37NO3Si2Na (M+Na)
+
: 382.2212, found: 382.2210. 
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(2S,3S,4R,5R)-3,4-Bis(benzyloxy)-2-(iodomethyl)-5-methoxytetrahydrofuran (29) 
The primary alcohol (152 mg, 0.44 mmole) and PPh3 (140 mg, 0.52 mmole) were dissolved in 
THF (15 mL). This solution was heated to 70 °C and a solution of imidazole (45 mg, 0.66 
mmole), I2 (135 mg, 0.52 mmole) in CH2Cl2 (3 mL) was added. After stirring for 3 h at 70 °C the 
solution was diluted with CH2Cl2 (15 mL), washed with 10% Na2S2O3 (15mL), H2O (20 mL) and 
brine (15 mL). The organic layer was dried (Na2SO4), concentrated in vacuo and purified using 
column chromatography (EtOAc/heptane = 1:3). Rf 0.68 (EtOAc/heptane, 1:1). 
1
H NMR (CDCl3, 300 MHz): δ 
7.37-7.28 (m, 10H), 4.93 (s, 1H), 4.66 (d, 2H, J = 12.0 Hz), 4.52 (d, 2H, J = 12.0 Hz), 4.59 (d, 2H, J = 11.7 Hz), 4.46 
(d, 2H, J = 11.7 Hz), 4.16 (ddd, 1H, J = 5.1 Hz, J = 5.7 Hz, J = 6.6 Hz, 1H), 3.97-3.89 (m, 2H), 3.37 (s, 3H), 3.32-3.27 
(m, 2H). 
13
C NMR (CDCl3, 75 MHz): δ 137.11, 137.03, 131.75, 131.53, 128.04, 127.97, 127.57, 127.54, 127.47, 
105.75, 81.27, 79.88, 79.65, 72.16, 71.89, 54.85, 8.14. Data are in agreement with literature.
25
 
 
(2R,3S)-2,3-Bis(benzyloxy)pent-4-enal (31) 
To a solution of 29 (1.5 g, 3.3 mmole) in THF/H2O (9:1) (33 mL), zinc (2.14 g, 10 equiv.) was 
added together with acetic acid (330 µL) and this mixture was stirred for 1 h at 70 °C. Next, it 
was filtered over celite and concentrated in vacuo. The organic layer was filtered through celite, 
dried (Na2SO4), concentrated in vacuo and purified using purified by column chromatography 
(EtOAc/heptane, 1:2) to afford 31 (830 mg, 88%) as a colorless oil. Rf 0.56 (EtOAc/heptane, 1:1). 
1
H NMR (CDCl3, 
75 MHz): δ 7.31-7.22 (m, 10H), 5.88 (ddd, 1H, J = 7.6 Hz, J = 10.5 Hz, J = 17.2 Hz), 5.40-5.35 (m, 2H), 4.77 (d, 1H, 
J = 11.8 Hz), 4.57 (d, 1H, J = 11.8 Hz), 4.59 (d, 1H, J = 12.0 Hz), 4.44 (d, 1H, J = 12.0 Hz), 4.16 (tdd, 1H, J = 0.9 Hz,  
J = 4.8 Hz, J = 7.6 Hz), 3.89 (dd, 1H, J = 2.0 Hz, J = 4.8 Hz.  
 
(2R,3S)-Methyl 2,3-bis(benzyloxy)pent-4-enoate (33) 
To a solution of 31 (1.66 g, 5.82 mmole) in DMF (20 mL), PDC (10.96 g, 5 equiv.) was added 
and this mixture was stirred for 16 h at room temperature. Next, it was filtered through celite 
and concentrated in vacuo. The mixture was redissolved in MeOH. TMSCHN2 was added until 
the solution remained yellow. The mixture was again concentrated in vacuo and purified by 
column chromatography (EtOAc/heptane, 1:1) to afford 33 (1.63 g, 89%) as a colorless oil. Rf 0.38 
(EtOAc/heptane, 1:1). [α] 
   -7.4 (c 0.005). IR (ATR) 1112, 1747, 2360, 2941 cm
−1
. 
1
H NMR (CDCl3, 400 MHz): δ 
7.34-7.21 (m, 10H), 6.58 (br s, 1H), 5.89 (ddd, 1H, J = 7.5 Hz, J = 11.0 Hz, J = 16.6 Hz), 5.42 (br s), 5.31-5.39 (m, 
2H), 4.92 (d, 1H, J = 12.0 Hz), 4.72 (d, 1H, J = 11.9 Hz), 4.63 (d, 1H, J = 12.0 Hz), 4.43 (d, 1H, J = 11.9 Hz), 4.16-
4.09 (m, 1H), 4.07 (d, 1H, J = 5.9 Hz). 
13
C NMR (CDCl3, 75 MHz): δ 170.63, 137.46, 136.69, 134.06, 127.81, 
127.54, 127.38, 127.20, 127.10, 119.29, 80.28, 80.24, 72.30, 70.22, 51.46. HRMS (ESI) m/z calcd for 
C17H37NO3Si2Na (M+Na)
+
: 382.2212, found: 382.2210. 
 
(2R,3S)-2,3-Bis(benzyloxy)pent-4-enamide (35) 
Methylester 33 (1.63 g, 5.18 mmole) was dissolved in MeOH (5 mL) and put in a sealed tube. 
Liquid NH3 20 mL) was added, the tube was sealed and the mixture was stirred at 40 °C for 3 
days. The tube was put in a -78 °C bath for 10 min, opened and allowed to warm to rt. The 
reaction mixture was concentrated in vacuo and purified by column chromatography (EtOAc) 
to afford 35 (987 mg, 61% yield) as a colorless oil. [α] 
   -13.7 (c 0.003). IR (ATR) 696, 1656, 3188, 3384 cm
−1
. 
1
H 
NMR (MeOD, 400 MHz): δ 7.31-7.22 (m, 10H), 5.89 (ddd, 1H, J = 7.5 Hz, J = 11.0 Hz, J = 16.6 Hz), 5.36-5.30 (m, 
2H), 5.33 (ddd, 1H, J = 0.9 Hz, J = 1.6 Hz, J = 8.1 Hz), 4.70 (d, 1H, J = 12.0 Hz), 4.61 (d, 1H, J = 11.9 Hz), 4.51 (d, 
1H, J = 12.0 Hz), 4.40 (d, 1H, J = 11.9 Hz), 4.14-4.06 (m, 1H), 4.07 (d, 1H, J = 5.9 Hz), 3.71 (s, 3H). 
13
C NMR 
(MeOD, 75 MHz): δ 171.88, 137.79, 136.95, 132.87, 128.02, 127.86, 127.52, 127.02, 119.39, 81.57, 73.18, 
70.22. HRMS (ESI) m/z calcd for C19H21NO3Na (M+Na)
+
: 334.1419, found: 334.1411. 
 
(2S,3S)-3-(Benzyloxy)-2-(iodomethyl)-5-methoxytetrahydrofuran (30) 
The primary alcohol (3.02 g, 6.32 mmole) and PPh3 (1.27 g, 1.2 eq.) were dissolved in THF (75 
mL). This solution was heated to 70 °C and a solution of imidazole (417 mg, 1.5 eq.), I2 (1.22 g, 
1.2 eq.) in CH2Cl2 (75 mL) was added. After stirring for 5 h,  the mixture was cooled to room 
temperature and diluted with CH2Cl2 (15 mL), washed with 10% Na2S2O3 (15mL), H2O (20 mL) 
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and brine (15 mL). The organic layer was dried (Na2SO4), concentrated in vacuo and purified using column 
chromatography (EtOAc/heptane = 1:5) to give 28 (1.08 g, 76% yield) as a white wax. Rf 0.67 (EtOAc/heptane, 
1:1). IR (ATR) 1035, 1098, 1209, 1365, 1727, 2907 cm
−1
. 
1
H NMR (CDCl3, 400 MHz): δ 7.31-7.26 (m, 10H), 5.16 
(dd, 1H, J = 2.1 Hz, J = 5.4 Hz), 5.08 (dd, 1H, J = 1.4 Hz, J = 5.6 Hz), 4.61 (d, 1H, J = 12.1 Hz), 4.57 (d, 1H, J = 11.7 
Hz), 4.52 (d, 1H, J = 11.7 Hz), 4.51 (d, 1H, J = 12.1 Hz), 4.28 (ddd, 1H, J = 3.2 Hz, J = 6.2 Hz, J = 8.0 Hz), 4.18 (ddd, 
1H, J = 3.1 Hz, J = 5.2 Hz, J = 6.8 Hz), 3.98 (q, 1H, J = 4.6 Hz), 3.83 (ddd, 1H, J = 3.0 Hz, J = 4.5 Hz, J = 8.1 Hz), 3.40 
(s, 3H), 3.37 (s, 3H), 3.20-3.16 (m, 4H), 2.24-2.19 (m, 3H), 2.03 (ddd, 1H, J = 1.5 Hz, J = 3.0 Hz, J = 14.1 Hz). 
13
NMR (CDCl3, 75 MHz): δ 137.36, 128.00, 105.37, 104.67, 83.70, 81.52, 81.25, 80.75, 71.46, 54.77, 39.41, 
38.58, 7.57, 7.50. HRMS (ESI) m/z calcd for C13H17INO3Na (M+Na)
+
: 371.0120, found: 371.0103. 
 
Methyl (S)-3-(benzyloxy)pent-4-enoate (34) 
To a solution of 30 (1.17 g, 3.36 mmole) in THF/H2O (9:1) (34 mL), zinc (2.18 g, 10 equiv.) was 
added together with acetic acid (330 µL) and this mixture was stirred for 1 h at 70 °C. Next, it 
was filtered through celite, concentrated in vacuo and purified by column chromatography 
(EtOAc/heptane, 1:2) to afford the aldehyde as a colorless oil. The aldehyde was immediately dissolved in DMF 
(20 mL), PDC (1096 g, 5 equiv.) was added and this mixture was stirred for 16 h at room temperature. Next, it 
was filtered over celite and concentrated in vacuo. The mixture was redissolved in MeOH. TMSCHN2 was added 
until the solution remained yellow. The mixture was again concentrated in vacuo and purified by column 
chromatography (EtOAc/heptane, 1:1) to afford 34 (1.63 g, 89%) as a colorless oil. Rf 0.38 (EtOAc/heptane, 1:1). 
[α] 
   -13.4 (c 0.005). IR (ATR) 1112, 1747, 2360, 2941 cm
−.
. 
1
H NMR (CDCl3, 400 MHz): δ 7.31-7.22 (m, 10H), 
6.58 (br s, 1H), 5.89 (ddd, 1H, J = 7.5 Hz, J = 11.0 Hz, J = 16.6 Hz), 5.42 (br s), 5.35-5.29 (m, 2H), 4.92 (d, 1H, J = 
12.0 Hz), 4.72 (d, 1H, J = 11.9 Hz), 4.63 (d, 1H, J = 12.0 Hz), 4.43 (d, 1H, J = 11.9 Hz), 4.14-4.07 (m, 1H), 4.07 (d, 
1H, J = 5.9 Hz). 
13
C NMR (CDCl3, 75 MHz): δ 170.63, 137.46, 136.69, 134.06, 127.81, 127.54, 127.38, 127.20, 
127.10, 119.29, 80.28, 80.24, 72.30, 70.22, 51.46. HRMS (ESI) m/z calcd for C17H37NO3Si2Na (M+Na)
+
: 382.2212, 
found: 382.2210. 
  
(S)-3-(Benzyloxy)pent-4-enamide (36) 
Methylester 34 (1.63 g, 5.18 mmole) was dissolved in MeOH (5 mL) and put in a sealed tube. 
Liquid NH3 20 mL) was added, the tube was sealed and the mixture was stirred at 40 °C for 3 
days. The tube was put in a -78 °C bath for 10 min, opened and allowed to warm to rt. The 
reaction mixture was concentrated in vacuo and purified by column chromatography (EtOAc) to afford 27 (987 
mg, 61% yield) as a colorless oil, which was stirred in NH3 for 8 days at 40 °C. The reaction was concentrated in 
vacuo and purified by column chromatography (CH2Cl2/MeOH) to give 36 (103 mg, 15% yield over 4 steps) as a 
colorless oil. Rf 0.34 (EtOAc/heptane, 1:1). [α] 
   -15.8 (c 0.015). IR (ATR) 697, 1050, 1664, 2855, 3343 cm
−1
. 
1
H 
NMR (CDCl3, 400 MHz): δ 7.29-7.23 (m, 5H), 5.78 (ddd, 1H, J = 7.4 Hz, J = 10.3 Hz, J = 17.3 Hz), 5.26 (dddd, 2H, J 
= 0.9 Hz, J = 1.7 Hz, J = 10.3 Hz, J = 18.6 Hz), 4.56 (s, 2H), 4.54 (d, 1H, J = 11.7 Hz), 4.37 (d, 2H, J = 11.7 Hz), 4.27-
4.18 (m, 1H), 2.50 (dd, 1H, J = 8.4 Hz, J = 14.2 Hz), 2.35 (dd, 1H, J = 5.1 Hz, J = 14.2 Hz). 
13
NMR (MeOD, 75 MHz): 
δ 173.99, 137.83, 136.88, 127.43, 126.96, 126.70, 126.39, 126.12, 116.41, 77.00, 69.78, 41.34. HRMS (ESI) m/z 
calcd for C12H15NO2Na (M+Na)
+
: 228.1001, found: 228.0990. 
 
(S)-2-(Benzyloxy)pent-4-enoic acid (40)  
To a solution of L-allylglycine (200 mg, 1.72 mmole) in DMF (12 mL), NaH (179.7 mg, 2.5 
equiv) was added at 0 °C. The resulting mixture was stirred at 0 °C for 15 min. Then BnBr (210 
µL, 1 equiv.) was added. Next, the mixture was stirred at rt for 16 h. The mixture was 
quenched with H2O (20 mL) and concentrated in vacuo. The resulting oil was dissolved in 
CH2Cl2 (60 mL) and the salts were filtered off. The solution was dried (Na2SO4) and concentrated in vacuo. The 
resulting oil was purified using column chromatography (EtOAc/heptane, 1:2) to give 40 (160 mg, 44% yield 
over 2 steps) as a colorless oil. Rf 0.30 (CH2Cl2/MeOH, 6:1).  [ ] 
   -33.4 (c 0.028). IR (ATR) 741, 698, 1100, 1579, 
1731, 3003 cm
−1
.
 1
H NMR (CDCl3, 300 MHz): δ 7.35-7.22 (m, 5H), 5.93-5.79 (m, 1H), 5.12-5.02 (m, 2H), 4.61 (d, 
1H, J = 11.7 Hz), 4.53 (d, 1H, J = 11.7 Hz), 3.96 (t, 1H, J = 5.4 Hz), 2.52 (t, 2H, J = 6.6 Hz). 
13
C NMR (CDCl3, 75 
MHz): δ 176.0, 137.4, 133.5, 127.8, 127.4, 127.1, 116.9, 77.9, 71.4, 44.8, 36.8.HRMS (ESI) m/z calcd for 
C12H14O3Na (M+Na)
+
: 229.0852, found: 229.0841. 
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(S)-2-(Benzyloxy)pent-4-enamide (42) 
To a solution of 40 (66 mg, 0.32 mmol) in THF/MeOH (3.5 mL, 1:1) was added TMS-
diazomethane 2.0 M in hexane (320 µL, 2 equiv.). This mixture was stirred for 2 h at rt, when 
it was concentrated in vacuo. The resulting oil was purified using column chromatography 
(EtOAc/heptane, 1:3) to give the methyl ester (47 mg, 67% yield) as a colorless oil. Rf 0.52 
(EtOAc/heptane, 1:2). [ ] 
   -30.7 (c 0.019).  IR (ATR) 1100, 741, 698, 1579, 1731, 3369 cm
−1
. 
1
H NMR (CDCl3, 
300 MHz): δ 7.35-7.26 (m, 5H), 5.89-5.76 (m, 1H), 5.15-5.07 (m, 2H), 4.58 (dd, 2H, J = 68.7, 12.0 Hz), 4.02 (t, 1H, 
J = 6.0 Hz), 3.74 (s, 3H), 2.53 (t, 2H, J = 6.3 Hz). 
13
C NMR (CDCl3, 75 MHz): δ 172.14, 136.95, 132.52, 127.96, 
127.58, 127.45, 117.56, 77.34, 71.86, 51.48, 36.94. HRMS (ESI) m/z calcd for C13H16O3Na (M+H)
+
: 221.1189, 
found: 221.1178. 
 
Then, 
 
To a solution of the methyl ester (47 mg, 0.21 mmol) in MeOH (2 mL) a 7 M solution of NH3 in 
MeOH (3 mL) was added. The mixture was stirred for 4 d at rt, concentrated in vacuo and 
residue was purified by column chromatography (EtOAc/heptane, 1:1) to afford 42 (26 mg, 
59% yield) as a white solid. Rf 0.08 (EtOAc/heptane, 1:2). [ ] 
   -17.7 (c 0.01). IR (ATR) 1104, 
1324, 1432, 1648, 3183, 3369 cm
−1
. 
1
H NMR (MeOD, 400 MHz): δ 7.27-7.20 (m, 5H), 5.85-5.78 (m, 1H), 5.10-
5.02 (m, 2H), 4.61 (d, 1H, J = 12.0 Hz), 4.46 (d, 1H, J = 12.0 Hz), 3.91 (t, 1H, J = 5.9 Hz), 2.45-2.39 (m, 2H). 
13
C 
NMR (MeOD, 75 MHz): δ 132.72, 127.54, 127.26, 115.16, 78.46, 71.31, 36.42. HRMS (ESI) m/z calcd for 
C12H15NO2Na (M+Na)
+
: 228.1001, found: 228.0997. 
 
(S)-(9H-Fluoren-9-yl)methyl 1-amino-1-oxopent-4-en-2-ylcarbamate (44) 
L-allylglycine amide (50 mg, 0.33 mmole) was dissolved in H2O (3 mL). The reaction was cooled 
to 0 °C and NaHCO3 (56 mg, 2 equiv) was added together with BzCl (77 µL, 2.0 equiv). The 
reaction was stirred for 1.5 h and then diluted with EtOAc. The organic layer was washed with 
brine, dried (MgSO4) and concentrated in vacuo to afford 44 as a white solid. 
1
H NMR (MeOD, 400 MHz): δ 8.05-
7.31 (m, 5H), 5.86-5.82 (m, 1H), 5.16 (d, 1H, J = 17.1 Hz), 5.08 (d, 1H, J = 9.5 Hz), 4.62 (dd, 1H, J = 5.4 Hz, J = 8.4 
Hz), 2.62-2.56 (m, 2H). 
13
C NMR (MeOD, 75 MHz): δ 174.48, 168.23, 133.06, 130.99, 127.67, 126.60, 116.74, 
52.70, 35.63. Data are in agreement with literature. 
 
(S)-Benzyl 1-amino-1-oxopent-4-en-2-ylcarbamate (45) 
 L-allylglycine amide (50 mg, 0.33 mmole) was dissolved in acetone (2 mL). The reaction was 
cooled to 0 °C and H2O (1 mL), Na2CO3 (70 mg, 2 equiv) was added together with CbzCl (57 µL, 
1.2 equiv). The reaction was stirred for 2 h and then diluted with EtOAc. The organic layer 
was washed with H2O, brine, dried (MgSO4) and concentrated in vacuo. The residue was 
purified by column chromatography (EtOAc/heptane, 2:1) to afford 45 (84 mg, 100% yield) as a white solid. 
1
H 
NMR (CDCl3, 400 MHz): δ 7.41-7.29 (m, 5H), 6.02 (br s, 1H), 5.88-5.81 (m, 1H), 5.56 (br s, 1H), 5.29 (br s, 1H), 
5.18-5.14 (m, 4H), 4.22-4.16 (m, 1H), 2.59-2.54 (m, 2H). 
13
C NMR (CDCl3, 75 MHz): δ 172.74, 155.62, 135.53, 
132.15, 128.11, 127.84, 127.77, 119.05, 66.78, 53.37, 36.14. 
 
(S)-2-Azidopent-4-enamide (46) 
NaN3 (1.3 g, 20 mmole) was dissolved in CH2Cl2 (20 mL) and (H2O (20 mL). The mixture was 
cooled to 0 °C and Tf2O (1.66 mL) was added dropwise. The reactio was stirred for 2 h at room 
temperature and then quenched with NaHCO3 (40 mL). The layers were separated and teh 
H2O-layer was washed with CH2Cl2 (20 mL). Then, L-allylglycine amide (500 mg, 3.3 mmole) was dissolved in 
H2O (40 mL). CuSO4 (50 mg) was added together with Et3N (500 µL). MeOH (100 mL) was added followed by 
addition of the TfN3-solution. The reaction was stirred for 2 h. The organic layer was evaporated and the H2O-
layer was extracted with EtOAc (2 × 100 mL). The organic layer was washed with brine, dried (MgSO4) and 
concentrated in vacuo. The residue was purified by column chromatography (EtOAc) to afford 46 (337 mg, 
72%) as a colorless oil. 
1
H NMR (MeOD, 400 MHz): δ 5.78-5.70 (m, 1H), 5.12 (d, 1H, J = 17.1 Hz), 5.08 (d, 1H, J = 
9.5 Hz), 3.89 (dd, 1H, J = 5.5 Hz, J = 7.7 Hz), 2.52-2.46 (m, 4H). 
NH2
O
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(4S,5S)-5-((Tert butyldiphenylsilyloxy)methyl)-4-ethyldihydrofuran-2(3H)-one (49) 
To a solution of PhSCu (47 mg, 0.27 mmole) in THF (1 mL) at -40 °C was dropwise added 
ethylmagnesium bromide (272 µL, 3 equiv). The reaction was stirred until it changed 
colour. Then, 48 (96 mg, 0.272 mmole) was added dropwise and the reaction was stirred 
for another 10 min. The reaction was quenched with NH4Cl (3 mL) and the temperature 
was raised to room temperature. The solution was diluted with CH2Cl2, filtered over celite, washed with water 
and dried (MgSO4) concentrated in vacuo and purified by column chromatography (EtOAc/heptane, 1:1) to 
afford 49 (81 mg, 78%) as a colorless oil. Rf 0.67 (EtOAc/heptane, 1:1). [ ] 
   +38.0 (c 0.025).
1
H NMR (MeOD, 
400 MHz): δ 7.60-7.68 (m, 4H), 7.42-7.37 (m, 6H), 4.20 (td, 1H, J = 3.4 Hz, J = 5.0 Hz), 3.87 (dd, 1H, J = 3.3 Hz, J = 
11.4 Hz), 3.69 (dd, 1H, J = 3.5 Hz, J = 11.5 Hz), 2.80 (dd, 1H, J = 9.1 Hz, J = 17.6 Hz), 2.44-2.37 (m, 1H), 2.21 (dd, 
1H, J = 6.2 Hz, J = 17.7 Hz), 1.49-1.42 (m, 2H), 1.06 (s, 9H), 0.91 (t, 3H, J = 7.4 Hz). Data are in agreement with 
literature. 
 
(4R,5S)-5-((Tert butyldiphenylsilyloxy)methyl)-4-isopropyldihydrofuran-2(3H)-one (50) 
To a solution of PhSCu (121 mg, 0.70 mmole) in THF (10 mL) at -40 °C was dropwise added 
iso-propylmagnesium bromide (2.1 mL, 3 equiv). The reaction was stirred until it changed 
colour. Then, 48 (246 mg, 0.70 mmole) was added dropwise and the reaction was stirred 
for another 10 min. The reaction was quenched with NH4Cl (3 mL) and the temperature 
was raised to room temperature. The solution was diluted with CH2Cl2, filtered over celite, washed with water 
and dried (MgSO4) concentrated in vacuo and purified by column chromatography (EtOAc/heptane, 1:1) to 
afford 50 (214 mg, 77%) as a colorless oil. Rf 0.64 (EtOAc/heptane, 1:1). [ ] 
   +18.0 (c 0.025). FTIR (ATR) 703, 
1112, 1779, 2859, 2963 cm
-1
.
 
H NMR (CDCl3, 400 MHz): δ 7.68-7.60 (m, 4H), 7.41-7.35 (m, 6H), 4.32 (dd, 1H, J = 
3.3 Hz, J = 7.2 Hz), 3.89 (dd, 1H, J = 3.1 Hz, J = 11.4 Hz), 3.65 (dd, 1H, J = 3.3 Hz, J = 11.4 Hz), 2.73 (q, 1H, J = 11.1 
Hz), 2.34-2.28 (m, 2H), 1.73-1.68 (m, 1H), 1.06 (s, 9H), 0.88 (t, 6H, J = 6.7 Hz). 
13
C NMR (CDCl3, 75 MHz): δ 
176.69, 135.19, 135.09, 132.50, 132.09, 129.44, 127.37, 82.73, 65.07, 41.81, 31.79, 30.52, 19.16, 18.60. HRMS 
(ESI) m/z calcd for C24H32NO3NaSi (M+Na)
+
: 419.2018, found: 419.2011. 
 
(4R,5S)-5-((Tert butyldiphenylsilyloxy)methyl)-4-isopropyldihydrofuran-2(3H)-one (51) 
To a solution of CuI (114 mg, 0.25 mmol) in Et2O (2 mL) at -20 °C was added PhLi (0.5 
mmol). After 30 min the solution was cooled to -78 °C and TMSCl (0.25 mmol) and 48 (71 
mg, 0.2 mmol) in THF (2 mL) and the reaction was stirred for another 10 min. The reaction 
was quenched with NH4Cl (3 mL) and the temperature was raised to room temperature. The solution was 
diluted with CH2Cl2, filtered over celite, washed with water and dried (MgSO4) concentrated in vacuo and 
purified by column chromatography (EtOAc/heptane, 1:1) to afford 51 (72 mg, 67%) as a colorless oil. Rf 0.58 
(EtOAc/heptane, 1:1). [ ] 
   +24.0 (c 0.021). FTIR (ATR) 504, 700, 1111, 1781, 2924 cm
-1
.
 
H NMR (CDCl3, 400 
MHz): δ 7.78-7.21 (m, 15H), 4.52-4.46 (m, 1H), 3.96 (dd, J = 2.9, 11.7 Hz, 1H), 3.75-3.68 (m, 2H), 3.10 (dd, J = 
9.4, 17.8 Hz, 1H), 2.71 (dd, J = 7.8, 17.8 Hz, 1H), 1.08 (s, 9H). 
13
C NMR (CDCl3, 75 MHz): δ 175.59, 140.13, 
135.20, 135.10, 132.45, 132.01, 129.48, 128.70, 127.40, 126.48, 86.22, 63.22, 41.83, 36.84, 26.35, 18.80. HRMS 
(ESI) m/z calcd for C27H30NO3NaSi (M+Na)
+
: 453.1848, found: 453.1862. 
 
(4S,5S)-4-Ethyl-5-(hydroxymethyl)dihydrofuran-2(3H)-one (52) 
To a solution of 49 (81 mg, 0.21 mmole) in THF (1 mL) at 0 °C was added TBAF (212 µL, 1 equiv) 
and this mixture was stirred for 2 h. The reaction was quenched with NH4Cl, extracted with 
CH2Cl2, dried (MgSO4) and concentrated in vacuo and purified by column chromatography 
(EtOAc/heptane, 1:1) to afford 52 (17 mg, 56%) as a colorless oil. Rf 0.23 (EtOAc/heptane, 1:1). [ ] 
   +12.1 (c 
0.09). FTIR (ATR) 916, 1709, 2930, 2963 cm
-1
. 
1
H NMR (CDCl3, 400 MHz): δ 4.26-4.18 (m, 1H), 3.89 (d, 1H, J = 
12.6 Hz), 3.63 (dd, 1H, J = 4.2 Hz, J = 12.6 Hz), 2.74 (dd, 1H, J = 8.5 Hz, J = 17.2 Hz), 2.65 (s, 1H), 2.37-2.31 (m, 
1H), 2.22 (dd, 1H, J = 8.0 Hz, J = 17.2 Hz), 1.56-1.45 (m, 1H), 0.94 (t, 1H, J = 7.4 Hz). 
13
C NMR (CDCl3, 75 MHz): δ 
176.53, 85.42, 62.80, 37.28, 34.42, 25.80, 11.23. HRMS (ESI) m/z calcd for C17H21NO4Na (M+Na)
+
: 167.0684, 
found: 167.0677. 
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(4S,5S)-4-Ethyl-5-(iodomethyl)dihydrofuran-2(3H)-one (53) 
Compound 52 (40 mg, 0.28 mmole) and PPh3 (88 mg, 1.2 eq.) were dissolved in THF (3 mL). This 
solution was heated to 70 °C and a solution of imidazole (29 mg, 1.5 eq.), I2 (85 mg, 1.2 eq.) in 
CH2Cl2 (2 mL) was added. After stirring for 1 hour at rt,  the mixture was diluted with CH2Cl2 (15 
mL) washed with 10% Na2S2O3 (15mL), H2O (20 mL) and brine (15 mL). The organic layer was dried (Na2SO4), 
concentrated in vacuo and purified using column chromatography (EtOAc/heptane = 1:1) to give 53 (52 mg, 
74% yield) as colorless oil. Rf 0.81 (EtOAc/heptane, 3:1). [ ] 
   +36.9 (c 0.0035). FTIR (ATR) 1148, 1170, 1776, 
2960 cm
-1
. 
1
H NMR (CDCl3, 400 MHz): δ 4.12 (dd, 1H, J = 5.2 Hz, J = 10.2 Hz), 3.36 (ddd, 1H, J = 5.1 Hz, J = 10.9 
Hz, J = 24.1 Hz), 2.79 (dd, 1H, J = 11.0 Hz, J = 19.8 Hz), 2.28-2.20 (m, 1H), 1.65-1.57 (m, 1H), 1.49-1.42 (m, 1H), 
0.97 (t, 3H, J = 7.4 Hz). 
13
C NMR (CDCl3, 300 MHz): δ 174.90, 82.62, 41.87, 34.05, 26.12, 11.12, 6.54. HRMS (ESI) 
m/z calcd for C17H22NO4 (M-H)
-
: 127.0759, found: 127.0759. 
 
(S)-3-Ethylpent-4-enoic acid (54) 
To a solution of 53 (372 mg, 1.75 mmole) in MeOH (20 mL), zinc (307 mg, 3.0 equiv.) was added 
and 10 drops of acetic acid. this mixture was stirred for 2 h at room temperature. Next, it was 
filtered over celite and concentrated in vacuo and purified by column chromatography 
(EtOAc/heptane, 1:2) to afford 54 (173 mg, 1.35 mmole, 86%) as a colorless oil. [ ] 
   +7.8 (c 0.004). FTIR (ATR) 
916, 1707, 2924, 2962 cm
-1
. 
1
H NMR (CDCl3, 400 MHz): δ 5.65-5.58 (m, 1H), 5.05-4.98 (m, 1H), 2.41-2.34 (m, 
1H), 1.51-1.45 (m, 1H), 1.36-1.32 (m, 1H), 0.88 (t, 1H, J = 7.4Hz). 
13
C NMR (CDCl3, 75 MHz): δ 177.82, 139.99, 
114.90, 41.23, 38.91, 26.76, 10.89. HRMS (ESI) m/z calcd for C17H20NO4 (M-H)
-
: 127.0759, found: 127.0759. 
 
(S)-3-Ethyl-pent-4-enoic acid amide (55) 
To a solution of 54 (173 mg, 1.37 mmole) in MeOH (4 mL) a 7 M solution of NH3 in MeOH (3 
mL) was added. The mixture was stirred for 4 d at rt, concentrated in vacuo and residue was 
purified by column chromatography (EtOAc/heptane, 1:1) to afford 55 (110 mg, 67% yield) as 
a white solid. Rf 0.08 (EtOAc/heptane, 1:2). [ ] 
   -12.7 (c 0.01). IR (ATR) 1409, 1631, 1667, 3179, 3351 cm
−1
. 
1
H 
NMR (MeOD, 400 MHz): δ 5.63 (ddd, 1H, J = 8.3 Hz, J = 10.3 Hz, J = 17.2 Hz) 5.41 (br s, 2H), 5.09-5.02 (m, 2H), 
2.43-2.36 (m, 1H), 2.23 (dq, 1H, J = 7.1 Hz, J = 14.3 Hz), 1.49-1.44 (m, 1H), 1.31-1.28 (m, 1H), 0.88 (t, 3H, J = 7.4 
Hz). 
13
C NMR (MeOD, 75 MHz): δ 173.93, 140.58, 115.09, 41.86, 41.02, 26.93, 10.97. HRMS (ESI) m/z calcd for 
C12H15NO (M+H)
+
: 128.1076, found: 128.1069. 
 
Ethyl 2-((2S,3S)-2,3-bis(benzyloxy)pent-4-enamido)acrylate (57) 
To a solution of amide 35 (310 mg, 1.0 mmole) in PhMe (20 mL), p-TsOH (38 mg, 20 
mol%) and ethyl pyruvate (379 µL, 2.0 equiv). The reaction mixture was stirred under 
Dean-Stark conditions applying vacuum for regulation. After 3 h the reaction was cooled 
to room temperature and poured over a plug of neutral Al2O3. The Al2O3 was washed two 
times with PhMe (25 mL). The organic layer was concentrated in vacuo to give 57 (299 mg, 0.73 mmole, 73%). 
Rf 0.67 (EtOAc/heptane 1:1).[ ] 
   +17.1 (c 0.505). IR (ATR) 696, 1656, 3188, 3384 cm
−1
. 
1
H NMR (CDCl3, 400 
MHz): δ 9.01 (br s, 1H), 7.33-7.21 (m, 10H), 6.74 (s, 1H), 5.94 (d, 1H, J = 1.6 Hz), 5.89 (ddd, 1H, J = 7.5 Hz, J = 
11.0 Hz, J = 16.6 Hz), 5.33-5.28 (m, 2H), 5.27 (ddd, 1H, J = 0.9 Hz, J = 1.6 Hz, J = 8.1 Hz), 4.81 (d, 1H, J = 12.0 Hz), 
4.74 (d, 1H, J = 11.9 Hz), 4.63 (d, 1H, J = 12.0 Hz), 4.44 (d, 1H, J = 11.9 Hz), 4.31 (tdd, 1H, J = 0.9 Hz, J = 2.7 Hz, J = 
7.9 Hz), 4.26 (dq, 2H, J = 1.0 Hz, J = 7.1 Hz), 4.22 (d, 1H, J=2.7Hz). 
13
C NMR (CDCl3, 75 MHz): δ 168.16, 163.05, 
137.76, 132.87, 130.37, 128.01, 127.86, 127.56, 127.04, 119.49, 108.37, 81.64, 81.52, 73.24, 70.16, 61.57, 
13.62. HRMS (ESI) m/z calcd for C24H27NO5Na (M+Na)
+
: 432.1787, found: 432.1773. 
 
(S)-Ethyl-2-(3-(benzyloxy)pent-4-enamido)acrylate (58) 
To a solution of amide 36 (65 mg, 0.20 mmole) in PhMe (4 mL), were added p-TsOH (38 
mg, 1 equiv) and ethyl pyruvate (70 µL, 2.0 equiv). The reaction mixture was stirred 
under Dean-Stark conditions applying vacuum for regulation. After 3 h the reaction was 
cooled to room temperature and poured over a plug of neutral Al2O3. The Al2O3 was 
washed two times with PhMe (25 mL). The organic layer was concentrated in vacuo. The residue was purified 
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by column chromatography (EtOAc/heptane 1:2) to give to give 58 (59 mg, 0.19 mmol, 59%). Rf 0.63 
(EtOAc/heptane 1:1). [ ] 
   -12.3 (c 0.033). IR (ATR) 619, 698, 1134, 1187, 1516, 1687, 1731 cm
−1
. 
1
H NMR 
(CDCl3, 400 MHz): δ 8.53 (br s, 1H), 7.40-7.31 (m, 5H), 6.58 (s, 1H), 5.89 (d, 1H, J = 1.5 Hz), 5.80 (ddd, 1H, J = 7.5 
Hz, J = 10.3 Hz, J = 17.3 Hz), 5.32-5.26 (m, 2H), 4.65 (d, 1H, J = 11.7 Hz), 4.47 (d, 1H, J = 11.7 Hz), 4.24 (dq, 1H, J = 
1.3 Hz, J = 7.1 Hz), 2.63 (dd, 1H, J = 7.8 Hz, J = 15.0 Hz), 2.56 (dd, 1H, J = 4.1 Hz, J = 15.0 Hz), 1.30 (t, 1H, J = 7.1 
Hz). 
13
C NMR (CDCl3, 75 MHz): δ 168.77, 163.38. 137.26, 136.23, 130.88, 127.88, 127.49, 127.22, 118.01, 
108.16, 70.13, 67.56, 61.54, 43.70, 13.64. HRMS (ESI) m/z calcd for C17H21NO4Na (M+Na)
+
: 326.1368, found: 
326.1362. 
 
Ethyl 2-((2S,3S)-2,3-bis(benzyloxy)-N-(4-methoxybenzyl)pent-4-enamido)acrylate (64) 
To a solution of 57 (254 mg, 0.62 mmole) in dry DMF (6 mL), were added at 0 °C NaH 
(45 mg, 1.5 equiv) and then PMBBr (141 µL, 1.2 equiv). The reaction mixture was stirred 
for 1 h and then quenched with H2O (10 mL) and extracted with a mixture of 
EtOAc/heptane (1:1) (3 × 10 mL). The organic layer was dried (MgSO4) and concentrated 
in vacuo. The residue was purified by column chromatography (EtOAc/heptane 1:2) to give 64 (217 mg, 0,41 
mmol, 66%) as a colorless oil. Rf 0.58 (EtOAc/heptane 1:1). [ ] 
   +19.3 (c 0.013). IR (ATR) 696, 1656, 3188, 
3384 cm
−1
. 
1
H NMR (CDCl3, 400 MHz): δ 9.01 (br s, 1H), 7.40-7.21 (m, 10H), 6.74 (s, 1H), 5.94 (d, 1H, J = 1.6 Hz), 
5.89 (ddd, 1H, J = 7.5 Hz, J = 11.0 Hz, J = 16.6 Hz), 5.34-5.27 (m, 2H), 5.27 (ddd, 1H, J = 0.9 Hz, J = 1.6 Hz, J = 8.1 
Hz), 4.81 (d, 1H, J = 12.0 Hz), 4.74 (d, 1H, J = 11.9 Hz), 4.63 (d, 1H, J = 12.0 Hz), 4.44 (d, 1H, J = 11.9 Hz), 4.31 
(tdd, 1H, J = 0.9 Hz, J = 2.7 Hz, J = 7.9 Hz), 4.26 (dq, 2H, J = 1.0 Hz, J = 7.1 Hz), 4.22 (d, 1H, J = 2.7 Hz). 
13
C NMR 
(CDCl3, 75 MHz): δ 169.41, 163.25, 158.56, 137.55, 137.37, 136.34, 134.90, 129.96, 129.42, 129.37, 128.29, 
127.80, 127.65, 127.47, 127.11, 127.00, 118.97, 113.19, 80.60, 70.95, 70.67, 61.22, 54.73, 49.56, 13.62. HRMS 
(ESI) m/z calcd for C24H27NO5Na (M+Na)
+
: 432.1787, found: 432.1773. 
 
(S)-Ethyl-2-(3-(benzyloxy)-N-(4-methoxybenzyl)pent-4-enamido)acrylate (65) 
 To a solution of 58 (59 mg, 0.19 mmole) in dry DMF (2 mL), were added at 0 °C NaH 
(12.4 mg, 1.2 equiv) and then PMBBr (36 µL, 1.2 equiv). The reaction mixture was stirred 
for 1 h and then quenched with H2O (10 mL) and extracted with a mixture of 
EtOAc/heptane (1:1) (3 × 10 mL). The organic layer was dried (MgSO4) and concentrated 
in vacuo. The residue was purified by column chromatography (EtOAc/heptane 1:2) to give 65 (42 mg, 0,10 
mmol, 52%) as a colorless oil. Rf 0.54 (EtOAc/heptane 1:1). [ ] 
   -17.6 (c 0.016). IR (ATR) 1178, 1247, 1511, 
1653, 1719, 2976 cm
−1
. 
1
H NMR (CDCl3, 400 MHz, major geometrical isomer): δ 7.34-7.27 (m, 5H), 7.15 (d, 1H, J 
= 8.6 Hz), 6.75 (d, 1H, J = 8.5 Hz), 6.30 (s, 1H), 5.76 (ddd, 1H, J = 7.4 Hz, J = 10.4 Hz, J = 17.6 Hz), 5.29-5.25 (m, 
3H), 4.84-4.77 (m, 3H), 4.55 (d, 1H, J = 11.3 Hz), 4.40 (d, 1H, J = 11.3 Hz), 4.44-4.36 (m, 1H), 4.24-4.16 (m, 2H), 
3.77 (s, 3H), 2.68 (dd, 1H, J = 7.8 Hz, J = 14.8 Hz), 2.35 (dd, 1H, J = 5.5Hz, J = 14.8 Hz), 1.25 (t, 3H, J = 7.1 Hz). 
13
C 
NMR (CDCl3, 75 MHz): δ 169.45, 158.44, 142.71, 137.93, 137.08, 134.51, 129.71, 128.19, 128.09, 127.79, 
127.30, 127.18, 126.98, 126.50, 117.10, 113.22, 77.60, 70.46, 61.33, 54.75, 49.65, 39.69, 13.64. HRMS (ESI) m/z 
calcd for C25H29NO5 (M+Na)
+
: 446.1943, found: 446.1946. 
 
(S)-2-(2-Benzyloxy pent-4-enoylamino)-acrylic acid ethyl ester (59) 
To a solution of amide 42 (197 mg, 0.12 mmole) in PhMe (10 mL), p-TsOH (182 mg, 1.0 
equiv) and ethyl pyruvate (240 µL, 2.0 equiv). The reaction mixture was stirred under 
Dean-Stark conditions applying vacuum for regulation. After 3 h the reaction was cooled 
to room temperature and poured over a plug of neutral Al2O3. The Al2O3 was washed 
two times with PhMe (25 mL). The organic layer was concentrated in vacuo to give 59 (120 mg, 0.39 mmole, 
38%). Rf 0.68 (EtOAc/heptane 1:1). [ ] 
   -7.8 (c 0.010). IR (ATR) 1169, 1241, 1501, 1666, 1734, 2940 cm
−1
. 
1
H 
NMR (CDCl3, 400 MHz): δ 7.39-7.21 (m, 5H), 6.60 (s, 1H), 5.94 (s, 1H), 5.88-5.78 (m, 1H), 5.19-5.11 (m, 2H), 4.61 
(d, 1H, 11.4 Hz), 4.59 (d, 1H, 11.4 Hz), 4.13 (q, 2H, J = 7.2 Hz), 3.97-3.90 (m, 1H), 2.63-2.57 (m, 2H), 1.15 (t, 3H, J 
= 7.2 Hz). 
13
C NMR (MeOD, 75 MHz): δ 170.43, 163.15, 136.34, 132.37, 130.31, 128.08, 127.68, 127.54, 117.81, 
108.49, 79.16, 72.31, 61.62, 36.44, 13.61. HRMS (ESI) m/z calcd for C17H21NO4Na (M+Na)
+
: 326.1368, found: 
326.1354. 
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(S)-Ethyl 2-(3-ethylpent-4-enamido)acrylate (63) 
To a solution of amide 55 (52 mg, 0.41 mmole) in PhMe (3 mL), p-TsOH (7.9 mg, 10 mol%) 
and ethyl pyruvate (90 µL, 2.0 equiv). The reaction mixture was stirred under Dean-Stark 
conditions applying vacuum for regulation. After 3 h the reaction was cooled to room 
temperature and poured over a plug of neutral Al2O3. The Al2O3 was washed two times with PhMe (25 mL). The 
organic layer was concentrated in vacuo to give 63 (52 mg, 0.23 mmole, 57%). Rf 0.66 (EtOAc/heptane 1:1). 
[ ] 
   +10.3 (c 0.01). IR (ATR) 1188, 1316, 1514, 1686, 2950, 3360 cm
−1
. 
1
H NMR (CDCl3, 400 MHz): δ 7.75 (s, 
1H), 6.60 (s, 1H), 5.87 (d, 1H, J = 1.4 Hz), 5.64 (ddd, 1H, J = 8.3 Hz, J = 10.3 Hz, J = 17.2 Hz), 5.10-5.02 (m, 2H), 
4.29 (q, 2H, J = 7.1 Hz), 2.51-2.42 (m, 1H), 2.39 (dd, 1H, J = 5.8 Hz, J = 14.4 Hz), 2.29 (dd, 1H, J = 8.4 Hz, J = 14.4 
Hz), 1.34 (t, 1H, J = 7.1 Hz), 0.89 (t, 1H, J = 7.4Hz). 
13
C NMR (MeOD, 75 MHz): δ 170.24, 163.71, 140.16, 130.50, 
115.31, 107.86, 61.70, 42.82, 41.83, 26.92, 13.63, 10.97. HRMS (ESI) m/z calcd for C12H19NO3Na (M+Na)
+
: 
248.1363, found: 248.1270. 
  
(S)-2-[(2-Benzyloxy pent-4-enoyl)-(4-methoxybenzyl)amino]acrylic acid ethyl ester (66) 
To a solution of 59 (14 mg, 0.046 mmole) in dry DMF (2 mL), were added at 0°C NaH 
(4.5 mg, 2.0 equiv) and then PMBBr (13.2 µL, 2.0 equiv). The reaction mixture was 
stirred for 1 h and then quenched with H2O (10 mL) and extracted with a mixture of 
EtOAc/heptane (1:1) (3 × 10 mL). The organic layer was dried (MgSO4) and concentrated in vacuo. The residue 
was purified by column chromatography (EtOAc/heptane 1:2) to give 66 (15 mg, 0,036 mmole, 78%) as a 
colorless oil. Rf 0.58 (EtOAc/heptane 1:1). [ ] 
   -13.5 (c 0.007). IR (ATR) 1169, 1241, 1501, 1666, 1734, 2940 
cm
−1
. 
1
H NMR (CDCl3, 400 MHz): δ 7.25-7.17 (m, 7H), 6.80 (d, 1H, J = 8.2 Hz), 6.21 (s, 1H), 5.12 (s, 1H), 5.10-5.01 
(m, 2H), 4.2-4.8 (br s, 2H), 4.51 (d, 1H, 11.5 Hz), 4.59 (d, 1H, 11.5 Hz), 4.11-4.06 (m, 3H), 3.81 (s, 3H), 2.51-2.44 
(m, 2H), 1.29 (t, 3H, J = 7.2 Hz). 
13
C NMR (CDCl3, 75 MHz): δ 170.38, 163.17, 158.63, 137.41, 137.08, 133.37, 
130.06, 128.55, 127.75, 127.44, 127.13, 127.09, 117.03, 113.32, 70.58, 61.35, 54.76, 50.07, 36.63, 29.23, 13.60. 
HRMS (ESI) m/z calcd for C17H21NO4Na (M+Na)
+
: 446.1943, found: 326.1921. 
 
(S)-Ethyl-2-(3-ethyl-N-(4-methoxybenzyl)pent-4-enamido)acrylate (67) 
To a solution of 60 (26 mg, 0.116 mmole) in dry DMF (2 mL), were added at 0°C NaH 
(11.4 mg, 2.0 equiv) and then PMBBr (33.2 µL, 2.0 equiv). The reaction mixture was 
stirred for 1 h and then quenched with H2O (10 mL) and extracted with a mixture of 
EtOAc/heptane (1:1) (3 × 10 mL). The organic layer was dried (MgSO4) and concentrated 
in vacuo. The residue was purified by column chromatography (EtOAc/heptane 1:2) to give 67 (31 mg, 0,090 
mmol, 77%) as a colorless oil. Rf 0.59 (EtOAc/heptane 1:1). [ ] 
   +5.6 (c 0.056). IR (ATR) 1177, 1248, 1512, 
1724 cm
−1
. 
1
H NMR (CDCl3, 400 MHz): δ  7.17 (d, 2H, J = 8.5 Hz), 6.81 (d, 2H, J = 8.4 Hz), 6.32 (s, 1H), 5.61-5.50 
(m, 1H), 5.31 (s, 1H), 5.05-4.97 (m, 1H), 4.69 (d, 1H, J = 15.2 Hz), 4.57 (d, 1H, J = 15.2 Hz), 4.22 (q, 2H, J = 7.2 Hz), 
3.78 (s, 3H), 2.56-2.48 (m, 1H), 2.21 (d, 1H, J = 7.3 Hz), 1.28 (t, 1H, J = 7.1 Hz), 0.85 (t, 1H, J = 7.4 Hz). 
13
C NMR 
(CDCl3, 75 MHz): δ 172.31, 171.14, 158.49, 140.78, 138.34, 135.10, 129.90, 127.54, 114.35, 113.22, 61.34, 
54.76, 49.72, 41.57, 38.57, 26.73, 13.64, 11.06 HRMS (ESI) m/z calcd for C20H27NO4Na (M+Na)
+
: 368.1838, 
found: 368.1838. 
 
 (S)-5-Benzyloxy-1-(4-methoxybenzyl)-6-oxo-1,4,5,6-tetrahydropyridine-2-carboxylic acid ethyl ester (69) 
A solution of 65 (15 mg, 0.036 mmole) in dry PhMe (2 mL) was flushed with nitrogen for 15 
min after which the temperature was raised to 80 °C. At 80 °C G2 (10 mol %, 3.0 mg) was 
added and the reaction was stirred for 1 h. After 1 h the organic layer was concentrated in 
vacuo. The residue was purified by column chromatography (EtOAc/heptane 1:2) to give 69 
(8.2 mg, 0.021 mmole, 58%) as a brown oil. Rf 0.34 (EtOAc/heptane 1:1). [ ] 
   -25.3 (c 0.02).FTIR (ATR) 1248, 
1512, 1686, 1721, 2950 cm
-1
. 
1
H NMR (CDCl3, 400 MHz): δ 7.40-7.31 (m, 5H), 7.05 (d, 2H, J = 8.1 Hz), 6.80 (d, 1H, 
J = 8.2 Hz), 6.21 (t, 1H, J = 2.8 Hz ), 5.38 (d, 1H, J = 12.2 Hz), 4.99 (d, 1H, J = 14.7  Hz), 4.82 (d, 1H, J = 12.3 Hz), 
4.67 (d, 1H, J = 14.7 Hz), 4.09 (q, 2H, J = 7.2 Hz), 4.02 (t, 1H, J = 4.4 Hz), 3.79 (s, 3H), 2.58-2.51 (m, 2H), 1.12 (t, 
3H, J = 7.2 Hz). 
13
C NMR (CDCl3, 300 MHz): δ 169.43, 161.72, 158.43, 137.16, 132.82, 128.96, 127.98, 127.76, 
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127.51, 127.40, 127.22, 118.016, 113.45, 113.32, 72.24, 71.92, 60.94, 54.74, 44.47, 26.64, 13.59. HRMS (ESI) 
m/z calcd for C17H21NO4 (M+Na)
+
: 418.1630, found: 418.1607. 
 
(S)-4-(Benzyloxy)-1-(4-methoxybenzyl)-6-oxo-1,4,5,6-tetrahydropyridine-2-carboxylic acid ethyl ester (70) 
A solution of 66 (20 mg, 0.047 mmole) in dry PhMe (2 mL) was flushed with nitrogen for 15 
min after which the temperature was raised to 80 °C. At 80 °C G2 (10 mol%, 3.0 mg) was 
added and the reaction was stirred for 1 h. After 1 h the organic layer was concentrated in 
vacuo. The residue was purified by column chromatography (EtOAc/heptane 1:2) to give 70 
(8.2 mg, 0.021 mmole, 58%) as a brown oil. Rf 0.56 (EtOAc/heptane 1:1). [ ] 
   -25.3 (c 0.02). 
FTIR (ATR) 1248, 1512, 1679, 1724, 2941 cm
-1
. 
1
H NMR (CDCl3, 400 MHz): δ 7.35-7.27 (m, 5H), 7.07 (d, 2H, J = 
8.8 Hz), 6.71 (d, 2H, J = 8.8 Hz), 6.30 (d, 1H, J = 4.7 Hz), 5.30 (d, 1H, J = 15.1 Hz), 4.87 (d, 1H, J = 15.1 Hz), 4.53 (d, 
2H, J = 1.4 Hz), 4.23 (dt, 1H, J = 4.8 Hz, J = 6.0 Hz), 4.15 (q, 2H, J = 7.1 Hz), 3.74 (s, 3H), 2.92 (ddd, 1H, J = 0.7 Hz, J 
= 5.9 Hz, J = 15.9 Hz), 2.77 (dd, 1H, J = 4.8 Hz, J = 15.9 Hz), 1.21 (t, 3H, J=7.1Hz). 
13
C NMR (CDCl3, 75 MHz): δ 
168.62, 162.14, 158.30, 137.15, 135.11, 128.89, 127.96, 127.34, 127.14, 118.51, 113.32, 69.81, 67.17, 61.19, 
54.71, 44.08, 37.57, 13.56. HRMS (ESI) m/z calcd for C17H21NO4Na (M+Na)
+
: 418.1630, found: 418.1600. 
 
(S)-4-Ethyl-1-(4-methoxybenzyl)-6-oxo-1,4,5,6-tetrahydropyridine-2-carboxylic acid ethyl ester (71) 
A solution of 67 (31 mg, 0.090 mmole) in dry PhMe (2 mL) was flushed with nitrogen for 15 
min after which the temperature for 1 h. After 1 h the organic layer was concentrated in 
vacuo. The residue was purified by column chromatography (EtOAc/heptane 1:2) to give 71 
(26 mg, 0.082 mmole, 91%) as a brown oil. Rf 0.41 (EtOAc/heptane 1:1). [ ] 
   -16.7 (c 0.02), 
CDCl3).FTIR (ATR) 1255, 1507, 1683, 1714, 2950 cm
-1
. 
1
H NMR (CDCl3, 400 MHz): δ 7.07 (d, 2H, 
J = 8.8 Hz), 6.79 (d, 2H, J = 8.8 Hz), 6.20 (dd, 1H, J = 0.8 Hz, J = 4.1 Hz), 5.22 (d, 1H, J = 14.9 Hz), 4.86 (d, 1H, J = 
14.9 Hz), 4.19-4.12 (m, 2H), 3.77 (s, 3H), 2.61 (ddd, 1H, J = 1.0 Hz, J = 5.0 Hz, J = 14.6 Hz), 2.46-2.38 (m, 1H), 2.33 
(dd, 1H, J = 10.6 Hz, J = 14.6 Hz), 1.47-1.40 (m, 2H), 1.24 (t, 3H, J = 7.1 Hz), 0.93 (t, 3H, J = 7.4 Hz). 
13
C NMR 
(CDCl3, 75 MHz): δ 170.00, 158.33, 128.99, 125.36, 113.35, 60.88, 54.73, 44.05, 36.27, 32.62, 25.63, 13.62, 
10.71 HRMS (ESI) m/z calcd for C18H23NO4Na (M+Na)
+
: 340.1525, found: 340.1523. 
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5 
A stereoselective approach to cis- and trans-3-substituted pipecolic 
acids 
 
Abstract 
 
3-Substituted pipecolic acid derivatives constitute a common structural subunit of a wide 
variety of naturally occurring alkaloids and drugs. As a result, we became interested in the 
synthesis of β-halogenated 2,3-unsaturated didehydropipecolic acids as a general building 
block for the introduction of substituents in the 3-position. This chapter describes the 
synthesis of both cis- and trans-3-substituted pipecolic acids. Two different strategies have 
been developed: (1) a palladium-catalyzed cross-coupling reaction of β-iodinated 
didehydropipecolic esters for the formation of carbon-carbon bonds and (2) an 
addition/elimination protocol onto β-iodinated dehydropipecolic esters for the formation of 
carbon-heteroatom bonds. Hydrogenation of the enamine and reduction of the amide 
completed the synthesis. A copper-catalyzed 1,4-addition, on the other hand, afforded the 
trans-substituted derivatives as single products. 
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5.1 Introduction 
  
Pipecolic acid is one of the most common structural subunits in nature and is found in many 
natural products (see Chapter 4). The relevance of this ring system has created a continuous 
interest in short and efficient routes to such highly functionalized building blocks. 
Considering the synthetic opportunities of the cyclic 2,3-didehydroamino ester building 
block described in the previous chapter, we dedicated further studies to the synthesis of 
functionalized pipecolic acids.  
 
A main group of interest is composed of 3-substituted pipecolic acid derivatives, which 
constitute the common structural subunit of a wide variety of naturally occurring alkaloids 
and drugs. For example, tetrazomine (1) is an antitumor antibiotic that contains the unusual 
amino acid cis-3-hydroxypipecolic acid (red) (Figure 5.1).1 3-Hydroxypipecolic acids have 
become synthetically accessible in enantiopure form through asymmetric induction using 
chiral auxiliaries (chiral imines,2 enantiopure β-amino alcohols,3 the Williams lactone)4 and 
asymmetric catalysis.5,6 Via similar asymmetric procedures alkylated,7,8,9 arylated10,11 and 
carboxylated12 variants have been synthesized over the past decades as well. The examples 
mentioned above demonstrate the versatility in synthetic pathways and their biological 
significance. Based on these observations, we aimed to design a novel pathway to increase 
the availability of pipecolic acid derivatives. Key in this approach are β-halogenated ,β-
unsaturated cyclic 2,3-dididehydroamino acids, which can be used as general building blocks 
for the synthesis of functionalized pipecolic acid derivatives via palladium-catalyzed cross-
coupling reactions.  
  
 
 
Figure 5.1 tetrazomine. 
 
The viability of palladium-catalyzed cross-coupling reactions using vinyl halides for carbon-
carbon bond formation has been widely demonstrated and has found numerous applications 
in organic synthesis.13,14 In particular, Scheme 5.1 shows the application of Suzuki-couplings 
of β-brominated didehydroamino ester 2 resulting in the Z-substituted didehydroamino 
esters 3 in good yields.15 Moreover, Sonogashira couplings of dibrominated didehydroamino 
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esters 4 have been described for the synthesis of novel amino acids.16 Synthesis of β-
branched cyclic didehydroamino esters, leading to tetrasubstituted alkenes, on the other 
hand so far has remained unknown.  
 
 
Scheme 5.1. Synthetic approaches to 3-(di)substituted β-branched didehydroamino esters. 
 
This literature precedent has led us to retrosynthetically derive the targeted cis-3-
substituted pipecolic acids 9 from our previously described cyclic didehydroamino esters 
(Scheme 5.2). The tetrasubstituted alkene 8 is an excellent precursor for the formation of 
the less common cis-3-substituted pipecolic acids 9. The alkene 8, in turn, is prepared 
through a palladium-catalyzed cross-coupling reaction of the β-halogenated cyclic 
didehydroamino ester 7. Finally, 7 is obtained from iodination of the cyclic didehydroamino 
ester 6, as has been described Chapter 2. In addition, the trans-3-substituted derivative 10 
was envisaged to be prepared via a copper-mediated 1,4-addition onto the same 
didehydroamino ester 6. 
 
 
Scheme 5.2. Retrosynthetic approach to 3-substituted pipecolic esters. 
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5.2 Synthesis of iodinated building block 11 
 
En route to the desired 3-substituted pipecolic acids, we initially focused our investigations 
on the formation of the iodinated didehydroamino ester 7, which could then serve as a key 
building block in palladium-catalyzed cross-coupling reactions. Initial attempts to iodinate 
enamide 6, involving treatment with the electrophilic reagent N-iodosuccinimide (NIS, 1 
equiv) in CH2Cl2 provided 7 albeit in only 6% isolated yield after stirring for 16 hours, 
together with a substantial amount of starting material (Scheme 5.3). An additional amount 
of reagent did not lead to higher yields. As expected, higher temperatures increased the 
iodination of the enamide, but also led to electrophilic aromatic substitution on the PMB-
group. Interestingly, when the reaction was performed in protic solvents to enhance the 
solubility of NIS, the corresponding iodohydrin derivative 11 was obtained as a 1:1 
diastereomeric mixture.17 
 
 
 
Scheme 5.3. Attempted iodination of didehydroamino ester 6. 
 
Due to these results, we decided to introduce the iodide after removal of the PMB-
protecting group. However, deprotection of 6 proved to be somewhat less trivial than 
expected. Oxidation with ceric ammonium nitrate (CAN) in acetonitrile led to long reaction 
times, while large excesses of reagents were required, resulting in multiple products. 
Alternatively, treatment with DDQ in H2O/CH2Cl2 mixtures did not show any conversion at 
all. Reaction with TFA in CH2Cl2 (1:4) at 50 °C on the other hand went smoothly providing 12 
in 79% yield (Scheme 5.4). With 12 in hand, iodination was again carried out in CH2Cl2 at 
room temperature, using 1 equiv of NIS. Although the starting material was now fully 
consumed within minutes, no clear product could be isolated. In the end, we were pleased 
to find that iodination of 6 in CH2Cl2 with NIS (1 equivalent) in the presence of TFA (1 equiv) 
afforded the desired compound 7, albeit in a moderate yield of only 44%. After extensive 
optimization, we found that addition of a premixed TFA/NIS solution (1:1, 1 equiv) 
completely suppressed the undesired electrophilic aromatic substitution, raising the yield to 
78%. 
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Scheme 5.4. Acid-mediated iodination of didehydroamino ester 6. 
 
The same approach was followed to prepare the iodinated isoquinolone 15 (Scheme 5.5). 
Interestingly, subjection of precursor 14 to the optimized conditions (CH2Cl2, NIS/TFA, rt) led 
to long reaction times, resulting in an inseparable mixture of both iodinated 15 and the 
undesired electrophilic substitution product 16. A plausible explanation is concealed in the 
poor nucleophilicity of the enamide due to the conjugation with the aromatic system. A 
careful and portionwise addition (3 x 0.5 equiv) of the TFA/NIS solution in order to prevent 
electrophilic aromatic substitution, resulted in 15 in a satisfactory yield of 79%. 
 
 
 
Scheme 5.5. Iodination of 1-oxo-1,2-dihydroisoquinoline carboxylate derivative 14. 
 
5.3 Palladium-catalyzed cross-coupling reactions 
 
With the synthesis of vinyl iodide 7 completed, the stage was set for investigation of the 
palladium-catalyzed cross-coupling reactions. Initially, we focused our attention on Suzuki 
reactions of iodide 7 with boronic esters. Surprisingly, no product was obtained by 
treatment of 7 with phenylboronic acid pinacol ester in the presence of Pd(OAc)2 at 55 °C. In 
sharp contrast, addition of the more reactive phenylboronic acid resulted in the formation of 
the tetrasubstituted alkene 17 in 62% yield (Scheme 5.6). In addition, vinyl iodide 7 was 
exposed to a 3-fluoro-substituted phenylboronic acid and a vinyl-substituted variant yielding 
the Suzuki products 18 and 19, respectively, in good yields. 
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Scheme 5.6. Suzuki couplings of vinyl iodide 7. 
 
In order to determine the scope of the cross-coupling reactions, Heck18, Stille19 and 
Sonogashira20 type reactions were also performed (Scheme 5.7). For example, Stille 
coupling, treating vinyl iodide 7 with tri-n-butylvinylstannane in the presence of Pd(PPh3)4, 
yielded product 20 in 74%. A Heck-type coupling reaction was also investigated. Surprisingly, 
several examples of Heck-coupling of acyclic didehydroamino esters with aryl iodides are 
known in literature,21 whereas reactions of β-halogenated didehydroamino esters with 
activated alkenes are virtually unexplored. Much to our satisfaction, treatment of 7 with 
ethyl acrylate proceeded well to give 21 in 79% yield. In sharp contrast, Sonogashira coupling 
with either TMS-acetylene or phenylacetylene remained unsuccessful. 
 
 
Scheme 5.7. Stille (1), Heck (2) and Sonogashira coupling (3). 
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 5.4 Copper-catalyzed addition/elimination reactions 
 
In addition to palladium-catalyzed cross-coupling methodology, we aimed to introduce 
heteroatoms via an addition/elimination approach. This method is based on nucleophilic 1,4-
addition of nitrogen, oxygen or sulfur onto β-halogenated didehydroamino esters. The 
alkene could thereby be regained via E1cB-elimination (Scheme 5.8). A nice example in this 
respect has been described by Matsumoto et al.22 by addition of a variety of nucleophiles 
onto highly activated systems, e.g., substituted methyl β-bromo--isocyano acrylates 25 as 
described in Scheme 5.8. Other examples described in literature for the addition onto less 
activated systems, e.g., synthesis of azabicyclic structures23 as well as for intramolecular 
cyclization preparing substituted oxazoles, imidazoles and thiazoles strengthen this 
concept.24  
 
 
 
Scheme 5.8. Nucleophilic addition onto halogenated didehydroamino esters and α-isocyano 
acrylates. 
 
When 7 was treated with in situ prepared sodium phenylmethoxide, no clear product could 
be isolated (Scheme 5.9). This result exemplifies the previously mentioned severe drawback 
in this carbon-oxygen bond forming process, which is the need for strong bases such as 
alkoxides which, in combination with the high temperatures, leads to low yields and multiple 
products.  
 
 
Chapter 5 
 
140 
 
 
 
CuI
Cu-OR
ROH + base
base + HI
N
I
Cu
I
ORN
N
OR
oxidative addition
reductive elimination
 
 
Scheme 5.9. Proposed mechanism for Ullmann-type reactions.25 
 
Nordmann and Buchwald,26 as well as others,27 have shown that tertiary alcohols, silanols, 
and phenols, all lacking β-hydrogen atoms, can be efficiently coupled with aryl chlorides and 
bromides under mild conditions using Cu-catalysts. Thus, we explored the possibilities for 
Ullmann type couplings of iodinated 7. As depicted in Scheme 5.9, treatment of iodide 7 with 
benzyl alcohol in the presence of copper iodide (10 mol%), 1,10-phenanthroline (20 mol%) 
and Cs2CO3 at 110 °C led to the formation of 27 in 73% yield. Under similar conditions, both 
phenol and thiophenol were also successfully introduced to afford 28 and 29 in 77 and 49% 
yield, respectively (Scheme 5.10). 
 
 
 
Scheme 5.10. Ullmann-type reactions of 7 with phenol and thiophenol. 
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With both aromatic alcohols and also thiols successfully incorporated, different amines were 
screened for nucleophilic addition. Although both primary and secondary aliphatic (n-BuNH2, 
BnNH2, Et2NH) and aromatic amines (p-anisidine) were to be unsuccessful, leading only to 
decomposition, primary amides and carbamates on the other hand reacted smoothly to 
provide the corresponding products 30 and 31, respectively, in very good yields (Scheme 
5.10).  
 
5.5 Deprotection and reduction to the 3-substituted pipecolic acids 
 
Since the synthesized β-substituted cyclic didehydroamino esters were intended as 
precursors for pipecolic ester formation, asymmetric hydrogenation of the olefin was 
eventually envisaged (Chapter 6). At this stage, a racemic approach was pursued using 
palladium on carbon in combination with hydrogen. Two pathways were investigated: 
removal of the PMB-protecting group prior to hydrogenation and vice versa.  
 
 
Scheme 5.11. Hydrogenation of β-substituted cyclic didehydroamino ester 33. 
 
Treatment of 17 with TFA at 60 °C for 16 h resulted in the deprotected lactam 33 in 78%. 
Subsequent hydrogenation was then performed with 10% Pd/C in MeOH at atmospheric 
pressure. Much to our surprise, reduction led to an inseparable diastereomeric mixture of 34 
(cis:trans = 93:7). Since catalytic hydrogenation of olefinic compounds is frequently 
accompanied by double bond migration, it was assumed that double bond isomerization 
under these conditions, followed by hydrogenation caused the mixture. In order to lowering 
the chance for isomerization, the reaction was carried out at higher pressure (60 bar). 
Interestingly, the diastereoselectivity dropped significantly (d.e. = 56%), suggesting that 
isomerization of the double bond prior to hydrogenation was even enhanced (Scheme 5.11). 
Due to these results, we decided to reverse the hydrogenation and deprotection events.  
While hydrogenation at atmospheric pressure did not show any conversion, hydrogenation 
at 40 °C and 60 bar using the H-Cube28 hydrogenation reaction resulted in a quantitative 
conversion into 35 in a completely diastereoselective fashion. Next, the amide was 
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deprotected under acidic conditions. Full conversion was achieved by stirring for 16 hours in 
neat TFA at 70 °C, while the stereochemistry was maintained.  
 
 
 
Scheme 5.12. Hydrogenation of β-substituted cyclic didehydroamino ester 17. 
 
Finally, reduction of the lactam moiety should be achieved for conversion into the desired 3-
substituted pipecolic acid derivatives. At first, the cyclic didehydroamino ester 6 was 
subjected to BH3·THF, which only led to degradation of the starting material. Then, the same 
conditions were applied to the functionalized heterocycles 34 and 35. Although the 
deprotected heterocycle 34 was fully consumed within minutes according to TLC, multiple 
products were observed. Reduction of heterocycle 35 on the other hand afforded the cis-3-
substituted pipecolic ester 38 in a yield of 71%.  
 
 
 
Scheme 5.13. Reduction to β-substituted cyclic didehydroamino esters 36-38. 
 
5.6 Conjugate addition onto α,β-unsaturated cyclic didehydroamino esters 
 
 
Since with the previous approach only cis-substituted 3-pipecolic acids were accessible, 
copper-catalyzed 1,4-addition of organometallic reagents onto α,β -unsaturated cyclic 
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didehydroamino esters was adopted for the synthesis of trans-substituted 3-pipecolic acids. 
Initially, enamide 6 was reacted with phenylmagnesium bromide in the presence of CuI at –
78 °C to avoid 1,2-addition (Scheme 5.14). As a result of the low reaction rate, the 
temperature was slowly raised to –20 °C, yielding trans-heterocycle 39 in 62% yield in a fully 
diastereoselective fashion. The selectivity of this reaction can only be explained by the 
possibility of isomerization of the cis and trans products (see scheme 5.14).29 Encouraged by 
these results, other Grignard reagents were reacted with 6 under identical conditions to 
provide conjugate addition products 40 and 41 with similar yields and selectivities.  
 
 
 
Scheme 5.14. Conjugate addition onto cyclic didehydroamino ester 6. 
 
Having identified suitable conditions for successful conjugate addition reactions, we decided 
to take a closer look at an enantioselective version. Although several enantioselective 
approaches onto conjugated cyclic systems are well described in literature,30 addition 
reactions onto cyclic α,β-unsaturated didehydroamino esters are not known. A 
straightforward approach would involve complexation of copper with a chiral ligand, which 
after transmetallation with the Grignard reagent should give rise to an enantioselective 
addition reaction.  
 
Table 5.1. Attempts to enantioselective organocopper addition. 
 
 
Entry PhMgBr (equiv) CuI (eq.) L* (equiv) Yield Temp (°C) d.e. e.e. 
1 3 3.0 - 62
 
-78 to -10 > 99
a 
0 
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adetermined by chiral HPLC 
 
After stirring the (R,S)-JOSIPHOS (11 mol %) ligand and copper iodide (10 mol %) in dry THF, 
the cyclic didehydroamino ester 6 was added at -78 °C together with an excess of 
phenylmagnesium bromide (3 equiv, entry 2). Slowly, the temperature was then raised from 
-78 to 0 °C. Although the diastereoselectivity remained excellent (d.e. >99%), no 
enantioselectivity was observed. Surprisingly, when a stoichiometric amount of both copper 
iodide and the ligand were used in combination with the Grignard reagent (1 equiv, entry 3), 
also no reaction occurred. Moreover, in the absence of copper, 1,4-addition proceeded well 
at low temperatures (entry 4), which renders a chiral approach involving organocopper 
complexes impossible. 
Although copper-catalyzed 1,4-additions of Grignard reagents are frequently employed, 
alternatives based on the use of other metal catalysts (Pd, Ni, Co) or organometallic reagents 
(R2Zn, R3Al) have been reported.
31 Therefore, a coupling with a boronic acid, was briefly 
investigated.32 Treatment of 6 with phenylboronic acid Pd(OAc)2 and (S,S)-
iPr-DuPHOS as a 
ligand, however, did not form any product. A zinc-mediated coupling with Et2Zn in the 
presence of Cu(OTf)2 and (S)-MONOPHOS also only led to the recovery of starting material. 
  
 
 
Scheme 5.15. Enantioselective addition attempts onto cyclic didehydroamino ester 6. 
 
5.7 Synthesis of 1,3,4-trisubstituted isoquinoline carboxylates  
 
With both cis- and trans-3-substituted pipecolic acids successfully synthesized, we decided 
to apply the same methodology to the 1-oxo-1,2-dihydroisoquinoline 3-carboxylate 15. 
Remarkably, a palladium-catalyzed Suzuki coupling with phenylboronic acid under the 
aforementioned conditions proceeded well (Scheme 5.16), while Stille and Sonogashira 
couplings remained unsuccessful.  
2 3 0.1 0.11 67
 
-78 to -10 > 99
a 
0 
3 1 1.1 1.2 0 -78 to -10 > 99
a 
0 
4 3 - - 76
 
-78 to -40 > 99
a 
0 
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Scheme 5.16. Suzuki coupling of 1-oxo-1,2-dihydroisoquinoline carboxylate 15. 
 
Deprotection of the 1-oxo-1,2-dihydroisoquinoline carboxylates 14 and 44 led to 
isomerization to 1-oxo-1,2-dihydroisoquinolines 46a and 46b as depicted in Scheme 5.17. It 
was suggested that addition of POCl3 would provide the 1-halogenated derivatives 47a and 
47b, giving rise to a precursor for a second Suzuki-coupling to afford 1,3,4-trisubstituted 
isoquinoline carboxylates. Indeed, when 46a and 46b were treated with POCl3, chlorides 47a 
and 47b were obtained in good yield. Finally, subjection of the chlorides to phenylboronic 
acid in the presence of Pd(OAc)2 and Na2CO3 led to the formation of 48a and 48b after silica 
gel purification in good yields of 82 and 78%, respectively.  
 
 
 
Scheme 5.17. Further conversions of 1-oxo-1,2-dihydroisoquinoline carboxylates 14 and 44. 
 
5.8 Conclusions 
 
After extensive investigations, a general and more widely applicable method for the 
synthesis of 3-substituted 2,3-didehydropipecolic esters has been developed starting from 
iodinated didehydroamino esters. Where Suzuki couplings seem to be suitable for the 
introduction of both (substituted) aromatics and alkenes, the scope of the reaction is 
broadened by the introduction of terminal alkenes (Stille coupling) and activated alkenes 
(Heck coupling). Secondly, a variation on the Ullmann-type addition/elimination protocol 
serves for the introduction of a variety of heteroatoms.  
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With the method developed, hydrogenation of the alkene and reduction of the amide 
provides cis-3-substituted pipecolic ester. The trans-3-substituted pipecolic esters were 
produced by a copper-catalyzed 1,4-addition onto the ,β-unsaturated didehydroamino 
esters followed by reduction of the lactam.     
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5.9 Experimental section 
 
General information 
 
For general experimental details, see Section 2.7 
 
Ethyl-3-iodo-1-(4-methoxybenzyl)-6-oxo-1,4,5,6-tetrahydropyridine-2-carboxylate (7) 
To a solution of 6 (50 mg, 0.173 mmol) in CH2Cl2 (2 mL), was added a mixture of NIS (43 mg, 
1.1 equiv) and TFA (13 mL, 1.0 equiv) in CH2Cl2 (2 mL) dropwise. The reaction mixture was 
stirred at rt. After 12 h another equivalent of NIS/TFA mixture was added and the reaction 
was stirred for three hours. After quenching with aqueous NaHCO3, the layers were 
separated. The organic layer was washed with H2O (50 mL) and brine (50 mL), dried (Na2SO4), and concentrated 
in vacuo. The residue was purified by column chromatography (EtOAc/heptane 1:2) to give 7 (57 mg, 0.137 
mmol, 78%) as a colorless oil. Rf 0.67 (EtOAc/heptane 1:1). FTIR (ATR) 1247, 1681, 1727, 2980 cm
-1
. 
1
H NMR 
(CDCl3, 400 MHz): δ 7.09 (d, 2H, J = 8.6 Hz), 6.82 (d, 2H, J = 8.7 Hz), 4.75 (s, 2H), 4.14 (q, 2H, J = 7.2 Hz), 3.78 (s, 
3H), 2.84 (t, 1H, J = 7.6 Hz). 
13
C NMR (CDCl3, 75 MHz): δ 168.46, 162.93, 158.66, 137.11, 128.57, 128.38, 113.45, 
74.24, 61.67, 54.88, 46.14, 34.65, 31.78, 13.33. HRMS (ESI) m/z calcd for C16H18INO4Na (M+Na)
+
: 438.0178, 
found: 438.0172.  
 
Ethyl-2-ethoxy-3-iodo-1-(4-methoxybenzyl)-6-oxopiperidine-2-carboxylate (11) 
To a solution of 10 (29 mg, 0.10 mmol) in MeCN/EtOH 2:1 (2 mL), was added NIS (24 mg, 1.1 
equiv). The reaction mixture was stirred at 40 °C. After 2 h the reaction was concentrated I. 
The residue was purified by column chromatography (EtOAc/heptane 1:2) to give 11 (45 mg, 
0.098 mmol, 81%) as a colorless oil. Rf 0.67 (EtOAc/heptane 1:1). FTIR (ATR) 1247, 1681, 1727, 
2980 cm
-1
. 
1
H NMR (CDCl3, 400 MHz): δ 7.23 (d, 2H, J = 8.8 Hz), 6.78 (d, 2H, J = 8.8 Hz), 4.82 (d, 1H, J = 14.7 Hz), 
4.44 (dd, 1H, J = 4.4 Hz, J = 13.2 Hz), 4.27 (d, 1H, J = 14.7 Hz), 3.97 (dq, 1H, J = 7.1 Hz, J = 10.7 Hz), 3.77 (s, 1H), 
3.73 (d, 1H, J = 7.1 Hz, J = 10.7 Hz), 3.72 (q, 1H, J = 7.2 Hz), 3.58 – 3.49 (m, 1H), 3.20-3.27 (m, 1H), 2.86-2.80 (m, 
1H), 2.63-2.58 (m, 1H), 2.40-2.36 (m, 1H), 1.23 (t, 1H, J = 7.0 Hz), 1.16 (t, 1H, J = 7.1 Hz). 
13
C NMR (CDCl3, 75 
MHz): δ170.7, 166.48, 158.31, 129.96, 128.49, 112.85, 91.17, 61.96, 57.05, 54.79, 44.54, 33.61, 29.38, 21.07, 
14.26, 13.43. HRMS (ESI) m/z calcd for C18H24INO5Na (M+Na)
+
: 484.0596, found: 484.0597.  
 
Ethyl-4-iodo-2-(4-methoxy-benzyl)-1-oxo-1,2-dihydroisoquinoline-3-carboxylate (15) 
To a solution of 14 (500 mg, 1.53 mmol) in CH2Cl2 (15 mL), was added a mixture of NIS (172 
mg, 0.5 equiv) and TFA (57 µL, 0.5 equiv) in CH2Cl2 (2 mL) dropwise. The reaction mixture was 
stirred at rt. After 3 h and 6 h another 0.5 equivalent of NIS/TFA mixture was added and the 
reaction was stirred for another 12 h. After quenching with aqueous NaHCO3, the layers were 
separated. The organic layer was washed with H2O (50 mL) and brine (50 mL), dried (Na2SO4), 
and concentrated in vacuo. The residue was purified by column chromatography (EtOAc/heptane 1:2) to give 
15 (673 mg, 1.49  mmol, 97%) as a colorless oil. Rf 0.34 (EtOAc/heptane 1:2). FTIR (ATR) 1254, 1654, 1730, 2980 
cm
-1
. 
1
H NMR (CDCl3, 400 MHz): δ 7.09 (d, 2H, J = 8.6 Hz), 6.82 (d, 2H, J = 8.7 Hz), 4.75 (s, 2H), 4.14 (q, 2H, J = 7.2 
Hz), 3.78 (s, 3H), 2.84 (t, 1H, J = 7.6 Hz). 
13
C NMR (CDCl3, 75 MHz): δ 168.44, 162.96, 158.63, 137.17, 128.54, 
128.35, 113.47, 74.25, 61.63, 54.88, 46.16, 34.64, 31.78, 13.33. HRMS (ESI) m/z calcd for C16H18INO4Na 
(M+Na)
+
: 438.0178, found: 438.0172.  
 
Ethyl-1-(4-methoxy-benzyl)-6-oxo-3-phenyl-1,4,5,6-tetrahydro-pyridine-2-carboxylate (17) 
To a solution of 7 (17.5 mg, 0.042 mmol) in EtOH (1 mL), was added a PhB(OH)2 (7.2 mg, 1.5 
equiv), Pd(OAc)2 (1 mg, 10 mol%) and Na2CO3 (8.3 mg, 2.0 equiv). The reaction mixture was 
stirred at 55 °C. After 1h H2O (10 mL) was added and the mixture was extracted with CH2Cl2 (2 
 10 mL). The organic layer was dried (Na2SO4) and concentrated in vacuo. The residue was 
purified by column chromatography (EtOAc/heptane 1:2) to give 21 (10 mg, 0.026 mmol, 70%) as a colorless 
N CO2Et
PMB
O
I
N CO2Et
PMB
O
I
OEt
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oil. Rf 0.42 (EtOAc/heptane 1:1). FTIR (ATR) 1248, 1678, 2976 cm
-1
. 
1
H NMR (CDCl3, 400 MHz): δ 7.31-7.21 (m, 
4H), 7.11-7.15 (m, 3H), 6.81 (d, 1H, J = 8.8 Hz), 4.87 (s, 3H), 3.79 (q, 2H, J = 7.2 Hz), 3.77 (s, 3H), 2.74-2.67 (m, 
4H), 0.74 (t, 3H, J = 7.2 Hz). 
13
C NMR (CDCl3, 75 MHz): δ 169.27, 163.76, 158.40, 138.75, 128.83, 128.76, 128.51, 
127.74, 126.95, 126.55, 125.49, 113.377, 60.80, 54.76, 44.82, 30.58, 26.92, 12.72. HRMS (ESI) m/z calcd for 
C22H23NO4Na (M+Na)
+
: 388.1525, found: 388.1538. 
 
Ethyl-3-(2-fluorophenyl)-1-(4-methoxybenzyl)-6-oxo-1,4,5,6-tetrahydropyridine-2-carboxylate (18) 
To a solution of 7 (17.5 mg, 0.042 mmol) in EtOH (1 mL), was added a m-F-C6H4B(OH)2 (9 mg, 
1.5 equiv), Pd(OAc)2 (1 mg, 10 mol%) and Na2CO3 (9 mg, 2.0 equiv). The reaction mixture was 
stirred at 55 °C. After 1 h H2O (10 mL) was added and the mixture was extracted with CH2Cl2 (2 
x 10 mL). The organic layer was dried (Na2SO4) and concentrated in vacuo. The residue was 
purified by column chromatography (EtOAc/heptane 1:2) to give 22 (57 mg, 0.137 mmol, 78%) 
as a colorless oil. Rf 0.42 (EtOAc/heptane 1:1). FTIR (ATR) 1178, 1248, 1296, 1512, 1681, 2954 
cm
-1
. 
1
H NMR (CDCl3, 400 MHz): δ 7.21-7.27 (m, 1H), 7.12 (d, 2H, J = 8.7 Hz), 6.84-6.94 (m, 3H), 6.81 (d, 2H, J = 
8.7 Hz), 4.86 (s, 2H), 3.82 (q, 2H, J = 7.2 Hz), 3.77 (s, 3H), 2.70 (s, 4H), 0.79 (t, 3H, J = 7.2 Hz). 
13
C NMR (CDCl3, 75 
MHz): δ 169.11, 163.67, 163.43, 160.41, 158.45, 140.57, 140.37, 131.15, 129.34, 129.23, 128.64, 128.41, 
123.71, 122.36, 122.33, 113.97, 113.78, 113.69, 113.49, 113.41, 113.38, 60.98, 54.77, 44.88, 30.50, 26.69, 
12.74. HRMS (ESI) m/z calcd for C22H22FNO4Na (M+Na)
+
: 406.1431, found: 406.1435. 
 
Ethyl-1-(4-methoxybenzyl)-6-oxo-3-styryl-1,4,5,6-tetrahydropyridine-2-carboxylate (19) 
To a solution of 7 (17.0 mg, 0.044 mmol) in EtOH (1 mL), was added a PhCH=CHB(OH)2 (9.8 
mg, 1.5 equiv), Pd(OAc)2 (1 mg, 10 mol%) and Na2CO3 (9 mg, 2.0 equiv). The reaction mixture 
was stirred at 55 °C. After 1h H2O (10 mL) was added and the mixture was extracted with 
CH2Cl2 (2 x 10 mL). The organic layer was dried (Na2SO4) and concentrated in vacuo. The 
residue was purified by column chromatography (EtOAc/heptane 1:2) to give 19 (21 mg, 
0.051 mmol, 86%) as a colorless oil. Rf 0.67 (EtOAc/heptane 1:1). FTIR (ATR) 1248, 1678, 2920 
cm
-1
. 
1
H NMR (CDCl3, 400 MHz): δ 7.37-7.21 (m, 5H), 7.18 (d, 1H, J = 16.0 Hz), 7.10 (d, 1H, J = 8.8 Hz), 6.81 (d, 
1H, J = 8.8 Hz), 6.65 (d, 1H, J = 16.0 Hz), 4.84 (s, 2H), 4.24 (q, 2H, J = 7.2 Hz), 3.77 (s, 3H), 2.72-2.60 (m, 4H), 1.28 
(t, 3H, J = 7.2 Hz). 
13
C NMR (CDCl3, 75 MHz): δ 169.77, 162.78, 158.48, 136.53, 131.17, 130.25, 128.58, 128.25, 
127.49, 126.05, 124.76, 123.40, 113.48, 61.21, 54.75, 45.80, 30.32, 29.23, 20.85, 13.67. HRMS (ESI) m/z calcd 
for C24H25NO4Na (M+Na)
+
: 414,1681, found: 414.1684. 
 
Ethyl-1-(4-methoxy-benzyl)-6-oxo-3-vinyl-1,4,5,6-tetrahydro-pyridine-2-carboxylate (20) 
To a solution of 7 (16 mg, 0.039 mmol) in DMF (1 mL), were added CuI (0.8 mg, 10 mol%), 
Pd(PPh3)4 (2.1 mg, 10 mol%), CsF (12 mg, 2.0 equiv) and CH2=CHSnBu3 (36.2 µL, 3.0 equiv). 
The reaction mixture was stirred at 45 0°C. After 2h the reaction mixture was cooled to room 
temperature, diluted with EtOAc (10 mL), washed with H2O (10mL), dried (MgSO4), and 
concentrated in vacuo. The residue was purified by column chromatography (EtOAc/heptane 
1:1) to give 20 (9 mg, 0.028 mmol, 74%) as a colorless oil. Rf 0.58 (EtOAc/heptane 1:1). FTIR (ATR) 1248, 1676, 
1722, 2946 cm
-1
. 
1
H NMR (CDCl3, 400 MHz): δ 7.09 (d, 1H, J = 8.8 Hz), 6.81 (d, 1H, J = 8.8Hz), 6.65 (dd, 1H, J = 
10.9 Hz, J = 17.2 Hz), 5.26 (ddd, 2H, J = 0.7 Hz, J = 14.1Hz, J = 11.5 Hz), 4.78 (s, 2H), 4.17 (q, 1H, J = 7.2 Hz), 3.77 
(s, 3H), 2.57-2.49 (m, 4H), 1.22 (t, 1H, J = 7.2 Hz). 
13
C NMR (CDCl3, 75 MHz): δ 169.69, 162.78, 158.45, 131.09, 
131.12, 128.48, 123.36, 115.27, 113.44, 61.22, 54.76, 45.63, 30.17, 19.95, 13.46. HRMS (ESI) m/z calcd for 
C18H21NO4Na (M+Na)
+
: 338.1368, found: 338.1372. 
 
Ethyl-3-(2-ethoxycarbonylvinyl)-1-(4-methoxybenzyl)-6-oxo-1,4,5,6-tetrahydropyridine-2-carboxylate (21) 
To a solution of 7 (16 mg, 0.039 mmol) in DMF (1 mL), was added CH2=CHCO2Me (8.4 µL, 
2.0 equiv), DIPEA (20 µL, 3.0 equiv) and Pd(OAc)2 (1 mg, 5 mol%). The reaction mixture was 
stirred at 80 °C. After 4h the reaction mixture was cooled to room temperature, diluted 
with EtOAc (10 mL), washed with H2O (10mL), dried (MgSO4), and concentrated in vacuo. 
The residue was purified by column chromatography (EtOAc/heptane 1:2) to give 21 (11 
mg, 0.028 mmol, 79%) as a colorless oil. Rf 0.46 (EtOAc/heptane 1:1). FTIR (ATR) 1176, 1248, 1686, 2980 cm
-1
. 
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1
H NMR (CDCl3, 400 MHz): δ 7.53 (d, 1H, J = 15.5 Hz), 7.08 (d, 2H, J = 8.8 Hz), 6.81 (d, 2H, J = 8.8 Hz), 5.89 (d, 1H, 
J = 15.5 Hz), 4.83 (s, 2H), 4.22 (q, 2H, J = 7.2 Hz), 4.19 (q, 1H, J = 7.1 Hz), 3.77 (s, 3H), 1.26 (dd, 1H, J = 7.2 Hz, J = 
15.2 Hz). 
13
C NMR (CDCl3, 75 MHz): δ 169.30, 166.23, 162.22, 158.60, 138.81, 137.05, 128.53, 128.10, 118.93, 
118.34, 113.52, 61.61, 60.01, 54.69, 29.89, 20.37, 13.80, 13.43. HRMS (ESI) m/z calcd for C21H25NO6Na (M+Na)
+
: 
410.1580, found: 410.1584. 
 
Ethyl-3-benzyloxy-1-(4-methoxybenzyl)-1,4,5,6-tetrahydropyridine-2-carboxylate (27) 
To a solution of 11 (15 mg, 0.036 mmol) in PhMe (1 mL), was added BnOH (7.5 µL, 2.0 equiv), 
CuI (1 mg, 10 mol%), [1,10]phenanthroline (2 mg, 20 mol%), and Cs2CO3 (18 mg, 1.5 equiv). 
The reaction mixture was stirred at 120 °C. After 24h the reaction mixture was cooled to 
room temperature, diluted with PhMe (9 mL), filtered and concentrated in vacuo. The 
residue was purified by column chromatography (EtOAc/heptane 1:1) to give 27 (10 mg, 0.026 mmol, 73%) as a 
colorless oil. Rf 0.24 (EtOAc/heptane 1:1). FTIR (ATR) 1182, 1247, 1669, 2984 cm
-1
. 
1
H NMR (CDCl3, 400 MHz): δ 
7.35-7.25 (m, 5H), 7.05 (d, 2H, J = 6.7 Hz), 6.80 (d, 2H, J = 6.7 Hz), 4.84 (s, 2H), 4.78 (s, 2H), 4.15 (q, 2H, J = 6.9 
Hz), 3.79 (s, 3H), 2.57-2.52 (m, 2H), 2.45-2.41 (m, 2H). 
13
C NMR (CDCl3, 75 MHz): δ 168.36, 161.87, 158.39, 
149.92, 135.31, 128.87, 128.06, 127.81, 127.22, 119.49, 113.37, 71.47, 60.61, 54.76, 45.25, 30.43, 22.04, 13.60. 
HRMS (ESI) m/z calcd for C23H25NO5Na (M+Na)
+
: 418.1630, found: 418.1633. 
 
Ethyl-1-(4-methoxybenzyl)-6-oxo-3-phenoxy-1,4,5,6-tetrahydropyridine-2-carboxylate (28) 
To a solution of 7 (15 mg, 0,036 mmol) in PhMe (1 mL), was added PhOH (2.0 equiv, 68 mg), CuI 
(1 mg, 10 mol%), [1,10]-phenanthroline (2 mg, 20 mol%), and Cs2CO3 (18 mg, 1.5 equiv). The 
reaction mixture was stirred at 120 °C. After 2h the reaction mixture was cooled to room 
temperature, diluted with PhMe (9 mL), filtered and concentrated in vacuo. The residue was 
purified by column chromatography (EtOAc/heptane 1:1) to give 28 (11 mg, 0.028 mmol, 77%) as a colorless 
oil. Rf 0.33 (EtOAc/heptane 1:1). FTIR (ATR) 1246, 1512, 1741, 2986 cm
-1
. 
1
H NMR (CDCl3, 400 MHz): δ 7.37-7.25 
(m, 5H), 7.13 (d, 2H, J = 8.8 Hz), 6.80 (d, 2H, J = 8.8 Hz), 4.82 (s, 2H), 4.18 (q, 2H, J = 7.2 Hz), 3.79 (s, 3H), 2.52-
2.56 (m, 2H), 2.42-2.38 (m, 2H). 
13
C NMR (CDCl3, 75 MHz): δ 168.86, 162.36, 158.53, 134.94, 133.48, 130.54, 
128.77, 128.60, 128.49, 127.15, 119.16, 113.44, 61.42, 54.77, 45.90, 31.48, 25.97, 13.39. HRMS (ESI) m/z calcd 
for C22H23NO5Na (M+Na)
+
: 404.1468, found: 404.1463. 
 
Ethyl-1-(4-methoxybenzyl)-6-oxo-3-phenylsulfanyl-1,4,5,6-tetrahydropyridine-2-carboxylate (29) 
To a solution of 7 (15 mg, 0.036 mmol) in PhMe (1 mL), was added PhSH (7.5 µL, 2.0 equiv), 
CuI (1 mg, 10 mol%), [1,10]-phenanthroline (2 mg, 20 mol%), and Cs2CO3 (18 mg, 1.5 equiv). 
The reaction mixture was stirred at 120 °C. After 2h the reaction mixture was cooled to room 
temperature, diluted with PhMe (9 mL), filtered and concentrated in vacuo. The residue was 
purified by column chromatography (EtOAc/heptane 1:4) to give 29 (7 mg, 0.018 mmol, 49%) as a colorless oil. 
Rf 0.67 (EtOAc/heptane 1:1). FTIR (ATR) 1247, 1293, 1512, 1685, 2976 cm
-1
. 
1
H NMR (CDCl3, 400 MHz): δ 7.37-
7.25 (m, 5H), 7.13 (d, 2H, J = 8.8 Hz), 6.80 (d, 2H, J = 8.8 Hz), 4.82 (s, 2H), 4.18 (q, 2H, J = 7.2 Hz), 3.79 (s, 3H), 
2.54-2.49 (m, 2H), 2.40 (m, 2H). 
13
C NMR (CDCl3, 75 MHz): δ 168.86, 162.36, 158.53, 134.94, 133.48, 130.54, 
128.77, 128.60, 128.49, 127.15, 119.16, 113.44, 61.42, 54.77, 45.90, 31.48, 25.97, 13.39. HRMS (ESI) m/z calcd 
for C22H23NO5Na (M+Na)
+
: 420.1245, found: 420.1243. 
 
Ethyl-3-benzyloxycarbonylamino-1-(4-methoxybenzyl)-6-oxo-1,4,5,6-tetrahydropyridine-2-carboxylate (30) 
 To a solution of 7 (21 mg, 0.051 mmol) in PhMe (2 mL), was added CbzNH2 (15.4 mg, 2.0 
equiv), CuI (1.5 mg, 10 mol%), [1,10]-phenanthroline (3.0 mg, 20 mol%), and Cs2CO3 (27.0 mg, 
1.5 equiv). The reaction mixture was stirred at 120 °C. After 2h the reaction mixture was 
cooled to room temperature, diluted with PhMe (9 mL), filtered and concentrated in vacuo. 
The residue was purified by column chromatography (EtOAc/heptane 1:1) to give 30 (19 mg, 0.043 mmol, 85%) 
as a colorless oil. Rf 0.46 (EtOAc/heptane 1:1). FTIR (ATR) 1246, 1512, 1741, 2986 cm
-1
. 
1
H NMR (CDCl3, 400 
MHz): δ 9.9 (s, 1H), 7.39-7.28 (m, 5H), 7.01 (d, 2H, J = 8.8 Hz), 6.81 (d, 2H, J = 8.8 Hz), 5.07 (s, 2H), 4.98 (s, 2H), 
4.14 (q, 2H, J = 7.2 Hz), 3.90 (s, 3H), 3.10-3.01 (m, 2H), 2.58 (m, 2H), 1.39 (t, 2H, J = 7.2 Hz). 
13
C NMR (CDCl3, 75 
N CO2Et
PMB
O
NHCbz
Chapter 5 
 
150 
 
MHz): δ 170.06, 163.55, 158.44, 152.21, 143.76, 128.74, 128.11, 127.99, 127.88, 113.51, 66.99, 60.91, 54.72, 
46.60, 30.53, 21.09, 13.72. HRMS (ESI) m/z calcd for C24H26N2O6Na (M+Na)
+
: 461.1689, found: 461.1689. 
 
Ethyl-3-benzoylamino-1-(4-methoxybenzyl)-6-oxo-1,4,5,6-tetrahydropyridine-2-carboxylate (31) 
To a solution of 7 (15 mg, 0.036 mmol) in PhMe (1 mL), was added BzNH2 (87 mg, 2.0 equiv), 
CuI (1 mg, 10 mol%), [1,10]-phenanthroline (2 mg, 20 mol%), and Cs2CO3 (18 mg, 1.5 equiv). 
The reaction mixture was stirred at 120 °C. After 2h the reaction mixture was cooled to room 
temperature, diluted with PhMe (9 mL), filtered and concentrated in vacuo. The residue was 
purified by column chromatography (EtOAc/heptane 1:4) to give 31 (11 mg, 0.018 mmol, 75%) as a colorless 
oil. Rf 0.67 (EtOAc/heptane 1:1). FTIR (ATR) 1247, 1672, 2950 cm
-1
. 
1
H NMR (CDCl3, 400 MHz): δ 11.36 (br. s, 
1H), 7.89 – 7.84 (m, 2H), 7.55 – 7.51 (m, 1H), 7.49-7.42 (m 2H), 7.03 (d, 2H, J = 8.6 Hz), 6.80 (d, 2H, J = 8.7 Hz), 
4.99 (s, 2H), 4.31 (q, 2H, J = 7.2 Hz), 3.77 (s, 3H), 3.38-3.34 (m, 2H), 2.62-2.58 (m, 2H). 
13
C NMR (CDCl3, 75 MHz): 
δ 170.26, 164.97, 164.14, 158.47, 144.64, 133.34, 132.05, 128.72, 128.56, 128.38, 127.04, 113.56, 61.21, 54.72, 
46.78, 30.63, 21.93, 13.73. HRMS (ESI) m/z calcd for C23H24N2O5Na (M+Na)
+
: 431.1583, found: 431.1560. 
 
Ethyl-6-oxo-3-phenyl-1,4,5,6-tetrahydropyridine-2-carboxylate (33) 
A solution of 17 (809 mg, 1.95 mmol) in TFA/CH2Cl2 1:4 (10.0 mL) was stirred for 16 h  at 65 °C. 
After 16 h, the temperature was decreased to 0 °C. The reaction mixture was diluted with 
CH2Cl2 and quenched with NaHCO3 (aq). The organic layer was washed with H2O (10 mL), dried 
over MgSO4 and concentrated in vacuo. The residue was purified by flash column 
chromatography (EtOAc/heptane 1:1) affording compound 33 (620 mg, 87%). Rf 0.36 (EtOAc/heptane 1:1). FTIR 
(ATR) 701, 735, 1683, 2915 cm
-1
. 
1
H NMR (CDCl3, 400 MHz): δ 7.65 (s, 1H), 7.32-7.35 (m, 3H), 7.18-7.15 (m, 2H), 
4.01 (q, 2H, J = 7.2 Hz), 2.78-2.74 (m, 2H), 2.65-2.60 (m, 2H), 0.92 (t, 3H, J = 7.1Hz). 
13
C NMR (CDCl3, 75 MHz): δ 
168.84, 139.10, 128.63, 127.50, 127.25, 127.10, 126.79, 123.19, 61.10, 29.76, 29.25, 12.94. HRMS (ESI) m/z 
calcd for C14H15NO3Na (M+Na)
+
: 268.0950, found: 268.0943. 
 
Ethyl-6-oxo-3-phenylpiperidine-2-carboxylate (34) 
A solution of 33 (110 mg, 0.30 mmol) in TFA (3.0 mL) was stirred for 16 h  at 65 °C. After 16 h, 
the temperature was decreased to 0 °C. The reaction mixture was diluted with CH2Cl2 and 
quenched with NaHCO3 (aq). The organic layer was washed with H2O (10 mL), dried over 
MgSO4 and concentrated in vacuo. The residue was purified by flash column chromatography 
(EtOAc/heptane 1:1) affording compound 34 (66 mg, 90%). Rf 0.36 (EtOAc/heptane 1:1). FTIR (ATR) 604, 1204, 
1669, 1736, 2933 cm
-1
. 
1
H NMR (CDCl3, 400 MHz): δ 7.28-7.22 (m, 5H), 6.32 (br. s, 1H), 4.42 (dd, 1H, J = 1.6 Hz, J 
= 5.3 Hz), 3.95 (q, 2H, J = 7.1 Hz), 3.62 (dd, 1H, J = 5.2 Hz, J = 11.6 Hz), 2.42 (dd, 1H, J = 6.1 Hz, J = 7.3 Hz), 2.26-
2.22 (m, 2H), 0.91 (t, 3H, J = 7.1 Hz). 
13
C NMR (CDCl3, 75 MHz): δ 171.06, 169.31, 136.82, 128.11, 127.11, 
126.79, 61.02, 58.04, 39.47, 28.27, 25.23, 13.20. HRMS (ESI) m/z calcd for C14H17NO3Na (M+Na)
+
: 270.1106, 
found: 270.1114. 
 
Ethyl-1-(4-Methoxybenzyl)-6-oxo-3-phenyl-piperidine-2-carboxylate (35) 
A solution of 17 (115 mg, 0.32 mmol) in MeOH (3.0 mL) was flushed through the H-cube      
(40 °C, 60 bar, flowrate 0.05 mL/min). The organic layer was then concentrated in vacuo. The 
residue was purified by flash column chromatography (EtOAc/heptane 1:1) affording 
compound 35 (66 mg, 90%). Rf 0.27 (EtOAc/heptane 1:1). FTIR (ATR) 1199, 1245, 1512, 1650, 
1735, 2928 cm
-1
. 
1
H NMR (CDCl3, 400 MHz): δ 7.22-7.15 (m, 7H), 6.84 (d, 2H, J = 8.3 Hz), 5.10 (d, 1H, J = 14.7 Hz), 
4.11 (d, 1H, J = 5.6 Hz), 3.88 (d, 1H, J = 14.7 Hz), 3.80 (s, 3H), 3.64-3.69 (m, 2H), 3.28-3.25 (m, 1H), 2.83-2.79 (m, 
1H), 2.66-2.61 (m, 2H), 1.96-1.90 (m, 1H), 0.81 (t, 1H, J = 7.1 Hz). 
13
C NMR (CDCl3, 75 MHz): δ 169.74, 169.25, 
158.67, 138.35, 129.55, 127.97, 127.01, 113.45, 63.78, 60.40, 54.80, 48.62, 41.84, 31.36, 21.14, 13.15. HRMS 
(ESI) m/z calcd for C22H25NO4Na (M+Na)
+
: 390.1681, found: 390.1681. 
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Ethyl-1-(4-methoxybenzyl)-3-phenylpiperidine-2-carboxylate (38) 
To a cooled solution (0 °C) of cis-35 (12 mg, 0.033 mmol) in THF (1.5 mL) was added BH3.THF (66 
µL, 2 equiv). The solution was stirred for 1 h  at room temperature, diluted with CH2Cl2 and 
quenched with NH4Cl (aq). The organic layer was washed with H2O (10 mL), dried over MgSO4 and 
concentrated in vacuo. The residue was purified by flash column chromatography 
(EtOAc/heptane 1:2) affording compound 38 (9 mg, 76%). Rf 0.56 (EtOAc/heptane 1:2). FTIR (ATR) 1178, 1512, 
1733, 2359 cm
-1
. 
1
H NMR (CDCl3, 400 MHz): δ 7.28-7.20 (m, 7H), 6.85 (d, 2H, J = 8.7 Hz), 3.82 (dq, 2H, J = 7.1 Hz, 
J = 10.8 Hz), 3.84 (s, 3H), 3.71 (d, 1H, J = 5.3 Hz), 3.62 (d, 1H, J = 13.3 Hz), 3.50 (d, 1H, J = 12.7 Hz), 3.14-3.18 (m, 
1H), 3.06 (dt, 1H, J = 3.2 Hz, J = 11.7 Hz), 2.65-2.60 (m, 1H), 2.29 (dq, 1H, J = 3.7 Hz, J = 12.7 Hz), 1.86-1.82 (m, 
1H), 1.74-1.69 (m, 1H), 1.68 – 1.64 (m, 1H), 0.87 (t, 1H, J = 7.1 Hz). 
13
C NMR (CDCl3, 75 MHz): δ 171.16, 164.77, 
158.14, 129.44, 127.64, 127.31, 126.10, 113.13, 66.26, 58.95, 58.64, 54.78, 45.73, 43.98, 24.99, 23.30, 13.48. 
HRMS (ESI) m/z calcd for C22H28N2O3Na (M+Na)
+
: 354.2069, found: 354.2058. 
 
Ethyl-1-(4-methoxybenzyl)-6-oxo-3-phenylpiperidine-2-carboxylate (39) 
To a cooled solution (-30 °C) of CuI (118 mg, 0.62 mmol) in Et2O (0.7 mL), phenylmagnesium 
bromide (0.1 mL, 0.31 mmol) was added. The solution was stirred for 20 minutes and was 
cooled to -70 °C. Then compound 6 (45 mg, 0.15 mmol), dissolved in Et2O (1 mL), was added 
and the temperature was slowly warmed to -30 °C. The reaction was diluted with Et2O and 
quenched with 0.1M HCl. The organic layer was washed with NaHCO3 (10 mL) and H2O (10 mL), dried over 
MgSO4 and concentrated in vacuo. The residue was purified by flash column chromatography (EtOAc/heptane 
1:1) affording compound 39 (34 mg, 62%). Rf 0.36 (EtOAc/heptane 1:1). FTIR (ATR) 1511, 1649, 1737, 2935 cm
-
1
. 
1
H NMR (CDCl3, 400 MHz): δ 7.21-7.16 (m, 5H), 6.98-6.94 (m, 2H), 6.87-6.80 (m, 2H), 5.39 (d, 1H, J = 14.6 Hz), 
4.18 (d, 1H, J = 4.7 Hz), 4.17-4.07 (m, 2H), 3.80 (s, 3H), 3.73 (d, 1H, J = 14.6 Hz), 3.34 (dt, 1H, J = 7.2 Hz, 4.6), 
2.57-2.32 (m, 2H), 2.20-2.11 (m, 1H), 2.03-1.92 (m, 1H), 1.18 (t, 3H, J = 7.1 Hz). 
13
C NMR (CDCl3, 75 MHz): δ 
170.91, 169.63, 158.75, 140.36, 130.18, 128.25, 127.86, 126.63, 126.57, 113.45, 63.13, 61.15, 54.87, 48.03, 
41.37, 29.45, 25.37, 13.62. HRMS (ESI) m/z calcd for C22H25NO4Na (M+Na)
+
: 390.1684, found: 390.1681. 
 
Ethyl-3-(2-fluorophenyl)-1-(4-methoxybenzyl)-6-oxo-piperidine-2-carboxylate (40) 
To a cooled solution (-30 °C) of CuI (118 mg, 0.62 mmol) in Et2O (0.7 mL), p-
fluorophenylmagnesium bromide (0.3 mL, 0.31 mmol) was added. The solution was stirred 
for 20 minutes and was cooled to -70 °C. Then compound 6 (45 mg, 0.15 mmol), dissolved 
in Et2O (1 mL), was added and the temperature was slowly warmed to -30 °C. The reaction 
was diluted with Et2O and quenched with 0.1 M HCl. The organic layer was washed with 
NaHCO3 (10 mL) and H2O (10 mL), dried over MgSO4 and concentrated under reduced pressure. The residue 
was purified by flash column chromatography (EtOAc/heptane 1:1) affording compound 40 (26 mg, 45%). Rf 
0.35 (EtOAc/heptane 1:1). FTIR (ATR) 1243, 1511, 1649, 1737, 2936 cm
-1
. 
1
H NMR (CDCl3, 400 MHz): δ 7.19-7.14 
(m, 2H), 6.94-6.80 (m, 4H), 5.42 (d, 1H, J = 14.6 Hz), 4.19-4.06 (m, 3H), 3.80 (s, 3H), 3.67 (d, 1H, J = 14.6 Hz), 
3.34 (dt, 1H, J = 7.1, 4.6 Hz), 2.58-2.35 (m, 2H), 2.19-2.09 (m, 1H), 1.99-1.88 (m, 1H), 1.20 (t, 3H, J = 7.1 Hz). 
13
C 
NMR (CDCl3, 75 MHz): δ 170.75, 169.46, 161.36 (d, J = 246.1 Hz), 158.84, 136.05 (d, J = 3.1 Hz), 130.03, 128.05 
(d, J = 7.9 Hz), 127.74, 115.03 (d, J = 21.3 Hz), 113.55, 63.26, 61.27, 54.85, 48.04, 40.63, 29.47, 25.35, 13.74. 
HRMS (ESI) m/z calcd for C22H24FNO4Na (M+Na)
+
: 408.1589, found: 408.1587. 
 
Ethyl-1-(4-methoxybenzyl)-6-oxo-3-vinylpiperidine-2-carboxylate (41) 
To a cooled solution (-30 °C) of CuI (3.15 g, 16.6 mmol) in Et2O (30 mL), a 1M vinylmagnesium 
bromide solution in THF (8.3 mL, 8.3 mmol) was added. The solution was stirred for 20 
minutes and was cooled to -70 °C. Then compound 6 (1.2 g, 4.15 mmol), dissolved in Et2O (10 
mL), was added and the temperature was slowly warmed to -10 °C. The reaction was 
quenched with 0.1 M HCl and washed with Na2S2O3 (2x40 mL), NaHCO3 (40 mL) and H2O (40 
mL), dried over MgSO4 and concentrated in vacuo. The residue was purified by flash column chromatography 
(EtOAc/heptane 1:1) affording compound 41 (0.95 g, 72%). Rf 0.41 (EtOAc/heptane 1:1). FTIR (ATR) 1511, 1649, 
1738, 2940 cm
-1
. 
1
H NMR (CDCl3, 400 MHz): δ 7.16 (d, 2H, J = 8.6 Hz), 6.84 (d, 2H, J = 8.7 Hz), 5.69-5.59 (m, 1H), 
5.35 (d, 1H, J = 14.7 Hz), 5.08-4.91 (m, 2H), 4.22-4.12 (m, 2H), 3.89 (dd, 1H, J = 3.9, 1.0 Hz), 3.79 (s, 3H), 3.69 (d, 
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1H, J = 14.7), 2.83-2.77 (m, 1H), 2.54-2.47 (m, 2H), 2.00-1.90 (m, 1H), 1.78-1.71 (m, 1H), 1.26 (t, 3H, J = 7.1 Hz). 
13
C NMR (CDCl3, 75 MHz): δ 170.98, 169.35, 158.78, 136.23, 129.85, 127.97, 116.33, 113.46, 61.98, 61.25, 
54.89, 48.14, 38.65, 28.33, 22.92, 13.78. HRMS (ESI) m/z calcd for C18H23NO4Na (M+Na)
+
: 340.1537, found: 
340.1525. 
 
Ethyl-3-phenylpiperidine-2-carboxylate (42) 
To a cooled solution (0 °C) of 39 (12 mg, 0.033 mmol) in THF (1.5 mL) was added BH3·THF (66 µL, 
2 equiv). The solution was stirred for 1 h  at room temperature, diluted with CH2Cl2 and 
quenched with NH4Cl (aq). The organic layer was washed with H2O (10 mL), dried over MgSO4 
and concentrated in vacuo. The residue was purified by flash column chromatography 
(EtOAc/heptane 1:2) affording compound 42 (9 mg, 73%). Rf 0.56 (EtOAc/heptane 1:2). FTIR (ATR) 1178, 1512, 
1733, 2359 cm
-1
. 
1
H NMR (CDCl3, 400 MHz): δ 7.50 (d, 2H, J = 8.8 Hz), 7.27 – 7.23 (m, 1H), 6.87 (d, 1H, J = 8.8 
Hz), 4.60 (d, 1H, J = 12.9 Hz), 4.38 (d, 1H, J = 13.0 Hz), 4.01 (d, 1H, J = 12.2 Hz), 3.92 (s, 3H), 3.90 (q, 1H, J = 7.7 
Hz), 3.38 (dt, 1H, J = 3.9 Hz, J = 12.5 Hz), 3.10-3.06 (m, 1H), 2.77 (dt, 1H, J = 2.7 Hz, J = 14.0 Hz), 2.12-2.09 (m, 
1H), 1.70-1.66 (m, 1H), 0.78 (t, 1H, J = 7.1 Hz). (CDCl3, 75 MHz): δ 167.84, 159.34, 139.00, 133.86, 130.24, 
128.07, 127.82, 127.47, 127.18, 123.20, 74.89, 60.09, 54.76, 54.65, 53.37, 39.98, 30.62, 20.08, 12. HRMS (ESI) 
m/z calcd for C23H24N2O5Na (M+Na)
+
: 376.1889, found: 376.1876. 
 
Ethyl-2-(4-methoxybenzyl)-1-oxo-4-phenyl-1,2-dihydroisoquinoline-3-carboxylate (44)  
To a solution of 15 (42  mg, 0.093 mmol) in EtOH (2 mL), was added a PhB(OH)2 (15.9 mg, 1.5 
equiv), Pd(OAc)2 (2 mg, 10 mol%) and Na2CO3 (22 mg, 2.0 equiv). The reaction mixture was 
stirred at 55 °C. After 16h H2O (10 mL) was added and the mixture was extracted with CH2Cl2 
(2 x 10 mL). The organic layer was dried (Na2SO4) and concentrated in vacuo. The residue was 
purified by column chromatography (EtOAc/heptane 1:2) to give 44 (17 mg, 0.042 mmol, 45%) 
as a colorless oil. Rf 0.67 (EtOAc/heptane 1:1). FTIR (ATR) 1246, 1512, 1655, 1723, 2976 cm
-1
. 
1
H NMR (CDCl3, 
400 MHz): δ 8.57-8.53 (m, 1H), 7.62-7.21 (m, 11H), 6.88 (d, 1H, J = 8.6 Hz), 5.45 (s, 2H), 3.76 (s, 3H), 3.67 (q, 2H, 
J = 7.1 Hz), 0.62 (t, 3H, J = 7.1 Hz). 
13
C NMR (CDCl3, 75 MHz): δ 163.40, 161.20, 161.13, 155.41, 138.70, 137.74, 
135.83, 134.30, 134.18, 132.21, 132.10, 131.98, 130.31, 130.20, 129.27, 128.98, 128.69, 128.55, 128.07, 
127.98, 127.88, 127.85, 127.75, 127.67, 127.60, 127.49, 127.38, 126.49, 125.44, 125.37, 118.58, 118.39, 
113.34, 111.92, 110.79, 110.32,61.42, 61.21, 55.91, 55.18, 47.30, 46.47, 12.65, 12.55. HRMS (ESI) m/z calcd for 
C26H23NO4Na (M+Na)
+
: 436.1525, found: 436.1526. 
 
Ethyl-1-hydroxy isoquinoline-3-carboxylate (46a) 
A solution of 14 (150 mg, 0.44 mmol) in TFA (4 mL) was stirred at 70 °C for 16 h. Then the 
reaction was diluted with CH2Cl2, washed with NaHCO3, H2O and NaCl (aq). The organic layer 
was dried over MgSO4 and concentrated in vacuo. The residue was purified by flash column 
chromatography (EtOAc/heptane 1:1) affording compound 46a (88 mg, 91%). Rf 0.37 
(EtOAc/heptane 1:1). FTIR (ATR) 1297, 1650, 29.75, 3075, 3174 cm
-1
. 
1
H NMR (CDCl3, 400 MHz): δ 9.02 (br. s, 
1H), 8.46 (d, J = 8.0 Hz, 1H), 7.71-7.66 (m, 3H), 7.38 (s, 1H), 4.45 (q, 1H, J = 7.1 Hz), 1.44 (t, 1H, J = 7.1 Hz). 
13
C 
NMR (CDCl3, 75 MHz): δ 161.24, 161.20, 135.56, 132.56, 128.86, 127.81, 127.66, 127.45, 110.67, 62.10, 13.76. 
HRMS (ESI) m/z calcd for C12H11ClNO3Na (M+Na)
+
: 240.0637, found: 240.0633. 
 
Ethyl-1-hydroxy-4-phenyl isoquinoline-3-carboxylate (46b) 
A solution of 44 (75 mg, 0.18 mmol) in TFA (2 mL) was stirred at 70°C for 16 h. Then the 
reaction was diluted with CH2Cl2, washed with NaHCO3 (aq), H2O and NaCl (aq). The organic 
layer was dried (MgSO4) and concentrated in vacuo. The residue was purified by flash 
column chromatography (EtOAc/heptane 1:1) affording compound 46b (32 mg, 61%). Rf 
0.26 (EtOAc/heptane 1:1). FTIR (ATR) 766, 1324, 1317, 1730, 2980 cm
-1
. 
1
H NMR (CDCl3, 400 
MHz): δ 9.34 (br s, 1H), 8.53-8.49 (m, 1H), 7.63 – 7.57 (m, 2H), 7.47-7.43 (m, 3H), 7.27-7.20 (m, 3H), 4.08 (q, 1H, 
J = 7.1 Hz), 0.91 (t, 1H, J = 7.2 Hz). 
13
C NMR (CDCl3, 75 MHz): δ 161.82, 160.67, 137.53, 135.27, 129.41, 128.88, 
128.58, 127.72, 127.46, 127.36, 127.30, 127.14, 124.30, 110.67, 61.69, 12.86. HRMS (ESI) m/z calcd for 
C18H15NO3 (M+Na)
+
: 316.0950, found: 316.0941. 
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Ethyl-1-chloro isoquinoline-3-carboxylate (47a) 
To a solution of 46a (60 mg, 0.275 mmol) in DMF (2 mL) was added POCl3 (81 µL, 0.83 mmol). 
The reaction was stirred at 80 °C for 3 h. Then the reaction was diluted with CH2Cl2, washed 
with NaHCO3, H2O and NaCl (aq). The organic layer was dried over MgSO4 and concentrated 
in vacuo. The residue was purified by flash column chromatography (EtOAc/heptane 1:3) 
affording compound 47a (54 mg, 83%). Rf 0.67 (EtOAc/heptane 1:1). FTIR (ATR) 1244, 1656, 1718, 2980 cm
-1
. 
1
H 
NMR (CDCl3, 400 MHz): δ 8.52 (d, 1H, J = 0.6 Hz), 8.42 – 8.37 (m, 1H), 8.07-8.00 (m, 1H), 7.86-7.80 (m, 2H), 4.53 
(q, 2H, J = 7.1 Hz), 1.48 (t, 1H, J = 7.1 Hz). 
13
C NMR (CDCl3, 75 MHz): δ 177.18, 164.16, 151.41, 140.26, 136.77, 
131.45, 130.28, 128.06, 126.28, 123.50, 61.64, 13.93. HRMS (ESI) m/z calcd for C12H10ClNO2Na (M+Na)
+
: 
258.0298, found: 258.0281. 
 
Ethyl-1-chloro-4-phenyl isoquinoline-3-carboxylate (47b) 
To a solution of 46b (32 mg, 0.11 mmol) in DMF (1 mL) was added POCl3 (33 µL, 0.33 mmol). 
The reaction was stirred at 80 °C for 3 h. Then the reaction was diluted with CH2Cl2, washed 
with NaHCO3 (aq), H2O and NaCl (aq). The organic layer was dried over MgSO4 and 
concentrated in vacuo. The residue was purified by flash column chromatography 
(EtOAc/heptane 1:3) affording compound 47b (25 mg, 0.08 mmol, 73%). Rf 0.67 (EtOAc/heptane 1:1). FTIR 
(ATR) 766, 1324, 1317, 1730, 2980 cm
-1
. 
1
H NMR (CDCl3, 400 MHz): δ 8.46-8.41 (m, 1H), 7.78-7.41 (m, 13H), 
4.12 (q, 2H, J = 7.1 Hz), 1.04 (t, 3H, J = 7.1 Hz). 
13
C NMR (CDCl3, 75 MHz): δ 165.40, 150.50, 140.47, 137.07, 
134.80, 133.35, 131.22, 129.28, 129.19, 127.82, 126.64, 126.09, 61.10, 13.23. HRMS (ESI) m/z calcd for 
C18H14ClNO2Na (M+Na)
+
: 334.0611, found: 334.0603. 
 
Ethyl1-phenyl isoquinoline-3-carboxylate (48a) 
To a solution of 47a (54 mg, 0.228 mmol) in EtOH (3 mL), was added a PhB(OH)2 (41 mg, 1.5 
equiv), Pd(OAc)2 (8 mg, 10 mol%) and Na2CO3 (48 mg, 2.0 equiv). The reaction mixture was 
stirred at 55 °C. After 16 h H2O (10 mL) was added and the mixture was extracted with CH2Cl2 
(2 x 10 mL). The organic layer was dried (Na2SO4) and concentrated in vacuo. The residue was 
purified by column chromatography (EtOAc/heptane 1:2) to give 48a (52 mg, 0.186 mmol, 82%) as a colorless 
oil. Rf 0.67 (EtOAc/heptane 1:1). FTIR (ATR) 1213, 1240, 1774, 2980 cm
-1
. 
1
H NMR (MeOD, 400 MHz): δ 8.56 -
7.03 (m, 10H), 4.45 (dq, 2H, J = 3.2 Hz, J = 7.1 Hz), 1.42-1.38 (m, 3H). 
13
C NMR (MeOD, 75 MHz): δ 134.38, 
131.73, 130.62, 130.56, 129.21, 128.31, 128.16, 127.85, 127.57, 126.85, 125.50, 123.50, 122.64, 61.23, 60.97, 
12.74, 12.70. HRMS (ESI) m/z calcd for C18H15NO2Na (M+Na)
+
: 300.1001, found: 300.1008. 
 
Ethyl-1,4-diphenyl isoquinoline-3-carboxylate (48b) 
To a solution of 47b (70 mg, 0.33 mmol) in EtOH (3 mL), was added a PhB(OH)2 (28 mg, 1.5 
equiv), Pd(OAc)2 (17 mg, 10 mol%) and Na2CO3 (36 mg, 2.0 equiv). The reaction mixture was 
stirred at 55 °C. After 16 h H2O (10 mL) was added and the mixture was extracted with CH2Cl2 
(2 x 10 mL). The organic layer was dried (Na2SO4) and concentrated in vacuo. The residue was 
purified by column chromatography (EtOAc/heptane 1:2) to give 48b (92 mg, 0.26 mmol, 78%) as a colorless 
oil. FTIR (ATR) 1213, 1240, 1712, 2980 cm
-1
. 
1
H NMR (CDCl3, 400 MHz): δ 8.45-8.40 (m, 1H), 8.17-7.41 (m, 13H), 
4.16 (q, 2H, J = 7.1 Hz), 1.07 (t, 3H, J = 7.1 Hz). 
13
C NMR (CDCl3, 75 MHz): δ 159.81, 156.30, 138.48, 135.89, 
129.98, 129.76, 129.56, 128.36, 127.90, 127.76, 127.60, 127.50, 127.26, 126.07, 60.78, 13.21. HRMS (ESI) m/z 
calcd for C24H19NO2Na (M+Na)
+
: 376.1313, found: 376.1303. 
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6 
 
Asymmetric hydrogenation of α,β-unsaturated cyclic 
didehydroamino acids 
 
Abstract  
 
Asymmetric catalytic hydrogenation represents one of the most efficient methods to 
prepare enantiomerically pure compounds via hydrogenation of substituted olefins. Major 
interest is directed toward the synthesis of enantiomerically pure α-amino acids to provide 
potentially new druglike molecules. The production of highly substituted, non-natural cyclic 
dehydroamino acids would therefore be of great interest as a starting point for more 
elaborate structures. While asymmetric hydrogenation of linear dehydroamino acids is 
commonly known, reduction of the corresponding cyclic derivatives has remained rather 
unexplored. This chapter describes the asymmetric hydrogenation of cyclic α,β-unsaturated 
dehydroamino esters. 
 
    
Chapter 6      
 
158 
 
6.1 Introduction 
 
Asymmetric catalytic hydrogenation represents one of the most powerful strategies to 
prepare enantiomerically pure compounds from substituted olefins. Historically, rhodium-
catalysed hydrogenation of olefins already dates from 1966, starting with the development 
of Wilkinson’s catalyst Rh(PPh3)3Cl.
1 Only a few years later, the first asymmetric examples 
appeared in literature, described by Knowles2 and Horner3 both using monodentate 
phosphine ligands (Scheme 6.1).  
 
 
 
Scheme 6.1. First asymmetric hydrogenation reaction by Knowles. 
 
Although the selectivities were rather low, probably caused by the rotational freedom of the 
rhodium-complexes, these examples for the first time showed the potential of asymmetric 
hydrogenation. A major improvement in selectivity was not long thereafter achieved by 
Dang and Kagan using the first bidentate non-P-chiral ligand DIOP (Scheme 6.2), which 
showed remarkably high ee’s at that time in the hydrogenation of  
2-acetamidocinnamic acid.4  
 
 
 
Scheme 6.2. Asymmetric hydrogenation using the bidentate ligand DIOP. 
 
Despite the fact that Knowles already showed the potency of using monodentate CAMP (7, 
Figure 6.1) for the formation of N-acetylphenylalanine with ee’s up to 88%, bidentate  
P-ligands were generally assumed to induce higher enantioselectivity for a long time. This 
led to the development and exploration of many chiral bidentate phosphine ligands in 
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asymmetric hydrogenation over the past decades.5 Preparation of these ligands, however, 
was often hampered by a lengthy synthesis. This changed with the development of BINAP-
based catalytic hydrogenation by Noyori in 1987 (8, Figure 6.1),6 for which he was awarded 
the 2001 Nobel Prize in Chemistry jointly with Knowles and Sharpless. More recently, several 
other phosphorous-based chiral bidentate ligands, such as bisphosphinites,7 
bisphosphonites8 and bisphosphites9 were developed, albeit that they appeared less 
successful in asymmetric hydrogenation.  
 
 
 
Figure 6.1. Chiral ligands for asymmetric hydrogenation. 
 
In 2000, the groups of Pringle,10 Reetz,11 and Feringa/de Vries12 reported the use of three 
new classes of monodentate ligands for asymmetric hydrogenation based on BINOL (9, 
Figure 6.1). These ligands are readily prepared and induced remarkably high 
enantioselectivities, comparable to the results obtained with bidentate phosphines in 
rhodium-catalyzed asymmetric hydrogenation.  
 
Substrates for hydrogenation 
 
Many classes of prochiral olefins can be hydrogenated with high enantioselectivity. As an 
example, hydrogenation of didehydroamino acids leads to the synthesis of enantiopure α-
amino acids. The strong demand for the latter compound class led to the development of 
various effective rhodium-catalysts using different types of ligands. In particular, examples 
with acyl substituents on the nitrogen atom (viz. 10, R2 = H) are well precedented in 
literature and the first examples were reported as early as in 1981.13 In sharp contrast, 
tetrasubstituted didehydroamino acids (viz. 10, R1, R2 ≠ H) are significantly more difficult to 
hydrogenate with high enantioselectivity and isolated yields are generally low (Scheme 
6.3).14   
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Scheme 6.3. Asymmetric hydrogenation of didehydroamino esters 10. 
 
While selective hydrogenation of linear α,β-unsaturated didehydroamino esters is well 
known, hydrogenation of the corresponding cyclic systems has remained limited to 
substrates with an acyl group onto the nitrogen heterocycle (Scheme 6.4).15  
 
 
 
 
Scheme 6.4. First asymmetric hydrogenation of cyclic dehydroamino acids and esters 12 by Beak.5 
 
Given the facile access to tetrasubstituted cyclic dehydroamino esters as described in 
Chapter 4, the corresponding saturated cyclic amino acids would be readily accessible upon 
hydrogenation. The latter compounds occur as structural elements in various drugs16 and 
natural products.17 We therefore set out to study the asymmetric hydrogenation of cyclic 
,β-unsaturated dehydroamino esters. 
 
6.2 Asymmetric hydrogenation of tetrasubstituted dehydroamino esters 
 
Over the past years, phosphoramidite ligands as developed by Feringa and Minnaard,18,19 
have proven their usefulness in asymmetric hydrogenation of a wide range of prochiral 
olefins, including α,β-unsaturated didehydroamino acids.20 Several approaches have been 
adopted for the synthesis of these ligands. The most common route entails the reaction of 
phosphoryl chloride intermediate 16 with a secondary amine (17, Scheme 6.5). Their ready 
accessibility has prompted us to investigate the asymmetric hydrogenation of cyclic 
didehydroamino acids with Rh(I) in combination with a phosphoramidite ligand library.  
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Scheme 6.5. Synthesis of phosphoramidites. 
 
The reactions were either performed in an Endeavor synthesizer21 or in an autoclave. The 
Endeavor is a parallel synthesizer containing eight reaction vessels, which can be 
independently controlled. Hydrogenations can be carefully followed in time by measuring 
the individual hydrogen uptake. Former studies have shown that the rates of hydrogenation 
of dehydroamino acids using rhodium-MonoPhosTM are not very high with a hydrogen 
atmosphere of 1 bar. Initial attempts were therefore performed at a pressure of 25 bar with 
0.075 mmol of substrate in 1.5 mL solvent. The experiments were carried out using 5 mol% 
of [Rh(COD)2]
+BF4
- and 10 mol % of ligand.  
 
Hydrogenation of tetrasubstituted alkene 19 in both methanol and dichloromethane using 
monodentate phosphoramidite ligands (L1-L7) only led to the recovery of starting material 
(Scheme 6.6). A raise in temperature to 70 °C did not give much conversion either, but 
instead slow decomposition of the starting material. Disappointingly, hydrogenations using 
bidentate phosphine ligands (L8-L10) remained unproductive too. 
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Scheme 6.6. Asymmetric hydrogenation of tetrasubstituted cyclic didehydroamino ester 19. 
 
While asymmetric hydrogenation of cyclic didehydroamino esters is only known for N-
heterocycles containing an exocyclic acyl substituent on the nitrogen, we decided to reduce 
the enamide prior to the hydrogenation (Scheme 6.7). Acidic removal of the PMB protecting 
group led to the formation of 21, which was immediately protected with a Boc-group to give 
23. Then, reduction of the lactam carbonyl to the corresponding hemiaminal, followed by N-
acyliminium ion-mediated triethylsilane reduction provided heterocycle 24 in a moderate 
yield of 36% over two steps. With both 21 and 24 in hand, we tested their behavior in the 
hydrogenation. Again, only starting material was recovered. 
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Scheme 6.7. Hydrogenation of cyclic dehydroamino esters 21 and 24. 
 
As a next step, we tried to hydrolyze the ester in order to enhance coordination of the 
didehydroamino carboxylate to the rhodium cation, thereby hopefully enhancing the 
enantioselectivity. Surprisingly, treatment of 26 with an excess of potassium hydroxide in a 
mixture of dioxane/H2O led to decarboxylation together with an unexpected auto-oxidation 
of the heterocycle to afford 27 in 81% yield (Scheme 6.8).  
 
 
 
Scheme 6.9. Attempted hydrolysis of cyclic dehydroamino ester 26. 
 
The reaction was repeated at low temperature in the presence of a stoichiometric amount of 
more reactive lithium hydroxide to avoid decarboxylation.  Indeed, hydrolysis was taking 
place according to mass measurements, but since the reaction was proceeding slowly, the 
temperature was raised to room temperature. Full conversion, however, was only reached 
after stirring the reaction for three days. Again, the oxidized aromatic lactam 27 was isolated 
as the main product.  
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6.3 Asymmetric hydrogenation of didehydroamino acids: screening 
 
Since it appeared difficult to hydrogenate the tetrasubstituted alkenes, we decided to 
investigate the possibility of reducing the didehydroamino esters 28a and 28b. The results of 
the experiments are summarized in Table 6.1. Although the reaction was not completed in 
16 h, we were pleased to find that hydrogenation of 28a proceeded well in dichloromethane 
at 0.05 M. From entry 2 is also clear that full conversion was obtained at higher 
concentration (0.2 M). The isoquinoline 28b, on the other hand, was unreactive toward 
hydrogenation (entries 3 and 4). This was probably due to conjugation of the double bond 
with both the aromatic ring and the ester, which decreased its reactivity. Apparently, there 
is a strong solvent effect clearly indicating that reactions in non-protic solvents are more 
reactive. Unfortunately, the enantioselectivity was rather low in all cases. 
 
Table 6.1. Asymmetric hydrogenation in the Endeavor: solvent screening. 
 
 
 
entry substrate ligand solvent product conversion (%) ee (%) 
1 28a  (S)-L1 CH2Cl2 29a 50 4 
2 28a (02 M) (S)-L1 CH2Cl2 29a >99 5  
3 28b (S)-L1 CH2Cl2 29b 0 n.d. 
4 28b (0.2 M) (S)-L1 CH2Cl2 29b 0 n.d. 
5 28a (S)-L1 MeOH 29a 24 6 
6 28b (S)-L1 MeOH 29b 0 n.d. 
7 28a (S)-L1 EtOAc 29a 53 4 
8 28b (S)-L1 EtOAc 29b 0 n.d. 
9 28a (S)-L1 acetone 29a 51 5 
10 28b (S)-L1 acetone 29b 0 n.d. 
 
Next, we investigated the influence of the amine substituent on the ligand. From the results 
in Table 6.2 it was concluded that phosphoramidite ligand PipPhos (L2) resulted in a 
significant decrease in reactivity (entries 1-2). Moreover, the enantiomeric excess was only 
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5%. In order to increase the selectivity, introduction of chiral amines on the 
phosphoramidite ligands was investigated. This led, however, to a complete loss of reactivity 
(entries 3-4). Probably, these ligands are too bulky for the hydrogenation to proceed. In 
addition, the influence of the ligand backbone was investigated (L5-7). The PipPhos-based 
ligands L5 and L6 showed a significant decrease in reactivity as compared to PipPhos (entry 
2). Phosphoramidites based on TADDOL (L7)22 have also been used, but were ineffective in 
the hydrogenation of 28a. 
 
Table 6.2. Asymmetric hydrogenation in the Endeavor: ligand screening. 
 
 
entry substrate ligand solvent product conversion (%) ee (%) 
1 28a (S)-L1 CH2Cl2 29a 50 4 
2 28a (S)-L2 CH2Cl2 29a 16 5 
3 28a (S)-L3 CH2Cl2 29a 0 n.d. 
4 28a (S)-L4 CH2Cl2 29a 0 n.d. 
5 28a (S)-L5 CH2Cl2 29a 22 4 
6 28a (S)-L6 CH2Cl2 29a 18 3 
7 28a (S)-L7 CH2Cl2 29a 0 n.d. 
  
Despite the fact that the rhodium-phosphoramidite complexes showed high conversions in 
some cases, the enantioselectivity of the reaction was always low. We therefore decided to 
shift our focus toward hydrogenation of the didehydroamino esters using bidentate 
phosphine ligands (Table 6.3). The reactivity was indeed significantly enhanced, leading to a 
full conversion within one hour, but again the enantioselectivity was low (ee <5%).  
 
Table 6.3. Asymmetric hydrogenation: bidentate phosphine ligands. 
 
 
entry substrate ligand solvent product conversion (%) ee (%) 
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1 28a (S)-L8 CH2Cl2 29a >99 4 
2 28a (R)-L8 CH2Cl2 29a >99 5 
3 28a (S,S)-L9 CH2Cl2 29a >99 4 
4 28a (R,S)-L10 CH2Cl2 29a >99 6 
  
Finally, we briefly investigated the use of metals other than rhodium. Much to our surprise, 
both the iridium as well as the ruthenium derivatives appeared to be unreactive in the 
hydrogenation. A plausible explanation could lie in the stronger coordinating properties of 
the cationic rhodium species. 
 
Table 6.4. Asymmetric hydrogenation: evaluation of different metals. 
 
 
entry substrate catalyst solvent ligand product conversion (%) ee (%) 
1 28a [Rh(COD)2]BF4 CH2Cl2 (S)-L8 29a >99 5 
2 28a [Ir(COD)Cl]2 CH2Cl2 (S)-L8 29b 0 n.d. 
3 28a RuCl2 CH2Cl2 (S)-L8 29a 0 n.d. 
1 28a [Rh(COD)2]BF4 CH2Cl2 (S)-L10 29a >99 5 
2 28a [Ir(COD)Cl]2 CH2Cl2 (S)-L10 29b 0 n.d. 
3 28a RuCl2 CH2Cl2 (S)-L10 29a 0 n.d. 
 
6.4 Asymmetric hydrogenation of didehydroamino acids 
 
The previous results let us to conclude that asymmetric hydrogenation of cyclic 
didehydroamino esters containing an acyl group on the amine substituent was rather 
difficult, resulting in low enantioselectivities (ee <10%). It was therefore suggested to 
hydrolyze the ester in order to enhance coordination of the didehydroamino carboxylate to 
the rhodium cation, thereby hopefully enhancing the enantioselectivity (Scheme 6.9). 
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Scheme 6.9. Hydrolysis of 28 and hydrogenation of dehydroamino acids 30. 
 
Treatment of didehydroamino esters 28a and 28b with potassium hydroxide in a mixture of 
dioxane/H2O (1:1) provided the carboxylic acids 30a and 30b in good yields of 91 and 83%, 
respectively. Hydrogenation was then investigated using both monodentate 
phosphoramidite L1 and bidentate phosphonate ligands L8-L10. Since acid 30 was poorly 
soluble in dichloromethane, the reactions were initially carried out in methanol. 
Hydrogenation of 30a using MonoPhosTM (L1) gave a slight increase of enantioselectivity of 
up to 8% ee (Table 6.5, entry 1). The bidentate phosphonate ligand (S,S)-DuPhos (L9) showed 
similar results (ee = 8%). Much to our satisfaction, subjection of carboxylate 30a to (S)-BINAP 
(L8) and (R,S)-JosiPhos (L10) led to a significant increase of enantioselectivity to 37% and 
39%, respectively (entries 2-4). In contrast, the isoquinoline derivative 30b did not react 
under any of these circumstances. 
 
Table 6.5. Hydrogenation of cyclic didehydroamino acids 30a: ligand screening. 
 
 
entry substrate ligand solvent product Conversion (%) ee (%) 
1 30a (S)-L1 MeOH 31a >99 8 
2 30a (S)-L8 MeOH 31a >99 37 
3 30a (S)-L9 MeOH 31a 75 8 
4 30a (S)-L10 MeOH 31a 73 39 
 
Encouraged by these results, we decided to investigate the solvent effect on hydrogenation 
with phosphine ligands L8 and L10 (Table 6.6). It became clear that the rhodium-L10 catalyst 
gave a higher hydrogenation rate than the rhodium-L8 complex. Furthermore, when the 
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reaction was performed with the rhodium-L8 catalyst in 2-propanol or tert-butyl alcohol, a 
slightly higher enantioselectivity was obtained (entries 1-3). With H2O as a co-solvent, the 
enantioselectivity dropped to 23%. Surprisingly, the highest selectivities were observed 
when the reaction was performed in toluene. The rate, however, was low, probably due to 
the poor solubility of the carboxylate.  
 
Table 6.6. Hydrogenation of cyclic dehydroamino acid 30a: solvent screening. 
 
 
entry solvent ligand conversion (%) ee (%) 
1 MeOH (S)-L8 >99 37 
2 iPrOH (S)-L8 73 45 
3 
t
BuOH
a 
(S)-L8 92 43 
4 
i
PrOH/H2O (1:1) (S)-L8 44 23 
5 PhMe (S)-L8 39 47 
7 CH2Cl2 (S)-L8 91 39 
8 MeOH (R,S)-L10 >99 39 
9 
i
PrOH (R,S)-L10 >99 45 
10 
t
BuOH
a 
(R,S)-L10 >99 44 
11 
i
PrOH /H2O (1:1) (R,S)-L10 >99 31 
12 PhMe (R,S)-L10 19 49 
13 CH2Cl2 (R,S)-L10 >99 36 
a 
Reaction was performed at 25 °C. The ee was determined by HPLC-measurements, using a Chiralpak AD-column upon 
esterification of the carboxylates with TMSCHN2.  
 
Based on the best results observed with (S)-BINAP and (R,S)-JosiPhos, we decided to screen 
several of these types of ligands. At first, we tested the sterically more demanding rhodium-
(S)-tolBINAP catalyst (as compared to (S)-BINAP, Table 6.7, entry 3). The enantioselectivity, 
however, was comparable as for (S)-BINAP (entry 1). The commercially available ferrocene-
based ligands L12-L15 were also screened. While the monodentate ligand L12 showed a 
significant decrease in enantioselectivity, the bidentate ligands L13-L15 showed comparable 
results as for (R,S)-JosiPhos. 
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Table 6.7. Hydrogenation of cyclic didehydroamino acid 30a: ligand screening. 
 
 
 
 
 
 
 
 
 
 
 
6.5 Conclusions 
 
Asymmetric hydrogenation of α,β-unsaturated dehydroamino esters appeared to be rather 
difficult, if not impossible. Although a high turnover rate was observed using the 
phosphoramidite ligands in combination with Rh(COD)2BF4, enantioselectivity of the 
reactions remained low. Moreover, the use of metals other than rhodium led to a total loss 
in reactivity. Enantioselectivity was slightly increased upon hydrogenation with bidentate 
phosphonate ligands. Reduction of the corresponding isoquinolone derivatives only led to 
the recovery of starting material. 
In sharp contrast, hydrolysis of the dehydroamino ester and subsequent hydrogenation of 
the resulting acids showed a significant increase in selectivity. While the enantiomeric access 
was only slightly higher upon using MonoPhosTM and (S,S)-DuPhos, we were pleased to find 
entry ligand conversion (%) ee (%) 
1 (R)-L8 93 38 
2 (R)-L9 89 37 
3 (S)-L11 91 37 
4 (R,S)-L10 100 39 
5 (R,S)-L12 100 8 
7 (R,S)-L13 100 25 
8 (R,S)-L14 100 33 
9 (R,S)-L15 100 23 
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that the use of (S)-BINAP and (R,S)-JosiPhos led to an ee of 37% and 39%, respectively. 
Furthermore, the selectivity was increased to 45% when the reactions were performed in 2-
propanol. Disappointingly, screening of a small library of both binaphthyl- and ferrocene 
phosphonate ligands did not lead to higher ee’s.  
 
Finally, hydrogenation of tetrasubstituted alkenes appeared to be unproductive, resulting 
solely in the recovery of starting material. Both PMB-deprotection and reduction of the 
amide prior to reduction did not lead to any conversion at all. 
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6.7 Experimental Section 
 
General information 
 
For general experimental details, see section 2.7 
 
General procedure for hydrogenation onto the Endeavor 
 
Reactant A (0.075 mmol) was weighed into the reaction vessel. Five mol % of the catalyst was added together 
with 6 mol% of the ligand (or 12 mol% in case of the monodenate ligands). The solvent (1.5 mL) was then 
added and the reaction vessel was closed. Pressure (25 bar) and reaction time (16 h) were set and the reaction 
was started. After 16 h the reaction vessel was opened and the reaction mixture was poured over a plug of 
silica. The organic layer was concentrated in vacuo and redissolved in propan-2-ol/hexane 1:10. 
Enantioselecivity was determined using chiral HPLC on a Chiralpak AD-H column (dimensions: 250  46 mm) 
using UV-detection.   
 
General procedure B for hydrogenation in the autoclave 
 
Reactant A (0.075 mmol) was weighed into the reaction vessel. Five Mol % of the catalyst was added together 
with 6 mol % of the ligand (or 12 mol % in case of the monodenate ligands). The solvent (1.5 mL) was then 
added and the autoclave was flushed with hydrogen and nitrogen for three times after which the vessel was 
closed. The pressure was set and the reaction was stirred at room temperature at a magnetic stirring machine. 
After 16 hours the reaction vessel was opened and the reaction mixture was poured over a plug of silica. The 
organic layer was concentrated in vacuo and redissolved in propan-2-ol/hexane 1:10. Enantioselecivity was 
determined using chiral HPLC on a Chiralpak AD-H column (dimensions: 250 x 46 mm) using UV-detection.   
 
Ethyl-6-Oxo-3-phenyl-1,4,5,6-tetrahydropyridine-2-carboxylate (21) 
A solution of 19 (809 mg, 1.95 mmol) in TFA/CH2Cl2 1:4 (10.0 mL) was stirred for 16 h at 65 °C. 
After 16 h, the temperature was decreased to 0 °C. The reaction mixture was diluted with 
CH2Cl2 and quenched with aqueous NaHCO3. The organic layer was washed with H2O (10 mL), 
dried over MgSO4 and concentrated in vacuo. The residue was purified by flash column 
chromatography (EtOAc/heptane 1:1) affording compound 21 (620 mg, 87%). Rf = 0.36 (EtOAc/heptane 1:1). 
FTIR (ATR) 701, 735, 1683, 2915 cm
-1
. 
1
H NMR (CDCl3, 400 MHz): δ 7.65 (s, 1H), 7.45 -7.34 (m, 3H), 7.17-7.04 (m, 
2H), 4.01 (q, 2H, J = 7.2 Hz), 2.83 – 2.77 (m, 2H), 2.66 – 2.62 (m, 2H), 0.92 (t, 3H, J = 7.1Hz). 
13
C NMR (CDCl3, 75 
MHz): δ 168.84, 139.10, 128.63, 127.50, 127.25, 127.10, 126.79, 123.19, 61.10, 29.76, 29.25, 12.94. HRMS (ESI) 
m/z calcd for C14H15NO3Na (M+Na)
+
: 268.0950, found: 268.0943. 
 
1-Tert-butyl-2-ethyl-6-Oxo-3-phenyl-5,6-dihydro-4H-pyridine-1,2-dicarboxylate(23) 
To a solution of 22 (185 mg, 0.76 mmol) in dry CH2Cl2 (8 mL) was added DMAP (111 mg, 1.0 
equiv) and Boc2O (246 mg, 1.5 equiv). The reaction mixture was stirred at room temperature 
for 16 h, quenched with aqueous NH4Cl and extracted with CH2Cl2. The organic layer was 
washed with H2O, dried (MgSO4) and concentrated in vacuo. The residue was purified by 
column chromatography (EtOAc/heptane 1:2) to give 23 (235 mg, 0.68 mmol, 86%) as a colorless oil. Rf = 0.51 
(EtOAc/heptane 1:2). FTIR (ATR) 1149, 1243, 1720, 1785 cm
-1
. 
1
H NMR (CDCl3, 400 MHz): δ 7.37-7.16 (m, 5H), 
3.96 (2H, q, J = 7.1 Hz), 2.73-2.68 (m, 4H), 1.51 (s, 9H), 0.91 (t, 3H, J = 7.1 Hz). 
13
C NMR (CDCl3, 75 MHz): δ 
N
H
CO2EtO
Ph
N CO2EtO
Boc
Ph
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168.62, 163.15, 149.38, 138.40, 131.73, 127.73, 127.68, 127.37, 126.73, 84.17, 60.77, 32.75.27.62, 27.26, 
12.85. HRMS (ESI) m/z calcd for C38H46N2O10Na (2M+Na)
+
: 713.3050, found: 713.3022. 
 
1-Tert-butyl-2-ethyl-3-Phenyl-5,6-dihydro-4H-pyridine-1,2-dicarboxylate (24) 
A solution of 23 (20 mg, 0.056 mmol) in dry THF (2 mL) was cooled to -78 °C, LiEt3BH4 (1.2 equiv, 
76 µL) was added and the reaction was stirred for 1 h. After 1 h the reaction was quenched with 
aqueous NaHCO3 (5 mL) and the temperature was raised to 0 °C, a drop of H2O2 was added and 
the reaction was stirred for another 20 min. The organic layer was concentrated and redissolved 
in CH2Cl2, dried (MgSO4) and concentrated in vacuo. The crude hemiaminal was dissolved in CH2Cl2 (2 mL) and 
Et3SiH (9 µL, 1.0 equiv) was added. The reaction mixture was cooled to -78 °C and stirred for 30 min. Then, 
another equivalent of Et3SiH was added together with BF3.Et2O (1.25 equiv, 9 µL). The reaction was stirred for 2 
h and quenched with aqueous NaHCO3 (5 mL). The organic layer was dried (MgSO4) and concentrated in vacuo. 
The residue was purified by column chromatography (EtOAc/heptane 1:3) to give 24 (11 mg, 0.032 mmol, 57%) 
as a colorless oil. Rf 0.88 (EtOAc/heptane 1:1). FTIR (ATR) 1158, 1369, 1382, 1704, 2976 cm
-1
. 
1
H NMR (CDCl3, 
400 MHz): δ 7.30-7.20 (m, 5H), 3.87 (br s, 2H), 3.67 (t, 2H, J = 5.4 Hz), 2.44 (t, 2H, J = 6.7 Hz), 1.97-1.90 (m, 2H), 
1.44 (s, 9H), 0.78 (s, 3H). 
13
C NMR (CDCl3, 75 MHz): δ 173.72, 165.19, 152.33, 140.18, 128.97, 127.54, 127.23, 
126.77, 81.65, 60.14, 42.24, 29.55, 27.62, 23.12, 12.80. HRMS (ESI) m/z calcd for C19H25NO4Na (M+Na)
+
: 
354.1681, found: 354.1688. 
 
1-(4-Methoxybenzyl)-5-phenyl-1H-pyridin-2-one (27) 
To a solution of 26 (351 mg, 0.85 mmol) in dioxane (8 mL) was added aqueous NaOH (4 mL, 2.5 
equiv, 85 mg). After 16 h amberlite IR 120+ was added. The reaction mixture was stirred for 
another hour and concentrated in vacuo. The residue was purified by column chromatography 
(10% MeCN/H2O) to give 27 (240 mg, 0.82 mmol, 96%) as a yellow oil. Rf = 0.38 (EtOAc/heptane 
1:1). FTIR (ATR) 1247, 1511, 1589, 1657 cm
-1
. 
1
H NMR (CDCl3, 400 MHz): δ 7.57 (dd, 1H, J = 2.7 Hz, J = 9.4 Hz), 
7.47 (dd, 1H, J = 0.5 Hz, J = 2.6 Hz), 7.39-7.23 (m, 5H), 6.86 (d, 2H, J = 8.8 Hz), 6.67 (dd, 1H, J = 0.4 Hz, J = 9.4 Hz), 
5.13 (s, 2H), 3.76 (s, 3H). 
13
C NMR (CDCl3, 75 MHz): δ 161.47, 159.01, 138.70, 136.02, 133.93, 129.27, 128.55, 
127.93, 126.80, 125.29, 120.61, 119.85, 113.85, 54.78, 51.28, 34.96, 31.42, 28.56, 25.98, 25.87, 22.23, 13.66. 
HRMS (ESI) m/z calcd for C19H17NO2Na (M+Na)
+
: 314.1157, found: 314.1159. 
 
Ethyl-1-(4-Methoxybenzyl)-6-oxopiperidine-2-carboxylate (29a) 
A solution of 28a (40 mg, 0.14 mmol) in MeOH (2 mL) was flushed with nitrogen for 15 min 
after which 10% Pd/C (10 
m
/m%) was added. The reaction was stirred for 1 h, filtered over 
Celite and concentrated in vacuo. The residue was purified by column chromatography 
(EtOAc/heptane 1:1) to give 29a (37 mg, 0.13 mmol, 92%) as a colorless oil. Rf = 0.41 
(EtOAc/heptane 1:1). FTIR (ATR) 1174, 1243, 1511, 1639, 1736, 2946 cm
-1
. 
1
H NMR (CDCl3, 400 MHz): δ 7.12 (d, 
2H, J = 8.5 Hz), 6.84 (d, 2H, J = 8.4 Hz), 5.14 (d, 1H, J = 14.8 Hz), 4.12 (q, 2H, J = 7.1 Hz), 4.04 (dd, 1H, J = 2.8 Hz, J 
= 5.8 Hz), 3.82 (d, 1H, J = 14.8 Hz), 3.76-3.70 (m, 3H), 2.45 -2.41 (m, 2H), 2.09 -2.01 (m, 1H), 1.94-1.88 (m, 1H), 
1.77-1.72 (m, 2H), 1.21 (dt, 1H, J = 0.6 Hz, J = 7.1 Hz). 
13
C NMR (CDCl3, 75 MHz): δ 171.06, 171.01, 158.92, 
128.92, 114.93, 113.21, 60.91, 58.01, 53.86, 48.07, 30.53, 25.29, 17.16, 12.59. HRMS (ESI) m/z calcd for 
C17H21NO4 (M+Na)
+
: 314.1530, found: 314.1601. 
 
Ethyl-2-(4-Methoxybenzyl)-1-oxo-1,2,3,4-tetrahydroisoquinoline-3-carboxylate(29b) 
A solution of 28b (20 mg, 0.12 mmol) in MeOH (2 mL) was pumped through the H-cube 
(flowrate = 1.0 mL/min, P = 10 bar, T = 40 °C). The organic layer was collected and 
concentrated in vacuo. The residue was purified by column chromatography (EtOAc/heptane 
1:2) to give 29b (26 mg, 0.082 mmol, 91%) as a colorless oil. Rf = 0.38 (EtOAc/heptane 1:1). 
FTIR (ATR) 1246, 1511, 1652, 1738, 2937 cm
-1
. 
1
H NMR (CDCl3, 400 MHz): δ 7.96 (dd, 1H, J = 1.1 
Hz, J = 7.7 Hz), 7.44 (dt, 1H, J = 1.4 Hz, J = 7.5 Hz), 7.38-7.31 (m, 1H), 7.26 (d, 1H, J = 8.7 Hz), 7.19 (d, 1H, J = 7.5 
Hz), 6.88 (d, 1H, J = 8.7 Hz), 5.24 (d, 1H, J = 14.8 Hz), 4.32 (dd, 1H, J = 2.1 Hz, J = 6.5 Hz), 4.18 (d, 1H, J = 14.7 Hz), 
3.99-3.94 (m, 2H), 3.75 (s, 3H), 3.34-3.30 (m, 1H), 3.19 (dd, 1H, J = 2.0 Hz, J = 16.3 Hz), 1.01 (t, 3H, J = 7.1 Hz). 
N CO2Et
PMB
O
N CO2Et
PMB
O
N
PMB
O
Ph
N CO2Et
Boc
Ph
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13
C NMR (CDCl3, 300 MHz): δ 170.27, 134.95, 131.60, 129.00, 128.15, 126.93, 126.67, 126.62, 113.27, 60.81, 
56.88, 53.83, 48.63, 30.24, 12.40. HRMS (ESI) m/z calcd for C18H23NO4 (M+H)
+
: 340.1525, found: 340.1523. 
 
1-(4-Methoxybenzyl)-6-oxo-1,4,5,6-tetrahydropyridine-2-carboxylic acid (30a) 
To a solution of 28a (720 mg, 2.49 mmol) in dioxane (20 mL) was added a solution of NaOH 
(2.5 equiv, 270 mg) in H2O (5 mL). The reaction was stirred for 6 h and neutralized with 
amberlite IR 120+, filtered and concentrated in vacuo. The residue was purified by column 
chromatography (10% H2O/MeCN to 25% H2O/MeCN) to give 30a (26 mg, 0.082 mmol, 91%) as a colorless oil. 
Rf = 0.28 (10% H2O/MeCN). 
1
H NMR (MeOD, 400 MHz): δ 7.11 (d, 2H, J = 8.7 Hz), 6.77 (d, 2H, J = 8.7 Hz), 6.09 (t, 
1H, J = 5.0 Hz), 5.00 (s, 2H), 3.71 (s, 3H), 2.45 (t, 2H, J = 7.2 Hz), 2.26-2.20 (m, 2H). 
13
C NMR (MeOD, 75 MHz): δ 
171.78, 167.47, 158.47, 138.30, 129.60, 128.69, 128.57, 128.47, 116.08, 112.95, 53.77, 44.07, 30.256, 18.57. 
HRMS (ESI) m/z calcd for C14H15NO4Na (M+Na)
+
: 284.0899, found: 284.0890. 
 
2-(4-Methoxybenzyl)-1-oxo-1,2-dihydroisoquinoline-3-carboxylic acid (30b) 
To a solution of 28b (573 mg, 1.70 mmol) in dioxane (15 mL) was added a solution of NaOH 
(2.5 equiv, 102 mg) in H2O (5 mL). The reaction was stirred for 6 h and neutralized with 
amberlite IR 120+, filtered and concentrated in vacuo. The residue was purified by column 
chromatography (10% H2O/MeCN to 25% H2O/MeCN) to give 30b (436 mg, 1.41 mmole, 83%) 
as a colorless oil. Rf = 0.28 (10% H2O/MeCN). FTIR (ATR) 690, 700, 1149, 1726, 2976 cm
-1
. 
1
H 
NMR (CDCl3, 400 MHz): δ 8.31 (d, 1H, 8.4 Hz), 7.61-7.91 (m, 3H), 7.45 (s, 1H), 7.07 (d, 2H, J = 8.8 Hz), 6.82 (d, 2H, 
J = 8.8 Hz), 5.84 (s, 2H), 4.82 (s, 3H). 
13
C NMR (CDCl3, 75 MHz): δ 166.25, 165,04, 160.96, 136.91, 134.81, 
131.69, 130.74, 130.49, 129.38, 129.25, 128.24, 115.42, 114.61, 56.18, 47.91. HRMS (ESI) m/z calcd for 
C18H15NO4 (M+Na)
+
: 332.0899, found: 332.0886. 
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O
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A stereoselective total synthesis of tangutorine 
 
 
Abstract 
We herewith describe a novel approach to racemic tangutorine (1) starting from the key 
building block 5.1 As shown below, a first disconnection of the pentacyclic tangutorine 
framework would involve a Bischler-Napieralski cyclization, followed by reduction giving rise 
to bicyclic precursor 2. Subsequently, quinoline 2 could be derived via RCM from the trans-
5,6-disubstituted lactam 3. We were hopeful that the primary iodide 4 would serve as a 
suitable precursor to deliver 5 via organozinc/copper-mediated coupling with ethyl  
2-(bromomethyl)acrylate. Finally, diastereoselective copper-catalyzed 1,4-addition onto 5, 
followed by some further functionalization was anticipated to lead to iodide 4. 
 
 
 
 
 
Sebastiaan (Bas) A. M. W. van den Broek, Jaap G. H. Lemmers, Floris L. van Delft, Floris P. J. T. Rutjes, Total 
Synthesis of the Monoterpenoid Alkaloid (±)-Tangutorine, Org. Biomol. Chem. 2012, 10, 945-951. 
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7.1. Introduction 
β-Carbolines (e.g. 1, 6 and 7, Figure 7.1), a family of monoterpenoid indole alkaloids, 
constitute an important class of natural products. They are one of the principal alkaloid 
groups in the plant kingdom and are biosynthetically derived from the amino acid 
tryptophan.2 Some of the alkaloids that are most widely used in medicine belong to this 
group and contain the yohimbine skeleton (viz. yohimbine (6)).3 For instance reserpine (7), 
an antihypertensive drug and one of the first medicinal monoterpenoid agents, has been 
used for many years to control high blood pressure and to relieve psychotic behaviors.4 
However, due to the many side effects, the use of reserpine as an antipsychotic has been 
almost completely abandoned nowadays. Despite these disadvantages, many derivatives of 
reserpine all containing the yohimbine substructure have been synthesized over the past 
decades in the search for compounds with equal activity, but less undesired side effects.  
 
 
 
 
Figure 7.1. Monoterpenoid indole alkaloids. 
 
Up till now, nearly 3000 monoterpenoid indole alkaloids with interesting pharmacological 
properties have been isolated from natural sources. A potentially relevant derivative, (±)-
tangutorine (1), was isolated in 1999 by Duan and colleagues from the leaves of the Chinese 
medical plant Nitraria tangutorine.5 Although tangutorine is structurally related to the 
yohimbine skeleton, it is the only known β-carboline alkaloid that contains a quinolizidine 
subunit. Biologically, tangutorine shows interesting effects on the regulation of cell cycle and 
cellular morphology of HT29, which are human colon cancer cells.6  
 
The first total synthesis of tangutorine was reported in 2001 by the group of Jokela.7 Their 
synthesis started with preparing dihydroquinolone 8 from 1,3-cyclohexanedione in two steps 
(Scheme 7.1). The ester substituent was introduced by refluxing the dihydroquinolone with 
dimethyl carbonate in the presence of sodium hydride and a catalytic amount of methanol. 
Next, alkylation of the nitrogen with tryptophyl bromide provided the pyridinium salt 9. 
Reduction with sodium dithionite in a water/methanol mixture in the presence of sodium 
                                                                                     A stereoselective total synthesis of tangutorine  
  179 
 
bicarbonate selectively led to cyclic enamine 10. Upon protonation of the double bond, 10 
was cyclized via a Pictet-Spengler reaction and subsequently reduced with sodium 
borohydride in glacial acetic acid. Mesylation of the alcohol, followed by elimination with 
DBU and reduction of the methyl ester with lithiumaluminum hydride gave tangutorine (1) in 
3.2% yield over ten steps. 
 
 
 
Scheme 7.1. First total synthesis of tangutorine (1) by Jokela et al. 
 
A different approach was published by Hsung and co-workers,8 who commenced their 
synthesis with the protection of tryptamine and subsequent bromination to form the Heck 
reagent 14 in three consecutive steps (Scheme 7.2). The bromide 14 underwent a Heck 
reaction with methyl acrylate to give the conjugated ester 16. In the next three steps the 
ester was reduced and the amine was deprotected. The resulting amine 17 was then 
condensed with cyclohexa-1,3-dione, followed by oxidation of the alcohol to aldehyde 19. 
Formation of the iminium ion 20 then initiated an intramolecular aza-[3+3] cycloaddition 
whereupon two rings were formed simultaneously. In the next four steps the double bonds 
were diastereoselectively reduced, after which another five steps were required for 
completion of the synthesis. The total synthesis was completed in 19 steps with an overall 
yield of 5.5%. 
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Scheme 7.2. Synthesis of tangutorine (1) by Hsung et al. 
 
In 2006, a third synthesis was published by Ho et al.9 In a nine-step sequence cyclohexa-1,3-
dione (18) was reacted with acrolein and the resulting acetal was subsequently converted 
into aldehyde 23 using lithiumaluminum hydride. The aldehyde was condensed with 
tryptamine, which directly underwent a Pictet-Spengler reaction, followed by an aza-Michael 
addition. In order to facilitate the purification, the indole was protected with a Boc-group. 
The allylic alcohol 25 was introduced under Vilsmeier-Haack conditions (POCl3/DMF) to 
generate the β-chloro α,β-unsaturated aldehyde, followed by sodium borohydride 
reduction. Finally, Na-naphthalenide was used to dechlorinate 25 providing Boc-protected 
tangutorine (1) in 3.0% yield over nine steps. 
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Scheme 7.3. Synthesis of tangutorine (1) by Ho et al. 
 
During the course of our research, an elegant biomimetic approach to tangutorine (1) was 
published by the Poupon group.10 Their synthesis commenced with glutaraldehyde, which 
under basic conditions dimerized to give an aldehyde/acetal equilibrium between 
compounds 27 and 28. Elimination of water under acidic conditions, followed by 
condensation with tryptamine and cyclization to the intermediate amine 30, afforded the 
pentacycle 31 after a second cyclization. The latter reaction proceeded via an intramolecular 
Pictet-Spengler reaction, followed by an extended aza-Michael addition in a single 
transformation, albeit in an inseparable 75:25 mixture. The aldehyde was then reduced with 
sodium borohydride in the presence of cesium chloride. Finally, recrystallization afforded 
diastereomerically pure tangutorine (1) in 3.8% yield over six steps. 
 
 
 
Scheme 7.4. Synthesis of tangutorine (1) by Poupon. 
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In our retrosynthetic strategy, we envisaged that two disconnections would be crucial: 
starting from tangutorine (1), Bischler-Napieralski-mediated ring-opening was envisaged to 
provide intermediate 32, which in turn, via RCM-induced cleavage of the olefin should 
provide structure 33. The required side chain was thought to be introduced via a Zn/Cu-
mediated coupling onto vinyl-substituted piperidine 34. The latter fragment may be derived 
from the α,β-unsaturated dehydroamino acid 35 via conjugate addition and reduction of the 
carboxylic ester.  
 
 
 
Scheme 7.5. Retrosynthetic approach to tangutorine. 
 
7.2 Synthesis of the quinolizidine precursor of tangutorine 
 
Our forward synthesis commenced with a copper-catalyzed 1,4-addition onto an α,β-
unsaturated cyclic dehydroamino ester, which was described in Chapter 5 as a new approach 
to access trans-5,6-disubstituted 2-oxopiperidine carboxylic esters.1 Based on this idea, 
lactam 38 was considered a suitable precursor to enter the quinolizidine substructure of 
tangutorine (1). Having the trans-5,6-disubstituted 2-oxopiperidine carboxylic esters 38 
available, we set out to investigate the potential of organozinc/copper couplings with 
primary iodides, which had to be prepared from ester 38. Reduction of ester 38 using DIBAL-
H at –78 °C was unproductive since only starting material was recovered. Use of LiAlH4 on 
the other hand gave no product and led to reduction of both the alcohol and amide 
functions. Gratifyingly, reduction with LiEt3BH at 0 °C appeared efficient yielding the desired 
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alcohol 39 in 95%. Conversion into the primary iodide 40 was accomplished in 67% yield 
using iodine in the presence of triphenylphosphine and imidazole.   
 
 
 
Scheme 7.6. Synthesis of iodide 40.  
 
With the desired iodide 40 in hand, substitution of the iodide substituent was explored. An 
organozinc/copper coupling onto iodide 40 was chosen as the method to introduce the 
second double bond.11 To probe the feasibility of this reaction, we decided to test a variety 
of electrophiles (Table 7.1).  
 
Table 7.1. Organozinc/copper coupling with different electrophiles. 
 
 
 
Interestingly, organozinc/copper coupling with acid chlorides (entry 1) did not lead to chain 
extension, but instead resulted in the ring-opened product 42 together with trace amounts 
of 43.12 Moreover, 1,4-addition onto 40 under identical conditions with either ethyl acrylate 
(entry 2) or acrylonitrile (entry 3) led to similar results. Gratingfyingly, reaction of 40 with 2-
Entry Electrophile Product Yield 41 (%) Yield 42 (%) 
1 
           
 
41a – 75 
2            
 
41b – 39 
3            
 
41c – 67 
4 
           
 
41d 44 46 
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bromoethylacrylic acid ethyl ester (SN2’-type reaction, entry 4) resulted in the RCM-
precursor 41d, the anticipated product for construction of the quinoline substructure, albeit 
in a moderate yield of 42%. In addition, a substantial amount of the ring-opened product 42 
was formed.  
 
 
 
Scheme 7.7. RCM of the quinoline-precursor 41d.  
 
With the dialkene 41d prepared, next a ring-closing metathesis was thought to provide the 
corresponding isoquinoline product. Treatment of 41d with G2 (10 mol%) indeed yielded 
quinoline 44 in 89% yield (Scheme 7.9). Without further optimization of the cyclization 
reaction, initial attempts to complete the synthesis of tangutorine (1) started with PMB-
deprotection of 44 followed by N-alkylation with Boc-protected tryptophyl bromide (47). 
Removal of the PMB-group under acidic conditions (TFA, 70 °C, 16 h) at elevated 
temperatures proceeded smoothly in 74% yield. In contrast, the resulting secondary amide 
proved to be unreactive toward alkylation with the aliphatic bromide 47 (Scheme 7.7). 
Alkylation in the presence of DIPEA at elevated temperatures only led to degradation of the 
starting material.13 Attempts to deprotonate the lactam with NaH prior to addition of the 
bromide were also met with failure. Addition of tetrabutylammonium iodide or potassium 
iodide did not show any improvement. A raise in temperature on the other hand, only led to 
degradation.  
 
 
7.3 Bischler-Napieralski cyclizations 
 
As indicated by the previous results, N-alkylation of quinoline 45 appeared less trivial than 
anticipated. We therefore chose to study introduction of the indole in the linear enamide 
stage prior to ring-closure (1) and 1,4-addition (2). Since N-alkylation of dehydroamino ester 
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48 would avoid the PMB-protection/deprotection sequence, it had our preference. 
However, deprotonation of 48 with NaH in DMF only led to rapid degradation of the starting 
material (Scheme 7.8). Reaction of 51 under similar conditions did result in N-alkylation, but 
the isolated yield never exceeded 10%. Remarkable, alkylation involving portionwise 
addition of NaH (5 times 0.25 equiv) led to a distinct increase in yield of 52 to an acceptable 
53%.  
 
 
 
Scheme 7.8. N-alkylation with Boc-protected tryptophyl bromide 47.   
 
With the indole successfully incorporated (52), a Bischler-Napieralski cyclization was 
envisioned to construct the pentacyclic system.14 To promote the selectivity of the reaction, 
a copper-catalyzed 1,4-addition with vinylmagnesium bromide was performed prior to the 
cyclization. Indeed, when 53 was reacted with POCl3 and toluene in CH2Cl2 at elevated 
temperatures, the iminium salt was obtained according to mass spectrometry (ESI). 
However, the reaction never reached full conversion. Reaction at higher temperatures in 
toluene on the other hand proceeded smoothly. The crude iminium salt 54 was immediately 
reduced to the amine upon treatment with sodium borohydride. Reduction led to the Boc-
deprotected pentacycle 55 in 78% yield as an inseparable 86:14 mixture of 
diastereoisomersaccording to 1H-NMR (Scheme 7.9).  
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Scheme 7.9. Bischler-Napieralski cyclization of 53.  
   
7.4 Completion of tangutorine 
 
Due to the cleavage of the Boc-group during the Bischler-Napieralski cyclization, 
reprotection of the tryptophyl moiety would be necessary to complete the synthesis of the 
quinolizidine moiety (Scheme 7.10).  
 
 
 
Scheme 7.10. Completion of the formal synthesis of (±)-tangutorine. 
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To avoid the reprotection step, the developed 1,4-addition/iodonation/organozinc-copper 
coupling sequence was successfully applied to convert 53 into the N-tryptophyl substituted 
cyclic dehydroamino ester 58 (Scheme 7.10) yielding the RCM precursor in three consecutive 
steps (36%) . Again, the ring-opened product was 59 was obtained as major by-product 
(17%). With 58 in hand, we were pleased to find that RCM (G2, 80 °C, 1 h, PhMe) proceeded 
in a nearly quantitative yield. Subsequently, this time Bischler-Napieralski cyclization 
proceeded in a completely diastereoselective fashion, as confirmed by 1H-NMR, to the 
energetically most favourable product. Since in the latter step, the Boc-group was only 
partially cleaved, pentacycle 61 was further reacted under acidic conditions (TFA/CH2Cl2 1:2) 
affording the known 62 – a known precursor for tangutorine7 – in a total yield of 45%. 
Finally, the ester was reduced according to known procedures yielding tangutorine (1) in 
82%.15 In overall, tangutorine has been prepared from commercial available chemicals in 
eleven consecutive steps with an overall yield of 3.0%. 
 
 
7.5 Conclusions 
 
In conclusion, we have shown that the cyclic dehydroamino ester, described in Chapter 2, 
can be efficiently converted into tangutorine in eight consecutive steps in an overall yield of 
6.5%. The viability of the complete synthesis was proven by N-alkylation of the cyclic 
dehydroamino ester with Boc-protected tryptophyl bromide prior to quinoline formation. 
Next, a 1,4-addition using vinylmagnesium bromide followed by chain extension onto the 
ester provided for the precursor for RCM. This chain extension was accomplished by 
conversion of the ester into the corresponding iodide, which was then treated with an 
organozinc/copper coupling sequence. After formation of the quinoline, a Bischler-
Napieralski cyclization afforded the pentacycle yielding tangutorine upon reduction of the 
corresponding ester.   
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7.7 Experimental Section 
 
General information 
 
For general experimental details, see Section 2.7 
 
6-(Hydroxymethyl)-1-(4-methoxybenzyl)-5-vinylpiperidin-2-one (39) 
To a cooled solution (0 °C) of compound 38 (0.95 g, 3.0 mmol) in THF (30 mL), LiEt3BH (9 mL, 
9.0 mmol (1 M solution in THF) was added. After 1.5 h stirring at 0 °C another portion of 
LiEt3BH (1.5 ml, 1.5 mmol) was added and the reaction was stirred for another 2 h. The 
reaction was quenched with ice-water (25 mL) and the product was extracted with CH2Cl2 (3 × 
25 mL), dried over MgSO4 and concentrated in vacuo. The residue was purified by flash 
column chromatography (EtOAc/heptane 1:1 to CH2Cl2/MeOH 9:1) affording compound 39 (0.78 g, 95%). Rf 
0.41 (DCM/MeOH 9:1). FTIR (ATR) 3376, 2948, 1613, 1512 cm
-1
. 
1
H NMR (CDCl3, 400 MHz): δ 7.20 (m, 2H), 6.85 
(m, 2H), 5.64-5.54 (m, 1H), 5.07-5.00 (m, 3H), 4.25 (d, 1H,  J = 14.8 Hz), 3.79 (s, 3H), 3.79-3.73 (m, 1H), 3.64-3.56 
(m, 1H), 3.21-3.16 (m, 1H), 2.72-2.63 (m, 1H), 2.58-2.37 (m, 2H), 2.05-1.95 (m, 2H), 1.72-1.60 (m, 1H).
 13
C NMR 
(CDCl3, 75 MHz): δ 171.05, 158.53, 138.56, 129.28, 128.95, 116.04, 113.63, 61.18, 60.65, 54.84, 46.92, 38.34, 
30.05, 23.86. HRMS (ESI) m/z calcd for C16H21NO3Na (M+Na)
+
: 298.1421, found: 298.1419. 
 
6-(Iodomethyl)-1-(4-methoxybenzyl)-5-vinylpiperidin-2-one (40) 
To a solution of compound 39 (105 mg, 0.38 mmol) in THF (4 mL), PPh3 (120 mg, 0.46 mmol) and 
imidazole (39 mg, 0.57 mmol) were added. The reaction was heated to 70  C and iodine (116 
mg, 0.46 mmol) was added. After 30 minutes the reaction was cooled to room temperature and 
concentrated in vacuo. The residue was purified by flash column chromatography 
(EtOAc/heptane 1:1) affording compound 40 (140 mg, 67%). Rf 0.82 (CH2Cl2/MeOH 9:1). FTIR 
(ATR) 2948, 1642, 1512, 1244, 519 cm
-1
. 
1
H NMR (CDCl3, 400 MHz): δ 7.16 (m, 2H), 6.86 (m, 2H), 5.59-5.49 (m, 
1H), 5.51 (d, 1H, J = 15.0 Hz), 5.14-5.04 (m, 2H), 3.80 (s, 3H), 3.75 (d, 1H, J = 15.1 Hz), 3.36-3.33 (m, 2H), 2.94-
2.89 (m, 1H), 2.68-2.60 (m, 1H), 2.60-2.41 (m, 2H), 1.95-1.86 (m, 1H), 1.78-1.66 (m, 1H). 
13
C NMR (CDCl3, 75 
MHz): δ 169.96, 158.68, 137.84, 129.12, 127.95, 116.94, 113.73, 57.84, 54.85, 45.48, 41.49, 30.05, 23.24, 9.43. 
HRMS (ESI) m/z calcd for C16H20INO2Na (M+Na)
+
: 408.0439, found: 408.0436. 
 
4-[1-(4-Methoxybenzyl)-6-oxo-3-vinylpiperidin-2-yl]-2-methylenebutyric acid ethyl ester (41d) 
Zinc dust (52.3 mg, 0.8 mmol) was weighed into a schlenk flask, which was dried with a 
flame and flushed with argon. 1,2-dibromoethane (3.3 μL, 0.04 mmol) in dry DMF (0.3 
mL) was added and the flask was heated to 60 °C for 1 hour. TMSCl (0.5 μL, 0.004 mmol) 
was added and the mixture was stirred at 60 °C for 30 minutes. Compound 40 (50 mg, 
0.13 mmol) was dissolved in DMF (0.4 mL), added to the mixture and stirred 10 min at 
60 °C. CuCN (11.6 mg, 0.13 mmol) and LiCl (11 mg, 0.26 mmol) were heated to 150 °C under vacuum for 2 
hours and cooled to room temperature. Addition of DMF (0.5 mL) formed a soluble CuCN·2LiCL complex. After 
cooling the organozinc reagent to –55 °C the Cu-complex was added and the solution was warmed to 0 °C. 
After stirring 10 min at 0 °C the solution was cooled to –55 °C and ethyl 2-(bromomethyl)acrylate (21.8 μL, 
0.156 mmol) was added. The solution was slowly warmed to room temperature and stirred over night. The 
mixture was filtered over celite, diluted with EtOAc, washed with aq. NH4Cl and brine, dried over MgSO4 and 
concentrated in vacuo. The residue was purified by flash column chromatography (EtOAc/heptane 1:1) 
affording compound 41d (43 mg, 45%). Rf 0.25 (EtOAc/heptane 1:1). FTIR (ATR) 2936, 1712, 1635, 1512, 1245 
cm
-1
. 
1
H NMR (CDCl3, 400 MHz): δ 7.18 (m, 2H), 6.83 (m, 2H), 6.16 (d, 1H, J = 1.2 Hz), 5.60-5.50 (m, 1H), 5.50 (d, 
1H, J = 1.2 Hz), 5.42 (d, 1H, J = 14.6 Hz), 5.01-4.92 (m, 2H), 4.23 (q, 2H, J = 7.1, Hz), 3.79 (s, 3H), 3.76 (d, 1H, J = 
14.6 Hz), 3.18-3.13 (m, 1H), 2.58-2.45 (m, 2H), 2.44-2.34 (m, 1H), 2.33-2.17 (m, 2H), 2.06-1.95 (m, 1H), 1.90-
1.63 (m, 3H), 1.32 (t, 3H, J = 7.1 Hz).
 13
C NMR (CDCl3, 75 MHz): δ 169.77, 166.35, 158.43, 139.48, 138.46, 
129.42, 128.94, 124.86, 115.63, 113.47, 60.34, 58.08, 54.85, 46.04, 39.34, 30.18, 28.99, 27.53, 22.54, 13.82. 
HRMS (ESI) m/z calcd for C22H29NO4Na (M+Na)
+
: 394.1997, found: 394.1994. 
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4-(methoxybenzyl)-4-Vinylhex-5-enamide (42) 
This compound was obtained as a side product in the organozinc-coupling. Rf 0.43 
(EtOAc/heptane 1:1). FTIR (ATR) 3282, 3073, 2930, 1641, 1512, 1246 cm
-1
.
 1
H NMR (CDCl3, 400 
MHz): δ 7.20 (m, 2H), 6.86 (m, 2H), 5.75-5.64 (m, 2H), 5.62 (br. s, 1H), 5.05-4.96 (m, 4H), 4.36 (d, 
2H, J = 5.6 Hz), 3.80 (s, 3H), 2.71 (p, 1H, J = 7.4 Hz), 2.19 (t, 2H, J = 7.4 Hz), 1.79 (m, 2H). 
13
C NMR 
(CDCl3, 75 MHz): δ 171.95, 158.66, 139.98, 129.95, 128.83, 114.59, 113.65, 54.84, 46.93, 42.64, 33.85, 29.32. 
HRMS (ESI) m/z calcd for C16H21NO2Na (M+Na)
+
: 282.1472, found: 282.1470. 
 
Ethyl-1-(4-methoxybenzyl)-2-oxo-1,2,3,4,4a,7,8,8a-octahydroquinoline-6-carboxylate(44) 
Compound 41d (40 mg, 0.11 mmol) was dissolved in toluene (4 mL) and flushed with 
argon. Grubbs second generation catalyst (9.2 mg, 0.01 mmol) was added and the 
solution was heated to 80 °C. After 1 hour the solution was cooled to room temperature 
and concentrated in vacuo. The residue was purified by flash column chromatography 
(EtOAc/heptane 1:1 to 2:1) affording compound 44 (34 mg, 86%). Rf 0.16 (EtOAc/heptane 
1:1). FTIR (ATR) 2933, 1708, 1639, 1512, 1244 cm
-1
. 
1
H NMR (CDCl3, 400 MHz): δ 7.13 (d, 2H, J = 8.8 Hz), 6.84 (d, 
2H, J = 8.8 Hz), 6.67 (d, 1H, J = 1.3 Hz), 5.06 (d, 1H, J = 15.4 Hz), 4.42 (d, 1H, J = 15.4 Hz), 4.17 (q, 2H, J = 7.1, Hz), 
3.79 (s, 3H), 3.08 (ddd, 1H, J = 12.2, 9.8, 2.5 Hz), 2.76-2.59 (m, 2H), 2.55-2.31 (m, 3H), 2.23-2.09 (m, 1H), 2.05-
1.97 (m, 1H), 1.60 (m, 1H), 1.42 (m, 1H), 1.27 (t, 3H, J = 7.1 Hz). 
13
C NMR (CDCl3, 75 MHz): δ 170.58, 166.13, 
158.21, 138.74, 129.36, 127.92, 126.77, 113.54, 60.17, 57.65, 54.88, 44.54, 39.50, 32.47, 26.45, 25.94, 24.03, 
13.75. HRMS (ESI) m/z calcd for C20H25NO4Na (M+Na)
+
: 366.1684, found: 366.1681. 
 
Tert-butyl-3-(2-bromoethyl)indole (47)  
To a cooled (0 °C) solution of tryptophyl bromide (1.33 g, 6 mmol), Et3N (1.6 mL, 12 mmol) 
and DMAP (147 mg, 1.2 mmol) in DCM (60 mL),  a solution of Boc2O (1.43 g, 6.6 mmol) was 
added dropwise. The solution was stirred 2 hours at 0 °C, then quenched with H2O, extracted 
with DCM, washed with H2O, dried over MgSO4 and concentrated under reduced pressure. 
The residue was purified by flash column chromatography (EtOAc/heptane 1:4) affording 
compound 48 (1.64 g, 85%). Rf 0.67 (EtOAc/heptane 1:1). 
1
H NMR (CDCl3, 400 MHz): δ 8.14 (br. d, 1H, J = 7.4 
Hz), 7.52-7.45 (m, 2H), 7.35-7.29 (m, 1H), 7.27-7.21 (m, 1H), 3.62 (t, 2H, J = 7.6 Hz), 3.26 (t, 2H, J = 7.6 Hz), 1.66 
(s, 9H). 
 
Ethyl-6-Oxo-1,4,5,6-tetrahydropyridine-2-carboxylate (51) 
The cyclic dehydroamino ester 50 (1.04 g, 3.6 mmol) was dissolved in a TFA/CH2Cl2 mixture 
(1:4, 36 mL) and stirred overnight at 50  C. The reaction was quenched with NaHCO3 and the 
organic compound was extracted with CH2Cl2, dried over Na2SO4 and concentrated in vacuo. 
The residue was purified by flash column chromatography (EtOAc/heptane 1:1) affording 
compound 51 (516 mg, 85%). Rf 0.14 (EtOAc/heptane 1:1). 
1
H NMR (CDCl3, 400 MHz): δ 7.58 (s, 1H), 6.29-6.26 
(m, 1H), 4.29 (q, 2H, J = 7.1 Hz), 2.53-2.50 (m, 4H), 1.33 (t, 3H, J = 7.1 Hz).
 13
C NMR (CDCl3, 75 MHz): δ 169.25, 
161.22, 128.46, 113.53, 61.47, 28.74, 20.33, 13.72.
16
 
3-{2-[6-Ethoxycarbonyl-2-oxo-3,4-dihydro-2H-pyridin-1-yl]ethyl}indole-1-carboxylate (52) 
Compound 51 (121 mg, 0.72 mmol) was dissolved in DMF (8 mL) and the Boc-protected 3-
(2-bromoethyl)indole (347 mg, 1.07 mmol) was added. NaH (45 mg, 0.9 mmol) was 
gradually added to the mixture over 2.5 h. The reaction was then stirred overnight at 
room temperature, diluted with EtOAc/heptane 1:1, cooled to 0 °C and quenched with 
H2O. The organic layer was extracted, dried over MgSO4 and concentrated under reduced 
pressure. The residue was purified by flash column chromatography (EtOAc/heptane 1:1) 
affording compound 52 (155 mg, 53%). Rf 0.40 (EtOAc/heptane 1:1). FTIR (ATR) 2977, 
1724, 1678, 1367, 1255, 1157 cm
-1
.
 1
H NMR (CDCl3, 400 MHz): δ 8.11 (d, 1H, J = 6.1 Hz), 7.62 (d, 1H, J = 7.7 Hz), 
7.36 (s, 1H), 7.32-7.20 (m, 2H), 6.27 (t, 1H, J = 5.0 Hz), 4.11 (dq, 2H, J = 7.1, 0.5 Hz), 4.10-4.04 (m, 2H), 3.01-2.95 
(m, 2H), 2.50 (t, 2H, J = 7.6 Hz), 2.35-2.26 (m, 2H), 1.66 (s, 9H), 1.25 (dt, 3H, J = 7.1, 0.5 Hz).
 13
C NMR (CDCl3, 75 
MHz): δ 170.14, 162.15, 149.27, 135.14, 134.58, 130.03, 123.84, 122.88, 121.94, 119.95, 118.74, 117.24, 
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114.73, 82.93, 60.95, 42.97, 30.47, 27.80, 23.96, 19.45, 13.64. HRMS (ESI) m/z calcd for C23H28N2O5Na (M+Na)
+
: 
435.1898, found: 435.1896. 
 
Tert-butyl-3-[2-(2-ethoxycarbonyl-6-oxo-3-vinylpiperidin-1-yl)ethyl]indole-1-carboxylate (53) 
To a cooled solution (–30 °C) of CuI (268 mg, 1.41 mmol) in Et2O (3 mL), a 1M 
vinylmagnesium bromide solution in THF (707 µL, 0.71 mmol) was added. The solution 
was stirred for 20 minutes and was cooled to –70 °C. Then compound 52 (155 mg, 0.35 
mmol), dissolved in Et2O (2 mL), was added and the temperature was slowly warmed to –
10 °C. The reaction was quenched with 0.1 M HCl and washed with Na2S2O3 (2x40 mL), 
NaHCO3 (10 mL) and H2O (10 mL), dried over MgSO4 and concentrated in vacuo. The 
residue was purified by flash column chromatography (EtOAc/heptane 1:1) affording 
compound 53 (112 mg, 73%). Rf 0.26 (EtOAc/heptane 1:1). FTIR (ATR) 2977, 1731, 1650, 
1454, 1373, 1158 cm
-1
.
 1
H NMR (CDCl3, 400 MHz): δ 8.12 (d, 1H, J = 7.8 Hz), 7.63 (d, 1H, J = 7.7 Hz), 7.39 (s, 1H), 
7.28 (m, 2H), 5.71 (m, 1H), 5.19-5.10 (m, 2H), 4.22 (dq, 2H, J = 7.1, 0.6 Hz), 4.18-4.12 (m, 1H), 3.91 (d, 1H, J = 4.1 
Hz), 3.10-2.86 (m, 3H), 2.85-2.77 (m, 1H), 2.56-2.38 (m, 2H), 1.98-1.87 (m, 1H), 1.78-1.69 (m, 1H), 1.66 (s, 9H), 
1.27 (dt, 3H, J = 7.1, 0.7 Hz).
 13
C NMR (CDCl3, 75 MHz): δ 171.01, 169.43, 149.26, 136.43, 135.06, 129.93, 
123.98, 122.84, 122.13, 118.65, 117.18, 116.44, 114.89, 83.03, 65.06, 61.39, 47.36, 39.24, 28.53, 27.86, 23.20, 
22.46, 13.88. HRMS (ESI) m/z calcd for C25H32N2O5Na (M+Na)
+
: 463.2211, found: 463.2209. 
 
Ethyl-3-Vinyl-1,2,3,4,6,7,12,12b-octahydroindolo[2,3-a]quinolizine-4-carboxylate (55) 
Compound 53 (20 mg, 0.045 mmol) was dissolved in toluene (1 mL) and POCl3 (42 μL, 
0.45 mmol) was added. The solution was stirred at 70 °C for 2 hours. The reaction was 
concentrated under reduced pressure and the residue was dissolved in EtOH (1 mL) 
and cooled to 0 °C. NaBH4 (3.4 mg, 0.09 mmol) was added and the reaction was 
stirred for 10 min at 0°C, diluted with CH2Cl2 and quenched with aq. NaHCO3. The organic layer was separated, 
dried over MgSO4 and concentrated in vacuo. The residue was purified by flash column chromatography 
(EtOAc/heptane 1:2) affording compound 55 (13.0 mg, 68%).Rf 0.48 (EtOAc/heptane 1:1). FTIR (ATR) 3342, 
2916, 1717, 1455, 611 cm
-1
. 
1
H NMR (CDCl3, 400 MHz): δ 7.69 (br. s, 1H), 7.46 (d, 1H, J = 7.8 Hz), 7.30 (d, 1H, J = 
7.7 Hz), 7.11 (ddt, 2H, J = 15.9, 7.1, 1.2 Hz), 5.68 (ddd, 1H, J = 17.1, 10.0, 8.7 Hz), 5.04 (dd, 1H, J = 10.2, 1.7 Hz), 
4.30-4.20 (m, 2H), 3.40 (br d, 1H, J = 11.4 Hz), 3.06-2.97 (m, 2H), 2.95 (d, 1H, J = 10.3 Hz), 2.76-2.68 (m, 1H), 
2.68-2.54 (m, 2H), 2.19-2.11 (m, 1H), 2.03-1.96 (m, 1H), 1.87-1.75 (m, 1H), 1.56-1.44 (m, 1H), 1.30 (t, 3H, J = 7.1 
Hz). 
13
C NMR (CDCl3, 300 MHz): δ 167.75, 137.96, 135.53, 133.57, 121.03, 119.07, 117.72, 116.17, 110.22, 
108.01, 105.73, 72.64, 60.32, 58.86, 50.73, 44.63, 29.79, 28.39, 21.45, 13.94. HRMS (ESI) m/z calcd for 
C20H24N2O2 (M+H)
+
: 325.1918, found: 325.1916. 
 
Tert-butyl-3-[2-(2-Hydroxymethyl-6-oxo-3-vinylpiperidin-1-yl)ethyl]indole-1-carboxylate (56) 
To a cooled solution (0 °C ) of compound 53 (93 mg, 0.21 mmol) in THF (2.5 mL) LiEt3BH 
(0.63 mL, 0.63 mmol, 1M solution in THF) was added. After 2.5 hours at 0 °C another 
equivalent of LiEt3BH (50 μl, 0.05 mmol) was added and the reaction was stirred for three 
hours. The reaction was then quenched with ice-water and the product was extracted 
with CH2Cl2, dried over MgSO4 and concentrated under reduced pressure. The residue was 
purified by flash column chromatography (EtOAc/heptane 1:1 to CH2Cl2/MeOH 9:1) 
affording compound 56 (74 mg, 88%). Rf 0.35 (CH2Cl2/MeOH 9:1). FTIR (ATR) 3322, 1731, 
1615, 1455, 1370 cm
-1
.
 1
H NMR (CDCl3, 400 MHz): δ 8.11 (d, 1H, J = 6.7 Hz), 7.69-7.60 (m, 
1H), 7.39 (d, 2H, J = 3.3 Hz), 7.33-7.19 (m, 2H), 5.73-5.55 (m, 1H), 5.16-5.00 (m, 2H), 4.11-4.00 (m, 1H), 4.00-
3.64(m, 2H), 3.32-3.14 (m, 2H), 3.08-2.85 (m, 2H), 2.53-2.40 (m, 2H), 2.39-2.23 (m, 1H), 2.07-1.84 (m, 1H), 1.68-
1.57 (m, 10H). 
13
C NMR (CDCl3, 75 MHz): δ 170.75, 170.43, 149.25, 138.57, 138.39, 135.04, 130.02, 130.07, 
124.08, 123.94, 122.70, 122.16, 118.85, 118.64, 117.47, 117.33, 115.84, 115.78, 115.54, 114.84, 83.07, 82.99, 
62.95, 62.03, 62.03, 61.96, 61.68, 46.06, 45.94, 45.87, 37.85, 37.79, 37.45, 29.44, 29.23, 29.06, 27.84, 23.13, 
22.87, 22.73, 22.62. HRMS (ESI) m/z calcd for C23H30N2O4Na (M+Na)
+
: 421.2106, found: 421.2103. 
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Tert-butyl-3-{2-[2-(Iodomethyl)-6-oxo-3-vinylpiperidin-1-yl]ethyl}indole-1-carboxylate (57) 
Compound 56 (20 mg, 0.125 mmol) was dissolved in THF (2 mL) and PPh3 (50 mg, 0.19 
mmol), imidazole (13 mg, 0.19 mmol) and iodine (48 mg, 0.19 mmol) were added. The 
resulting reaction mixture was stirred at room temperature for 4 hours. The reaction was 
diluted with CH2Cl2, washed with Na2S2O3 and H2O, dried over Na2SO4 and concentrated 
under reduced pressure. The residue was purified by flash column chromatography 
(heptane to EtOAc/heptane 1:3 to 1:2) affording compound 57 (50 mg, 78%). Rf 0.80 
(CH2Cl2/MeOH 9:1). FTIR (ATR) 1975, 1731, 1646, 1455, 1373, 1157 cm
-1
.
 1
H NMR (CDCl3, 
400 MHz): δ 8.13 (d, 1H, J = 7.0 Hz), 7.66 (d, 1H, J = 7.7 Hz), 7.35-7.23 (m, 3H), 5.67-5.56 (m, 
1H), 5.23-5.10 (m, 2H), 4.20-2.11 (m, 1H), 3.43-3.37 (m, 1H), 3.36-3.29 (m, 1H), 3.16-2.91 (m, 4H), 2.72-2.64 (m, 
1H), 2.55-2.36 (m, 2H), 1.95-1.85 (m, 1H), 1.75-1.63 (m, 10H).
 13
C NMR (CDCl3, 75 MHz): δ 169.86, 149.23, 
137.84, 135.06, 129.97, 124.03, 122.78, 122.16, 118.64, 117.23, 116.89, 114.85, 83.08, 60.93, 44.95, 40.92, 
29.73, 27.85, 22.92, 22.66, 9.34. HRMS (ESI) m/z calcd for C23H29IN2O3Na (M+Na)
+
: 531.1123, found: 531.1121. 
 
Tert-butyl-3-{2-[2-(3-Ethoxycarbonylbut-3-enyl)-6-oxo-3-vinylpiperidin-1-yl]ethyl}indole-1-carboxylate (58)  
Zinc dust (42 mg, 0.65 mmol) was weighed in to a schlenk flask, which was dried 
with a flame and flushed with argon. 1,2-dibromoethane (2.8 μL, 0.03 mmol) in dry 
DMF (0.2 mL) was added and the flask was heated to 60 °C for 1 hour. TMSCl (0.41 
μL, 0.003 mmol) was added and the mixture was stirred at 60 °C for 30 minutes. 
Compound 57 (55 mg, 0.11 mmol) was dissolved in DMF (0.3 mL), added to the 
mixture and stirred 10 min at 60 °C. CuCN (10 mg, 0.11 mmol) and LiCl (9.2 mg, 
0.22 mmol) were heated to 150 °C under vacuum for 2 hours and cooled to room 
temperature. Addition of DMF (0.3 mL) formed a soluble CuCN·2LiCL complex. After 
cooling the organozinc reagent to –55 °C the Cu-complex was added and the solution was warmed to 0 °C. 
After stirring 10 min at 0°C the solution was cooled to –55 °C and the ethyl 2-(bromomethyl)acrylate (18.2 μL, 
0.13 mmol) was added. The solution was slowly warmed to room temperature and stirred over night. The 
mixture was filtered over celite, diluted with EtOAc, washed with aq. NH4Cl and brine, dried over MgSO4 and 
concentrated under reduced pressure. The residue was purified by flash column chromatography 
(EtOAc/heptane 1:1) affording compound 58 (28 mg, 52%). Rf 0.27 (EtOAc/heptane 1:1). FTIR (ATR) 2977, 1728, 
1637, 1454, 1372, 1158 cm
-1
.
 1
H NMR (CDCl3, 400 MHz): δ 8.13 (d, 1H, J = 7.0 Hz), 7.66 (d, 1H, J = 7.8 Hz), 7.41 
(s, 1H), 7.28 (m, 2H), 6.15 (s, 1H), 5.71 (m, 1H), 5.51 (s, 1H), 5.16-5.06 (m, 2H), 4.19 (q, 2H, J = 6.9 Hz), 4.21-4.12 
(m, 1H), 3.19-3.13 (m, 1H), 3.09-2.93 (m, 3H), 2.54-2.44 (m, 2H), 2.40-2.16 (m, 3H), 2.07-1.96 (m, 1H), 1.88-1.68 
(m, 4H), 1.66 (s, 9H), 1.28 (t, 3H, J = 7.2 Hz).
 13
C NMR (CDCl3, 75 MHz): δ 169.54, 166.35, 149.22, 139.36, 138.57, 
135.03, 130.04, 124.86, 123.92, 122.87, 122.04, 118.77, 117.34, 115.65, 114.83, 82.98, 61.15, 60.33, 45.59, 
38.43, 31.35, 28.63, 27.96, 27.87, 22.64, 22.23, 13.72. HRMS (ESI) m/z calcd for C29H38N2O5Na (M+Na)
+
: 
517.2681, found: 517.2678. 
Tert-butyl-3-{2-[(4-Vinylhex-5-enoyl)amino]ethyl}indole-1-carboxylate (59) 
This compound was obtained as a side product in the organozinc-coupling. Rf 0.43 
(EtOAc/heptane 1:1). FTIR (ATR) 3293, 2976, 1731, 1643, 1377, 1159.
 1
H NMR (CDCl3, 400 
MHz): δ 8.14 (d, 1H, J = 7.7 Hz), 7.55 (d, 1H, J = 7.8 Hz), 7.41 (s, 1H), 7.29 (m, 2H), 5.68 (m, 
2H), 5.51 (t, 1H, J = 5.5 Hz), 5.04-4.96 (m, 4H), 3.59 (dt, 2H, J = 6.7 Hz, J = 6.6 Hz), 2.91 (t, 2H, 
J = 6.8 Hz), 2.68 (p, 1H, J = 7.3 Hz), 2.15-2.10 (m, 2H), 1.74 (dt, 2H, J = 7.8 Hz, J = 7.3 Hz), 1.67 
(s, 9H). 
13
C NMR (CDCl3, 75 MHz): δ 172.35, 149.22, 139.95, 135.12, 129.96, 124.12, 122.76, 
122.10, 118.49, 117.25, 114.93, 114.52, 83.27, 46.84, 38.65, 33.87, 29.33, 27.86, 24.72. 
HRMS (ESI) m/z calcd for C23H30N2O3Na (M+Na)
+
: 405.2156, found: 405.2154. 
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Ethy-1-2-[(1-tert-Butoxycarbonyl-1H-indol-3-yl)ethyl]-2-oxo-1,2,3,4,4a,5,6,8a-octahydroquinoline-7-
carboxylate (60) 
Compound 58 (28 mg, 0.056 mmol) was dissolved in toluene (1 mL) and argon was 
flushed through the solvent. Grubbs catalyst second generation (5 mg, 0.005 mmol) 
was added and the solution was heated to 80°C. After 1 hour the solution was cooled 
to room temperature and concentrated in vacuo. The residue was purified by flash 
column chromatography (EtOAc/heptane 1:1) affording compound 60 (26 mg, 98%). 
Rf 0.38 (EtOAc/heptane 2:1). FTIR (ATR) 2922, 1728, 1639, 1450, 1369, 1256, 1157 cm
-
1
.
 1
H NMR (CDCl3, 400 MHz): δ 8.12 (d, 1H,  J = 7.0 Hz), 7.69 (d, 1H, J = 7.2 Hz), 7.43 (s, 
1H), 7.35-7.22 (m, 2H), 6.70 (d, 1H, J = 1.1 Hz), 4.21 (q, 2H, J = 6.9 Hz), 3.84-3.68 (m, 2H), 3.14 (ddd, 1H, J = 12.1 
Hz, J = 9.7 Hz, J = 2.2 Hz), 3.09-3.00 (m, 1H), 2.83-2.73 (m, 1H), 2.69-2.53 (m, 3H), 2.46-2.36 (m, 2H), 2.34-2.23 
(m, 1H), 2.04-1.96 (m, 1H), 1.67 (s, 9H), 1.63-1.50 (m, 2H), 1.31 (t, 3H, J = 7.1 Hz).
 13
C NMR (CDCl3, 75 MHz): δ 
170.25, 166.12, 149.36, 138.72, 135.03, 130.05, 129.78, 128.53, 127.72, 124.83, 124.08, 122.42, 122.14, 
118.72, 117.54, 114.82, 83.04, 60.26, 58.13, 42.38, 39.64, 32.53, 27.80, 26.86, 26.04, 24.16, 23.74, 13.89. HRMS 
(ESI) m/z calcd for C27H34N2O5Na (M+Na)
+
: 489.2368, found: 489.2365. 
 
 
2,4a,5,6,11b,12,13,13a-Octahydro-1H-4b,11-diazaindeno[2,1-a]phenanthrene-3,11-dicarboxylic acid 11-tert-
butyl ester 3-ethyl ester (61) 
Compound 60 (26 mg, 0.056 mmol) was dissolved in toluene (1 mL) and POCl3 (52 
μL, 0.56 mmol) was added. The solution was stirred at 70°C for 2 hours when more 
POCl3 (27 μL, 0.27 mmol) was added and the reaction was stirred for another hour 
at 70°C. The reaction was concentrated under reduced pressure and the residue 
was dissolved in EtOH (1 mL) and cooled to 0°C. NaBH4 (4.2 mg, 0.11 mmol) was 
added and the reaction was stirred for 10 min at 0 ºC, diluted with DCM and quenched with aq. NaHCO3. The 
organic layer was extracted, dried over MgSO4 and concentrated in vacuo. The residue was purified by flash 
column chromatography (EtOAc/heptane 1:2) affording compound 61 (11.5 mg, 46%). Rf 0.63 (EtOAc/heptane 
2:1). Rf 0.63 (EtOAc/heptane 2:1). FTIR (ATR) 2933, 1725, 1477, 732 cm
-1
.
 1
H NMR (CDCl3, 400 MHz): δ 8.16 (d, 
1H, J = 8.0 Hz), 7.41 (d, 1H, J = 7.2 Hz), 7.29-7.19 (m, 2H), 6.70 (s, 1H), 4.51 (d, 1H, J = 10.9 Hz), 4.21 (q, 1H, J = 
7.2 Hz), 3.08-2.95 (m, 2H), 2.87-2.71 (m, 3H), 2.62 (dd, 1H, J = 15.8 Hz, J = 4.2 Hz), 2.39 (t, 2H, J = 10.7 Hz), 2.10-
1.97 (m, 3H), 1.90-1.76 (m, 2H), 1.65 (s, 9H), 1.53-1.40 (m, 1H), 1.31 (t, 3H, J = 7.1 Hz).
 13
C NMR (CDCl3, 75 MHz): 
δ 166.93, 149.62, 141.83, 136.46, 136.03, 129.47, 128.82, 123.48, 122.14, 117.49, 115.34, 114.57, 83.13, 63.34, 
60.06, 58.27, 36.35, 33.33, 30.82, 27.83, 26.86, 25.84, 25.37, 21.57, 13.84. HRMS (ESI) m/z calcd for C27H35N2O4 
[M+H]
+
: 451.2599, found: 451.2597. 
 
Ethyl-1,2,4a,5,6,11,11b,12,13,13a-Decahydro-4b,11-diazaindeno[2,1-a]phenanthrene-3-carboxylate (62) 
Compound 61 (4 mg, 20%) was isolated as a side product of the Bischler-
Napieralski reaction with compound 62. Rf 0.54 (EtOAc/heptane 2:1). FTIR (ATR) 
2919, 1700, 1648, 1255, 736 cm
-1
.
 1
H NMR (CDCl3, 400 MHz): δ 7.70 (s, 1H), 7.39 (d, 
1H, J = 7.9 Hz), 7.21 (d, 1H, J = 7.9 Hz), 7.16-7.06 (m, 2H), 6.68 (s, 1H), 4.21 (q, 2H, J 
= 7.2 Hz, J = 7.1 Hz), 3.62 (ddd, 1H, J = 10.4 Hz, J = 4.8 Hz, J = 2.1 Hz), 3.48 (d, 1H, J = 
11.4 Hz), 2.98-2.88 (m, 1H), 2.79 (d, 1H, J = 15.5 Hz), 2.62 (dd, 1H, J = 16.1 Hz,  5.2 Hz, 1H), 2.45-2.27 (m, 4H), 
2.25-2.14 (m, 2H), 2.09-2.02 (m, 1H), 1.82 (dq, J =  12.2 Hz, J = 3.6 Hz), 1.62-1.33 (m, 3H), 1.31 (t, 3H, J = 7.1 Hz). 
13
C NMR (CDCl3, 75 MHz): δ 167.24, 141.62, 136.07, 135.14, 129.55, 127.36, 121.47, 119.49, 118.25, 110.74, 
108.47, 64.05, 60.57, 60.43, 45.74, 40.78, 30.34, 30.00, 26.03, 25.02, 22.14, 14.34. HRMS (ESI) m/z calcd for 
C22H27N2O2 [M+H]
+
: 351.2074, found: 351.2073. 
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Summary 
 
The formation of carbon-carbon bonds is a crucial issue in organic synthesis. Out of all 
methodologies available, the metathesis reaction has over the past decade evolved as one of 
the most useful tools in this field to rapidly construct the skeleton of carba- and heterocyclic 
molecules. Only twenty years have elapsed since Grubbs and Fu reported that Schrock’s 
molybdenum catalyst (S1) could be used to induce efficient cyclization of functionalized ,-
diene-amines. The key step of the metathesis reaction entails the metal-catalyzed 
redistribution of two carbon-carbon double bonds by a scission-recombination process. 
Since then, a wide range of ring-closing metathesis reactions to form nitrogen heterocyclic 
products have been reported, including applications in the synthesis of natural products 
using the more general applicable ruthenium catalysts (e.g. G1, G2).  
 
 
 
This thesis describes the metathesis behaviour of ,β-unsaturated didehydroamino acids, 
thereby generating a general cyclic building block for further functionalization. In addition, 
the diversity of this methodology is demonstrated by the construction of more elaborated 
heterocycles, including the heterocyclic natural product tangutorine. 
 
Chapter 1 gives an historical overview of RCM used in the synthesis of natural products. It 
shows that especially five- and six-membered heterocyclic rings are ideal targets for RCM 
and that applications in larger rings are lacking behind. These applications have been greatly 
facilitated by the advent of new and more reactive RCM catalysts, thereby continuously 
widening the range of substrates and increasing the scope of the metathesis processes. 
 
Chapter 2 describes the synthesis of didehydroamino esters from condensation of olefinic 
amides 1 with a pyruvate followed by RCM, leading to the introduction of substituents at 
both the allylic and the -position of the amide.  
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This chapter focuses on the formation and scope of the condensation of allylic amides with a 
pyruvate ester to the dehydroamino ester 2. In a second step, ring closure to the 
didehydroamino ester 4 was accomplished by alkylation of the enamide. 
 
Similarly, condensation of hydroxy-substituted amides followed by intramolecular conjugate 
addition gives rise to the synthesis of substituted morpholines 8, as described in Chapter 3.  
 
 
 
Although condensation of the amides 5 to the dehydroamino esters 7 was straightforward 
and hydrolysis induced intramolecular conjugate addition was successful (R1 = H), cyclization 
of more substituted dehydroamino acids 7 (R1 ≠ H) appreared difficult to reproduce.  
 
Chapter 4 describes the condensation and RCM of more elaborated olefinic amides to 
optically active 3- and 4-substituted cyclic dehydroamino acids 14 from enantiomerically 
pure carbohydrates 9, lactones 10 and amino acids 11. 
 
 
 
The application to more elaborated 2-substituted pipecolic esters is discussed in Chapter 5 
upon intermolecular conjugate addition for the synthesis of trans-substituted derivatives. 
Moreover, synthesis of cis-substituted variants is described based on reduction of 
tetrasubstituted cyclic dehydroamino acids. 
 
 
 
 As an extension of this research, asymmetric hydrogenation of the cyclic dehydroamino 
acids is discussed in Chapter 6 with an ee up to 45%. 
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Inspired by the results of RCM on dehydroamino acids, the developed methodology was 
applied to an eight step synthesis of the natural product tangutorine starting from the cyclic 
didehydroamino ester 4, which is described in Chapter 7. 
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Samenvatting 
 
De vorming van koolstof-koolstof bindingen is een cruciale transformatie in de organische 
synthese. Ondanks dat het pas twintig jaar geleden is dat Grubbs en Fu de Schrock’s 
molybdeen katalysator (S1) publiceerden die gebruikt kon worden voor de ringsluiting van 
gefunctionaliseerde ,-dieen-amines, heeft de metathesereactie zich het laatste 
decennium ontwikkeld als een van de meest algemeen toepasbare reacties voor de vorming 
van koolstof- en heterocyclische verbindingen. De belangrijkste stap in deze reactie is de 
metaal-gekatalyseerde redistributie van twee koolstof-koolstof dubbele bindingen door een 
recombinatie process. Een grote varieteit van ringsluitingsmetathese reacties voor de 
vorming van stikstof heterocyclische producten is sindsdien gepubliceerd, inclusief 
applicaties voor de synthese van natuurlijke producten waarbij de commercieel beschikbare 
ruthenium katalysatoren worden gebruikt (bijvoorbeeld G1, G2) 
 
 
 
Dit proefschrift beschrijft de mogenlijkheden tot ringsluiting van ,β-onverzadigde 
dehydroaminozuren voor de vorming van algemene bouwstoffen geschikt voor verdere 
functionalizering. De ontwikkelde synthese is vervolgens toegepast voor de bereiding van 
gesubstitueerde heterocyclische verbindingen, inclusief de bereiding van de natuurlijke 
verbinding tangutorine. 
 
Hoofdstuk 1 geeft een historisch overzicht van ringsluitingsmetathese in de synthese van 
natuurlijke stoffen. Het overzicht laat zien dat met name heterocyclische vijf- en zesringen 
geschikt zijn om gemaakt te worden door middel van ringsluiting. Sinds de ontwikkeling van 
de Ruthenium katalysator is het aantal syntheseroutes waarin RCM wordt gebruikt enorm 
toegenomen door de ontwikkeling van nieuwe, en meer reactieve RCM katalysatoren, 
waarbij bereik van substraten geschikt voor RCM continue wordt vergroot. 
 
Hoofdstuk 2 beschrijft de synthese van cyclische didehydroamino esters gemaakt door 
condensatie van gesubstitueerde allylische amides 1 met een pyruvaatester, gevolgd door 
ringsluiting, voor de introductie van substituenten op zowel de allylische en -positie van de 
ring. 
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Het hoofdstuk bescrhijft de ontwikkelng en de algemene toepasbaarheid van de condensatie 
reactie van allylische amides met een pyruvaat ester voor de vorming van dehydroamino 
ester 2. In een tweede stap wordt de ring 4 gevormd door ringsluitings metathese, waarbij 
de noodzaak van alkylering van de stikstof wordt beschreven. 
 
Een vergelijkbare strategie wordt beschreven in hoofstuk 3 voor de condensatie van 
hydroxy-gesubstitueerde amides. Een intramoleculaire conjugaat additie leidt vervolgens tot 
de gesubstitueerde morpholines 8. 
 
 
 
Alhoewel condensatie van de amides 5 tot de dehydroamino esters 7 algemeen toepasbaar 
is en de intramoleculaire conjugaatadditie succesvol (R1 = H), zijn de opbrengsten van de 
conjugaatadditie voor α-gesubstitueerde hydroxylamides variabel en niet reproduceerbaar.   
 
Hoofdstuk 4 beschrijft de condensatie en ringsluiting van gesubstitueerde, optisch actieve 3- 
en 4-gesubstitueerde cyclische dehydroaminozuren 14. Enantiomeer zuivere amides 12 zijn 
gemaakt van suikers 9, lactonen 10 en aminozuren 11.  
 
 
 
Hoofdstuk 5 beschrijft de synthese van trans-2-gesubstitueerde pipecol esters 15 via 
intermoleculaire conjugaatadditie. Cis-2-gesubstitueerde pipecol esters 15 zijn bereid door 
hydrogeneringsreactie van de enamide. 
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Een uitbreiding hiervan is beschreven in hoofdstuk 6, waarbij een asymmetrische 
hydrogeneringsreactie van de cyclische dehydroaminozuren 18 resulteert in 2-pipecolesters 
19 met een ee van 45%.  
 
 
 
Geinspireerd door deze resultaten is de ontwikkelde methodologie toegepast in de synthese 
van de natuurlijke stof tangutorine. De syntese is beschreven in hoofdstuk 7 en succesvol 
voltooid in acht stappen, startend met de cyclische dehydroamino ester 4.  
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